Anexo

NVX-COV2373

RBD-Dimer

SCB-2019

UB-612

VAT0002

Soberana 2

EPIVacCorona

Abdala

Estratégia de busca

Derwent Innovation		Search results for:	Collections searched:																	
Publication Number	Publication Date	Application Date	Optimized Assignee	Title (Original)	Title - DWPI	Abstract - DWPI	Claims	Priority Number	Priority Date	DWPI Manual Codes	IPC - Current - DWPI	CPC - Current - DWPI	DWPI Accession	DWPI Family Members	Dead/Alive DWPI	INPADOC Family ID	INPADOC Family	Dead/Alive INPADOC	Ultimate Parent	CATEGORIA
BR112013001514A2	2016-06-07	2011-07-25	NOVAVAX INC	VACINA PARA INFLUENZA	Composition, useful e.g. as immune stimulating medicine for treating against influenza, comprises	Composition (A) comprises at least one immune stimulating complex (ISCOM) and at least one	CLAIMS 1. Composition comprising at least one ISCOM complex and at least one ectodomain	US2010366983P | WO2011SE50968A	2010-07-23 | 2011-07-25	B04-B01B | B04-B04C | B04-L05B | B04-L05B0E | B04-N03K | B04-N03K0E | B04-N08 | B14-A02B2 | B14-G01 |	A61K (IPC 1-7) | A61K003939 (IPC 1-7) | A61K0039145 (IPC 1-7) | A61P (IPC 1-7) | A61P003116 (IPC 1-7) |	A61K003912 | A61K0039145 | A61K003939 | A61P003116 | A61P003702 |	2012B28387	WO2012011868A1 | AU2011280259A1 | CA2805741A1 | AU2011280259A8 | EP2595653A1 |	Alive	20120126CA2805741A1	BR112013001514A2 | AU2011280259A1 | AU2011280259A8 | AU2011280259B2 | AU2011280259B8 |	Alive	NOVAVAX INC	Vacina de proteína recombinante e adjuvante
BR112013011194A2	2017-06-27	2011-11-07	NOVAVAX INC	PARTÍCULAS DE GLICOPROTEÍNA SEMELHANTES A VÍRUS (VLPS) DA RAIVA.	Purified micelle used in pharmaceutical vaccine composition for e.g. vaccinating mammal against viral infection	A purified micelle comprises at least one rabies virus (RV) glycoprotein (G protein).	CLAIMS: 1. A purified micelle comprising one or more rabies vims (RV) glycoproteins (G	US2010410767P | WO2011US59602A	2010-11-05 | 2011-11-07	B04-B01B | B04-C01G | B04-E02F | B04-E03F | B04-E08 | B04-E99 | B04-F0100E | B04-N03K1 | B04-N03K1E |	A61K0009127 (IPC 1-7) | A61K0039205 (IPC 1-7) | A61K003900 | A61K003912 | A61K0039145 |	A61K0039205 | A61K003912 | A61P003112 | A61P003114 | A61P003116 |	2012F38458	WO2012061815A2 | WO2012061815A3 | AU2011323090A1 | CA2817005A1 | EP2635257A2 |	Alive	20120510CA2817005A1	BR112013011194A2 | AU2011323090A1 | AU2011323090B2 | BR112013011194B1 | CA2817005A1 |	Alive	NOVAVAX INC	Vacina partíula semelhante a vírus (VLP)
BR112013016239A2	2016-11-22	2011-12-22	NOVAVAX INC	PROTEÍNAS DE HEMAGLUTININA DA GRIPE MODIFICADA E SEUS USOS	New virus-like particle comprising a recombinant influenza virus hemagglutinin protein, useful for	A virus-like particle (VLP) comprising a recombinant influenza virus hemagglutinin (HA) protein, where	CLAIMS: 1. A virus- like particle (VLP) comprising a recombinant influenza virus hemagglutinin	US2010426390P | WO2011US66867A	2010-12-22 | 2011-12-22	B04-E99 | B04-F1100E | B14-A02B2 | B14-G01 | B14-S11A | B14-S11D3 | C04-E99 | C04-F1100E | C14-A02B2 |	A61K0039145 (IPC 1-7) | C12N001544 (IPC 1-7) | A61K0039145 | A61P003116 | A61P003704 |	C12N000700 | A61P003116 | A61P003704 | A61K003900 | A61K20395258 |	2012H43402	WO2012088428A1 | AU2011348160A1 | CA2822443A1 | EP2654787A1 | MX2013007255A |	Alive	20120628CA2822443A1	BR112013016239A2 | AU2011348160A1 | CA2822443A1 | CN103384531A | EP2654787A1 |	Indeterminate	NOVAVAX INC	Vacina de proteína geral
BR112014007616A2	2017-04-04	2012-09-27	NOVAVAX INC	VACINA DE NANOPARTÍCULA F DE RSV RECOMBINANTE PARA O VÍRUS SINCICIAL	New respiratory syncytial virus (RSV) fusion (F) protein comprising modification or	Respiratory syncytial virus (RSV) fusion (F) protein comprising: either at least one modification or	CLAIMS 1. A respiratory syncytial virus (RSV) fusion (F) protein comprising at least one	US2011542040P | US2011542721P | US2012611834P | US2012614286P | WO2012US57546A	2011-09-30 | 2011-10-03 | 2012-03-16 | 2012-03-22 | 2012-09-27	B04-E02H | B04-E08 | B04-E99 | B04-F0100E | B04-F1100E | B04-N03K0E | B04-N0600E | B04-N08 | B14-A02 |	A61K0039155 (IPC 1-7) | A61K003912 | A61K0039155 | A61K003939 | A61P003112 |	A61K0039155 | A61K003912 | A61P003112 | A61P003114 | A61P003704 |	2013F09016	WO2013049342A1 | AU2013201495A1 | US20130122032A1 | CA2849471A1 | KR2014077169A |	Alive	20130404CA2849471A1	BR112014007616A2 | AU2013201495A1 | AU2013201495B2 | CA2849471A1 | CN104080476A |	Alive	NOVAVAX INC	VLP
BR112015019126A2	2017-08-22	2014-02-11	NOVAVAX INC	VACINA DE COMBINAÇÃO PARA VÍRUS SINCICIAL RESPIRATÓRIO E INFLUENZA	Immunogenic composition useful for inducing protective response against RSV and influenza strain in	Immunogenic composition comprises respiratory syncytial virus (RSV) fusion (F) component and	CLAIMS 1. An immunogenic composition comprising a respiratory syncytial	US2013763309P | US2013875327P	2013-02-11 | 2013-09-09	B04-C01G | B04-E99 | B04-G0800E | B04-G2100E | B04-L05B0E | B04-N03K1E | B04-N08 | B14-A02B2 | B14-G01	A61K0039145 (IPC 1-7) | A61K0039155 (IPC 1-7) | A61K003900 | A61K003912 | A61K0039145 |	A61K003912 | A61K0039155 | A61K0039145 | A61P003114 | A61P003116 |	2014P60172	US20140227309A1 | WO2014124423A1 | CA2900489A1 | AU2014214590A1 | IL240504A |	Alive			No associated INPADOC family	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
BR112015023651A2	2017-10-24	2014-03-10	NOVAVAX INC	EXPRESSÃO AUMENTADA DE PROTEÍNAS DE PICORNAVÍRUS	New fusion protein comprising amino-terminal signal peptide and immunogenic polypeptide, useful in	Fusion protein comprising an amino-terminal signal peptide, and an immunogenic polypeptide is new,	Atty Dkt No, NOVV-052/01WO 305047-2445 1. A fusion protein comprising	US2013790114P | WO2014US22399A	2013-03-15 | 2014-03-10	B04-E02H | B04-E99 | B04-F0100E | B04-G0100E | B04-N0300E | B04-N08 | B12-K04A4B | B14-A01 |	C12N001562 (IPC 1-7) | A61K0039135 (IPC 1-7) | C07K001409 (IPC 1-7) | C07K000708 (IPC 1-7) | C12N000510 (IPC 1-7)	C07K0014005 | A61K0039135 | A61K0047646 | C12N000700 | A61K003912 |	2014T38899	US20140271697A1 | WO2014150150A1 | CA2904382A1 | AU2014237485A1 | KR2015139528A |	Indeterminate	20140918US20140271697A1	BR112015023651A2 | AU2014237485A1 | CA2904382A1 | CN105209620A | EP2970984A1 |	Indeterminate	NOVAVAX INC	Adjuvante
BR112016006122A2	2017-09-26	2014-09-19	NOVAVAX INC	COMPOSIÇÕES IMUNOGÊNICAS E MÉTODOS COM CORONAVÍRUS DA SÍNDROME	Immunogenic composition useful to produce high affinity antibody for inducing immune responses	Immunogenic composition comprises middle east respiratory syndrome coronavirus (MERS-CoV)	We Claim: 1. An immunogenic composition comprising a MERS-CoV nanoparticle,	US2013880111P | WO2014US56517A	2013-09-19 | 2014-09-19	B04-F11B | B04-G01 | B12-M11Q | B14-G01 | B14-S11A | C04-F11B | C04-G01 | C12-M11Q | C14-G01 | C14-S11A |	A61K0039215 (IPC 1-7) | A61K003900 | A61K003912 | A61K0039145 | A61K0039215 |	A61K0039215 | A61K003912 | A61K003942 | A61P003114 | C07K0014005 |	201521200B	WO2015042373A1 | CA2922258A1 | CN105555306A | KR2016055164A | US20160206729A1 |	Alive	20150326CA2922258A1	BR112016006122A2 | CA2922258A1 | CN105555306A | CN105555306B | EP3046579A1 |	Alive	NOVAVAX INC	vacina de proteína, coronavírus
BR112018004242A2	2018-09-25	2016-09-06	NOVAVAX INC	COMPOSIÇÕES DE VACINA QUE POSSUEM ESTABILIDADE E IMUNOGENICIDADE AUMENTADAS	Vaccine composition used for preventing a viral infection, i.e. Ebola Virus infection or disease, and inducing	A vaccine composition comprises (i) a nanoparticle comprising a non-ionic detergent core and a	CLAIMS 1. A vaccine composition comprising: (i) a nanoparticle	US62213947P | US62255786P | US62309216P | US62350973P | WO2016US50413A	2015-09-03 | 2015-11-16 | 2016-03-16 | 2016-06-16 | 2016-09-06	A10-E07B | A10-E08A | A10-E08B | A12-V01 | B04-A07E | B04-C03C | B04-E02H | B04-E99 | B04-F0100E | B04-G08	A61K0039155 (IPC 1-7) | A61K000900 (IPC 1-7) | A61K003814 | A61K003900 | A61K003912 |	A61K00091623 | A61K003912 | A61K0039155 | A61K00090019 | A61K00091611 |	2017172593	WO2017041100A2 | WO2017041100A3 | US20170202948A1 | CA2996007A1 | AU2016315478A1 |	Alive	20170309CA2996007A1	BR112018004242A2 | AU2016315478A1 | AU2016315478A2 | CA2996007A1 | CN108697790A |	Alive	NOVAVAX INC	Adjuvante
BR112019019117A2	2020-05-05	2018-03-15	NOVAVAX INC	MÉTODOS E COMPOSIÇÕES PARA INDUZIR RESPOSTAS IMUNES CONTRA CLOSTRIDIUM	New multivalent immunogenic polypeptide comprising portions of at least four Clostridium difficile	Multivalent immunogenic polypeptide comprising portions of at least four Clostridium difficile	CLAIMS: 1. A multivalent immunogenic polypeptide comprising portions of at least four	US62471636P | US62474434P | WO2018US22597A	2017-03-15 | 2017-03-21 | 2018-03-15	B04-E02F | B04-E03F | B04-E99 | B04-N03J | B14-S11D3 | D05-C12 | D05-H07 | D05-H12A | D05-H17A | D05-H99	A61K003900 (IPC 1-7) | A61K003908 (IPC 1-7) | A61K003939 (IPC 1-7) | A61K003816 | A61K003900	A61K003908 | A61K0039116 | A61K003939 | A61P003104 | C07K001433 |	201874027P	WO2018170238A2 | WO2018170238A3 | AU2018236352A1 | CA3056090A1 | KR2019125470A |	No associated DWPI family status	20180920CA3056090A1	BR112019019117A2 | AU2018236352A1 | CA3056090A1 | CN110691609A | EP3595709A2 |	Alive	NOVAVAX INC	Adjuvante
BR112020019108A2	2020-12-29	2019-03-19	NOVAVAX INC	VACINAS POLIVALENTES DE NANOPARTÍCULAS DE INFLUENZA	Multivalent immunogenic influenza composition for stimulating an immune response against	Multivalent immunogenic influenza composition comprises a detergent-core nanoparticle, where	CLAIMS 1. A multivalent immunogenic influenza composition comprising	US62644623P | US62787980P | WO2019US22930A	2018-03-19 | 2019-01-03 | 2019-03-19	B04-N03K0E | B04-N0600E | B11-C02 | B11-C06 | B12-M11Q | B14-A02B2 | B14-G01 | B14-S11A | B14-S11D3	A61K0039155 (IPC 1-7) | A61K0039145 (IPC 1-7) | A61K0039295 (IPC 1-7) | C12N000700 (IPC 1-7) | A61K003900 |	A61K0039145 | A61P003116 | A61K00090051 | A61K000951 | A61K003912 |	201982329V	WO2019183063A1 | US20190314487A1 | AU2019238171A1 | CA3092984A1 | BR112020019108A2 |	No associated DWPI family status	20190926CA3092984A1	BR112020019108A2 | AU2019238171A1 | CA3092984A1 | CN112469436A | EP3768308A1 |	Alive	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
BR199506885A	1997-08-19	1995-01-11	MICROPAK INC	Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos	New influenza vaccine contg. adjuvant comprising paucilamellar lipid vesicles having non-	A vaccine for producing an antigenic response to influenza, in vivo in mammals, comprises an effective		US1994201346A | WO1995US475A	1994-02-24 | 1995-01-11	A12-V01 | B04-B01B | B14-A02B2	A61K003900 (IPC 1-7) | A61K0039155 (IPC 1-7) | A61K0039145 (IPC 1-7) | A61K003938 (IPC 1-7) | A61K0009127 (IPC	B82Y000500 | A61K003912 | A61K0039145 | A61K003939 | A61P003112 |	1995358310	WO1995022989A1 | AU199515660A | EP746338A1 | BR199506885A | JP10500662A |	Dead	19940721CA2153780A1	BR199506885A | AT280585T | AU199460188A | AU199515660A | CA2153780A1 |	Dead	MICROPAK INC	Adjuvante
BR200312472A	2005-04-26	2003-07-07	NOVAVAX INC	Prepração de uma composição compreendendo uma mistura de complexos de iscom e uso da dita	Composition for use an immunomodulating pharmaceutical, adjuvant or vaccine against microbial	A composition comprising a mixture of two iscom complexes, comprising iscom or iscom matrix	REIVINDICAÇÕES 1. Composição compreendendo uma mistura de pelo menos dois complexos de	SE20022110A | WO2003SE1180A	2002-07-05 | 2003-07-07	B04-A08 | B04-A10 | B14-A01 | B14-S11A | B14-S11B | D05-H07	A61K (IPC 1-7) | A61K003600 | A61K003618 | A61K003673 | A61K003939 |	A61K003939 | A61P003104 | A61P003112 | A61P003114 | A61P003116 |	2004083463	WO2004004762A1 | AU2003245220A1 | BR200312472A | EP1539231A1 | ZA200500073B |	Alive	20020705SE200202110D0	BR200312472A | AT434443T | AU2003245220A1 | AU2003245220B2 | BRPI0312472B1 |	Alive	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
BR200408587A	2006-03-21	2004-03-24	NOVAVAX INC	composição compreendendo partìculas de iscom e microrganismos vivos	Use of an iscom particle as an adjuvant for preparing an antigenic or vaccine composition	An iscom particle is used as adjuvant for preparing an antigenic composition, which comprises at least one	REIVINDICAÇÕES 1. Uso de uma partícula de iscom caracterizado pelo fato de ser como adjuvante na	SE2003795A | WO2004SE451A	2003-03-24 | 2004-03-24	B04-B04C | B04-F10 | B04-F11 | B14-S11 | D05-H04 | D05-H06A | D05-H07	A61K003939 (IPC 1-7) | A61K003900 (IPC 1-7) | A61K003900 | A61K003912 | A61K0039145 |	A61K003939 | A61K0039145 | A61K0039155 | A61P003114 | A61P003116 |	2004710275	WO2004084941A1 | AU2004224487A1 | EP1635867A1 | BR200408587A | ZA200506988B |	Alive	20030324SE200300795D0	BR200408587A | AT544471T | AU2004224487A1 | AU2004224487B2 | CA2519806A1 |	Alive	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
BR200412444A	2006-09-19	2004-07-07	NOVAVAX INC	fração de quil a com baixa toxidez e seu uso	Use of fraction A of Quil A together with another adjuvant (e.g. saponins) for the preparation of an	Fraction A of Quil A together with at least one other adjuvant are used for the preparation of an	1. REIVIN'DICAÇÕES 1. Uso da fração A de Quil A em conjunto com pelo menos um outro adjuvante,	SE20031998A | WO2004SE1038A	2003-07-07 | 2004-07-07	B04-A07E | B04-B01B | B04-C03 | B04-H02B | B04-H04C | B04-N05 | B14-G03 | B14-S09	A61K003939 (IPC 1-7) | A61K003819 | A61K003900 | A61K003910 | A61K0039106 |	A61K003939 | A61K203955577 | A61K203957	2005075654	WO2005002620A1 | EP1648505A1 | AU2004254152A1 | BR200412444A | US20060239963A1 |	Alive	20030707SE200301998D0	BR200412444A | AT442164T | AU2004254152A1 | AU2004254152B2 | BRPI0412444B1 |	Alive	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
BR200412519A	2006-09-19	2004-07-09	NOVAVAX INC	partìculas tipo vìrus da influenza funcional (vlps)	New macromolecular protein structure (e.g. influenza virus-like particle) comprising influenza virus M1	A macromolecular protein structure comprising a first influenza virus M1 protein and an	REIVINDICAÇÕES 1. Estrutura de proteína macromolecular compreendendo: (a)	US2003617569A | WO2004US22001A	2003-07-11 | 2004-07-09	B04-B04C1 | B04-G08 | B04-N03 | B11-C07A | B12-K04A4A | B14-A02B2 | B14-S11A | D05-H07 | D05-H09 |	A01H000500 (IPC 1-7) | A61K (IPC 1-7) | A61K003912 (IPC 1-7) | A61K0039145 (IPC 1-7) | C07K001411 (IPC 1-7)	A61K0039145 | C07K0014005 | A61K003912 | A61P003116 | A61P003704 |	2005074521	US20050009008A1 | WO2005020889A2 | EP1644037A2 | AU2004268510A1 | BR200412519A |	Alive	20050113US20050009008A1	BR200412519A | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
BRPI0606481A2	2009-06-30	2006-01-20	NOVAVAX INC	composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a	Composition for vaccination of mammals comprises fibronectin binding protein, truncated	A composition comprising at least one fibronectin binding protein, at least one truncated fibronectin	REIVINDICAÇÕES 1. Composição caracterizada pelo fato de compreender pelo menos uma proteína	US2005593504P | WO2006SE82A	2005-01-20 | 2006-01-20	B04-A07E | B04-B01B | B04-N02 | B12-M11F | B14-S11B1 | C04-A07E | C04-B01B | C04-N02 | C12-M11F | C14-	A61K0039085 (IPC 1-7) | A01N006300 | A61K003900 | A61K003902 | A61K0039085 |	A61K0039092 | A61K0039085 | A61P003104 | A61P003702 | A61K203952 |	2006503239	WO2006078213A1 | EP1838341A1 | IN200705215P1 | CN101107009A | BRPI0606481A2 |	Alive	20060727CA2592627A1	BRPI0606481A2 | CA2592627A1 | CA2592627C | CN101107009A | CN101107009B |	Alive	NOVAVAX INC	VLP
BRPI0617486A2	2011-07-26	2006-10-18	NOVAVAX INC	VACINA QUE COMPREENDE PARTÍCULAS SIMILARES A VÍRUS DA GRIPE FUNCIONAIS (VLP) E	Use of influenza virus like particle comprising specified influenza virus protein and specified influenza	In the preparation of a vaccine (V1), an influenza virus like particle (VLP) (I) comprising an	1. Vacina caracterizada pelo fato de que compreende VLP de gripe, em que o dito VLP compreende M1	US2005727513P | US2006780847P | US2006800006P | US2006831196P | US2006832116P	2005-10-18 | 2006-03-10 | 2006-05-15 | 2006-07-17 | 2006-07-21 | 2006-09-19 | 2006-10-18	B04-E08 | B04-F11B0E | B12-K04 | B14-C01 | B14-C04 | B14-J05 | B14-K01B | B14-N04 | B14-N05 | B14-S11A |	A61K0039145 (IPC 1-7) | A61K003900 (IPC 1-7) | C12N000704 (IPC 1-7) | A61K003900 | A61K003512 |	A61K0039145 | C12N000700 | A61K003912 | A61K003939 | A61P003114 |	2007476927	WO2007047831A2 | US20070184526A1 | EP1937301A2 | AU2006304640A1 | IN200804133P1 |	Alive	20050113US20050009008A1	BRPI0617486A2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
BRPI0908861A2	2018-02-06	2009-02-25	NOVAVAX INC	PARTÍCULAS SEMELHANTES A VÍRUS DE AÇUCAR VITRIFICADO (VLPS)	Composition, useful as a vaccine against diseases e.g. influenza, comprises a virus like particle e.g. influenza	Composition comprises at least one virus like particle and a sugar glass. INDEPENDENT CLAIMS are included	Claims: 1. A composition comprising at least one virus like particle (VLP) and a sugar glass.	US200831243P | WO2009US35122A	2008-02-25 | 2009-02-25	B04-D01 | B04-L05B | B04-N03 | B14-A02B2 | B14-S11 | D05-H	A61K000914 (IPC 1-7) | A61K003912 | A61K0039145 | A61K003921 | A61K003925 |	A61K00091623 | A61K000919 | A61K003912 | A61K003939 | A61K004726 |	2009N21372	WO2009108689A1 | EP2254554A1 | CA2716546A1 | IN201006013P1 | MX2010009351A |	Dead	20090903CA2716546A1	BRPI0908861A2 | CA2716546A1 | CN102014873A | EP2254554A1 | JP2011514337A |	Dead	NOVAVAX INC	VLP
BRPI0922867A2	2016-09-27	2009-12-09	NOVAVAX INC	PROTEINA DE FUSAO (F) DE VIRUS SINCICIAL RESPIRATORIO (RSV) E METODOS PARA SEU USO	New respiratory syncytial virus fusion protein comprising at least one modification/mutation	A respiratory syncytial virus (RSV) fusion (F) protein comprising at least one modification or mutation that	CLAIMS: 1. A respiratory syncytial virus (RSV) fusion (F) protein comprising at least one	US2008121126P | US2009169077P | US2009224787P | WO2009US67269A	2008-12-09 | 2009-04-14 | 2009-07-10 | 2009-12-09	B04-B01B | B04-E02H | B04-E99 | B04-F0100E | B04-F1100E | B04-N08 | B14-A02 | B14-G01 | B14-S11A | B14-	A61K003800 | A61K003900 | A61K003912 | A61K0039155 | A61K003939 |	A61K0039155 | C07K0014005 | C07K001900 | A61K00090019 | A61K00091075 |	2010H91330	WO2010077717A1 | US20100239617A1 | AU2009333484A1 | CA2746228A1 | EP2370099A1 |	Alive	20100708CA2746228A1	BRPI0922867A2 | AU2009333484A1 | AU2009333484B2 | BRPI0922867B1 | CA2746228A1 |	Alive	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
EP1320381A1	2003-06-25	2001-10-01	NOVAVAX INC	NEUER IMMUNOGENER KOMPLEX | NOUVEAU COMPLEXE IMMUNOLOGIQUE	An immunogenic complex for use as immunostimulating complexes (iscoms) or matrixes comprises a	An immunogenic complex comprising one glycoside and one lipid, integrated into an iscom complex or	CLAIMS. 1. An immunogenic complex comprising at least one glycoside and at least one lipid,	SE20003538A | WO2001SE2117A	2000-09-29 | 2001-10-01	B04-B01B | B04-C01G | B04-C02 | B04-L01 | B04-N03A | B04-N04 | B14-S11 | C04-C01B | C04-C02 | C04-L01 |	A61K003902 (IPC 1-7) | A61K003939 (IPC 1-7) | A61K0039145 | A61K0039385 | A61K003939 |	A61K0039145 | A61K003912 | A61K003939 | A61P003704 | A61K2039542 |	2002372091	WO2002026255A1 | AU200192493A | EP1320381A1 | US20040052815A1 | AU2001292493B2 |	Alive	20000929SE200003538D0	EP1320381A1 | AT419870T | AU2001292493B2 | AU200192493A | CA2423983A1 |	Alive	NOVAVAX INC	Vacina de proteina subunidade proteíca e adjuvante
EP1467771A2	2004-10-20	2002-11-13	NOVAVAX INC	MYCOBAKTERIELLER IMPFSTOFF | VACCIN MYCOBACTERIEN	Vaccine useful for producing in vivo T cell-mediated immune response to a mycobacterium	A vaccine comprises a formalin-inactivated mycobacterium and an adjuvant. The adjuvant comprises oil-	We claim: 1. An adjuvanted vaccine for producing an in vivo T cell-mediated immune	US2001335917P | WO2002US36336A	2001-11-14 | 2002-11-13	B04-F0100E | B04-F10B2 | B11-A01 | B12-M05 | B14-A01B1 | B14-S11B | D05-H07 | D05-H08	A61K003904 (IPC 1-7) | A61K004900 (IPC 1-7) | A61K003900 (IPC 1-7) | A61K003902 (IPC 1-7) | A61K003905 (IPC 1-7) |	A61K003904 | A61P003104 | A61P003106 | A61K2039521 | A61K203955555	2003532967	WO2003051288A2 | AU2002364952A1 | EP1467771A2 | KR2004081423A | US20050118201A1 |	Alive	20030626CA2467271A1	EP1467771A2 | AT392216T | AU2002364952A1 | AU2002364952B2 | CA2467271A1 |	Alive	NOVAVAX INC	adjuvante

EP1988918A2	2008-11-12	2007-02-22	NOVAVAX INC	ADJUVANZ- UND IMPFSTOFFZUSAMMENSETZUNGEN | COMPOSITIONS D'ADJUVANT ET DE	New composition comprising an emulsion and aluminum salt nano-/micro-particles	A new composition comprises an emulsion and aluminum salt nano-/micro-particles surface stabilized with	What Is Claimed Is: 1. A composition comprising an emulsion and aluminum salt nano-	US2006775346P | US2006861245P | WO2007US4470A	2006-02-22 | 2006-11-28 | 2007-02-22	B01-D02 | B03-H | B04-B01C | B04-C03 | B04-N04 | B05-A01B | B10-C04E | B10-J02 | B12-M03 | B12-M09 | B14-	A61K003900 | A61P003704	A61K003939 | A61K004702 | A61P003704 | A61K203955505 | A61K203955566	2008E47680	WO2007098186A2 | WO2007098186A3 | EP1988918A2 | US20100226932A1 | EP1988918A4	Dead	20070830WO2007098186A2	EP1988918A2 | EP1988918A4 | US20100226932A1 | WO2007098186A2 | WO2007098186A3	Dead	NOVAVAX INC	adjuvante
EP2035565A2	2009-03-18	2007-06-27	NOVAVAX INC	VERFAHREN ZUR ERWEITERUNG DER PROTEININKORPORATION IN VIRUSÄHNLICHEN	Increasing glycoprotein incorporation on the surface of virus-like particles comprises expressing chimeric	Increasing glycoprotein incorporation on the surface of virus-like particles (VLPs) comprises expressing a	Claims 1. A method of increasing glycoprotein incorporation on the surface of VLPs,	US2006817402P | WO2007US72272A	2006-06-30 | 2007-06-27	B04-F1100E | B14-G01 | B14-S11D3 | D05-H07	A61K003912 | C12N0015867 | C12N000700 | C12Q000170	C07K0014005 | A61K20395258 | C07K231902 | C07K231903 | C12N271014143 |	2008B39700	WO2008005777A2 | EP2035565A2 | WO2008005777A3 | US20100143406A1 | EP2035565A4	Dead	20080110WO2008005777A2	EP2035565A2 | EP2035565A4 | US20100143406A1 | WO2008005777A2 | WO2008005777A3	Dead	NOVAVAX INC	VLP
EP2052082A2	2009-04-29	2008-03-25	NOVAVAX INC	CHIMÄRE VLPs DES NEWCASTLE-KRANKHEITSVIRUS | PSEUDO-PARTICULES VIRALES (VLP)	New chimeric virus like particle (VLP) comprising a Newcastle Disease Virus (NDV) core protein (M) and a	A new chimeric virus like particle (VLP) comprises a Newcastle Disease Virus (NDV) core protein (M) and at	CLAIMS 1. A chimeric virus like particle (VLP) comprising a Newcastle Disease Virus (NDV)	US2007902337P | WO2008US54570A	2007-02-21 | 2008-02-21	B04-F11 | B04-L05B | B04-N03 | B04-N08 | B14-A01 | B14-A02 | B14-G01 | B14-S11 | C04-F11 | C04-L05B |	A61K003500 | A61K003900 | A61K0039145 | A61K0039155 | A61K003917 |	C12N000700 | A61P003114 | C07K0014005 | A61K20395258 | C12N271014143 |	2008L73264	WO2008103819A2 | WO2008103819A3 | EP2052082A2 | CA2678966A1 | CN101668857A |	Dead	20080828CA2678966A1	EP2052082A2 | CA2678966A1 | CN101668857A | EP2052082A4 | US20100247574A1 |	Dead	NOVAVAX INC	VLP
EP2089515A2	2009-08-19	2007-11-16	NOVAVAX INC	VIRUSÄHNLICHE PARTIKEL DES RESPIRATORISCHEN SYNZYTIALVIRUS | PARTICULES DE TYPE	New virus like particle (VLP) comprises respiratory syncytial virus (RSV) M protein, useful for vaccinating a	A virus like particle (VLP) comprising a respiratory syncytial virus (RSV) M protein, is new. INDEPENDENT	CLAIMS: 1. A virus like particle (VLP) comprising a respiratory syncytial virus (RSV) M protein.	US2006859290P | US2007901652P | WO2007US85011A	2006-11-16 | 2007-02-16 | 2007-11-16	B04-B04C1 | B04-F11B | B04-N03E0E | B14-A02B | B14-S11A | C04-B04C1 | C04-F11B | C04-N03E0E | C14-	A61K0039145 | A61K0039155 | A61P003112 | C07K001600 | C12N000700	A61K0039155 | A61K003912 | A61P003112 | C07K0014005 | A61K20395258 |	2008G54808	WO2008061243A2 | US20080233150A1 | WO2008061243A3 | EP2089515A2 | EP2089515A4	Dead	20080522WO2008061243A2	EP2089515A2 | EP2089515A4 | US20080233150A1 | WO2008061243A2 | WO2008061243A3	Dead	NOVAVAX INC	VLP
EP2152730A2	2010-02-17	2008-05-02	UNIVERSITY OF ALABAMA | EMORY UNIVERSITY	ERWEITERUNG DER GLYCOPROTEININKORPORATION IN VIRUSÄHNLICHEN PARTIKELN |	New recombinant nucleic acid encoding a chimeric HIV-Env polypeptide comprises a first domain encoding	A recombinant nucleic acid encoding a chimeric HIV-Env polypeptide comprises a first domain encoding	CLAIMS We claim: 1. A recombinant nucleic acid encoding a chimeric HIV-Env	US2007927208P | WO2008US62516A	2007-05-02 | 2008-05-02	B04-E02H | B04-E08 | B04-F1100E | B04-G01 | D05-H11 | D05-H12	A61K003912 | A61K003921 | C07H002104 | C07K0014155 | C07K001416 |	C07K001443572 | A61K003912 | A61K003921 | C07K0014005 | C12N00092442 |	2009B44395	WO2009009215A2 | WO2009009215A3 | AU2008275513A1 | EP2152730A2 | US20100196419A1 |	Alive	20090115AU2008275513A1	EP2152730A2 | AU2008275513A1 | CA2688548A1 | EP2152730A4 | US20100196419A1 |	Alive	UNIVERSITY OF ALABAMA | EMORY UNIVERSITY	Vacina de proteina recombinante e adjuvante
EP2175882A1	2010-04-21	2008-07-21	NOVAVAX INC	VARICELLA ZOSTER VIRUS-VIRUSÄHNLICHE PARTIKEL (VLP) UND ANTIGENE | PARTICULES DE TYPE	New purified Varicella Zoster virus (VZV) virus-like particle (VLP) comprises VZV glycoprotein E (gE),	A purified Varicella Zoster virus (VZV) virus-like particle (VLP) comprising VZV glycoprotein E (gE),	Claims: 1. A purified Varicella Zoster Virus (VZV) virus like particle (VLP) comprising VZV gE,	US2007950707P | WO2008US70635A	2007-07-19 | 2008-07-21	B04-F11A0E | B04-N0600E | B14-A01 | B14-A02 | B14-G01 | B14-S11 | C04-F11A0E | C04-N0600E | C14-	A61K0039145 (IPC 1-7) | A61K003925 (IPC 1-7) | A61K0039145 | A61K0039155 | A61K0039245 |	A61K0039145 | C07K0014005 | C12N000700 | A61K003912 | A61K0039155 |	2009E02856	WO2009012486A1 | AU2008275895A1 | EP2175882A1 | KR2010063030A | US20100184192A1 |	Alive	20050113US20050009008A1	EP2175882A1 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
EP2175883A2	2010-04-21	2008-07-21	NOVAVAX INC	CHIMÄRE VARICELLA ZOSTER VIRUS-VIRUSÄHNLICHE PARTIKEL | PSEUDO-PARTICULES VIRALES	New chimeric virus-like particle (VLP) comprises a viral core protein and at least one varicella zoster	A chimeric virus-like particle (VLP) comprising a viral core protein and at least one varicella zoster	Claims 1. A chimeric VLP comprising a viral core protein and at least one varicella zoster	US2007950707P | US2007970592P | US200871835P | WO2008US70636A	2007-07-19 | 2007-09-07 | 2008-05-20 | 2008-07-21	B04-L05B0E | B04-N0300E | B04-N0600E | B04-N08 | B14-A01 | B14-A02 | B14-G01 | B14-S11 | B14-S12 |	A61K003576 | A61K003900 | A61K0039145 | A61K0039155 | A61K003925 |	C07K0014005 | A61K003912 | A61K0039145 | A61K0039155 | A61P003122 |	2009E02855	WO2009012487A2 | WO2009012487A3 | EP2175883A2 | CN101801411A | JP2010533737A |	Alive	20050113US20050009008A1	EP2175883A2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
EP2176427A1	2010-04-21	2008-07-21	NOVAVAX INC	VOGEL-INFLUENZA-VLP-CHIMÄREN | PSEUDO-PARTICULES VIRALES DE LA GRIPPE AVIAIRE CHIMÈRE	Increasing the efficiency of influenza virus-like particle (VLP) production comprises expressing an avian	Increasing the efficiency of influenza virus-like particle (VLP) production comprises expressing an avian	CLAIMS: 1. A method of increasing the efficiency of influenza VLP production	US2007950707P | US2007970592P | US200871835P | WO2008US70638A	2007-07-19 | 2007-09-07 | 2008-05-20 | 2008-07-21	B04-L05B0E | B04-N0300E | B04-N08 | B14-A02 | B14-G01 | B14-S11A | C04-L05B0E | C04-N0300E |	A61K0039145 | A61K0039155 | C07K001411 | C07K0014135 | C07K0014165 |	C07K0014005 | A61K003912 | A61K0039145 | A61K0039155 | A61P003122 |	2009E33501	WO2009012489A1 | EP2176427A1 | EP2176427A4	Dead	20050113US20050009008A1	EP2176427A1 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
EP3658118A1	2020-06-03	2018-07-24	NOVAVAX INC	VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ATEMWEGSERKRANKU	Reducing exacerbations of chronic obstructive pulmonary disease in human, involves	Method (M1) of reducing exacerbations of chronic obstructive pulmonary disease (COPD) in a human	CLAIMS 1. A method of reducing exacerbations of chronic obstructive pulmonary disease	US62536235P | WO2018US43431A	2017-07-24 | 2018-07-24	B04-C01G | B04-E99 | B04-L05B | B04-N03K | B04-N06 | B14-A02B2 | B14-K01 | B14-S11A | B14-S11D1 | D05-A02C	A61K0031047 | A61K003816 | A61K003912 | A61K0039145 | A61K004726 |	A61K00095115 | A61K003912 | A61P003114 | C12N276018522 | C12N276018534	201912233V	WO2019023196A1 | CN111148509A | EP3658118A1 | JP2020528883A | EP3658118A4	No associated DWPI family status	20190131WO2019023196A1	EP3658118A1 | CN111148509A | EP3658118A4 | JP2020528883A | WO2019023196A1	Alive	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
EP914134A1	1999-05-12	1997-02-06	NOVAVAX INC	PROPRIETES ADJUVANTES DE DENDRIMERES DE POLYAMIDOAMINES | EIGENSCHAFTEN VON	Influenza vaccine containing antigen and starburst dendrimer as adjuvant, allowing reduction in antigen	Influenza vaccine comprises an influenza antigen (Ag) and a starburst dendrimer (I) in a carrier. The	1. A vaccine for Influenza comprising an effective amount of a composition formed of an Influenza antigen	US1996597938A | WO1997US1664A	1996-02-07 | 1997-02-06	A10-E18 | A12-V01 | B04-B01C1 | B14-S11A | D05-H07	A61K003174 (IPC 1-7) | A61K003912 (IPC 1-7) | A61K0039145 | A61K003939	A61K003939 | A61K003912 | A61K0039145 | A61K0039385 | A61K20395252 |	1997415066	WO1997028809A1 | AU199718541A | US5795582A | EP914134A1 | JP2000507921A |	Dead	19970814CA2249544A1	EP914134A1 | AT298580T | AU199718541A | CA2249544A1 | DE69733652D1 |	Dead	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
EP972048A1	2000-01-19	1998-04-09	UNITED STATES NAVY	PROTEINES DE RECOMBINAISON D'UNE SOUCHE PAKISTANAISE DE L'HEPATITE E ET LEURS	New hepatitis E virus DNA from Pakistani strain SAR-55 used for, e.g. developing products for diagnosis	DNA molecule (I) having a sequence comprises the nucleotides encoding amino acids 112-607 of	° CLAIMS 1. A DNA molecule having a sequence consisting essentially of the nucleotides which	US1997840316A | WO1998US7418A	1997-04-11 | 1998-04-09	B04-E02F | B04-E03F | B04-E08 | B04-F0100E | B04-F11 | B04-G08 | B04-N0300E | B11-C07A | B12-K04A4 |	C12N001509 (IPC 1-7) | C12N001551 (IPC 1-7) | A61K003800 (IPC 1-7) | A61K003929 (IPC 1-7) | A61P000116 (IPC 1-7) |	C07K0014005 | A61P000116 | A61P003114 | A61P003120 | A61K003900 |	1998568733	WO1998046761A1 | AU199872470A | EP972048A1 | US6054567A | CN1260000A |	Dead	19981022CA2286399A1	EP972048A1 | AT389021T | AT530563T | AU199872470A | AU739915B2 |	Dead	UNITED STATES NAVY	Vacina de proteina recombinante e adjuvante
US20040063188A1	2004-04-01	2003-02-14	NOVAVAX INC	Kit for treating gastrointestinal tract	Purifying a recombinant human papillomavirus (HPV) L1, useful for diagnosing, preventing	Purifying a recombinant extracellular or intracellular virus-like particle, is new.	What is claimed is: 1. A process for purifying a recombinant extracellular virus-like	US2002356152P | US2002356151P | US2002356150P | US2002356162P | US2002356126P |	2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-	B04-F1100E | B11-B | B12-K04A4 | B14-A02A6 | B14-S11A | D05-H06 | D05-H09 | D05-H12F | D05-H13	C12N000702 (IPC 1-7) | C12Q000170 (IPC 1-7) | C12P002106 (IPC 1-7) | C12P0021066 (IPC 1-7) | A61K003912 |	C07K0014005 | C12N000700 | A61K20395258 | C12N251002 | C12N271014143 |	2003679645	WO2003068993A1 | US20040063188A1 | AU2003217413A1	Dead	20030821WO2003068163A2	US20040063188A1 | AU2003213060A1 | AU2003213060A8 | AU2003213065A1 | AU2003213065A8 |	Dead	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
US20040121465A1	2004-06-24	2003-02-14	NOVAVAX INC	Optimization of gene sequences of virus-like particles for expression in insect cells	New codon optimized polynucleotide encoding a viral capsid protein that self assembles into a virus-	A codon optimized polynucleotide encoding a viral capsid protein that self assembles into a virus-	What is claimed is: 1. A codon optimized polynucleotide encoding a viral capsid protein that self	US2002356152P | US2002356151P | US2002356150P | US2002356162P | US2002356126P |	2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-	B04-B04C1 | B04-C01G | B04-E02F | B04-E04 | B04-E08 | B04-F0100E | B04-F1100E | B04-N03A0E | B14-A02 |	C07H002102 (IPC 1-7) | A01N006300 (IPC 1-7) | A61K003900 (IPC 1-7) | C07H002104 (IPC 1-7) | C12N001500 (IPC 1-7) |	C07K0014005 | C12N000700 | A61K20395258 | C12N251002 | C12N271014143 |	2003689664	WO2003068933A2 | AU2003219760A1 | US20040121465A1 | AU2003219760A8 | WO2003068933A3	Dead	20030821WO2003068163A2	US20040121465A1 | AU2003213060A1 | AU2003213060A8 | AU2003213065A1 | AU2003213065A8 |	Dead	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
US20050118191A1	2005-06-02	2004-08-13	NOVAVAX INC	Optimization of gene sequences of chimeric virus-like particles for expression in insect cells	New chimeric virus-like particles comprising a recombinant viral capsid protein encapsulating a	A chimeric virus-like particle comprising a recombinant viral capsid protein that encapsulates a	1. A chimeric virus-like particle comprising a recombinant viral capsid protein that encapsulates a	US2002356152P | US2002356151P | US2002356150P | US2002356162P | US2002356126P |	2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-	B04-E02F | B04-E08 | B04-F07A0E | B04-F1100E | B11-C08E | B12-K04A4 | B14-A02 | B14-S03A | B14-S11A |	A61K003912 (IPC 1-7) | C07H002102 (IPC 1-7) | A01N006300 (IPC 1-7) | A61K003900 (IPC 1-7) | C07H002104 (IPC 1-7) |	C07K0014005 | C12N000700 | A61K20395258 | C12N251002 | C12N271014143 |	2003689598	WO2003068163A2 | AU2003213060A1 | US20050118191A1 | AU2003213060A8 | WO2003068163A3	Dead	20030821WO2003068163A2	US20050118191A1 | AU2003213060A1 | AU2003213060A8 | AU2003213065A1 | AU2003213065A8 |	Dead	NOVAVAX INC	VLP
US20120107353A1	2012-05-03	2012-01-10	NOVAVAX INC	COMPOSITION	Composition useful as immune stimulating medicine/vaccine for low responders e.g. elderly people	A composition (C1) comprises: at least one immune stimulating complex (ISCOM), and at least one internal	1. Composition comprising at least one ISCOM complex and at least one internal antigen which is not a	US2009224479P | WO2010SE50798A	2009-07-10 | 2010-07-09	B04-A07E | B04-A08C2 | B04-A09 | B04-A10 | B04-B01B | B04-B04C1 | B14-A02 | B14-G01 | B14-S11D2 | C04-A07E	A61K003900 (IPC 1-7) | A61K003900 | A61K003902 | A61K0039085 | A61K003912 |	A61K0039205 | A61K0039002 | A61K0039085 | A61K0039102 | A61K003912 |	2011A57580	WO2011005183A1 | CA2766285A1 | AU2010269148A1 | US20120107353A1 | CN102470168A |	Indeterminate	20110113CA2766285A1	US20120107353A1 | AU2010269148A1 | CA2766285A1 | CN102470168A | WO2011005183A1	Dead	NOVAVAX INC	Vacina de proteina subunidade proteíca e adjuvante
US20140294879A1	2014-10-02	2014-03-21	NOVAVAX INC	MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE	Virus-like particles useful for a vaccine composition for immunizing subject against viral infection,	A virus-like particle (VLP) comprises at least a bovine respiratory syncytial virus (BRSV) matrix protein and at	1. A respiratory syncytial virus (RSV) fusion (F) protein comprising: (i) a deletion of one or	US2008121126P | US2009169077P | US2009224787P | US2009633995A	2008-12-09 | 2009-04-14 | 2009-07-10 | 2009-12-09	B04-B04C | B04-E99 | B04-F11 | B04-L05B | B04-N0200E | B04-N03 | B04-N0300E | B04-N05 | B04-N06 | B04-	A61K0039155 | C07K0014005	A61K0039155 | C07K0014005 | C07K001900 | A61K00090019 | A61K00091075 |	2010H90973	WO2010077712A1 | US20140294879A1	Alive	20100708CA2746228A1	US20140294879A1 | AU2009333484A1 | AU2009333484B2 | BRPI0922867A2 | BRPI0922867B1 |	Alive	NOVAVAX INC	VLP
US20170354729A1	2017-12-14	2017-03-16	NOVAVAX INC	VACCINE COMPOSITIONS CONTAINING MODIFIED ZIKA VIRUS ANTIGENS	New Zika virus polypeptide comprising an envelope dimer (EnvD) polypeptide, useful for inducing an	A Zika virus polypeptide comprising (i) an envelope dimer (EnvD) polypeptide, where the EnvD	1. A Zika virus polypeptide comprising (a) an EnvD polypeptide, wherein the EnvD polypeptide	US62309216P | US62407887P | US62420941P | US62439374P	2016-03-16 | 2016-10-13 | 2016-11-11 | 2016-12-27	B04-E99 | B04-N03K | B14-G01 | B14-S11A | C04-E99 | C04-N03K | C14-S11A | D05-H10 | D05-H99	A61K003900 | A61K003912 | C07K0014005 | C07K001418 | C07K001610 |	A61K003912 | C07K0014005 | C07K00161081 | C12N000700 | A61K2039505 |	2017659358	WO2017161151A1 | US20170354729A1	Dead	20170309CA2996007A1	US20170354729A1 | AU2016315478A1 | AU2016315478A2 | BR112018004242A2 | CA2996007A1 |	Alive	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
US20180369368A1	2018-12-27	2018-01-18	NOVAVAX INC	QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF	Use of fraction A of Quil A (Saponin adjuvant) together with at least one other adjuvant for preparing	Use of fraction A of Quil A (RTM: Saponin adjuvant) together with at least one other adjuvant for the	1. Use of fraction A of Quil A together with at least one other adjuvant for the preparation of an	SE20031998A | WO2004SE1038A | US2003562866A | US14445690A | US14714664A |	2003-07-07 | 2004-07-07 | 2004-07-07 | 2014-07-29 | 2015-05-18 | 2016-02-26	B14-G01 | B14-G03 | B14-S09 | B14-S11 | D05-H07	A61K003939	A61K003939 | A61K203955577 | A61K203957	2018A4181S	US20180369368A1	Dead	20030707SE200301998D0	US20180369368A1 | AT442164T | AU2004254152A1 | AU2004254152B2 | BR200412444A |	Alive	NOVAVAX INC	Adjuvante
US20200345840A1	2020-11-05	2019-12-03	NOVAVAX INC	QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF	Use of fraction A of Quil A with at least one other adjuvant for preparing adjuvant composition with	Use of fraction A of Quil A with at least one other adjuvant is claimed for preparing an adjuvant	1. Use of fraction A of Quil A with at least one other adjuvant for the preparation of an adjuvant composition	SE20031998A | WO2004SE1038A | US2003562866A | US14445690A | US14714664A |	2003-07-07 | 2004-07-07 | 2004-07-07 | 2014-07-29 | 2015-05-18 | 2016-02-26 | 2018-01-18	B14-G01 | B14-G03 | B14-S09 | D05-H	A61K003939	A61K003939 | A61K203955577 | A61K203957	2020A70141	US20200345840A1	No associated DWPI family status	20030707SE200301998D0	US20200345840A1 | AT442164T | AU2004254152A1 | AU2004254152B2 | BR200412444A |	Alive	NOVAVAX INC	Adjuvante
US6387373B1	2002-05-14	1997-04-24	IGI LAB INC | IMMUNOGENETICS CO LTD	Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants	Adjuvanted influenza vaccines for vaccinating mammals against influenza, comprises influenza	An adjuvanted influenza vaccine, comprising an influenza antigen and oil-containing	What is claimed is: 1. An adjuvanted influenza vaccine for producing an antigenic response to influenza,	US19935008A | US1994201346A	1993-01-15 | 1994-02-24	B01-C02 | B01-D02 | B04-B01B | B04-B01C1 | B04-B01C3 | B04-C03C | B04-C03D | B04-F11 | B04-F1100E |	A61K003900 (IPC 1-7) | A61K0039145 (IPC 1-7) | A61K0039155 (IPC 1-7) | A61K0009127 (IPC 1-7) | A61K0039145 |	A61K003939 | A61K00091272 | A61K003912 | A61K0039145 | A61K20395252 |	2002478437	US6387373B1	Dead	19940721CA2153780A1	US6387373B1 | AT280585T | AU199460188A | AU199515660A | BR199506885A |	Dead	IGI LAB INC | IMMUNOGENETICS CO LTD	Vacina de proteina subunidade proteíca e adjuvante
US7041500B2	2006-05-09	2003-02-14	NOVAVAX INC	Insect cell line	New insect cell line designated ATCC PTA-4047, useful for replicating baculoviruses to	A cell line comprising a cell that is a clone, derivative, mutant and/or transfectant of a cell line designated	What is claimed is: 1. The cell line ATCC PTA-4047, or a clone or a transfectant thereof. 2. The cell line of claim	US2002356152P | US2002356151P | US2002356150P | US2002356162P | US2002356126P |	2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-02-14 | 2002-	B04-F0100E | B12-K04A | B14-S11 | C04-F0100E | C12-K04A | C14-S11 | D05-H14 | D05-H17	C12N000510 (IPC 1-7) | C12N0015866 (IPC 1-7) | C12N000700 (IPC 1-7) | C12N000702 (IPC 1-7) | C12N000704 (IPC 1-7)	C07K0014005 | C12N000700 | A61K20395258 | C12N251002 | C12N271014143 |	2003646475	WO2003068804A2 | US20030228696A1 | AU2003213065A1 | AU2003213065A8 | US7041500B2 |	Dead	20030821WO2003068163A2	US7041500B2 | AU2003213060A1 | AU2003213060A8 | AU2003213065A1 | AU2003213065A8 |	Dead	NOVAVAX INC	Vacina de proteina recombinante e adjuvante
US7763450B2	2010-07-27	2006-03-10	NOVAVAX INC	Functional influenza virus-like particles (VLPs)	Virus like particle useful as vaccine for inducing protective immunity to influenza in human comprises	A virus like particle (VLP) comprising human influenza proteins, where the proteins comprise	What is claimed: 1. A method of making an influenza virus-like particle (VLP), comprising expressing	US2003617569A	2003-07-11	B04-E02F | B04-F0100E | B04-L05B | B04-N03 | B04-N0300E | B12-K04A4A | B14-A02B2 | B14-S11A | B14-S11D3	A61K0039145 | C07H002104 | C07K001411 | C12N000700 | C12N000701 |	A61K0039145 | C07K0014005 | A61K003912 | A61P003116 | A61P003704 |	2007148648	US20060263804A1 | US7763450B2	Alive	20050113US20050009008A1	US7763450B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP

US850696 7B2	2013-08-13	2008-12-19	NOVAVAX INC	Functional influenza virus like particles (VLPs)	New vaccine, useful e.g. to induce immunity to influenza virus infection in human, comprises an influenza	Vaccine comprising an influenza virus like particle (VLP) is new, The VLP comprises influenza matrix (M1),	We claim: 1. A method of inducing substantial immunity to an influenza virus	US2003617569A | US2005727513P | US2006780847P | US2006800006P | US2006831196P |	2003-07-11 | 2005-10-18 | 2006-03-10 | 2006-05-15 | 2006-07-17 | 2006-07-21 | 2006-09-19 | 2006-10-18 | 2007-	B04-B01B | B04-F11B | B04-L05B | B04-N03E | B12-K04A4A | B14-A02B2 | B14-S11A | C04-B01B | C04-F11B |	A61K0039145 | A61P003116 | C12N000700	A61K0039145 | A61K003912 | A61P003116 | C07K0014005 | C12N000700 |	2010F75914	US2010012940 1A1 | US850696 7B2	Alive	20050113US20050009 008A1	US850696 7B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
US869708B2	2014-04-15	2008-05-27	NOVAVAX INC	VLPs derived from cells that do not express a viral matrix or core protein	New purified virus-like particle (VLP), comprises a chimeric influenza membrane protein or influenza	A purified virus-like particle (VLP) comprising at least one chimeric influenza membrane protein or	The invention claimed is: 1. A method of making a virus-like particle (VLP) in a cell that	US2007940201P	2007-05-25	B04-B04C1 | B04-N0300E | B04-N08 | B14-A02B2 | B14-G01 | B14-S11A | D05-H07 | D05-H18	A61K0039145 | A61P003116 | C07K0014005 | C12N000700 | C12P002102 |	A61K0039145 | A61P003116 | C07K0014005 | C12N000700 | A61K20395258 | C07K2319001 |	2009A43187	WO2008148104A1 | WO2008148104A8 | US2009017066A1 | US869708B2 | US2014023437 2A1 |	Alive	20081204WO20081481 04A1	US869708B2 | US2009017066A1 | US2014023437 2A1 | US9381239B2 | WO2008148104A1 |	Alive	NOVAVAX INC	VLP
US899293 9B2	2015-03-31	2011-10-24	NOVAVAX INC	Highly efficient influenza matrix (M1) proteins	New virus-like particle useful for e.g. inducing immunity in vertebrates, preventing or treating	A virus-like particle (VLP) comprising an influenza M1 protein, is new, where the M1 protein comprises the	We claim: 1. A virus-like particle (VLP) comprising an influenza M1 protein and at least one of an	US2003617569A | US2005727516P | US2006780847P | US2006372466A | US2006800006P |	2003-07-11 | 2005-10-18 | 2006-03-10 | 2006-05-15 | 2006-07-17 | 2006-07-21 | 2006-09-19 | 2006-	B04-E99 | B04-F11B | B04-F11B0E | B04-L05B0E | B04-N03K1 | B04-N08 | B14-A02 | B14-G01 | B14-S11A |	A61K003912 | A61K0039145 | A61P003704 | C07K001411 | C12N000700 |	C12N000700 | A61K003912 | A61P003704 | C07K0014005 | C12N00092402 |	2013C17520	US20130039938A 1 | US899293 9B2	Alive	20050113US20050009 008A1	US899293 9B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	Adjuvante
US914460 7B2	2015-09-29	2013-03-12	NOVAVAX INC	Functional influenza virus-like particles (VLPs)	Composition useful e.g. for preventing influenza virus infections caused by avian H5 and H7	Composition comprises (i) a virus-like particle (VLP) comprising influenza structural proteins, where the	The invention claimed is: 1. A composition comprising: i) a virus-like particle	US2003617569A	2003-07-11	B04-F1100E | B04-L0580E | B04-N0200E | B04-N03K0E | B12-K04 | B14-A02B2 | B14-S11A | B14-S11D3 |	A61K0039145 | C07H002104 | C07K0014005 | C07K001411 | C12N000700 |	A61K0039145 | C07K0014005 | A61K003912 | A61P003116 | A61P003704 |	2013L74639	US20130177587A 1 | US914460 7B2	Alive	20050113US20050009 008A1	US914460 7B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
US946427 6B2	2016-10-11	2015-02-23	NOVAVAX INC	Highly efficient influenza matrix (M1) proteins	Increasing expression of a virus-like particle comprises expressing a mutated influenza matrix, hemagglutinin	Increasing expression of a virus-like particle (VLP) comprises expressing a mutated influenza matrix (M1)	We claim: 1. A method of increasing production of a VLP comprising expressing a mutated	US2003617569A | US2005727516P | US2006780847P | US2006372466A | US2006800006P |	2003-07-11 | 2005-10-18 | 2006-03-10 | 2006-05-15 | 2006-07-17 | 2006-07-21 | 2006-09-19 | 2006-	B04-E99 | B04-F1100E | B14-A02 | B14-G01 | B14-S11A | B14-S11D3 | C04-E99 | C04-F1100E | C14-A02 |	A61K003912 | C07K0014005 | C12N000700 | C12N000704 | C12N00092402 |	C12N000700 | A61K003912 | A61P003704 | C07K0014005 | C12N00092402 |	20156620 6G	US20150307849A 1 | US946427 6B2	Alive	20050113US20050009 008A1	US946427 6B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	Adjuvante
US947479 9B2	2016-10-25	2015-04-30	NOVAVAX INC	Functional influenza virus-like particles (VLPS)	Preventing influenza in a vertebrate by administering a vaccine to the vertebrate, where the vaccine	Prevention of influenza in a vertebrate comprises administering a vaccine to the vertebrate,	The invention claimed is: 1. A method of preventing influenza in a vertebrate	US2003617569A | US1379612 5A	2003-07-11 | 2013-03-12	B04-E99 | B04-L05B | B04-N03K | B14-A02B2 | B14-S11A | B14-S22 | C04-E99 | C04-L05B | C04-N03K | C14-A02B2	A61K003912 | A61K0039145 | C07H002104 | C07K0014005 | C07K001411 |	A61K0039145 | C07K0014005 | A61K003912 | A61P003116 | A61P003704 |	201565987J	US20150306206A 1 | US947479 9B2	Alive	20050113US20050009 008A1	US947479 9B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
US995131 7B2	2018-04-24	2016-10-06	NOVAVAX INC	Highly efficient influenza matrix (M1) proteins	New virus-like particle comprising influenza matrix protein and an influenza neuraminidase protein,	A virus-like particle (VLP) comprising influenza proteins where the influenza proteins consist of an	We claim: 1. A virus-like particle (VLP) comprising influenza proteins wherein the influenza	US2003617569A | US2005727516P | US2006780847P | US2006800006P | US2006831196P |	2003-07-11 | 2005-10-18 | 2006-03-10 | 2006-05-15 | 2006-07-17 | 2006-07-21 | 2006-09-19 | 2006-10-18 | 2007-	B04-C01G | B04-E99 | B04-F11B | B04-F11B0E | B14-A02B2 | B14-G01 | B14-S11A | C04-C01G | C04-E99 |	A61K003912 | A61K0039145 | C07K0014005 | C0N001586 | C12N000700 |	C12N000700 | A61K003912 | A61P003704 | C07K0014005 | C12N00092402 |	2017616969	US2017053861A 1 | US995131 7B2	Alive	20050113US20050009 008A1	US995131 7B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	Adjuvante
US995628 0B2	2018-05-01	2016-10-24	NOVAVAX INC	Functional influenza virus-like particles (VLPs)	Preventing influenza in vertebrate comprises administering a vaccine to the vertebrate, where vaccine	Preventing influenza in a vertebrate comprises administering a vaccine to the vertebrate, where the vaccine	The invention claimed is: 1. A method of making a virus-like particle (VLP) comprising	US2003617569A | US1379612 5A | US1470057A	2003-07-11 | 2013-03-12 | 2015-04-30	B04-E99 | B04-L05B | B04-N03K | B14-A02B2 | B14-G01 | B14-S11A | B14-S22 | C04-E99 | C04-L05B | C04-N03K |	A61K003912 | A61K0039145 | C07H002104 | C07K0014005 | C07K001411 |	A61K0039145 | C07K0014005 | A61K003912 | A61P003116 | A61P003704 |	20175660 9G	US2017023209 5A1 | US995628 0B2	Alive	20050113US20050009 008A1	US995628 0B2 | AT538810T | AU2004268510A1 | AU2004268510B2 | AU2006304640A1 |	Alive	NOVAVAX INC	VLP
WO2010148386A1	2010-12-23	2010-06-21	NOVAVAX INC	PARTICULES DU TYPE VIRUS DE LA GRIPPE A PORCINE (H1N1) ET LEURS PROCÉDÉS D'UTILISATION	Influenza virus-like particle useful for preventing or reducing a viral infection and in vaccine comprises	An influenza virus-like particle (VLP) comprises a matrix (M1) protein. INDEPENDENT CLAIMS	CLAIMS: 1. An influenza virus-like particle (VLP) comprising an MI protein, an HA protein,	US2009218704P | US2009222789P	2009-06-19 | 2009-07-02	B04-B04C | B04-H1900E | B04-L05B0E | B04-N03K0E | B14-A02 | B14-G01 | B14-S11A | B14-S11D3 | C04-	A61K0039145 | C12N000700	A61K0039145 | A61K003912 | C07K0014005 | C12N000700 | A61K20395258 |	2010Q65864	WO2010148386A1	Dead	20101223WO20101483 86A1	WO2010148386A1	Dead	NOVAVAX INC	VLP e Adjuvante
WO2011088451A1	2011-07-21	2011-01-18	OREKOV T | NOVAVAX INC	UTILISATIONS DE PARTICULES DE TYPE VIRUS DE LA GRIPPE (VLPS) POUR LA CARACTÉRISATION DE	Determining influenza antibody activity in a sample, comprises incubating the sample with an influenza virus-	Determining influenza antibody activity in a sample, comprises: incubating the sample with an influenza virus-	CLAIMS: 1. A method of determining influenza antibody activity in a sample, comprising:	US2010295434P | US2010353682P	2010-01-15 | 2010-06-11	B04-E99 | B04-F11 | B04-G08 | B04-H19 | B04-L05B | B11-C0783 | B12-K04A | D05-H09	A61K0039145 | C12Q000170	C12N000700 | G01N003356983 | C12N276016022 | C12N276016023 | G01N233311 |	2011J42151	WO2011088451A1	Dead	20110721WO20110884 51A1	WO2011088451A1	Dead	OREKOV T | NOVAVAX INC	VLP
WO2020176524A1	2020-09-03	2020-02-25	NOVAVAX INC	MÉTHODES DE PRÉVENTION D'UNE MALADIE OU D'UN TROUBLE CAUSÉ PAR UNE INFECTION PAR LE	Inducing immune response against symptom associated with respiratory syncytial virus (RSV)	Inducing an immune response against at least one symptom associated with respiratory syncytial	CLAIMS 1. A method of maternal immunization comprising administering a	US62811945P	2019-02-28	A10-E07 | A10-E08A | A10-E08B | A12-V01 | B04-C01A | B04-C01B | B04-C03C | B04-E99 | B04-N03K2 | B05-A01B	A61K003800 | A61K003900 | A61K003912 | A61K0039155 | C12N001500	A61K003912 | A61K203955 | A61K203955555 | C12N276018534	2020854871	WO2020176524A1	No associated DWPI family status	20200903WO20201765 24A1	WO2020176524A1	Alive	NOVAVAX INC	Adjuvante
AU2010212374A1	2010-09-02	2010-08-16	UNITED STATES HEALTH & HUMAN SERVICES | NOVAVAX INC	Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines	New DNA molecule having sequence consisting of nucleotides which encode hepatitis E	A DNA molecule having a sequence consisting of nucleotides which encode a hepatitis E virus open-reading	THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A DNA molecule having a sequence	AU2010212374A	2010-08-16	B04-E02F | B04-E03F | B04-E08 | B04-E99 | B04-F0100E | B04-G01 | B04-N03F | B11-C07A | B12-K04A4A | B14-	A61K003929 | C07K001408 | C07K001610 | C12N001551 | G01N0033576	A61K003929 | A61K003912 | C07K001610 | C12N000700 | G01N0033576 |	2010M68301	AU2010212374A1	Dead	20100902AU20102123 74A1	AU2010212374A1	Dead	UNITED STATES HEALTH & HUMAN SERVICES | NOVAVAX INC	Vacina de proteína recombinante e adjuvante

Derwent Innovation		Search results for:	Collections																		
Publication Number	Publication Date	Application Date	Optimized Assignee	Title (Original)	Title - DWPI	Abstract - DWPI	Claims	Priority Number	Priority Date	DWPI Manual Codes	IPC - Current - DWPI	CPC - Current - DWPI	DWPI Accession	DWPI Family	Dead/Alive DWPI	INPADOC Family ID	INPADOC Family	Dead/Alive	Ultimate Parent	Categoria
CN101745104B	2012-04-25	2010-02-09	ANHUI LONGCOME BIOLOGICAL PHARMACY CO | NAT INST FOOD & DRUG CONTROL	含有复合佐剂的结核亚单位疫苗	Tuberculosis subunit vaccine comprises culture filtrate antigen fusion protein, heat shock	Tuberculosis subunit vaccine comprises 10 μ g of Ag85b, 5 μ g of ESAT6-10 kilodalton (kDa) culture filtrate	1.一种结核亚单位疫苗，其特征在于包含Ag^b、ESAT6、CFP10和HspX蛋白，并	CN201010107449A	2010-02-09	B04-B04C | B04-E01 | B04-N0300E | B04-N08 | B04-N09 | B05-A01B | B14-A01B1A | B14-S11B1 | B14-	A61K003904 | A61K003939 | A61P003100 | A61P003106		2010J68463	CN101745104A | CN101745104B	Alive	20100623CN101745104 | 04A_	CN101745104A | CN101745104A	Alive	ANHUI LONGCOME BIOLOGICAL PHARMACY CO | NAT INST FOOD & DRUG CONTROL	Vacina de proteina subunidade proteica e adjuvante
CN102641498A	2012-08-22	2012-05-10	UNIV HUNAN AGRIC | ANHUA IMMIGRANTS DEV AUTHORITY	斑点叉尾鮰肠套叠二联灭活疫苗的制备方法	Preparing Ictaclurus punctatus intussusception duplex inactivated vaccine, comprises	Preparing Ictaclurus punctatus intussusception duplex inactivated vaccine, comprises	1.斑点叉尾鮰肠套叠二联灭活疫苗制备方法，其特征在于： A、疫苗的抗原为嗜	CN201210143659A	2012-05-10	B04-A09H | B04-A98 | B04-B04C1 | B04-F10A | B14-F08 | B14-S11 | C04-A09H | C04-A98 | C04-	A61K003902 | A61K0039116 | A61P003104		2012Q41580	CN102641498A	Dead	20120822CN102641498 | 98A_	CN102641498A	Dead	UNIV HUNAN AGRIC | ANHUA IMMIGRANTS DEV AUTHORITY	vacina de virus inativado
CN103913578B	2016-01-20	2014-03-11	ANHUI RUNMINJIANG BIOTECHNOLOGY CO LTD	一种蟑螂过敏原制剂的质量控制方法	Quality control of cockroach allergen preparation by performing standardization of	Quality control method of cockroach allergen preparation, involves performing	1.一种蟑螂过敏原制剂的质量控制方法，其特征在于：包括如下步骤：(1)蟑螂的标准化饲	CN201410100108A	2014-03-11	B04-B04C9 | B11-A04A | D05-H08 | S03-E14H	A61K003935 | A61P003708 | G01N003368	G01N003368 | G01N003300	2014R99822	CN103913578A | CN103913578B	Alive	20140709CN103913578 | 78A_	CN103913578B | CN103913578A	Alive	ANHUI RUNMINJIANG BIOTECHNOLOGY CO LTD	vacina de virus inativado
CN103920147B	2016-08-17	2014-03-11	ANHUI RUNMINJIANG BIOTECHNOLOGY CO LTD	一种美洲大蠊过敏原制剂的制备方法	Preparing recombinant cockroach allergen from Periplaneta americana involves	Preparing recombinant cockroach allergen involves storing Periplaneta	1.一种美洲大蠊过敏原制剂的制备方法，其特征在于：包括如下步骤：(1)美洲大蠊在-	CN201410100109A	2014-03-11	B04-B04C9 | B11-B03A | D05-H17A5	A61K003935 | A61P001106 | A61P003708		2014S31702	CN103920147A | CN103920147B	Alive	20140716CN103920147 | 47A_	CN103920147B | CN103920147A	Alive	ANHUI RUNMINJIANG BIOTECHNOLOGY CO LTD	vacina de virus inativado
CN104756943A	2015-07-08	2015-03-17	ANHUI QIANGYING DUCK IND GROUP CO LTD	鸭流行性感冒的控制方法	Controlling duck influenza virus, by pre-processing tool of exotic ducks and chickens, prohibiting	Method for controlling duck influenza virus, involves (a) pre-processing tool of	1.鸭流行性感冒的控制方法，由发病前预防和发病后治疗配合而成，其特征在于，所述的发	CN201510117184A	2015-03-17	B02-C01 | B04-A08 | B04-A09 | B04-A10 | B04-A98 | B10-B02G | B14-A02B2 | B14-S11A | B14-S12 |	A01K006702 | A23K000114 | A23K000116 | A23K000118 | A61K00368998 |		201553420G	CN104756943A	Dead	20150708CN104756943 | 43A_	CN104756943A	Dead	ANHUI QIANGYING DUCK IND GROUP CO LTD	vacina em geral
CN105693826A	2016-06-22	2016-03-11	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL	一种汉逊酵母表达的重组乙肝表面抗原的分离纯化方法及其应用	Separating and purifying recombinant hepatitis B surface antigen used for	Separating and purifying recombinant hepatitis B surface antigen involves	1.一种分离纯化汉逊酵母表达的重组乙肝表面抗原的方法，其特征在于，包括以下步	CN201610137254A	2016-03-11	A03-A00A | A10-E07C | A10-E08A | A10-E08B | A12-L04A | A12-V01 | B04-B04C1 | B04-	A61K003929 | A61P003120 | C07K000116 | C07K000118 | C07K000134 |	C07K0014005 | A61K003900 | C12N273010151	2016415722	CN105693826A	Dead	20160622CN105693826 | 26A_	CN105693826A	Dead	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL	vacina em geral
CN105944096A	2016-09-21	2016-05-06	ANHUI JIUCHUAN BIOLOGICAL TECHNOLOGY CO	一种鸡疫苗用免疫增强剂	Chicken vaccine used for improving cellular immune response and humoral immune response	Chicken vaccine is prepared by mixing chicken genetic engineered cytokine complex with	1.一种鸡疫苗用免疫增强剂，其特征在于，所述鸡疫苗用免疫增强剂由鸡基	CN201610293284A	2016-05-06	B04-H02B0E | B04-H05A0E | B04-H05C0E | B14-G02D | B14-S11 | B14-S12 | B14-S18 | C04-	A61K003917 | A61K003939 | A61P003114		20162694L	CN105944096A	Dead	20160921CN105944096 | 96A_	CN105944096A	Dead	ANHUI JIUCHUAN BIOLOGICAL TECHNOLOGY CO	vacina em geral
CN105949303B	2020-02-07	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	一种特异性肿瘤抗原CEA的CTL识别表位肽及其应用	Cytotoxic T lymphocytes epitope peptide used for preparing therapeutic	Cytotoxic T lymphocytes epitope peptide is nonapeptide, which comprises nine	1.一种特异性肿瘤抗原CEA的CTL识别表位肽，其特征在于，所述CTL识别表位肽为九肽，其氨	CN201610483231A	2016-06-24	B04-B04C | B04-C01B | B04-E99 | B04-F04B1 | B11-A04A | B11-C08 | B12-K04G2A | B14-	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |	C07K00144748 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	201667729Q	CN105949303A | CN105949303B	Alive	20160921CN105949303 | 03A_	CN105949303B | CN105949303A	Alive	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN105999288A	2016-10-12	2016-07-20	ANHUI DIVINITY BIOLOGICAL PROD CO LTD	一种猪丹毒活疫苗耐热保护剂、制备方法及应用	Thermal resistant live Erysipelothrix protecting agent vaccine comprises gelatin, lactose,	Thermal resistant live Erysipelothrix protecting agent vaccine comprises 2-6 wt.% gelatin, 8-24	1.一种猪丹毒活疫苗耐热保护剂，其特征在于由以下重量百分含量的组分组成：明胶2-	CN201610573467A	2016-07-20	B04-N02 | B14-A01B | B14-S11B1 | B14-S11D2	A61K003909 | A61K004726 | A61K004742 | A61P003104		2016659602	CN105999288A	Dead	20161012CN105999288 | 88A_	CN105999288A	Dead	ANHUI DIVINITY BIOLOGICAL PROD CO LTD	vacina em geral
CN106008692A	2016-10-12	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	一种肿瘤抗原GPC3的CTL识别表位肽及其应用	New specific tumor antigen GPC3 cytotoxic T lymphocyte recognition epitope	Specific tumor antigen GPC3 cytotoxic T lymphocyte (CTL) recognition epitope	1.一种特异性肿瘤抗原GPC3的CTL识别表位肽，其特征在于，所述CTL	CN201610483210A	2016-06-24	B04-B04C8 | B04-C01B | B04-N02A | B14-H01E5 | B14-S11C | D05-H07	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |	C07K00144748 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	201669324S	CN106008692A	Dead	20161012CN106008692 | 92A_	CN106008692A	Dead	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN106075425A	2016-11-09	2016-06-24	ANHUI MUXIANG POULTRY IND CO LTD	一种淮南麻黄鸡新城疫防治方法	Preventing Huainan chicken Newcastle disease comprises e.g. immunizing old chicken with	Preventing Huainan chicken Newcastle disease comprises e.g. immunizing 7 days old chicken	**1.一种淮南麻黄鸡新城疫防治方法，其特征在于，包括以下几个方面：（1）7日龄用新城**	**CN201610466304A**	**2016-06-24**	**B11-C04 | B14-A02B | B14-S11A | B14-S11D1 | B14-S12 | C11-C04 | C14-A02B0 | C14-S11A |**	**A61K003917 | A61P003114**		**2016723698**	**CN106075425A**	**Dead**	**20161109CN106075425 | 25A_**	**CN106075425A**	**Dead**	**ANHUI MUXIANG POULTRY IND CO LTD**	vacina de virus inativado
CN106084027A	2016-11-09	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	特异性肿瘤抗原EphA2的CTL识别表位肽及其应用	New cytotoxic T-lymphocyte (CTL) recognition of epitope peptide of species-specific	A cytotoxic T-lymphocyte (CTL) recognition of epitope peptide of species-specific	**1.一种特异性肿瘤抗原EphA2的CTL识别表位肽，其特征在于，所述CTL识别表位肽为九**	**CN201610483249A**	**2016-06-24**	**B04-C01B | B04-E99 | B04-N02A | B14-H01E5 | B14-S11C | D05-C11 | D05-H99**	**A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |**	**C07K00144748 | A61K003515 | A61K003517 | C07K014705 | C12N00050636 |**	**201672289R**	**CN106084027A**	**Dead**	**20161109CN106084027 | 27A_**	**CN106084027A**	**Dead**	**ANHUI SINOBIOWAY CELL THERAPY CO LTD**	vacina em geral
CN106084035A	2016-11-09	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	特异性肿瘤抗原IL13RA的CTL识别表位肽及应用	New specific tumor antigen interleukin-13RA of cytotoxic T lymphocytes epitope peptide useful for	Specific tumor antigen interleukin-13RA of cytotoxic T lymphocytes (CTL) epitope peptide	1.一种特异性肿瘤抗原IL13RA的CTL识别表位肽，其特征在于，所述CTL识别表位肽为	CN201610483209A	2016-06-24	B04-F04B2A | B04-K01G | B12-M11Q | B14-H01J1 | B14-S11C | D05-H07 | D05-H08B	A61K003900 | A61P003500 | C07K0014715 | C12N00050784	C07K0147155 | C12N00050639 | A61K003900	201672289Q	CN106084035A	Dead	20161109CN106084035 | 35A_	CN106084035A	Dead	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN106084042B	2020-01-14	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	一种全人源抗MAGEA1的全分子IgG抗体及其应用	New human anti MAGEA1 antibody IgG whole molecule useful for preparing MAGEA1-related	Human anti MAGEA1 antibody IgG whole molecule comprises light chain variable region and heavy	1.一种全人源抗MAGEA1的全分子IgG抗体，包含轻链可变区和重链可变区，其特征在于，	CN201610483247A	2016-06-24	B04-C01G | B04-E02A | B04-E03A | B04-E08 | B04-E99 | B04-F0100E | B04-G27G | B11-C07A |	A61K0039395 | A61P003500 | C07K001618 | C12N001513 | G01N0033574	C07K001618 | A61K003900 | C07K231752 | C07K231756 | C07K2317565 |	201672289N	CN106084042A | CN106084042B	Alive	20161109CN106084042 | 42A_	CN106084042B | CN106084042A	Alive	ANHUI SINOBIOWAY CELL THERAPY CO LTD	Vacina de proteina recombinante
CN106117334B	2020-02-11	2016-06-24	SINOBIOWAY HEALTH CITY DEV CO LTD	一种肿瘤抗原MAGE3的CTL识别表位肽及其应用	New human leukocyte antigen(HLA)-A2-restricted cytotoxic T lymphocytes	A human leukocyte antigen(HLA)-A2-restricted cytotoxic T lymphocytes (CTL) recognition epitope	1.一种特异性肿瘤抗原MAGE3的HLA-A2限制性CTL识别表位肽在制备乳腺癌治疗性多肽疫苗中	CN201610481371A	2016-06-24	B04-E99 | B04-F02 | B04-F04B2A | B04-N02 | B11-A04A | B14-H01D1 | D05-H08B | D05-H99	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |	C07K00144748 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	201677440R	CN106117334A | CN106117334B	Alive	20161116CN106117334 | 34A_	CN106117334B | CN106117334A	Alive	SINOBIOWAY HEALTH CITY DEV CO LTD	vacina em geral
CN106117335B	2020-02-07	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	肿瘤抗原survivin的CTL识别表位肽及其应用	New CTL recognized epitope peptide of specific tumor antigen survivin useful for tumor	CTL recognized epitope peptide of specific tumor antigen survivin comprising fully	1.一种特异性肿瘤抗原survivin的CTL识别表位肽，其特征在于，所述CTL识别表位肽为十五肽，	CN201610481386A	2016-06-24	B04-B04C8 | B04-C01C | B04-E99 | B04-F04B2A | B04-N02A | B14-H01E8 | B14-S11C | D05-H07	A61K003900 | A61P003500 | C07K001447 | C12N00050783 | C12N00050784	C07K0144747 | C12N00050639 | C12N00050646 | A61K003900 | C12N250148	201677440Q	CN106117335A | CN106117335B	Alive	20161116CN106117335 | 35A_	CN106117335B | CN106117335A	Alive	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN106117336A	2016-11-16	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	肿瘤抗原NY-ESO-1的CTL识别表位肽及其应用	Cytotoxic T lymphocyte recognition epitope peptide of specific tumor antigen NY-	Cytotoxic T lymphocyte recognition epitope peptide of specific tumor antigen NY-	1.一种特异性肿瘤抗原NY-ESO-1的CTL识别表位肽，其特征在于，所述CTL识别表位肽	CN201610483182A	2016-06-24	B04-C01C | B04-E99 | B04-F04B2A | B04-N02A | B11-A04A | B14-H01C | B14-S11C | B14-S11D3 |	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |	C07K00144748 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	201677440P	CN106117336A	Dead	20161116CN106117336 | 36A_	CN106117336A	Dead	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN106117337B	2020-02-11	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	一种特异性肿瘤抗原SF的CTL识别表位肽及其应用	New cytotoxic T lymphocytes (CTL)-recognizing epitope peptide of specific tumor antigen serum	A cytotoxic T lymphocytes (CTL)-recognizing epitope peptide of a specific tumor antigen serum	1.一种特异性肿瘤抗原SF的CTL识别表位肽，其特征在于，所述CTL识别表位肽为九肽，其氨基	CN201610483184A	2016-06-24	B04-E99 | B04-F02 | B04-F04B2A | B04-N02 | B11-A04A | B14-H01E5 | D05-H08B | D05-H99	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |	C07K00144748 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	201677440N	CN106117337A | CN106117337B	Alive	20161116CN106117337 | 37A_	CN106117337B | CN106117337A	Alive	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral

CN106117338B	2020-01-10	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	细胞角蛋白19的HLA-A0201限制性CTL表位	New specific tumor antigen cytokeratin 19 HLA-A0201-restricted cytotoxic T-lymphocyte	Specific tumor antigen cytokeratin 19 HLA-A0201-restricted cytotoxic T-lymphocyte	1.一种特异性肿瘤抗原细胞角蛋白19的HLA-A0201限制性CTL识别表位肽，其特征	CN201610483234A	2016-06-24	B04-E99 | B04-F04B2A | B04-N02A | B14-G01 | B14-H01K3 | B14-S11C | B14-S11D3 | D05-	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |	C07K00144748 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	201677440M	CN106117338A | CN106117338B	Alive	20161116CN106117338A_	CN106117338B | CN106117338A	Alive	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN106117339A	2016-11-16	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	一种特异性肿瘤抗原NSE的CTL识别表位肽及其应用	Specific neuron-specific enolase tumor antigen used for preparing therapeutic	Specific neuron-specific enolase (NSE) tumor antigen is recognized by cytotoxic T	1.一种特异性肿瘤抗原NSE的CTL识别表位肽，其特征在于，所述CTL识别表位肽为九	CN201610483248A	2016-06-24	B04-B04C8 | B04-E99 | B04-F04B2A | B11-A04 | B12-M11Q | B14-H01K3 | B14-S11C | B14-S11D3 |	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C07K001447 |	C07K00144748 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	201677440L	CN106117339A	Dead	20161116CN106117339A_	CN106117339A	Dead	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN106119231A	2016-11-16	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	一种肿瘤抗原PSA的CTL识别表位肽及其应用	Cytotoxic T lymphocytes epitope peptide for recognizing tumor specific-prostate-	Cytotoxic T lymphocytes (CTL) epitope peptide comprises 9 amino acids (SEQ ID NO:	1.一种特异性肿瘤抗原PSA的CTL识别表位肽，其特征在于，所述CTL识别表位肽为九	CN201610483235A	2016-06-24	B04-C01B | B04-E99 | B04-F01 | B04-F04B2A | B04-N04A | B11-A04A | B14-H01F4 | B14-S11C |	A61K003515 | A61K003517 | A61K003900 | A61P003500 | C12N00050783 |	C12N00096424 | A61K003515 | A61K003517 | C12N00050638 | C12N00050639 |	2016774398	CN106119231A	Dead	20161116CN106119231A_	CN106119231A	Dead	ANHUI SINOBIOWAY CELL THERAPY CO LTD	vacina em geral
CN106397587A	2017-02-15	2016-06-24	ANHUI SINOBIOWAY CELL THERAPY CO LTD	一种全人源抗MAGEA3的全分子IgG抗体及其应用	Whole human anti-MAGEA3 full molecule IgG antibody useful for preparing tumor	Whole human anti-MAGEA3 full molecule IgG antibody comprises light chain variable	1.一种全人源抗MAGEA3的全分子IgG抗体，包含轻链可变区和重链可	CN201610483079A	2016-06-24	B04-C01G | B04-E02A | B04-E03A | B04-E08 | B04-E99 | B04-F0100E | B04-G01 | B04-G23 | B04-	A61K0039395 | A61P003500 | C07K001618 | C12N001513 | G01N0033574	C07K001618 | G01N003357484 | A61K2039505 | C07K231721 | C07K231756 |	201713243S	CN106397587A	Dead	20170215CN106397587A_	CN106397587A	Dead	ANHUI SINOBIOWAY CELL THERAPY CO LTD	Vacina de proteina recombinante
CN106692962A	2017-05-24	2016-11-11	ANHUI DIVINITY BIOLOGICAL PROD CO LTD	一种猪多杀性巴氏杆菌病抗原的制备方法及应用	Preparing pig Pasteurella multocida antigen useful for preparing vaccine by preparing	Method for preparing pig Pasteurella multocida antigen involves preparing	1.一种猪多杀性巴氏杆菌病抗原的制备方法，其特征在于，该方法的操作步骤如下：	CN201611026618A	2016-11-11	B04-B04C1 | B11-A01A | B14-S11 | C04-B04C1 | C11-A01A | C14-S11 | D05-H07	A61K0039102 | A61P003104	A61K0039102	2017408597	CN106692962A	Dead	20170524CN106692962A_	CN106692962A	Dead	ANHUI DIVINITY BIOLOGICAL PROD CO LTD	vacina em geral
CN106893696A	2017-06-27	2017-03-21	ANHUI ANLONG GENE MEDICAL LAB CO LTD	一种非小细胞肺癌全细胞抗原树突状细胞瘤苗的制备方法	Preparing non-small cell lung cancer cell antigen dendritic cell tumor vaccine comprises e.g. taking	Preparing non-small cell lung cancer cell antigen dendritic cell tumor vaccine comprises (i) taking	1.一种非小细胞肺癌全细胞抗原树突状细胞瘤苗的制备方法，其特征在于：具体步骤	CN201710170723A	2017-03-21	B02-A | B02-G | B04-F02A | B11-A04A | B14-S11C | D05-H07	A61K003900 | A61P003500 | C12N00050784	C12N00050639 | A61K00390011 | A61K20395154 | C12N250190	201745361Q	CN106893696A	Dead	20170627CN106893696A_	CN106893696A	Dead	ANHUI ANLONG GENE MEDICAL LAB CO LTD	vacina em geral
CN107174658B	2020-11-27	2017-04-29	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	人用水痘病毒灭活疫苗及其制备方法	Preparing varicella virus inactivated vaccine useful for human, comprises culturing of human	Preparing varicella virus inactivated vaccine comprises: (1) culturing of human embryonic	1.人用水痘病毒灭活疫苗的制备方法，其特征在于，包括以下步骤：（1）将MRC-	CN201710297864A	2017-04-29	B04-B04D4 | B04-F02 | B04-F11A | B04-N02 | B04-N04 | B07-A03 | B11-A04A | B14-A02A3 | B14-	A61K003925 | A61L000218 | A61P003122 | A61L010136	A61K003912 | A61L00020088 | A61K20395252 | A61K203955 | A61L220221 |	201764977T	CN107174658A | CN107174658B	No associated DWPI family status	20170919CN107174658A_	CN107174658B | CN107174658A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	vacina em geral
CN107432930B	2020-10-20	2017-08-08	ANHUI DIVINITY BIOLOGICAL PROD CO LTD	一种I群4型禽腺病毒DNA疫苗及其制备方法和应用	DNA vaccine for preventing chicken pericardial effusion-inclusion body hepatitis syndrome,	DNA vaccine comprises group I type 4 avian adenovirus penton gene. An	1.一种I群4型禽腺病毒DNA疫苗，其特征在于，所述I群4型禽腺病毒DNA疫苗含有I群4型禽腺	CN201710668978A	2017-08-08	B04-E01A | B14-C03 | B14-N12 | B14-S11D3 | B14-S12 | C04-E01A | C14-C03 | C14-N12 | C14-	A61K0039235 | A61P000116 | A61P003114 | C12N001534 | C12N001579	A61K003912 | C07K0014005 | C12N001579 | A61K203953 | A61K2039552 |	201787135L	CN107432930A | CN107432930B	No associated DWPI family status	20171205CN107432930A_	CN107432930B | CN107432930A	Alive	ANHUI DIVINITY BIOLOGICAL PROD CO LTD	vacina em geral
CN107823638B	2020-01-03	2017-11-05	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	一种B群脑膜炎球菌重组嵌合蛋白疫苗及其制备方法	Recombinant chimeric protein vaccine formulation useful for preventing group B	Recombinant chimeric protein vaccine formulation comprises P2-factor H-binding protein	1.一种预防B群脑脊髓膜炎的重组嵌合蛋白疫苗制剂，其特征在于，所述疫苗制剂含有：P2-	CN201711073721A	2017-11-05	B04-C01G | B04-E02 | B04-E08 | B04-E99 | B04-F10A3E | B04-L08 | B04-N02 | B04-N04A0E | B14-A01 |	A61K0039095 | A61P002500 | A61P003104 | C07K001900 | C12N001570	A61K0039095 | C07K001422 | C12N001562 | C12N001570 | A61K20395158 |	2018258214	CN107823638A | CN107823638B	Alive	20180323CN107823638A_	CN107823638B | CN107823638A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	Vacina de proteina recombinante e adjuvante
CN107982532B	2021-02-12	2017-12-05	ANHUI QIANGYING DUCK IND GROUP CO LTD	一种鸭甲肝病毒抗原抗体复合物疫苗及其制备方法	New duck hepatitis A virus antigen and antibody complex vaccine, prepared by inoculating duck	Duck hepatitis A virus antigen and antibody complex vaccine including antigen-antibody	1.一种鸭甲肝病毒抗原抗体复合物疫苗，其特征在于，包括体积比为1：50的3型鸭甲肝病毒抗	CN201711263722A	2017-12-05	B02-P03 | B02-S | B04-A09H | B04-B04C1 | B04-B04N1 | B04-F11B | B04-G01 | B05-A01B | B05-	A61K0039125 | A61K003942 | A61K004746 | A61P003114	A61K003912 | A61K003942 | A61K004746 | A61K230000 | A61K2039505 |	201837930E	CN107982532A | CN107982532B	No associated DWPI family status	20180504CN107982532A_	CN107982532B | CN107982532A	Alive	ANHUI QIANGYING DUCK IND GROUP CO LTD	vacina em geral
CN108245674A	2018-07-06	2018-01-18	BEIJING ZHIFEI GREEN BAMBOO BIO-PHARM CO | ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTIC	一种多价肺炎球菌结合物组合疫苗的处方及其制备方法	Multivalent pneumococcal conjugate combined vaccine used for preventing infectious	A multivalent pneumococcal conjugate combined vaccine comprises pneumococcal	1.一种多价肺炎球菌结合物组合疫苗，所述组合疫苗由选自肺炎球菌血清型2、8、9N、	CN201810051856A	2018-01-18	A03-A01 | A12-V01 | B04-C02F | B04-C02V | B04-H02 | B04-H04 | B04-H05 | B04-H08 | B04-N03J | B04-	A61K003909 | A61K0039116 | A61K0039385 | A61P003104	A61K003909 | A61K0039385 | A61K20396031 | A61K20396037 | A61K20396068 |	201858143E	CN108245674A	Dead	20180706CN108245674A_	CN108245674A	Dead	BEIJING ZHIFEI GREEN BAMBOO BIO-PHARM CO | ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTIC	Vacina de proteina proteica e adjuvante
CN108707585A	2018-10-26	2018-06-12	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	一种B群脑膜炎球菌fHBP B亚家族单克隆抗体及其制备方法	New group B meningococcal fHBP B subfamily antigen monoclonal antibody hybridoma cell line	A group B meningococcal fHBP B subfamily antigen monoclonal antibody hybridoma cell line	1.一种B群脑膜炎球菌fHBP B亚家族抗原单克隆抗体杂交瘤细胞株，保藏编号为CGMC	CN201810599759A	2018-06-12	A05-H03 | A12-V01 | A12-V03C2 | A12-W11L | B04-B04C1 | B04-C03C | B04-E99 | B04-G01 | B04-G21	A61K003940 | A61P003104 | C07K001612 | C12N000520 | G01N0033569 |	C07K00161217 | A61P003104 | G01N003356911 | G01N0033577 | A61K2039505 |	2018861170	CN108707585A	Alive	20181026CN108707585A_	CN108707585A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	Vacina de proteina recombinante e adjuvante
CN108753735A	2018-11-06	2018-06-12	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	一种B群脑膜炎球菌fHBP A亚家族单克隆抗体及其制备方法	New group B meningococcus fHBP A subfamily monoclonal antibody hybridoma cell	Group B meningococcus fHBP A subfamily monoclonal antibody hybridoma cell	1.一种B群脑膜炎球菌fHBP A亚家族单克隆抗体杂交瘤细胞株，保藏编号为CGMCC	CN201810599591A	2018-06-12	A05-H03 | A12-V01 | A12-V03C2 | B04-B04C1 | B04-C03C | B04-E99 | B04-F05 | B04-F10A | B04-G21	A61K003940 | A61P003104 | C07K001612 | C12N000520 | G01N0033569 |	C12N00005163 | A61P003104 | C07K00161217 | C12N001502 | G01N003356911 |	2018885363	CN108753735A	Alive	20181106CN108753735A_	CN108753735A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	Vacina de proteina recombinante e adjuvante
CN108939061A	2018-12-07	2018-08-03	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	一种多组分B群脑膜炎球菌疫苗及其制备方法	Multi-component B meningococcal vaccine useful for preventing invasive diseases, contains	Multi-component B meningococcal vaccine comprises 5-40 μ g/dose group B meningococcal	1.一种多组分B群脑膜炎球菌疫苗，其特征在于，所述疫苗包括：B群脑膜炎球菌低内毒	CN201810880033A	2018-08-03	B04-B04C1 | B04-E99 | B04-N03J0E | B04-N0500E | B14-A01A | B14-C03 | B14-F01 | B14-K01 | B14-N16	A61K0039095 | A61P003104 | C07K0014775 | C12N000121 | C12N001570	A61K0039095 | A61P003104 | C07K0014775 | C12N001570 | A61K203970	2018A0732Q	CN108939061A	Alive	20181207CN108939061A_	CN108939061A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	vacina em geral
CN108992667A	2018-12-14	2018-08-09	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	一种带状疱疹疫苗及其制备方法、应用	Herpes zoster vaccine useful for preparing medicine for preventing or improving herpes	Herpes zoster vaccine comprises antigen and Poly(I:C) adjuvant is one of varicella zoster virus	1.一种带状疱疹疫苗，其特征在于，包括如下组分：抗原和Poly(I:C)佐剂，所述抗原为	CN201810902356A	2018-08-09	B02-K | B04-B04C1 | B04-C03C | B04-E01B | B04-N02 | B11-A01B | B14-A02 | B14-S11A | B14-	A61K0039245 | A61K003939 | A61P002500 | A61P003122	A61K003939 | A61K003912 | A61P002500 | A61P003122 | A61K20395252 |	2018A3687S	CN108992667A	Alive	20181214CN108992667A_	CN108992667A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	Vacina de proteina recombinante e adjuvante
CN109078177A	2018-12-25	2018-08-09	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | NAT INST FOOD & DRUG CONTROL |	一种预防结核病的疫苗及联合用药物和制备方法、应用	Tuberculosis preventing vaccine of mycobacteria containing microbial complex adjuvant	Tuberculosis preventing vaccine of mycobacteria containing microbial complex adjuvant	1.一种含有分枝杆菌类微生物复合佐剂的预防结核病疫苗，其特征在于，包含Ag85b蛋	CN201810902885A	2018-08-09	B02-R | B04-C02A1 | B04-C02B2 | B04-C02D | B04-F10B2 | B04-N03J | B06-E05 | B07-A02 | B07-	A61K003904 | A61K003939 | A61K004506 | A61P003106	A61K003904 | A61K003939 | A61K004506 | A61P003106 | A61K203955594	201901715R	CN109078177A	Alive	20181225CN109078177A_	CN109078177A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | NAT INST FOOD & DRUG CONTROL |	Vacina de proteina recombinante e adjuvante
CN109771640A	2019-05-21	2019-02-28	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	多价肺炎球菌结合疫苗	Multivalent pneumococcal conjugate vaccine used for preventing infections caused by	A multivalent pneumococcal conjugate vaccine comprises Streptococcus	1.一种多价肺炎球菌结合疫苗，至少由选自肺炎球菌血清型24和35的肺炎球菌结合物组合制	CN201910149597A	2019-02-28	B04-C02F | B04-F10B4 | B14-A02 | B14-S11B1	A61K003909 | A61K0039116 | A61K0039385 | A61K003939 | A61P003104		2019470427	CN109771640A	Dead	20190521CN109771640A_	CN109771640A	Dead	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	Vacina de proteina recombinante e adjuvante
CN110170048A	2019-08-27	2019-05-27	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	一种灭活轮状病毒疫苗的制备方法	Preparing an inactivated rotavirus vaccine comprises e.g. producing cell resuscitation,	Preparing an inactivated rotavirus vaccine comprises e.g. producing cell resuscitation,	1.一种灭活轮状病毒疫苗的制备方法，其特征在于，包括以下步骤：1)生产细胞复苏，	CN201910445069A	2019-05-27	B04-F11B | B04-L05 | B11-C05 | B14-A02B | B14-S11A | D05-A02C | D05-H07	A61K003915 | A61K003939 | A61P003114 | C12N000700	A61K003912 | A61K003939 | A61P003114 | C12N000700 | A61K20395252 |	2019755594	CN110170048A	Alive	20190827CN110170048A_	CN110170048A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	Vacina de proteina recombinante e adjuvante
CN110711247A	2020-01-21	2019-10-28	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	一种含有BCG-CpG-DNA佐剂的狂犬病疫苗组合物	Rabies vaccine composition for preparing medicine for preventing rabies caused by rabies	Rabies vaccine composition comprises an inactivated purified rabies virus and BCG-	1.一种狂犬病疫苗组合物，其包含灭活的纯化的狂犬病病毒和BCG-CpG-DNA佐剂，其中所	CN201911035600A	2019-10-28	B14-A02B4 | B14-G01 | B14-S11A | B14-S11D1 | C14-A02B4 | C14-G01 | C14-S11A | C14-	A61K0039205 | A61K003939 | A61P003114	A61K003939 | A61K003912 | A61P003114 | A61K203955561 | C12N276020134	202009767V	CN110711247A	Alive	20200121CN110711247A_	CN110711247A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	Vacina de proteina recombinante e adjuvante

CN110743007A	2020-02-04	2019-09-10	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	一种联合疫苗及其制备方法、应用	Combined vaccine useful for preparing medicament, reagent or kit for preventing Japanese	Combined vaccine comprises 0.4-1 parts inactivated Japanese encephalitis virus	1.一种联合疫苗，其特征在于，所述联合疫苗包括灭活乙型脑炎病毒和灭活水痘带状疱疹病	CN201910851923A	2019-09-10	B04-N03K | B14-A02B9 | B14-C03 | B14-N16 | B14-S11D1 | C04-N03K | C14-A02B9 | C14-	A61K003912 | A61K003925 | A61K0039295 | A61P003114 | A61P003122 |	A61K003912 | A61P003114 | A61P003122 | C12N000700 | A61K20395252 |	2020117781	CN110743007A	Alive	20200204 07A_	CN1107430	CN110743007A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	vacina em geral
CN111135294A	2020-05-12	2020-01-19	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	一种联合疫苗	Combined vaccine for meningococcus and Haemophilus influenzae type B, comprising	Combined vaccine comprises component A and component B. Component A is a	1.一种联合疫苗，其特征在于，由A组分和B组分组成，其中，A组分为：AC群脑膜炎球菌结合	CN202010060600A	2020-01-19	B04-B04C1 | B04-C02F | B04-N03J | B04-N06 | B11-C01A1 | B14-A01A | B14-S11B1 | B14-S18	A61K003905 | A61K003908 | A61K0039095 | A61K003910 | A61K0039102 |	A61K0039099 | A61K003905 | A61K003908 | A61K0039095 | A61K0039102 |	202044066B	CN111135294A	No associated DWPI family status	20200512 94A_	CN1111352	CN111135294A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | CHONGQING ZHIFEI BIOLOGICAL	Vacina de proteina recombinante e adjuvante
CN111821432A	2020-10-27	2020-08-05	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	一种多价肺炎球菌结合疫苗	Multivalent pneumococcal conjugate vaccine used in preparation of drugs for	Multivalent pneumococcal conjugate vaccine comprises two portions, which are	1.一种多价肺炎球菌结合疫苗，其特征在于，由液体注射剂和冻干粉剂两部分组成，其中，	CN202010774340A	2020-08-05	B04-C02 | B05-A01B | B05-B02A3 | B05-B02C | B05-C07 | B07-A02B | B07-D04A | B10-A15 |	A61K003909 | A61K0039116 | A61K0039385 | A61P003104	A61K0039092 | A61K0039385 | A61P003104 | A61K203954 | A61K203955505 |	2020A75513	CN111821432A	No associated DWPI family status	20201027 32A_	CN1118214	CN111821432A	Alive	ANHUI ZHIFEI LONGKEMA BIOPHARMACEUTICAL | BEIJING ZHIFEI GREEN BAMBOO BIO-	Vacina de proteina recombinante e adjuvante
WO2014015831A1	2014-01-30	2013-07-26	BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL	PEPTIDE ANTIGÉNIQUE TUMORAL ET SON APPLICATION EN TANT QUE VACCIN	New separated peptide or variant of peptide useful in preparation of vaccine or	A separated peptide or its variant comprising a 24 amino acid sequence (SEQ ID NO: 1) fully	According to claim 1. A separate polypeptide or variant thereof, said polypeptide	CN201210265629A | CN201210265422A	2012-07-27 | 2012-07-27	B04-C01E | B04-E02 | B04-E03 | B04-E99 | B04-F02 | B04-F04B1A | B04-F04B2A | B04-N04A	A61K003817 | A61K003900 | A61K004800 | A61P003500 | C07K001447 |	A61K003900117 | C07K001447 | C07K00144727 | A61K00390011 | A61K0048005 |	2014C37738	WO2014015831A1 | CN103570818A | CN103570821A | CN103570818B	Alive	20140130 5831A1	WO201401	WO2014015831A1 | CN103570818A | CN103570818B | CN103570821A	Alive	BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL	Vacina de proteina recombinante

Derwent Innovation Patent Export, 2021-0		Search results for: CK Collections																	
Publication Number	Publication Date	Application Date	Optimized Assignee	Title (Original)	Title - DWPI	Abstract - DWPI	Claims	Priority Number	Priority Date	DWPI Manual Codes	IPC - Current - DWPI	CPC - Current - DWPI	DWPI Accession Num	DWPI Family Membe	Dead/Alive DWPI Far	INPADOC Family ID	INPADOC Family Mer	Dead/Alive INPADOC	Ultimate Parent	Categoria
US10618949B2	2020-04-14	2017-05-31	CLOVER BIOPHARMACEUTICALS INC	Method and compositions for producing disulfide-linked trimeric TNF family of cytokines	New secreted fusion protein having soluble ligand from TNF family of cytokines joined by in-	Secreted fusion protein comprising a soluble ligand from TNF family of cytokines joined by in-	What is claimed is: 1. A method for treating cancer in a mammal, comprising the step of	US15609612A	2017-05-31	B04-C01G | B04-E99 | B04-H0100E | B04-N0200E | B04-N08 | B14-H01 | B14-L06 | B14-S25 | D05-H17C	A61K003817 | A61K0039395 | A61K004506 | A61K000900 | A61P003500 |	C07K001470575 | A61K0038177 | A61K004506 | A61P003500 | C07K001478 |	201896634H	US20180346549A1 | US10618949B2	No associated DWPI family status	20181206US201803 46549A1	US10618949B2 | US20180346549A1 | US20200190181A1 | US20200199187A1	Alive	CLOVER BIOPHARMACEUTICALS INC	PLATAFORMA
US20200199187A1	2020-06-25	2020-03-03	CLOVER BIOPHARMACEUTICALS INC	Method and Compositions for Producing Disulfide-Linked Trimeric TNF Family of Cytokines	Treating metastatic pleural effusion and malignant ascites comprises administering	Treating (M1) metastatic pleural effusion in a mammal comprises administering a	What is claimed is: 1. A method of treating metastatic pleural effusion, comprising the step	US15609612A | US16803126A	2017-05-31 | 2020-02-27	B04-E99 | B04-G04 | B04-H0100E | B04-N08 | B14-H01 | B14-L06 | B14-N08 | D05-H11 | D05-H99	A61K000900 | A61P003500 | C07K001452 | C07K001628	A61K000900 | C07K001452 | C07K0016241 | A61K00090019 | A61K0038191 | A61K003993955 |	2020571697	US20200199187A1	No associated DWPI family status	20181206US201803 46549A1	US20200199187A1 | US10618949B2 | US20180346549A1 | US20200190181A1	Alive	CLOVER BIOPHARMACEUTICALS INC	PLATAFORMA
US20200190181A1	2020-06-18	2020-02-27	CLOVER BIOPHARMACEUTICALS INC	Method and Compositions for Producing Disulfide-Linked Trimeric TNF Family of Cytokines	Treating cancer e.g. gastrointestinal cancer, colorectal cancer, lung cancer, pancreatic cancer,	Treating cancer in a mammal, comprises administering a disulfide bond-linked trimeric 4-1 BB	What is claimed is: 1. A method for treating cancer in a mammal, comprising the step of	US15609612A	2017-05-31	B04-C01G | B04-E99 | B04-N02A | B04-N0600E | B04-N08 | B14-H01 | B14-L06 | B14-S21 | D05-H99	A61K000900 | A61P003504 | C07K001624	A61P003504 | C07K0016241 | A61K00090019 | A61K0038191 | A61K003993955 |	202053944M	US20200190181A1	No associated DWPI family status	20181206US201803 46549A1	US20200190181A1 | US10618949B2 | US20180346549A1 | US20200199187A1	Alive	CLOVER BIOPHARMACEUTICALS INC	PLATAFORMA
BR112017025533A2	2018-08-07	2016-05-26	MERCK & CO. INC. | DYNAVAX TECHNOLOGIES CORP	MÉTODO PARA TRATAR CÂNCER EM UM PACIENTE HUMANO	Treating cancer e.g. renal cell carcinoma and bladder cancer, comprises administering	Treating (M1) cancer in a human patient, comprises administering a combination therapy	CLAIMS 1. A method for treating cancer in a human patient comprising	US62168470P | US62169321P | WO2016US34285A	2015-05-29 | 2015-06-01 | 2016-05-26	B04-B03C | B04-E99 | B04-G01 | B04-G0100E | B04-G02 | B04-G04 | B04-G21 | B04-G23 | B12-	A61K0039395 (IPC 1-7) | A61P003100 (IPC 1-7) | A61P0003500 (IPC 1-7) | A61K00317125 |	A61K0039395 | A61K0039395 | A61K0039395 | A61K00317115 | A61K003939 |	201846969J	US20180161427A1 | BR112017025533A2 | WO2016196178A1 | MX2017015311A | EP3302554A1 |	Indeterminate	20161201US201603 46312A1	BR112017025533A2 | AU2016270782A1 | AU2016271018A1 | AU2016271023A1 |	Alive	MERCK & CO. INC. | DYNAVAX TECHNOLOGIES CORP	Adjuvante
BRPI0814899A2	2015-02-03	2008-08-21	DYNAVAX TECHNOLOGIES CORP	COMPOSIÇÃO, VACINA, METODO PARA AMENIZAR UM OU MAIS SINTOMAS ASSOCIADOS À	New composition comprises a multimer of an extracellular domain of influenza matrix	A composition comprising a multimer of an extracellular domain of influenza matrix	CLAIMS 1. A composition comprising a muftimer of an extracellular domain	US2007957157P | US20881640P | WO2008US73921A	2007-08-21 | 2008-07-17 | 2008-08-21	B04-F11B | B04-N04 | B14-G01 | B14-G03 | B14-S11A | D05-H07	A61K0039145 (IPC 1-7) | A61K0039145 | A61K0039155 | A61K0039939 | A61K004702 |	A61K0039145 | A61K003912 | A61P003116 | C07K0014005 | A61K203955505 |	2009F32716	WO2009026465A2 | WO2009026465A3 | US20090196915A1 | AU2008288866A1 | EP2187961A2 |	Dead	20090226AU200828 8866A1	BRPI0814899A2 | AU2008288866A1 | CA2697049A1 | CN101835487A | EP2187961A2 |	Dead	DYNAVAX TECHNOLOGIES CORP	Vacina e Adjuvante
EP1003850A1	2000-05-31	1998-06-05	UNIVERSITY OF CALIFORNIA | DYNAVAX TECHNOLOGIES CORP	INHIBITOREN VON IMMUNSTIMULATORISCHEN DNA SEQUENZ AKTIVITÄT | INHIBITEURS DE	New oligonucleotide that inhibits action of immunostimulatory sequence oligonucleotides	Oligonucleotide (I) having a hexamer region of sequence 5'- Pu-Pu-Y-Z-Py-Py or 5'- Pu-Pu-Y-Z-Py-polyPy	CLAIMS The invention claimed is: 1. A	US199748793P | WO1998US11391A	1997-06-06 | 1998-06-05	B04-B03C | B14-C03 | B14-G01 | D05-H12A	A61K0039395 (IPC 1-7) | C12N001500 (IPC 1-7) | C12N001509 (IPC 1-7) | A61K00317052 (IPC 1-7) | A61K004800	C07H002100 | A61K003939 | A61P003702 | A61P003706 | A61P004300 |	1999080827	WO1998055609A1 | AU199878113A | EP1003850A1 | US622529281 | JP2002505580A |	Dead	19981210CA229148 3A1	EP1003850A1 | AT252596T | AT432348T | AU199878113A | AU199878178A |	Alive	UNIVERSITY OF CALIFORNIA | DYNAVAX TECHNOLOGIES CORP	Adjuvante
EP1113818A1	2001-07-11	1999-09-17	DYNAVAX TECHNOLOGIES CORP	PROCEDES DE TRAITEMENT DE TROUBLES ASSOCIES A IgE ET COMPOSITIONS	Treating immunoglobulin E (IgE) related disorders such as allergies by	A method (I) of treating immunoglobulin E (IgE) related disorders such as	Claims 1. A method of treating an allergic response to an antigen or allergy-	US1998100838P | US1999136600P | US1999397198A | WO1999US21686A	1998-09-18 | 1999-05-28 | 1999-09-16 | 1999-09-17	B04-B04C | B04-C01 | B04-E03 | B04-G01 | B04-N0400E | B04-P01 | B11-A | B11-C07A | B11-C09 |	A61K0039395 (IPC 1-7) | A61K0031711 (IPC 1-7) | A61K0039900 (IPC 1-7) | A61P003300	C07K00164291 | A61K003935 | A61K003939 | A61K0039395 | A61K003939566 | A61P0003300 |	2000283452	WO2000016804A1 | AU199961537A | EP1113818A1 | US20030064064A1 | JP2003524602A |	Dead	20000330CA234305 2A1	EP1113818A1 | AT326239T | AU199961537A | AU766492B2 | CA2343052A1 |	Dead	DYNAVAX TECHNOLOGIES CORP	Adjuvante
EP1121373A2	2001-08-08	1999-06-04	DYNAVAX TECHNOLOGIES CORP	IMMUNSTIMULIERENDE OLIGONUKLEOTIDE MIT MODIFIZIERTEN BASEN UND DEREN	Novel immunomodulatory oligonucleotide used to induce a Th1-type immune response,	Immunomodulatory oligonucleotide (I) containing an immunostimulatory sequence (ISS) that	CLAIMS We claim: 1. An immunomodulatory oligonucleotide comprising an	US199888310P | US1999324191A | WO1999US12538A	1998-06-05 | 1999-06-01 | 1999-06-04	B04-B04C2 | B04-E05 | B11-C08E5 | B12-K04F | B14-G01 | D05-H07 | D05-H12D1 | D05-H18	A61K0031711 | A61K003900 (IPC 1-7) | A61K003939 | A61K004748 |	C07H002100 (IPC 1-7) | A61K003900 (IPC 1-7) | A61K004754 | A61P003704 | C07H002100 |	2000105687	WO1999062923A2 | AU199944194A | EP1121373A2 | US6562798B1 | AU760304B |	Dead	19991209CA233022 5A1	EP1121373A2 | AU199944194A | AU760304B2 | CA2330225A1 | US20040092468A1 |	Dead	DYNAVAX TECHNOLOGIES CORP	Adjuvante
EP2094849A2	2009-09-02	2007-11-09	DYNAVAX TECHNOLOGIES CORP	LANGFRISTIGE MODIFIKATION EINER ERKRANKUNG MITHILFE IMMUNSTIMULATO	Treating asthma in an individual comprises administering to the individual multiple	Treating asthma in an individual comprises administering to the individual multiple	CLAIMS What is claimed is: 1. A method for treating asthma in an individual in need thereof	US2006865089P | WO2007US84358A	2006-11-09 | 2007-11-09	B04-A08C2 | B04-A09 | B04-A10 | B04-B03C | B04-B04C9 | B14-G01 | B14-K01A	A61K0031711 | A61K003900 | A61K003936 | A61K003939 | A61K004800 |	C12N0015117 | A61P001106 | A61P003704 | A61P003708 | C12N231017 |	2008K07324	WO2008073661A2 | WO2008073661A3 | US20090068208A1 | AU2007333368A1 | EP2094849A2 |	Alive	20080619AU200733 3368A1	EP2094849A2 | AU2007333368A1 | AU2007333368B2 | AU2007333368C1 | CA2669137A1 |	Alive	DYNAVAX TECHNOLOGIES CORP	Adjuvante
EP2300102A2	2011-03-30	2009-05-15	DYNAVAX TECHNOLOGIES CORP	Immunstimulatorische Sequenzen enhaltend CpG zur Verwendung bei der Behandlung der	Method useful for treating individual, e.g. human with allergic rhinitis but not asthma, involves	Treating an individual involves administering to the individual multiple administrations of an	CLAIMS What is claimed is: 1. A method for treating an individual in need thereof	US200853605P | WO2009US44192A	2008-05-15 | 2009-05-15	B04-B03C | B14-G01 | B14-G02A | B14-G03 | B14-K01A | B14-N04 | D05-H12D6	A01K0067027 | A01N004304 | A61K00317052 | A61K00317088 | A61K0031711 |	A61K003939 | A01K0067027 | A61K00317088 | A61K003935 | A61K003936 |	2009R37619	WO2009140626A2 | WO2009140626A3 | AU2009246169A1 | CA2724418A1 | EP2300102A2 |	Alive	20091119AU200924 6169A1	EP2300102A2 | AU2009246169A1 | AU2009246169B2 | CA2724418A1 | EP2300102B1 |	Alive	DYNAVAX TECHNOLOGIES CORP	Adjuvante
EP3442568A1	2019-02-20	2017-04-14	DYNAVAX TECHNOLOGIES CORP	INTRATUMORALE VERABREICHUNG VON PARTIKELN MIT EINEM TOLL-LIKE-REZEPTOR-9-	Treating cancer such as breast cancer, prostate cancer, lung cancer, colorectal cancer, uterine	Treating cancer in a mammalian subject involves administering the subject to an an	CLAIMS 1. A method of treating cancer in a mammalian subject, the method	US62323622P | US62439438P | WO2017US27788A	2016-04-15 | 2016-12-27 | 2017-04-14	A10-E01 | A12-V | A12-V01 | B02-B | B02-D | B02-M | B04-A07A1 | B04-B03A | B04-B03D | B04-	A61K0039900 (IPC 1-7) | A61K0031711 (IPC 1-7) | A61K0039939 (IPC 1-7) | A61K004702	A61K003939 | A61K00090019 | A61K00317088 | A61K00390011 | A61K003939 |	20171244E	WO2017181128A1 | US20170326232A1 | AU2017250348A1 | CA3020873A1 | KR2018129903A |	Alive	20171019CA302087 3A1	EP3442568A1 | AU2017250348A1 | CA3020873A1 | CN109475612A | EP3442568A4 |	Alive	DYNAVAX TECHNOLOGIES CORP	Adjuvante
EP986572A2	2000-03-22	1998-06-05	DYNAVAX TECHNOLOGIES CORP	OLIGONUCLEOTIDES IMMUNOSTIMULATORS, COMPOSITIONS CORRESPONDANTES ET LEURS PROCEDES	Immunostimulatory oligonucleotides regulate the immune system and contain an immune-	An immunomodulatory oligonucleotide (I) comprising ≥1 immunostimulatory	1. CLAIMS We claim 1 An immunomodulatory oligonucleotide comprising at least	US199748793P | WO1998US11578A	1997-06-06 | 1998-06-05	B04-B03C | B04-E01 | B14-A02 | B14-H01 | B14-K01A | B14-S11 | D05-H07	C07H002100 (IPC 1-7) | A61K003170 | A61K00317052 | A61K00317088 | A61K00317115 |	C07H002100 | C12N0015117 | A61K003939 | A61P003702 | A61P003706 |	1999059898	WO1998055495A2 | AU199878178A | EP986572A2 | JP2002517156A | AU753172B |	Dead	19981210CA229148 3A1	EP986572A2 | AT252596T | AT432348T | AU199878113A | AU199878178A |	Alive	DYNAVAX TECHNOLOGIES CORP	Adjuvante
US10314907B2	2019-06-11	2018-01-18	DYNAVAX TECHNOLOGIES CORP	Methods and compositions for eliciting an immune response against hepatitis B virus	Eliciting immune response against hepatitis B virus, comprises administering first	Eliciting an immune response against hepatitis B virus (HBV) in a human subject who is a	I claim: 1. A method for eliciting an immune response against hepatitis B virus	US2014754548P | US2015559054P | US13448302A | US15264498A	2011-04-14 | 2011-11-12 | 2012-04-16 | 2016-09-13	B04-B04C1 | B04-E01 | B04-E99 | B04-N03K | B04-N03K0E | B14-A02A5 | B14-G01 | B14-S11A |	A61K0031713 | A61K003900 | A61K003912 | A61K003929 | A61K003939 |	C07H002100 | A61K003939292 | A61K003912 | A61K003939 | A61P003114 | A61P003704 |	2018675135	US2018024340 7A1 | US10314907B2	Alive	20121018US201202 63755A1	US10314907B2 | US20120263755A1 | US20170087245A1 | US20180243407A1 | US9452212B2 |	Alive	DYNAVAX TECHNOLOGIES CORP	Vacina e Adjuvante
US5656298A	1997-08-12	1995-02-28	CONTINENTAL AG (GERMANY FED. REP.)	Immunobooster for delayed release of immunogen	Immuno-booster for delayed release of immunogen comprising an immunogen-	A novel immunobooster for delivering an immunogen to a subject comprises an An	We claim: 1. A method for preparing a polymer matrix including a swelling agent for	US1992951460A	1992-09-25	B04-B04C1 | B04-C03C | B05-A01B | B12-M10A | B14-A02B3 | B14-H01A | B14-S11A	A61K000914 (IPC 1-7) | A61K000916 (IPC 1-7) | A61K000920 (IPC 1-7) | A61K003939 |	A61K003939 | A61K00091611 | A61K00091647 | A61K00092009 | A61K0009204 |	1994135175	WO1994007469A1 | AU199349324A | US5656298A	Dead	19940414WO19940 07469A1	US5656298A | AU199349324A | WO1994007469A1	Dead	CONTINENTAL AG (GERMANY FED. REP.)	Adjuvante
US6589940B1	2003-07-08	1999-04-22	DYNAVAX TECHNOLOGIES CORP	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof	New immunomodulatory oligonucleotide for modulating immune responses or for	An immunomodulatory oligonucleotide comprising a sequence of 22 bp	What is claimed is: 1. An immunomodulatory oligonucleotide comprising the	US199748793P | US199892329A	1997-06-06 | 1998-06-05	B04-E01 | B14-A01 | B14-A02 | B14-A03 | B14-A04 | B14-G02A | B14-G03 | B14-H01 | B14-S03A	A01N004304 (IPC 1-7) | A61K003800 (IPC 1-7) | C07H002102 (IPC 1-7) | C12N001588	C12N0015117 | A61K003935 | A61K003939 | C07H002100 | C07H002104 |	2003895228	US6589940B1	Dead	19981210CA229148 3A1	US6589940B1 | AT252596T | AT432348T | AU199878113A | AU199878178A |	Alive	DYNAVAX TECHNOLOGIES CORP	Adjuvante
US9452212B2	2016-09-27	2012-04-16	DYNAVAX TECHNOLOGIES CORP	Methods and compositions for eliciting an immune response against hepatitis B virus	Eliciting an immune response against hepatitis B virus comprises administering to the	Eliciting an immune response against hepatitis B virus (HBV) in a human subject who is a	We claim: 1. A method for eliciting a seroprotective immune response	US2014754548P | US2015559054P	2011-04-14 | 2011-11-12	B04-B04C1 | B04-E01 | B04-E99 | B04-J03A | B04-N03K | B04-N03K0E | B14-A02A5 | B14-S11A |	A61K0031713 | A61K003900 | A61K003912 | A61K003929 | A61K003942 |	C07H002100 | A61K003939292 | A61K003912 | A61K003939 | A61P003114 | A61P003704 |	2012N60217	US20120263755A1 | US9452212B2	Alive	20121018US201202 63755A1	US9452212B2 | US10314907B2 | US20120263755A1 | US20170087245A1 | US20180243407A1 |	Alive	DYNAVAX TECHNOLOGIES CORP	Adjuvante
US9884110B2	2018-02-06	2016-09-13	DYNAVAX TECHNOLOGIES CORP	Methods and compositions for eliciting an immune response against hepatitis B virus	Eliciting seroprotective immune response against hepatitis B virus (HBV) in human	Eliciting an immune response against hepatitis B virus (HBV) in a human subject who is a	I claim: 1. A method for eliciting a seroprotective immune response	US2014754548P | US2015559054P | US13448302A	2011-04-14 | 2011-11-12 | 2012-04-16	B04-B04C1 | B04-E01 | B04-E99 | B14-N10 | D05-H99	A61K0039900 | A61K003929 | A61K003939 | C12N000700	A61K003939292 | A61K003912 | A61K003939 | A61P003114 | A61P003704 |	2017218778W	US20170087245A1 | US9884110B2	Alive	20121018US201202 63755A1	US9884110B2 | US10314907B2 | US20120263755A1 | US20170087245A1 | US20180243407A1 |	Alive	DYNAVAX TECHNOLOGIES CORP	VACINA E ADJUVANTE
WO2012138325A1	2012-10-11	2011-04-04	DYNAVAX TECHNOLOGIES CORP	PROCÉDÉS ET COMPOSITIONS POUR INDUIRE UNE RÉPONSE IMMUNITAIRE	Eliciting an immune response against hepatitis B virus (HBV) in a human subject having a	Eliciting an immune response against hepatitis B virus (HBV) in a human subject having a	CLAIMS 1. A method for eliciting an immune response against hepatitis B virus	WO2011US31139A	2011-04-04	B04-B04C1 | B04-E99 | B04-N03K | B04-N03K0E | B14-A02A5 | B14-G01 | D05-H07	A61K004800 | C07H002102	C07H002102 | A61K003912 | A61K003929 | A61K203955561 | C12N273010134	2012N19407	WO2012138325A1 | AU2011365013A1 | AU2011365013B2	Alive	20121011WO20121 38325A1	WO2012138325A1 | AU2011365013A1 | AU2011365013B2	Alive	DYNAVAX TECHNOLOGIES CORP	Adjuvante
WO2020081398A1	2020-04-23	2019-10-11	UNIVERSITY OF CALIFORNIA | H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE	COMBINAISON COMPRENANT UN OLIGONUCLÉOTIDE DE TYPE CPG-C ET UN ANTAGONISTE	Treating breast cancer in mammalian subject used in manufacture of medicament,	Treating breast cancer in mammalian subject in need involves administering CpG-C	CLAIMS 1. A method of treating breast cancer in a mammalian subject	US62745421P	2018-10-14	B02-D | B04-B03C | B04-E99 | B04-G01B | B04-G04 | B04-G21 | B04-G23 | B05-B01J | B06-A03A |	A61K0031337 | A61K0031519 | A61K003939 | A61P003500 | C07K001628	A61K0031337 | A61K0031675 | A61K0031704 | A61K0031711 | A61K003939 |	202032899C	WO2020081398A1	No associated DWPI family status	20200423WO20200 81398A1	WO2020081398A1	Alive	UNIVERSITY OF CALIFORNIA | H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE	Adjuvante

Derwent Innovation Publication Number	Publication Date	Search results for: Application Date	Collections Optimized Assignee	Title (Original)	Title - DWPI	Abstract - DWPI	Claims	Priority Number	Priority Date	DWPI Manual Codes	IPC - Current - DWPI	CPC - Current - DWPI	DWPI Accession	DWPI Family	Dead/Alive DWPI	INPADOC Family ID	INPADOC Family	Dead/Alive	Ultimate Parent	Categoria
BR112013001231A2	2016-06-07	2010-07-08	UNITED BIOMEDICAL INC	VACINA CONTRA PCV2 COM BASE EM PEPTÍDEO PROJETADO.	Porcine circovirus type 2 vaccine composition, useful e.g. for protecting piglets that are or	Porcine circovirus type 2 (PCV2) vaccine composition, comprises a peptide antigen and a	CLAIMS: 1. A porcine circovirus type 2 (PCV2) vaccine composition,	WO2010US41406A	2010-07-08	A10-E07B | A10-E08A | A12-V | A12-V01 | B04-B03C | B04-B04C1 | B04-B04D4 | B04-B04D5	A61K003912 | A61K003816 | A61K003912,201601 01,3 | A61K003912,200601	A61K003912,201301 01,13,20160426,KR,F , | C07K001401 | A61K003816 | A61K003912,201301	2012A78999	WO2012005732A1 | TW201201833A | CA2804604A1 | AU2010357208A1 | MX2013000316A |	Alive	20120112CA2804604 A1	BR112013001231A2 | AU2010357208A1 | AU2016219738A1 | AU2016219738B2 | CA2804604A1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BR112014015898A2	2020-10-27	2011-12-30	UNITED BIOMEDICAL INC	COMPOSIÇÕES DE VACINA PARA A SÍNDROME REPRODUTIVA E RESPIRATÓRIA DO	Vaccine composition, useful for protecting piglets against porcine reproductive and	Porcine reproductive and respiratory syndrome (PRRS) vaccine composition comprises a peptide	CLAIMS 1. A Porcine Reproductive and Respiratory Syndrome (PRRS)	WO2011US68133A	2011-12-30	A10-E07B | A12-V | A12-V03C2 | B04-B04C2 | B04-B04D4 | B04-B04D5 | B04-C01 | B04-E99 | B04-	A61P003112 (IPC 1-7) | A61K003810 | A61K003816 | A61K003900,200601 01,5 |	A61K003912,201301 01,1,20130725,EP;US ,F, | A61P001500 | A61P003100 | A61P003104 |	2013L69279	WO2013101195A1 | TW201329100A | CN103648527A | AU2011384799A1 | CA2859944A1 |	No associated DWPI family status	20130704CA2859944 A1	BR112014015898A2 | AU2011384799A1 | AU2017276249A1 | AU2017276249B2 | CA2859944A1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BR112015010756A2	2017-08-22	16/11/2012	UNITED BIOMEDICAL INC	COMPOSIÇÃO DE VACINA PARA A DOENÇA DO PÉ-E-BOCA (FMD), MÉTODOS PARA	Composition used to protect animal from foot-mouth disease, includes synthetic immunogenic	Foot and mouth disease (FMD) vaccine composition, comprises: (a) a synthetic	CLAIMS 1. A foot and mouth disease (FMD) vaccine composition, comprising a) a	WO2012US65386A	2012-11-16	A12-V | B04-B04C1 | B04-C01E | B04-C01G | B04-C03 | B04-E99 | B04-N03K1 | B04-N04A |	A61K003912 | A61K003800 (IPC 1-7) | A61K003800 | A61K003816 | A61K003900,200601	A61K0039135,20130 101,13,20151029,US, F, | A61K003800 | A61K003912,201301 01,2,20140617,EP;US	2014J95509	WO2014077825A1 | TW201420114A | CN104244973A | CA2890678A1 | AU2012394394A1 |	Alive	20140522CA2890678 A1	BR112015010756A2 | AU2012394394A1 | AU2018232999A1 | AU2018232999B2 | BR112015010756A8	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BR112015023105A2	2017-11-21	2013-04-23	UNITED BIOMEDICAL INC	CONSTRUTO DE IMUNÓGENO DE PEPTÍDEO A?, COMPOSIÇÕES, ANTICORPO E USOS	New amyloid beta peptide immunogen construct comprising N-terminus of amyloid beta peptide	An amyloid beta peptide immunogen construct comprising N-terminus of the amyloid beta peptide	CLAIMS 1. An Aβ peptide immunogen construct comprising the following	US13843883A | WO2013US37865A	2013-03-15 | 2013-04-23	B04-B03C | B04-B04C2 | B04-C01 | B04-C01B | B04-E99 | B04-G01 | B04-G23 | B04-N02A | B14-	A61K (IPC 1-7) | A61K003900 | C07K (IPC 1-7) | C07K000100 (IPC 1-7) | C07K001400 (IPC	C07K00144711 | A61K00090019 | A61K00390005,2013 0101,4,20200331,IL; US,L, |	2014R51588	WO2014143087A1 | US2014027169OA1 | TW201434478A | US910275ZB2 | CA2906313A1 |	Alive	20140916TW201434 478A_	BR112015023105A2 | AU2013381835A1 | AU2017203425A1 | AU2017203425B2 | AU2019246916A1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BR112017000354A2	2017-11-07	2014-07-25	UNITED BIOMEDICAL INC	COMPOSIÇÃO IMUNOGÊNICA DE LHRH E USO DA MESMA EM SUÍNOS	Luteinizing-hormone-releasing hormone (LHRH) veterinary composition for inhibiting	A veterinary composition comprises: (a) a peptide immunogen selected from (i) a	CLAIMS 1. A veterinary composition comprising: (a) a peptide	WO2014US48164A	2014-07-25	B04-C01 | B04-E99 | B04-N02A | B14-D01 | B14-G01 | B14-S12 | C04-C01 | C04-E99 | C04-N02A | C14-	A61K003822 | A61K003900,200601 01,3 | A61K003900,200601 01,4 |	A61K00390006,2013 0101,1,20160629,EP; US,F, | A61K00390006,2013 0101,6,20200720,RU,	2016080648	WO2016014071A1 | TW201603821A | AU2014401765A1 | CA2956065A1 | EP3191119A1 |	Alive	20160128CA2956065 A1	BR112017000354A2 | AU2014401765A1 | CA2956065A1 | CN107073086A | EP3191119A1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BR112019002734A2	2019-05-14	2017-08-13	UBI IP HOLDINGS	TRATAMENTO E REMISSÃO VIROLÓGICA SUSTENTADA DE INFECÇÃO POR HIV	Antibody for treating subject with human immunodeficiency virus infection, is directed against	Antibody is directed against a cluster of differentiation 4 (CD4) molecule, and the antibody	CLAIMS 1. An antibody directed against a CD4 molecule, wherein	US62374752P | WO2017US46668A	2016-08-13 | 2017-08-13	A10-E07C | A10-E08A | A10-E08B | A12-V01 | B04-C03C | B04-E99 | B04-G01 | B04-G08 | B04-G21	C07K001628 (IPC 1-7) | A61K003900,200601 01,1 | A61K0039395,20060	C07K00162812 | A61K00393955,2013 0101,18,20190627,U S,L | A61K004506 | A61P003118 |	2018183835B	WO2018035001A1 | TW201808998A | CA3033728A1 | AU2017312887A1 | SG11201901203A1 |	Alive	20180222CA3033728 A1	BR112019002734A2 | AU2017312887A1 | CA3033728A1 | CN109996815A | EP3497133A1 |	Alive	UBI IP HOLDINGS	peptídeo
BR112020011308A2	2020-11-17	2018-12-11	UBI IP HOLDINGS	IMUNÓGENOS PEPTÍDICOS DE IL-31 E FORMULAÇÕES DOS MESMOS PARA TRATAMENTO E/OU	Interleukin-31 peptide immunogen construct has heterologous spacer, bone marrow cell	Interleukin-31 peptide immunogen construct is represented by group of structural	CLAIMS 1. An IL-31 peptide immunogen construct can be represented by the	US62597130P | WO2018US65025A	2017-12-11 | 2018-12-11	B04-B03C | B04-B04C2 | B04-E99 | B04-G06 | B04-G23 | B04-H02T0E | B04-N03K1E | B04-N08 |	C07K001454 (IPC 1-7) | A61K003900 | C07K0014005 (IPC 1-7) | C07K001900 (IPC 1-7) |	C07K001454 | A61K00390008,2013 0101,1,20191129,EP; US,L, | A61K003935,201301	201951793N	WO2019118512A2 | TW201927813A | WO2019118512A3 | CA3085318A1 | AU2018383708A1 |	No associated DWPI family status	20190620CA3085318 A1	BR112020011308A2 | AU2018383708A1 | CA3085318A1 | CN111448208A | EP3724218A2 |	Alive	UBI IP HOLDINGS	vacina peptídeo e adjuvante
BR112020013352A2	2020-12-01	2017-12-31	UNITED BIOMEDICAL INC	IMUNÓGENOS DE PEPTÍDEO E FORMULAÇÕES DOS MESMOS DIRECIONADOS A	IgE EMPD peptide immunogen construct to induce apoptosis of IgE-expressing B cells	IgE EMPD peptide immunogen construct is represented by linear structure	CLAIMS 1. An IgE EMPD peptide immunogen construct represented by the	WO2017US69174A	2017-12-31	B04-B03E | B04-B04C | B04-C01G | B04-E99 | B04-G01 | B04-G23 | B04-G27E | B14-G02A | B14-H03	A61P003708 (IPC 1-7) | A61K0039385 | A61K003944 | C07K001642 (IPC 1-7) | A61K003817 |	A61P003708 | A61K00390008,2013 0101,1,20191218,EP, L, | A61K003935,201301	201959224B	WO2019133024A1 | TW201930346A | CA3087036A1 | AU2017445171A1 | CN111565801A | EP3731934A1 |	No associated DWPI family status	20190704CA3087036 A1	BR112020013352A2 | AU2017445171A1 | CA3087036A1 | CN111565801A | EP3731934A1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BR112020022443A2	2021-02-09	2019-05-03	UBI IP HOLDINGS	EPITOPOS DE CÉLULAS T AUXILIARES PROMÍSCUOS ARTIFICIAIS QUE	Treating condition such as Alzheimer's disease, involves administering peptide to subject in	Treating a condition involves administering a peptide to a subject in need, where the	CLAIMS 1. A method of treating a condition comprising administering a	US62667123P | WO2019US30649A	2018-05-04 | 2019-05-03	B04-B04C2 | B04-E99 | B04-N02 | B14-C03 | B14-G01 | B14-J01A4 | D05-H99	A61K003900 | A61K003912 | C07K0014005 (IPC 1-7) | C07K001600 (IPC 1-7) | C07K000723	A61K00390007,2013 0101,1,20191129,EP, F, | A61K003939,201301 01,18,20210120,KR,F	201993763B	WO2019213555A1 | TW201946649A | CA3099296A1 | AU2019262609A1 | CN112218655A | EP3790581A1 |	No associated DWPI family status	20191107CA3099296 A1	BR112020022443A2 | AU2019262609A1 | CA3099296A1 | CN112218655A | EP3790581A1 |	Alive	UBI IP HOLDINGS	peptídeo
BR199911388A	2001-03-20	1999-06-21	UNITED BIOMEDICAL INC	Imunógeno de somatostatina sintético para promoção de crescimento em	New somatostatin helper T-cell epitope conjugate for raising anti-somatostatin antibodies to	Peptide conjugate comprising a helper T-cell epitope (Tc-h) attached to somatostatin (ST) or		US1998100415A | WO1999US13923A	1998-06-20 | 1999-06-21	B04-C01C | B04-C01D | B04-C01E | B04-C01F | B04-C01G | B04-G02 | B14-E11 | B14-S12 |	A61K003831 (IPC 1-7) | A61K003900 | A61K003902 | A61K003929 | C07K001465 (IPC 1-7) |	A61K00390005,2013 0101,1,20130101,EP, F, | A61P000300 | A61P004300 | C07K014655 |	2000160560	WO1999066950A1 | AU199948267A | EP1087784A1 | BR199911388A | CN1311688A |	Dead	19991229CA2329755 A1	BR199911388A | AU199948267A | CA2329755A1 | CN1311688A | EP1087784A1 |	Dead	UNITED BIOMEDICAL INC	peptídeo
BR199911389A	2001-03-20	1999-06-21	UNITED BIOMEDICAL INC	Composição de peptídio como imunógeno para o tratamento de alergia	New antigenic peptide from the CH3 domain of immunoglobulin E, fusions for	Immunoglobulin E (IgE)-CH3 domain antigenic peptide (I) is new. (I) is of 25-29 amino acids (aa)		US1998100287A | WO1999US13959A	1998-06-20 | 1999-06-21	B04-B04C2 | B04-C01E | B04-C01F | B04-E02F | B04-G01 | B14-G02A | B14-G02B | B14-K01A	A61K003944 | C07K001646 (IPC 1-7) | A61K003944,200601 01,16 | C07K001646	A61K00390008,2013 0101,2,20130101,EP, L, | A61K003985,20130	2000160578	WO1999067293A1 | AU199945802A | EP1090039A1 | BR199911389A | ZA200006384B |	Alive	19991229CA2329754 A1	BR199911389A | AT429448T | AU199945802A | AU757919B2 | BRPI9911389B1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo
BR199912175A	2001-04-10	1999-06-21	UNITED BIOMEDICAL INC	Composição de peptídios para prevenção e tratamento de infecção por hiv e	New antigenic peptide from the CDR2 domain of CD4, for immunization against e.g. human	A CD4-CDR2 antigenic peptide (I) is new. (I) of 30-46 amino acids (aa) contains two Cys		US1998100409A | WO1999US14030A	1998-06-20 | 1999-06-21	B04-B04C2 | B04-C01F | B04-C01G | B04-E02F | B04-E07 | B04-G01 | B12-K04F | B14-A02B1 |	A61K0039395 | C07K001900 (IPC 1-7) | A61K003800 | A61K0039385,20060 101,7 |	C07K001470514 | A61P003118 | A61P003704 | A61K003800 | A61K003900,201301	2000160579	WO1999067294A1 | AU199947048A | US6090388A | BR199912175A | EP1098910A1 |	Alive	19991229CA2330235 A1	BR199912175A | AT447585T | AU199947048A | AU766955B2 | BRPI9912175B1 |	Alive	UNITED BIOMEDICAL INC	Peptídeo
BR199912176A	2002-11-05	1999-06-21	UNITED BIOMEDICAL INC	Epítopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de	New peptide immunogen containing luteinizing hormone-releasing hormone antigen	Peptide immunogen (A) containing at least one antigenic target site (I), i.e. luteinizing hormone-		US1998100414A | WO1999US13960A	1998-06-20 | 1999-06-21	B04-J07 | B04-N02B | B04-N03B | B14-A01 | B14-A02B1 | B14-D02 | B14-E11 | B14-G02A | B14-G03	A61K003800 (IPC 1-7) | A61K003900 | C07K001400 (IPC 1-7) | C07K001900 (IPC 1-7) | C07K000500	C07K001400 5 | A61P001516 | A61P001518 | A61P003100 | A61P003500 |	2000160562	WO1999066952A1 | US6025468A | AU199945803A | AU764961B2 | CA2330249A1 | US6228987B1 |	Dead	19991229CA2330249 A1	BR199912176A | AU199945803A | AU764961B2 | CA2330249A1 | CN1315869A |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
BR199912177A	2001-04-10	1999-06-21	UNITED BIOMEDICAL INC	Epítopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de	New artificial T helper cell epitope and derived immunogens with target antigenic site,	T helper cell epitope (Th) is new. has any of 25 specified sequences, reproduced. (Th) has		US1998100412A | WO1999US13975A	1998-06-20 | 1999-06-21	B04-N02B | B04-N03B | B14-A02B1 | B14-A03B | B14-D02 | B14-E11 | B14-F07 | B14-G02A | B14-	A61K004500 (IPC 1-7) | C07K001900 (IPC 1-7) | A61K003800 | A61K003810 | A61K003900,200601	C07K001900 | A61P000910 | A61P001500 | A61P003104 | A61P003112 |	2000160564	WO1999066957A2 | AU199945808A | EP1089760A1 | BR199912177A | CN1306439A |	Alive	19991229CA2329772 A1	BR199912177A | AT463255T | AT510563T | AU199945808A | AU763543B2 |	Alive	UNITED BIOMEDICAL INC	Peptídeo
BR199912178A	2001-04-10	1999-06-21	UNITED BIOMEDICAL INC	Vacinas de peptídeo sintéticas para febre aftosa	Synthetic peptide used in protecting animals against foot and mouth disease virus infections	Synthetic peptide (I) comprising a foot and mouth disease virus (FMDV) epitope conjugate to a helper		US1998100600A | WO1999US13921A	1998-06-20 | 1999-06-21	B04-B04C | B04-C01G | B04-E02F | B04-E03F | B04-F11 | B12-K04A4 | B14-G01 | B14-S11 | C04-	A61K0039245 | C07K001409 (IPC 1-7) | G01N003368 (IPC 1-7) | A61K003900,200601	C07K0014005 | A61P003112 | A61P003114 | C12N001552 | A61K003900,201301	2000160563	WO1999066954A1 | AU199948266A | US6107021A | EP1089759A1 | BR199912178A |	Alive	19991229CA2330178 A1	BR199912178A | AR19152A1 | AU199948266A | AU754939B2 | BRPI9912178B1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo
BR200210010A	2005-10-25	2002-04-02	UNITED BIOMEDICAL INC	Composição de peptídeo imunogênico para prevenção e tratamento da	Novel peptide immunogen comprising a helper T cell epitope, an N-terminal fragment of	A peptide immunogen (I) of about 20-100 amino acids, comprising a helper T cell (Th)		US2001865294A | WO2002US10293A	2001-05-25 | 2002-04-02	A12-V | A12-V01 | B04-A08C2 | B04-A10G | B04-B01B | B04-B01C1 | B04-C01E | B04-C01F |	A61K (IPC 1-7) | C07K000500 (IPC 1-7) | A61K003800 | A61K003802 | A61K003900,200601	C07K00144711 | A61P002528 | A61P003704 | A61K003900,201301 01,1,20130101,EP,L,	2003201258	WO2002096350A2 | US2003006832SA1 | AU2002303211A1 | US2004024761 2A1 | EP1497313A2 |	Alive	20021205CA2448171 A1	BR200210010A | AT474000T | AT496937T | AU2002303211B2 | AU2008202270A1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BR200307724A	2007-04-27	2003-02-14	UNITED BIOMEDICAL INC	sistemas para distribuição de imunógenos sintéticos estabilizados	Stabilized immunostimulating complex, useful for vaccination, e.g. against human	Stabilized immunostimulating complex (A) contains a cationic peptide immunogen (I) and	REIVINDICAÇÕES 1. Complexo imunoestimulador estabilizado, que compreende um	US200276674A | WO2003US4711A | US2003355161A	2002-02-14 | 2003-02-14 | 2003-05-21	A12-V01 | B04-B03C | B04-N02A | B04-N03A | B14-A01 | B14-A02B1 | B14-A02B3 | B14-A03B |	A61K (IPC 1-7) | A61K003940 | A61K003900 | A61K003912 | A61K003921 |	A61K00390006,2013 0101,1,20130101,EP, F, | A61K003939,201301 01,2,20130101,EP,L,	2003778890	WO2003068169A2 | US2003016547 8A1 | AU2003213091A1 | EP1572074A2 | JP2005530690A |	Alive	20030821CA2475102 A1	BR200307724A | AT540697T | AU2003213091A1 | AU2003213091B2 | AU2003213091C1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
BRPI0307724B1	2019-06-18	2003-02-14	UNITED BIOMEDICAL INC	SISTEMAS PARA DISTRIBUIÇÃO DE IMUNÓGENOS SINTÉTICOS ESTABILIZADOS	Stabilized immunostimulatory complex useful for treating allergy, HIV infection or prostate	Stabilized immunostimulatory complex comprising a cationic peptide immunogen and	1. Complexo imunoestimulador estabilizado microparticulado, caracterizado pelo	US200276674A | WO2003US4711A | US2003355161A	2002-02-14 | 2003-02-14 | 2003-05-21	A12-V01 | B04-C01 | B04-E01 | B05-A01B | B05-B02A | B14-A02B1 | B14-D01 | B14-G02A | B14-H01	A61K003900 | A61K00317084 (IPC 1-7) | A01N004304 | A61K003170 | A61K00317084 |	A61K00390006,2013 0101,1,20130101,EP, F, | A61K003939,201301 01,2,20130101,EP,L,	2004212745	US2004009897A1 | TW200307557A | CN101001646A | US8084015B2 | TWI3590258 |	Alive	20030821CA2475102 A1	BRPI0307724B1 | AT540697T | AU2003213091A1 | AU2003213091B2 | AU2003213091C1 |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante

DE19549390C2	1997-10-23	1995-10-27	UNITED BIOMEDICAL INC	Gespleisste Peptidzusammensetzungen zur Diagnose und zum Nachweis von Hepatitis C Virus	Compsn. contg. synthetic peptide(s) reactive with hepatitis C related antibodies used for	A novel peptide compsn. comprises at least one linear or branched peptide (A) of formulae: P1-Y; P2-	1. Gespleißte Peptidzusammensetzung umfassend ein lineares gespleißtes Peptid, in dem der C-	US1995530550A | DE19540105A	1995-09-19 | 1995-10-27	B04-B04D4 | B04-B04D5 | B04-G08 | B11-C07 | B12-K04A4 | D05-H09 | D05-H11 | S03-E09F	A61K003921 | A61K005100 (IPC 1-7) | C07K001418	C07K0014005 | C12N277024222	1997471945	DE19549390A1 | DE19549390C2 | NL1005556C2 | NL1005557C2 | IN2002004251 2	Dead	19950215GB1994256 04D0	DE19549390C2 | AU199539669A | DE19500394A1 | DE19500394C2 | DE19540105C1 |	Dead	UNITED BIOMEDICAL INC	Peptideo
EP214709A2	1987-03-18	1986-04-29	UNITED BIOMEDICAL INC	Peptide synthétique et procédé pour son utilisation dans la détection d'anticorps de HTLV-	Synthetic peptide(s) for detecting antibodies to HTLV-III useful in diagnosis of aids, pre-aids etc.	(1) Peptide for detecting antibodies to HTLV-III in body fluids and for diagnosing AIDS,	1. A peptide for the detection of antibodies to HTLV-III in body fluids and diagnosis of AIDS,	US1985774644A | US1986837566A | US1986847102A	1985-09-11 | 1986-03-04 | 1986-04-02	A12-V03C2 | B02-V02 | B04-B04C6 | B04-C01E | B12-K04A4 | D05-H06 | D05-H07 | S03-	C07K000700 (IPC 1-7) | A61K003702 (IPC 1-7) | C07K001500 (IPC 1-7) | C12P002100 (IPC 1-	C07K0014005 | A61P003112 | A61P003118 | A61P003704 | C07K001610 |	1987074076	EP214709A1 | JP62061996A | NO198601697A | AU198656803A | DK198601980A |	Dead	19860430DK1986019 80D0	EP214709A2 | AT114672T | AT95190T | AU198656803A | AU579467B |	Indeterminate	UNITED BIOMEDICAL INC	vacina peptídeo
EP278148A2	1988-08-17	1987-06-15	UNITED BIOMEDICAL INC	Composition peptidique et procédé pour la détection d'anticorps contre	Peptide compsn. used in detection of antibodies of HTLV-iii	A peptide compsn. for the detection of antibodies to HTLV-III in body fluids and diagnosis of AIDS,	1. A peptide composition for the detection of antibodies to HTLV-III in body fluids and	US198713014A	1987-02-10	B02-V02 | B04-B02B4 | B04-B04C3 | B04-C01G | B11-C07A | B12-K04A4 | D05-H06 | D05-H09	G01N003353 (IPC 1-7) | A61K003702 (IPC 1-7) | A61K003912 (IPC 1-7) | C07K000704 (IPC 1-7) |	C07K0014005 | C07K001610 | G01N003356988 | A61K003900,201301 01,1,20130101,EP,L,	1988147753	ZA1987047759B | EP278148A1 | JP63196856A | NO198702473A | DK198702960A |	Dead	19860430DK1986019 80D0	EP278148A2 | AT114672T | AT95190T | AU198656803A | AU579467B |	Indeterminate	UNITED BIOMEDICAL INC	vacina peptídeo
EP328403A2	1989-08-16	1989-02-10	UNITED BIOMEDICAL INC	Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung |	Synthetic peptide(s) corresp. to HIV-GP120 regions used for detecting antibodies to HIV or	Peptides are claimed characterised in that they have specific immunoreactivity to antibodies to HIV	1. A peptide (composition) characterised in that it has specific immunoreactivity to	US1988155321A	1988-02-12	B02-V02 | B04-B04C6 | B04-C01 | B11-C07A | B12-K04A | D05-H07 | S03-E14H4	C07K001416 (IPC 1-7) | A61K003816 (IPC 1-7) | A61K003921 | G01N0033569 (IPC 1-7) | A61K003800 |	C07K0014005 | A61P003112 | A61P003118 | A61P003700 | A61K003800 |	1989235721	EP328403A1 | JP2022296A | EP328403B1 | DE68928130D1 | CA1341285C |	Dead	19890816EP328403A 2	EP328403A2 | AT154610T | CA1341285C | DE68928130D1 | DE68928130T2 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP346022A1	1989-12-13	1989-06-02	UNITED BIOMEDICAL INC	Fragments peptidiques du VIH | Peptidfragmente von HIV	A peptide having the amino acid sequence of a fragment of HIV which interacts with particular human leucocyte antigen class 1	1. A peptide having the amino acid sequence of a fragment of HIV which interacts	GB198813746A | GB198815956A | GB198826445A	1988-06-10 | 1988-07-05 | 1988-11-11	B04-B04C2 | B04-C01C | B04-C01D | B11-C07A | B12-A06 | B12-K04 | D05-C11 | D05-H07	C07K000708 (IPC 1-7) | A61K003700 (IPC 1-7) | A61K003800 (IPC 1-7) | A61K003800 |	C07K0014005 | A61P003112 | A61P003118 | A61P003700 | A61K003800 |	1989365758	EP346022A1 | GB2220939A | JP2036198A | GB2220939B | SG199401306A |	Dead	19880713GB1988137 46D0	EP346022A1 | AT134195T | DE346022T1 | DE68925660D1 | DE68925660T2 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP404935A1	1991-01-02	1990-01-16	UNITED BIOMEDICAL INC	COMPOSITIONS DE PEPTIDES SYNTHETIQUES IMMUNOREACTIFS PAR RAPPORT A DES	Synthetic peptide(s) corresponding to HTLV-1 and op. HIV used for detection of antibodies, in	(A) A peptide compsn. having specific immunoreactivities to antibodies to	1. A peptide having the amino acid sequence of a fragment of HIV which interacts	US1989297635A | WO1990US260A	1989-01-13 | 1990-01-16	B02-V02 | B04-B04C6 | B04-C01 | B12-K04A4 | D05-C11 | D05-H07 | D05-H09 | S03-E14H4	C07K000708 (IPC 1-7) | C07K000710 (IPC 1-7) | C12Q000170 (IPC 1-7) | G01N0033569 (IPC 1-	C07K0014005 | C12N274014022	1990254015	WO1990008162A1 | EP404935A1 | JP3504165A | EP404935B1 | DE69015708D1 |	Dead	19881208JP6330189 6A_	EP404935A1 | AT116660T | CA2025019A1 | CA2025019C | CA2034611A1 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP412766A1	1991-02-13	1990-08-07	UNITED BIOMEDICAL INC	Fragments peptidiques du VIH | Peptidfragmente von HIV	New penta:deca:peptide HIV fragment which stimulates cytotoxic T-cell immunity and	A peptide is claimed which has the amino acid sequence of a fragment of HIV which interacts	1. A peptide having the amino acid sequence of a fragment of HIV which interacts	GB198918200A	1989-08-09	B04-C01C | B04-C01D | B12-A01 | B12-A06 | D05-C11 | D05-H07 | D05-H09 | D05-H12 | S03-	C07K000708 (IPC 1-7) | A61K003702 (IPC 1-7) | G01N003356 (IPC 1-7) | G01N0033569 (IPC 1-	C07K0014005 | A61P003112 | A61P003118 | A61K003900,201301 01,1,20130101,EP,L,	1991045891	EP412766A1 | WO1991001996A1 | GB2250994A | JP4507100A | GB2250994B |	Dead	19890920GB1989182 00D0	EP412766A1 | AT103294T | CA2064691A1 | DE69007571D1 | DE69007571T2 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
EP439077A2	1991-07-31	1991-01-18	UNITED BIOMEDICAL INC	Composition peptidique ayant une activité immunologique contre des anticorps	Peptide compsns. corresp. to envelope fragments of HTLV-1,2 for detecting antibodies to these	The following are new. (1) a peptide compsn. specifically immunoreactive with anti-HTLV-1	1. A peptide composition having specific immunoreactivities to antibodies to	US1990469291A	1990-01-24	B04-B02C | B04-B04C6 | B04-B04D4 | B04-C01 | B05-A04 | B11-C07A | B12-K04A4 | D05-H09 |	C07K001415 (IPC 1-7) | G01N0033569 (IPC 1-7) | A61K003900,200601 01,1 | C07K001415 |	C07K0014005 | C12N274014022	1991224505	EP439077A1 | CA2034611A1 | FI199100245A | EP439077B3 | JP5247091A |	Dead	19881208JP6330189 6A_	EP439077A2 | AT116660T | CA2025019A1 | CA2025019C | CA2034611A1 |	Dead	UNITED BIOMEDICAL INC	Peptídeo
EP442394A2	1991-08-21	1991-02-08	UNITED BIOMEDICAL INC	Peptides synthétiques spécifiques pour la détection d'anticorps contre	New synthetic peptide(s) from immuno-dominant regions of virus for diagnosis of hepatitis	Peptide compsns. comprising oligopeptides (IF), (IIG), (IIH), (IIIF), (IV), (VE), (VIE), (VII),	1. A peptide composition comprising a peptide with an amino acid sequence selected	US1990481348A | US1990510153A | US1990558799A	1990-02-16 | 1990-04-16 | 1990-07-26	B02-V02 | B04-B02B4 | B04-B02C2 | B04-B04C3 | B04-B04D4 | B04-C01 | B05-C08 | B10-B01B	A61K003912 | C07K001410 (IPC 1-7) | C07K000708 (IPC 1-7) | G01N0033576 (IPC 1-7) |	C07K0014005 | A61P000116 | C07K0016109 | A61K003900,201301 01,1,20130101,EP;US	1991247104	EP442394A1 | CA2036463A1 | FI199100720A | AU199174399A | CA2047792A1 |	Dead	19910214FI1991007 20A0	EP442394A2 | AT179184T | AT195532T | AU199174399A | AU199181390A |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP468527A2	1992-01-29	1991-07-26	UNITED BIOMEDICAL INC	Peptides synthétiques, spécifiques pour le dépistage d'anticorps contre	New synthetic peptide specific for HCV antibodies for detection of HCV or NANBHV e.g. by	A compsn. comprises a peptide selected from Pep1-Pep19 having specified aminoacid	1. A peptide composition comprising a peptide having an amino acid sequence selected	US1990558799A | US1991651735A | US1991667275A | US1991719819A	1990-07-26 | 1991-02-07 | 1991-03-11 | 1991-06-24	B02-V02 | B04-B02B4 | B04-B04D4 | B04-B04H | B04-C01 | B11-C07A | B11-	C07K001402 (IPC 1-7) | C12Q000170 (IPC 1-7) | A61B001000 | A61K003900,200601	C07K0014005 | A61P000116 | C07K0016109 | A61K003900,201301 01,1,20130101,EP,L,	1992034279	EP468527A1 | AU199181390A | FI199103560A | JP5222094A | AU646275B |	Dead	19910214FI1991007 20A0	EP468527A2 | AT179184T | AT195532T | AU199174399A | AU199181390A |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP510054A1	1992-10-28	1991-01-04	UNITED BIOMEDICAL INC	FRAGMENTS DE LA PROTEINE DU NOYAU DE VIH-1 | HIV-1-CORE-PROTEINFRAGMENT	Peptide fragments of HIV-1 core protein react specifically with HLA class 1 mols., to stimulate	New peptides (A) having a sequence of an HIV fragment chosen from those given in the	CLAIMS 1. A peptide having the amino acid sequence of a fragment of HIV	GB1990287A | GB1990357 7A	1990-01-05 | 1990-02-16	B02-V02 | B04-B04C1 | B04-C01C | B04-C01D | B11-C07A | B12-K04A | D05-H06 | D05-H07	A61K003921 | C07K000708 (IPC 1-7) | C12P002100 (IPC 1-7) | C12Q000100 (IPC 1-7) |	C07K0014005 | A61K003900,201301 01,1,20130101,EP,L, | C12N274016222	1991222843	WO1991009869A1 | EP510054A1 | GB2255093A | GB2273709A | GB2273710A |	Dead	19900307GB1990002 87D0	EP510054A1 | CA2072351A1 | GB199000287D0 | GB199003577D0 | GB199213025D0 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo e adjuvante
EP662082A1	1995-07-12	1993-09-15	UNITED BIOMEDICAL INC	NOUVEAUX PEPTIDES RAMIFIES HYBRIDES EN GRAPPES, EFFICACES POUR	New branched peptides for detecting non-A, non-B hepatitis antibodies to identify	Peptide compsn. contains at least one branched peptide of formulae (peptide)2X,	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Thr	US1992946054A | WO1993US8638A	1992-09-15 | 1993-09-15	B04-B04D4 | B04-C01 | B04-G01 | B11-C07A7 | B12-K04A | D05-H06 | D05-H07 | D05-H09	C07K000000 (IPC 1-7) | C07K001418 (IPC 1-7) | C07K000700 (IPC 1-7) | C12Q000170 (IPC 1-	C07K0014005 | C07K0016109 | A61K003900,201301 01,1,20130101,EP,L, | C12N277024222	1994118396	WO1994006826A1 | AU199351276A | FI199501198A | NO199500977A | EP662082A1 |	Dead	19910214FI1991007 20A0	EP662082A1 | AT179184T | AT195532T | AU199174399A | AU199181390A |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP708656A1	1996-05-01	1994-04-28	UNITED BIOMEDICAL INC	PEPTIDES IMMUNOGENES DE LA LHRH ET STIMULATORS D'IMMUNITE	Immunogenic luteinising hormone releasing hormone peptide(s) that suppress LHRH	A peptide (I) that stimulates an immune response to luteinising hormone releasing hormone	9. The peptide of Claim 2 wherein at least one A is an invasin domain. 10. The peptide of	US199357166A | US1994229275A | WO1994US4832A	1993-04-27 | 1994-04-14 | 1994-04-28	B04-C01F | B04-C01G | B04-N03A | B14-D02 | B14-E08 | B14-H01 | B14-P01 | B14-S04 | B14-S11 |	C07K000700 (IPC 1-7) | A61K003702 (IPC 1-7) | A61K003704 (IPC 1-7) | A61K003743 (IPC 1-	C07K0014005 | C07K0016109 | A61K003900,201301 0101,1,20130101,EP; | A61P000104 | A61P000310 |	1994357910	WO1994025060A1 | AU199466702A | NO199504279A | FI199505101A | EP708656A1 |	Dead	19941110CA2161445 A1	EP708656A1 | AT221387T | AU199466702A | AU687805B | CA2161445A1 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP710294A1	1996-05-08	1994-06-22	UNITED BIOMEDICAL INC	PEPTIDES LINEAIRES ET RAMIFIES EFFICACES DANS LE DIAGNOSTIC ET LA DETECTION DE	Linear and branched peptide(s) comprising, e.g. PepB and PepC useful in vaccines	Peptide compsn. comprises at least 1 linear or branched peptide of formula:(peptide)-Y,	1. A peptide composition comprising at least one linear or	US199383947A | WO1994US7088A	1993-06-28 | 1994-06-22	B04-G01 | B04-L01 | B04-N04B | B11-C07A4 | B12-K04A4 | B14-S11A | D05-H07 | D05-H09	C12N001509 (IPC 1-7) | C12Q000170 (IPC 1-7) | A61K003912 | A61K003929 |	C07K0014005 | A61P003112 | C07K0016109 | A61K003900,201301 01,1,20130101,EP,L,	1995052105	WO1995000670A1 | AU199472123A | EP710294A1 | JP9500784A | US5639594A |	Dead	19910214FI1991007 20A0	EP710294A1 | AT179184T | AT195532T | AU199174399A | AU199181390A |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP725838A1	1996-08-14	1994-10-26	UNITED BIOMEDICAL INC	BIBLIOTHEQUES STRUCTUREES D'ANTIGENES DE SYNTHESE UTILISABLES A DES	Structured antigenic peptide libraries contain some invariant amino acids accommodate	A novel library of peptides (I) comprising a known antigen site, epitope or ligand on a	We Claim: 1. A library of peptides comprising a known antigenic site, epitope or	US1993143412A | WO1994US12268A	1993-10-26 | 1994-10-26	B04-C01 | B04-N04 | B12-K04A4 | B14-A02 | B14-S11A | D05-H07 | D05-H09 | D05-H17A5	C12Q000170 (IPC 1-7) | A61K003929 | C07K001418 (IPC 1-7)	C07K000706 | C07K0001047 | C07K0014005 | C07K0014420 | C07K0014295 |	1995178890	WO1995011998A1 | AU199480916A | EP725838A1 | EP725838A4	Dead	19941229IL111417D 0	EP725838A1 | AU199480916A | CA2175579A1 | EP725838A4 | IL111417D0 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
EP787150A1	1997-08-06	1995-10-25	UNITED BIOMEDICAL INC	IMMUNOGENES PEPTIDIQUES SYNTHETIQUES DU DOMAINE D'ANCRAGE DE LA	Peptide immunogen useful in treatment of allergy comprises membrane-bound IgE epsilon-chain	Peptide immunogens (I) of formula (A)n-(Th)m-(B)o-(mIGE peptide) and (mIgE peptide)-	1. A peptide immunogen selected from the group consisting of: (A)n-	US1994328519A | WO1995US13841A	1994-10-25 | 1995-10-25	B04-N04 | B14-G02A | B14-S11 | D05-H07	C07K001600 (IPC 1-7) | C07K0016100 (IPC 1-7) | C07K001646 (IPC 1-7) | A61K003900 |	C07K0014005 | A61K00390008,2013 0101,2,20130101,EP, L, | C07K001600 | A61K003800 |	1996230555	WO1996012740A1 | AU199540120A | EP787150A1 | CN1167491A	Alive	19960502CA2203165 A1	EP787150A1 | AU199540120A | CA2203165A1 | CN1167491A | WO1996012740A1	Alive	UNITED BIOMEDICAL INC	vacina peptídeo
EP811016A1	1997-12-10	1995-03-24	UNITED BIOMEDICAL INC	IMMUNOGENES A BASE DE PEPTIDE SYNTHETIQUE POUR LE TRAITEMENT DE L'ALLERGIE | AUF	Synthetic peptide-based immunogen contg. IgE CH4 peptide and helper T cell epitope useful	A peptide immunogen of formula (A)n-(Th)m-(B)o-(IgE CH4 peptide) (I) is new,	I claim: 1. A peptide immunogen represented by the formula: (A)n- (Th)m	US1994218461A | US1994328912A | WO1995US3741A	1994-03-28 | 1994-10-25 | 1995-03-24	B04-C01C | B04-G01 | B04-N04B | B14-G02A | D05-H07	C07K001900 (IPC 1-7) | A61K003900 | A61K0039395 | C07K001646 (IPC 1-7) |	C07K0014005 | A61K00390005,2013 0101,1,20130101,EP, L, | A61P003708 | C07K00164291 |	1995351297	WO1995026365A1 | AU199521953A | EP811016A1 | JP9510975A | EP811016A4 |	Dead	19951005CA2186595 A1	EP811016A1 | AU199521953A | CA2186595A1 | CN1146772A | EP811016A4 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
US4833071A	1989-05-23	1987-01-09	UNITED BIOMEDICAL INC	Peptide composition as anitgen for detection of antibodies to HTLV-I, as a vaccine for ATL	Antigen for detection of antibody against HTLV-I used in peptide compsn. for	(I), (II), (III), their analogue, their segment, their	We claim: 1. A peptide composition having specific immunoreactivity to	US19871885A	1987-01-09	B04-B04C2 | B04-B04C3 | B04-C01 | B12-K04A4 | D05-H06 | J04-B01B | S03-E14H4	A61K003921 | A61K0039395 | B65D006900 (IPC 1-7) | C07K001512 (IPC	C07K0014005 | A61P003112 | A61P003502 | C12N274014022 | Y10S043580 5	1989082937	JP63301896A | US4833071A | JP0285127 8B2	Dead	19881208JP6330189 6A_	US4833071A | AT116660T | CA2025019A1 | CA2025019C | CA2034611A1 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
US5683695A	1997-11-04	1993-02-10	UNITED BIOMEDICAL INC	Production of recombinant proteins containing multiple antigenic determinants linked	New recombinant proteins contg multiple antigenic determinants linked by flexible hinge	A recombinant protein (I) which comprises alternating peptide (PD) and spacer (SD)	1. A recombinant protein which comprises alternating peptide	US199315770A	1993-02-10	B04-E03F | B04-N02A0E | B14-S11A | D05-H07 | D05-H17A5 | D05-H17C	A61K003900 | C07K000706 (IPC 1-7) | A61K003902 | A61K003912 | A61K003913 |	C07H002100 | C07K0014005 | A61K003900,201301 01,1,20130101,EP,L, | C12N274016122	1994279687	WO1994018234A1 | AU199461740A | US5683695A	Dead	19940818WO199401 8234A1	US5683695A | AU199461740A | WO1994018234A1	Dead	UNITED BIOMEDICAL INC	vacina peptídeo

US5763160A	1998-06-09	1995-06-07	UNITED BIOMEDICAL INC	Synthetic peptides and process of using same for the detection of antibodies to human	HIV gp120 peptides useful as immunoassay reagents or vaccine components	Peptide compositions comprise: (a) Peptide 127; (b) a peptide that is from	I claim: 1. A composition comprising a peptide selected from the group consisting of:	US1988155321A | US1991663262A | US1991726605A | US1994326676A	1988-02-12 | 1991-03-01 | 1991-07-09 | 1994-10-19	B04-N03A | B11-C07A | B12-K04A4 | B14-A02B1 | B14-S11A | D05-H06 | D05-H07 | S03-	C12Q000170 (IPC 1-7) | A61K003921 | C07K001416 (IPC 1-7) | G01N0033569 (IPC 1-7)	C07K0014005 | A61K003800 | A61K003900,201301 01,2,20130101,EP,L, | C12N274016122	1998347301	US5763160A	Dead	19890816EP328403A 2	US5763160A | AT154610T | CA1341285C | DE68928130D1 | DE68928130T2 |	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
US6048538A	2000-04-11	1997-10-03	UNITED BIOMEDICAL INC	Peptides derived from the non-structural proteins of foot and mouth disease virus as	Peptide from non-structural proteins useful for detecting foot-and-mouth disease virus	Isolated peptide comprising an immunogenic epitope specific to antibodies of foot-	We claim: 1. A peptide having an N-terminus and a C-terminus, useful for the detection of	US1997943173A	1997-10-03	B04-C01G | B04-F11 | B04-G08 | B04-N03A | B11-C07A4 | B12-K04A4 | C04-C01G | C04-F11 |	C07K001409 (IPC 1-7) | G01N0033566 (IPC 1-7) | A61P003112 | C07K001409	C07K0014005 | A61P003112 | C12N277032122 | Y10S0435975 | Y10S0530826	2000328034	US6048538A | TW585872B	Dead	20000411US6048538 A_	US6048538A | TW585872B	Dead	UNITED BIOMEDICAL INC	vacina peptídeo
US6780969B2	2004-08-24	2000-12-22	UNITED BIOMEDICAL INC	Synthetic peptide composition as immunogens for prevention of urinary tract infection	Novel peptide immunogen, useful for evoking antibodies to prevent adherence	A peptide immunogen (I), comprising a helper T cell epitope sequence (Th) or a	What is claimed is: 1. A FAFSD target peptide selected from the group consisting of SEQ ID	US2000747802A	2000-12-22	B04-C01 | B04-F04 | B04-N04A | B04-N04A0E | B14-A01 | B14-L06 | B14-N07	C07K (IPC 1-7) | C07K0014245 (IPC 1-7) | A61K003800 (IPC 1-7) | A61K003824 (IPC 1-7) |	C07K00147055 | A61P001300 | C07K0014245 | A61K003800 | C07K231900	2002528681	WO2002051860A2 | US20030027979A1 | AU2002232917A1 | US20040141993A1 | US6780969B2 |	Alive	20020704WO200205 1860A2	US6780969B2 | AR36006A1 | AU2002232917A1 | AU2002232917A8 | TWI254050B |	Alive	UNITED BIOMEDICAL INC	vacina peptídeo
WO1996022067A2	1996-07-25	1995-12-15	UNITED BIOMEDICAL INC	BANQUES DE PEPTIDES A ENCLIQUETAGE POUR VACCINS ET THERAPEUTIQUES	Ratchet library of peptide(s) contg. an immuno:stimulatory CTL epitope derived from longer	Ratchet library comprises peptides (I) contg. at least one immunostimulatory cytotoxic T-	We Claim: 1. A ratchet library of peptides comprising at least one immunostimulatory	US1994366332A	1994-12-27	B04-C01 | B14-A02 | B14-A03B | B14-G01 | B14-H01B | B14-S11 | D05-H07 | D05-H10	A61K000000 (IPC 1-7) | A61K003800 (IPC 1-7) | C07K000100 | C07K0014005 | C07K0014435 |	C07K001482 | C07K0001047 | C07K0014005 | C07K0014445 | C07K00144727 |	1996354273	WO1996022067A2 | AU199658497A | WO1996022067A3	Dead	19960725WO199602 2067A2	WO1996022067A2 | AU199658497A | WO1996022067A3	Dead	UNITED BIOMEDICAL INC	vacina peptídeo

<table>
<tr><th>Derwent Innovation Publication Number</th><th>Publication Date</th><th>Application Date</th><th>Optimized Assignee</th><th>Title (Original)</th><th>Title - DWPI</th><th>Abstract - DWPI</th><th>Claims</th><th>Priority Number</th><th>Priority Date</th><th>DWPI Manual Codes</th><th>IPC - Current - DWPI</th><th>CPC - Current - DWPI</th><th>DWPI Accession</th><th>DWPI Family</th><th>Dead/Alive DWPI</th><th>INPADOC Family ID</th><th>INPADOC Family</th><th>Dead/Alive</th><th>Ultimate Parent</th><th>Categoria</th></tr>
<tr><td>BR112012003837A2</td><td>2016-11-15</td><td>2010-08-20</td><td>MERIAL</td><td>VACINA AVIÁRIA DE PARAMYXOVIRUS RECOMBINANTE E MÉTODOS PARA PREPARAÇÃO E USO</td><td>Producing recombinant avian paramyxovirus viral vector to induce immunological</td><td>Producing (M1) recombinant avian paramyxoviruses (APMV) viral vector (V1) involves</td><td>CLAIMS
1. A composition or vaccine comprising (i) a recombinant APMV viral vector</td><td>US2009235912P | WO2010US46179A</td><td>2009-08-21 | 2010-08-20</td><td>B04-B04C | B04-E01 | B04-E08 | B04-E99 | B04-F11B0E | B14-G01 | B14-S11A | C04-B04C | C04-E01</td><td>A61K (IPC 1-7) | A61K003900 (IPC 1-7) | A61K0039155 (IPC 1-7) | A61K003912 (IPC 1-</td><td>C12N000700 | A61K003900 | A61K003912 | A61K0039155 | A61P003112 |</td><td>2011B93459</td><td>WO2011022656A2 | US20110081374A1 | WO2011022656A3 | CA2771540A1 | EP2467158A2 |</td><td>Alive</td><td>20110224CA2771540A1</td><td>BR112012003837A2 | CA2771540A1 | CA2771540C | CL2012000447A1 | CL2015002175A1 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina Recombinante</td></tr>
<tr><td>BR112012015596A2</td><td>2015-11-03</td><td>2010-12-21</td><td>SANOFI PASTEUR</td><td>"PROCESSO DE PRODUÇÃO DE CÉLULAS ADERENTES E UTILIZAÇÃO DAS MESMAS"</td><td>Producing adherent cells comprises introducing adherent cell suspension into culture vessel</td><td>Producing adherent cells comprises: (a) introducing a suspension of adherent cells into a</td><td>REVENDICATIONS
1. Un procédé de production de cellules adhérentes selon lequel :</td><td>FR200959472A | FR201051754A | WO2010FR52850A</td><td>2009-12-23 | 2010-03-11 | 2010-12-21</td><td>B04-F02 | B04-L05C | C04-F02 | C04-L05C | D05-H08</td><td>C12N000500 (IPC 1-7) | A61K003512 | A61K003900 | A61K0039205 | A61P003100 |</td><td>C12N000500 | C12N00050056 | C12N00050075 | C12N00050602 | A61P003100 |</td><td>2011H20549</td><td>US20110151506A1 | WO2011077035A1 | FR2957355A1 | AU2010334723A1 | MX2012007117A |</td><td>Alive</td><td>20110623US20110151506A1</td><td>BR112012015596A2 | AR79710A1 | AU2010334723A1 | AU2010334723B2 | AU2010334723C1 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BR112012019637A2</td><td>2016-05-03</td><td>2011-01-21</td><td>SANOFI PASTEUR</td><td>MÉTODO DE INDUÇÃO DE ANTICORPOS NEUTRALIZANTES CONTRA QUATRO</td><td>Inducing neutralizing antibodies against four serotypes of dengue fever, mumps virus,</td><td>Inducing neutralizing antibodies against four serotypes of dengue fever, mumps virus,</td><td>Claims:
1. A method of inducing neutralizing antibodies against four serotypes of</td><td>EP2010305114A | WO2011EP50800A</td><td>2010-02-04 | 2011-01-21</td><td>B04-F11B | B14-A02B | B14-G01 | B14-S11A | D05-H07</td><td>A61K003912 (IPC 1-7) | A61K0039295 (IPC 1-7) | A61K003912 | A61K0039295 |</td><td>A61K0039295 | A61K00390015 | A61K00390018 | A61K003905 | A61K003908 |</td><td>2011J84675</td><td>US20110189226A1 | EP2353609A1 | WO2011095402A1 | AU2011212647A1 | CN102740879A |</td><td>Alive</td><td>20110804US20110189226A1</td><td>BR112012019637A2 | AR80111A1 | AU2011212647A1 | AU2011212647B2 | CN102740879A |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BR112012021545A2</td><td>2018-09-04</td><td>2011-02-25</td><td>MERIAL</td><td>COMPOSIÇÕES CDV RECOMBINANTES E SEUS USOS</td><td>Vector useful in composition for vaccinating animal comprises polynucleotide</td><td>A vector (v1) comprises: at least one polynucleotide encoding at least one polypeptide</td><td>WHAT IS CLAIMED IS:
1. A composition comprising:
a) an expression</td><td>US2010308620P | WO2011US26378A</td><td>2010-02-26 | 2011-02-25</td><td>B04-B04C1 | B04-E08 | B04-E99 | B04-F1100E | B12-K04 | B14-G01 | B14-S11A | B14-S11D3 | B14-</td><td>A61K00317088 | A61K003576 | A61K003900 | A61K0039002 | A61K003912 |</td><td>A61K0039175 | A61K0048005 | A61K003912 | A61K0039205 | A61N00050613 |</td><td>2011L10242</td><td>WO2011106743A1 | US20110236419A1 | AU2011220410A1 | CA2791787A1 | EP2538972A1 |</td><td>Alive</td><td>20110901CA2791787A1</td><td>BR112012021545A2 | AR80313A1 | AU2011220410A1 | AU2011220410B2 | AU2011220410B9 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina e vetor</td></tr>
<tr><td>BR112013007486A2</td><td>2018-05-02</td><td>2011-08-29</td><td>MERIAL</td><td>VACINAS DE HERPESVÍRUS VETORIZADAS COM VÍRUS DA DOENÇA DE NEWCASTLE</td><td>Composition or vaccine useful for eliciting a protective response in an animal against</td><td>A composition or vaccine comprises: (i) one or more recombinant Newcastle Disease</td><td>CLAIMS
1. A composition or vaccine comprising (i) one or more recombinant</td><td>US2010378575P | WO2011US49554A</td><td>2010-08-31 | 2011-08-29</td><td>B04-E99 | B04-F11B0E | B14-G01 | B14-S11A | C04-E99 | C04-F11B0E | C14-G01 | C14-S11A |</td><td>A61K0039145 (IPC 1-7) | C07K0014035 (IPC 1-7) | A61K003912 | A61K0039145 |</td><td>A61K003917 | A61K003912 | A61K0039245 | A61P003112 | A61P003122 |</td><td>2012C77446</td><td>US20120052089A1 | WO2012030720A1 | CA2809127A1 | EP2611460A1 | JP2013536847A |</td><td>No associated DWPI family status</td><td>20120301US20120052089A1</td><td>BR112013007486A2 | BR112013007486B1 | CA2809127A1 | CA2809127C |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina e Vetor</td></tr>
<tr><td>BR112013009524A2</td><td>2018-12-11</td><td>2011-10-17</td><td>SANOFI PASTEUR</td><td>MÉTODO DE ARMAZENAMENTO DE UMA VACINA CONTENDO UM ADJUVANTE DE</td><td>Storing a vaccine composition containing an antigen adsorbed on an aluminum</td><td>Storing a vaccine composition containing an antigen adsorbed on an aluminum</td><td>What is claimed
1. A method for storing a vaccine composition containing an</td><td>FR201058464A | US2011454248P | WO2011EP68090A</td><td>2010-10-18 | 2011-03-18 | 2011-10-17</td><td>A04-E10 | A06-A00E1 | A11-B05 | A12-P06 | B04-B04C | B04-C03F | B11-C06 | D05-H07 | Q32-</td><td>A61K (IPC 1-7) | A61K003900 (IPC 1-7) | A61M (IPC 1-7) | A61M0005178 (IPC 1-7) | A61K003900 |</td><td>A61K003912 | B65D0051005 | A61J000100 | A61K003900 | A61K003905 |</td><td>2012E52021</td><td>FR2966044A1 | US20120091026A1 | WO2012052394A1 | FR2966044B1 | AU2011317649A1 |</td><td>Alive</td><td>20120419US20120091026A1</td><td>BR112013009524A2 | AP2013006876A0 | AR84491A1 | AU2011317649A1 | AU2011317649B2 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BR112014001287A2</td><td>2017-02-21</td><td>2012-02-02</td><td>CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC | MERIAL | INSTITUT GUSTAVE ROUSSY |</td><td>VACINA RECOMBINANTE DO VÍRUS DA LEUCEMIA FELINA CONTENDO GENE OTIMIZADO</td><td>Composition used for eliciting an immune response and vaccinating against Feline</td><td>A composition comprises (a) an expression vector, where the vector comprises one or</td><td>CLAIMS
1. A composition comprising:
a) an expression vector comprising a</td><td>US2011509912P | WO2012US23658A</td><td>2011-07-20 | 2012-02-02</td><td>B04-E08 | B04-E99 | B04-F11B1E | B14-G01 | B14-S03A | B14-S11A | B14-S11D3 | C04-E08 |</td><td>A61K (IPC 1-7) | A61K003912 (IPC 1-7) | C07K (IPC 1-7) | C07K0014005 (IPC 1-7) | C12N (IPC 1-7) |</td><td>C07K0014005 | A61K003104 | A61K0038162 | A61K003912 | A61K003921 |</td><td>2013B44463</td><td>US20130022632A1 | CN103957932A | JP2014528699A | US8895027B2 | WO2013012446A1 |</td><td>Alive</td><td>20051013AU2005229411A1</td><td>BR112014001287A2 | AT472334T | AU2005229411A1 | AU2005229411B2 | AU2012284558A1 |</td><td>Alive</td><td>CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC | C.H. BOEHRINGER SOHN AG & CO KG |</td><td>Vacina Recombinante</td></tr>
<tr><td>BR112014017416A2</td><td>2017-06-13</td><td>2013-01-17</td><td>SANOFI PASTEUR</td><td>PROCESSO DE FORMULAÇÃO DE UMA VACINA CONTENDO PELO MENOS DOIS</td><td>Preparing vaccine combination comprising two antigens to adsorb to aluminum</td><td>Preparing a vaccine combination comprising at least two antigens to adsorb to aluminum</td><td>Revendications
1. Procédé de préparation d'une combinaison vaccinale liquide</td><td>FR201250464A | WO2013FR50106A</td><td>2012-01-17 | 2013-01-17</td><td>B05-A01B | B14-A02A5 | B14-C03 | B14-S11 | B14-S24 | D05-H07</td><td>A61K (IPC 1-7) | A61K0039295 (IPC 1-7) | A61P (IPC 1-7) | A61P003104 (IPC 1-7) | A61P003112 (IPC</td><td>A61K004702 | A61K003905 | A61K003908 | A61K0039099 | A61K0039102 |</td><td>2013L85120</td><td>FR2985663A1 | WO2013107988A1 | CA2861304A1 | AU2013210927A1 | MX2014007850A |</td><td>Alive</td><td>20130719FR2985663A1</td><td>BR112014017416A2 | AP2014007848A0 | AR89737A1 | AU2013210927A1 | AU2013210927B2 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BR112014023414A2</td><td>2017-07-11</td><td>2013-03-15</td><td>MERIAL INC. (US)</td><td>VACINA DE HERPESVIRUS-1 EQUINO RECOMBINANTE CONTENDO UMA</td><td>Composition or vaccine for vaccinating animal, and for eliciting protective response</td><td>Composition or vaccine comprises a recombinant equine herpes virus-1 (EHV-1), where the EHV-1</td><td>CLAIMS
1. A composition or vaccine comprising a recombinant Equine Herpesvirus -1 (EHV-</td><td>US2012613151P | WO2013US32491A</td><td>2012-03-20 | 2013-03-15</td><td>B04-C01G | B04-E02F | B04-E03F | B04-E99 | B04-F11A0E | B14-A02A3 | B14-G01 | B14-</td><td>A61K0039245 (IPC 1-7) | C12N000700 (IPC 1-7) | A61K000000 (IPC 1-7) | A61K003500 (IPC</td><td>A61K0039245 | A61K003912 | A61P003122 | C07K0014005 | C12N000700 |</td><td>2013N68574</td><td>US20130251747A1 | WO2013142371A1 | AU2013235423A1 | CA2867893A1 | US8916371B2 |</td><td>Alive</td><td>20130926CA2867893A1</td><td>BR112014023414A2 | AR90450A1 | AU2013235423A1 | AU2013235423B2 | CA2867893A1 |</td><td>Alive</td><td>MERIAL INC. (US)</td><td>Vacina Recombinante</td></tr>
<tr><td>BR112015001313A2</td><td>2017-08-01</td><td>2013-07-24</td><td>SANOFI PASTEUR</td><td>COMPOSIÇÕES DE VACINA</td><td>New dengue virus serotype 2 vaccine composition useful for preparing pharmaceutical</td><td>A dengue virus serotype 2 vaccine composition comprising, (a) dengue antigen</td><td>CLAIMS
1 . A dengue virus serotype 2 vaccine composition comprising:</td><td>EP2012305908A | EP2012305911A | WO2013EP65669A</td><td>2012-07-24 | 2012-07-25 | 2013-07-24</td><td>B04-B04C1 | B04-E08 | B04-E99 | B04-F11B | B04-F11B0E | B04-N03K | B14-A02B9 | B14-S11A |</td><td>A61K003912 (IPC 1-7) | A61K0039295 (IPC 1-7) | A61K003576 | A61K003900 |</td><td>A61K003912 | A61K0039295 | A61P003112 | A61P003114 | C12N000700 |</td><td>2014C33697</td><td>WO2014016362A1 | CA2878599A1 | AU2013295016A1 | KR2015036593A | SG11201500439A1 |</td><td>Alive</td><td>20140130CA2878599A1</td><td>BR112015001313A2 | AU2013295016A1 | CA2878599A1 | CN104812408A | EP2877207A1 |</td><td>Alive</td><td>SANOFI SA</td><td>Vacina e Vetor</td></tr>
<tr><td>BR112015002268A2</td><td>2017-11-07</td><td>2013-07-29</td><td>SANOFI PASTEUR</td><td>PRODUÇÃO DE VÍRUS INFLUENZA INFECCIOSOS</td><td>Producing infectious influenza viruses comprises transfecting cells with expression</td><td>Producing infectious influenza viruses comprises (a) transfecting cells with a set of</td><td>CLAIMS
1 . A method for producing infectious influenza viruses, wherein said method</td><td>EP2012305968A | WO2013EP65920A</td><td>2012-08-03 | 2013-07-29</td><td>B04-E08 | B04-E99 | B04-F0200E | B04-F11B0E | B14-A02B2 | B14-G01 | B14-S11A | B14-S11D3 |</td><td>C12N000702 (IPC 1-7) | C12N001585 (IPC 1-7) | C12N000700 (IPC 1-7) | A61K0039145 |</td><td>C12N000700 | A61K0039145 | C12N001585 | A61K20395254 | C12N276000051 |</td><td>2014C50599</td><td>WO2014019990A1 | CA2880409A1 | AU2013298632A1 | KR2015038374A | SG11201500508A1 |</td><td>Alive</td><td>20140206CA2880409A1</td><td>BR112015002268A2 | AU2013298632A1 | AU2013298632B2 | CA2880409A1 | CN104704112A |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BR112017004197A2</td><td>2017-12-12</td><td>2015-09-02</td><td>SANOFI PASTEUR</td><td>COMPOSIÇÕES DE VACINA CONTRA DOENÇAS DO VÍRUS DA DENGUE</td><td>Vaccine composition used for protecting human against dengue disease caused by dengue</td><td>Vaccine composition comprises dengue antigen of serotypes 1-4, where the dengue antigens of</td><td>CLAIMS
1. A vaccine composition for use in a method of protecting a human</td><td>EP2014306350A | EP2015305851A | WO2015EP70060A</td><td>2014-09-02 | 2015-06-04 | 2015-09-02</td><td>B04-B04C1 | B04-F11B0E | B14-A02B9 | B14-G01 | B14-S11A | B14-S11D2 | B14-S11D3 | D05-</td><td>A61K003912 (IPC 1-7) | A61K003900 (IPC 1-7) | A61K0039295 (IPC 1-7) | A61K003900 |</td><td>A61K003912 | A61K0039295 | A61P003114 | A61P003704 | C12N000700 |</td><td>201614916U</td><td>WO2016034629A1 | TW201620546A | AU2015310951A1 | KR2017043660A | CA2958949A1 |</td><td>Alive</td><td>20160310CA2958949A1</td><td>BR112017004197A2 | AU2015310951A1 | CA2958949A1 | CN106999564A | EP3188751A1 |</td><td>Alive</td><td>SANOFI SA</td><td>vacina geral</td></tr>
<tr><td>BR112017005833A2</td><td>2018-02-27</td><td>2015-09-23</td><td>MERIAL</td><td>VACINAS RECOMBINANTES FMDV E SEUS USOS</td><td>Composition or vaccine for vaccinating animal susceptible to FMDV infection or eliciting</td><td>Composition or vaccine comprises a foot and mouth disease virus (FMDV) antigen or a</td><td>CLAIMS
1. A composition or vaccine comprising a foot and mouth Disease Virus</td><td>US62054073P | WO2015US51755A</td><td>2014-09-23 | 2015-09-23</td><td>B04-B04C1 | B04-E08 | B04-E99 | B04-F07A0E | B04-F1100E | B04-N04 | B14-A02B3 | B14-</td><td>A61K (IPC 1-7) | A61K003912 (IPC 1-7) | A61K003576 | A61K0035761 | A61K003816 |</td><td>A61K003912 | A61K0039135 | A61P003112 | A61P003114 | A61P003704 |</td><td>2016193850</td><td>WO2016049209A1 | US20160220659A1 | TW201625297A | AR102006A1 | IN201747011549A |</td><td>Alive</td><td>20160331CA2962225A1</td><td>BR112017005833A2 | AP2017009834A0 | AR102006A1 | AU2015320673A1 | AU2015320673B2 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina Recombinante</td></tr>
<tr><td>BR112017024395A2</td><td>2018-07-24</td><td>2016-05-13</td><td>MERIAL</td><td>APLICADOR POR SPRAY DE MAIOR ALCANCE</td><td>Extended-range spray applicator used to e.g. vaccine avian animal against respiratory</td><td>Extended-range spray applicator (1) comprises air supply means (10), for providing flow of air</td><td>What is Claimed:
1. An extended-range spray applicator comprising:</td><td>US62161440P | WO2016US32337A</td><td>2015-05-14 | 2016-05-13</td><td>B04-B04C | B04-F09 | B04-F10 | B11-C04D | B12-M01 | B14-K01 | B14-S11E | B14-S12 | C04-</td><td>A61D (IPC 1-7) | B05B (IPC 1-7) | A01K004500 | A61D000102 | A61K0035741 |</td><td>A01K004500 | B05B00031014 | A61D000102 | A61D0001025 | A61K00090073 |</td><td>201670486J</td><td>US20160332174A1 | WO2016183430A1 | CA2986024A1 | AU2016260409A1 | CN107787182A |</td><td>Alive</td><td>20161117CA2986024A1</td><td>BR112017024395A2 | AU2016260409A1 | AU2016260409B2 | CA2986024A1 | CN107787182A |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina Geral</td></tr>
<tr><td>BR112017027895A2</td><td>2018-11-06</td><td>2016-06-23</td><td>MERIAL</td><td>VETORES VIRAIS RECOMBINANTES CONTENDO PROTEÍNAS MENORES DE PRRSV</td><td>Immunological or vaccine composition used for eliciting protective response against porcine</td><td>Immunological or vaccine composition, comprises (a) one or more recombinant viral vectors,</td><td>WHAT IS CLAIMED IS:
1. A safe and effective immunological or</td><td>US62183410P | WO2016US38964A</td><td>2015-06-23 | 2016-06-23</td><td>B04-E08 | B04-E99 | B04-F1100E | B14-A02B | B14-G01 | B14-K01 | B14-S03A | B14-S11A | B14-</td><td>A61K (IPC 1-7) | C07K001408 (IPC 1-7) | A61K003912 (IPC 1-7) | C07K (IPC 1-7) | C12N (IPC 1-7) |</td><td>A61K003912 | A61P003112 | C07K0014082 | C12N000700 | C12N001586 |</td><td>2016817159</td><td>US20160375122A1 | WO2016210094A1 | TW201713358A | AR105482A1 | CA2990643A1 |</td><td>Alive</td><td>20161229CA2990643A1</td><td>BR112017027895A2 | AR105482A1 | AU2016282772A1 | AU2016282772B2 | AU2019275585A1 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina e Vetor</td></tr>
<tr><td>BR112018006567A2</td><td>2018-12-11</td><td>2016-09-14</td><td>MERIAL</td><td>VACINAS DE PARTÍCULAS SEMELHANTES A VÍRUS (VLP) DO PARVOVIRUS</td><td>Combination vaccine useful for eliciting immune response against canine parvovirus and foot-</td><td>Combination vaccine comprises a virus-like particle (VLP) component and a modified-live virus</td><td>CLAIMS
1. A combination vaccine comprising a virus-like particle (VLP) component</td><td>US62234196P | WO2016US51736A</td><td>2015-09-29 | 2016-09-14</td><td>B04-C01G | B04-E08 | B04-E99 | B04-F1100E | B04-N03K1 | B14-A02B | B14-G01 | B14-S11A |</td><td>A61K (IPC 1-7) | A61K003912 (IPC 1-7) | A61K003900 | A61K003912 | A61K0039135 |</td><td>A61K003923 | A61K003912 | A61K0039135 | A61P003100 | A61P003120 |</td><td>2017218727</td><td>US20170087244A1 | WO2017058521A1 | AR106026A1 | CA3000352A1 | AU2016332037A1 |</td><td>Alive</td><td>20170330US20170087244A1</td><td>BR112018006567A2 | AR106026A1 | AU2016332037A1 | AU2016332037B2 | CA3000352A1 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>VLP</td></tr>
<tr><td>BR112018010494A2</td><td>2018-11-13</td><td>2016-11-16</td><td>MERIAL</td><td>PROTEÍNAS DE FUSÃO FMDV E E2 E SEUS USOS</td><td>Composition for protecting or preventing the host against Foot and Mouth Disease Virus</td><td>A composition comprises a Foot and Mouth Disease Virus (FMDV) antigen or polypeptide.</td><td>CLAIMS
1. A composition comprising an FMDV antigen or polypeptide.</td><td>US62259043P | WO2016US62367A</td><td>2015-11-23 | 2016-11-16</td><td>B04-B04C1 | B04-C01G | B04-E08 | B04-E99 | B04-F0100E | B04-F1100E | B04-N03K1 | B04-</td><td>A61K (IPC 1-7) | A61K0039135 (IPC 1-7) | A61K003900 (IPC 1-7) | C07K (IPC 1-7) | C07K001432 (IPC 1-</td><td>A61K0039135 | C07K0014005 | A61K0039385 | A61P003114 | C07K001432 |</td><td>2017336671</td><td>US20170143819A1 | WO2017091418A1 | TW201726708A | AR106792A1 | US9913891B2 |</td><td>Alive</td><td>20170525US20170143819A1</td><td>BR112018010494A2 | AR106792A1 | AU2016361305A1 | AU2016361305B2 | BR112018010494A8</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Método/Processo</td></tr>
<tr><td>BR112018075078A2</td><td>2019-03-06</td><td>2017-06-02</td><td>SANOFI PASTEUR</td><td>MODIFICAÇÃO DE POLIPEPTÍDEOS DA HEMAGLUTININA DO INFLUENZA MANIPULADOS</td><td>Recombinant influenza hemagglutinin polypeptide used to identify</td><td>Recombinant influenza hemagglutinin (HA) polypeptide comprises</td><td>CLAIMS
1. A recombinant influenza hemagglutinin (HA) polypeptide</td><td>US62345502P | WO2017US35738A</td><td>2016-06-03 | 2017-06-02</td><td>B04-E02F | B04-E03F | B04-E08 | B04-E99 | B04-F0100E | B04-N03K0E | B14-A02B2 | D05-H12A | D05-</td><td>C07K0014005 (IPC 1-7) | A61K003802 | A61K003816 | A61K003900 | A61K0039145 |</td><td>A61K0039145 | C07K0014005 | A61K0038162 | A61P003116 | A61P003704 |</td><td>201783409F</td><td>WO2017210592A1 | AU2017275663A1 | CA3026094A1 | IN201847049302A | SG11201810758A1 |</td><td>Alive</td><td>20171207CA3026094A1</td><td>BR112018075078A2 | AU2017275663A1 | CA3026094A1 | CN109563138A | EA201892385A1 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
</table>

BR112019010830A2	2019-10-01	2017-11-30	BOEHRINGER INGELHEIM GMBH	VACINAS ATENUADAS DE INFLUENZA SUÍNA E MÉTODOS DE PRODUÇÃO E USO	Vaccinating composition useful for eliciting protective immune response in porcine	Vaccinating composition comprises an attenuated swine influenza virus (SIV)	WHAT IS CLAIMED IS: 1. A vaccine comprising an attenuated swine	US62428062P | WO2017US64017A	2016-11-30 | 2017-11-30	B04-E08 | B04-E99 | B04-F0100E | B04-F11B | B04-F11B0E | B14-S11D2 | B14-S12 | C04-E08 | C04-E99	A61K003900 (IPC 1-7) | A61K003912 (IPC 1-7) | A61K0039145 (IPC 1-7) | C12N0000700 (IPC 1-	A61K003912 | A61K0039145 | A61P003116 | A61P003704 | A61P004300 |	2018438985	US20180147276A1 | WO2018102586A1 | AU2017367644A1 | CA3045315A1 | KR20190992118A |	Alive	20180531US20180147276A1	BR112019010830A2 | AU2017367644A1 | CA3045315A1 | CN110225765A | EA201991319A1 |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Atenuada
BR112020004747A2	2020-09-24	2018-09-11	SANOFI PASTEUR	COMPOSIÇÃO IMUNOGÊNICA DE CITOMEGALOVÍRUS HUMANO	Immunogenic composition used as human cytomegalovirus (HCMV) vaccine for	Immunogenic composition comprises (a) an human cytomegalovirus	CLAIMS 1. An immunogenic composition comprising: - an HCMV gB	EP2017306179A | WO2018EP74369A	2017-09-13 | 2018-09-11	A04-F04 | A12-V01 | B04-B04C1 | B04-C02V | B04-E99 | B04-F12 | B04-N03K | B14-A02A3 | B14-	A61K0039245 (IPC 1-7) | A61K003900 (IPC 1-7) | A61P003112 (IPC 1-7) | A61K003900 |	A61K0039245 | A61K003939 | A61P003112 | A61P003122 | C12N000700 |	201926131N	WO2019052975A1 | CA3075207A1 | WO2019052975A9 | AU2018331874A1 | KR2020051778A |	No associated DWPI family status	20190321CA3075207A1	BR112020004747A2 | AU2018331874A1 | CA3075207A1 | CN111344009A | EP3681534A1 |	Alive	SANOFI SA	Método/Processo
BR112020018879A2	2021-01-26	2019-04-02	SANOFI PASTEUR	CEPA DO VÍRUS DA FEBRE AMARELA VIVO ATENUADO ADAPTADA PARA SE DESENVOLVER EM	Live-attenuated yellow fever virus strain for preventing an infection by a yellow fever virus,	Live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow	CLAIMS 1. A live-attenuated yellow fever virus strain adapted to grow on Vero cells	EP2018305405A | WO2019EP58268A	2018-04-06 | 2019-04-02	B04-E99 | B04-F0200E | B04-F11B | B04-F11B0E | B14-A02B9 | B14-S11A | B14-S11D2 | D05-	A61K003912 (IPC 1-7) | C12N000708 (IPC 1-7) | A61K003912 | A61P003114 |	C12N000700 | C12N000708 | A61K003912 | A61P003114 | C12N277024134 |	201984961J	WO2019192997A1 | EP3549603A1 | AR114471A1 | CA3095438A1 | CN111918669A |	No associated DWPI family status	20191009EP3549603A1	BR112020018879A2 | AR114471A1 | AU2019249329A1 | CA3095438A1 | CN111918669A |	Alive	SANOFI SA	VLP
BR199407182A	1996-09-17	1994-08-04	AVENTIS SA	Composição imunogênica processo de preparo de composição não-imunopotencializado	Respiratory syncytial virus immunogenic compsn. used for protection against disease or for	The following are claimed: (A) an immunogenic compsn. which is capable of producing		US1993102742A | WO1994CA425A	1993-08-06 | 1994-08-04	B04-F11 | B04-G01 | B11-C07A | B12-K04A4 | B14-A02 | B14-K01 | D05-H06 | D05-H09 | D05-H11	C12N000702 (IPC 1-7) | A61K0039155 | A61P003112 | A61P003114 | C12N000702 |	C12N000700 | A61K003912 | A61K0039155 | A61P003112 | A61P003114 |	1995090684	WO1995004545A1 | AU199473801A | EP714306A1 | BR199407182A | JP9501912A |	Dead	19950216CA2167274A1	BR199407182A | AT164313T | AU199473801A | AU677090B | CA2167274A1 |	Dead	SANOFI SA	Método/Processo
BR199712970A	2001-08-28	1997-07-11	AVENTIS SA	Método para produção de vacina para proteção contra vírus sincitial respiratório, mistura	Purified respiratory syncytial virus fusion, attachment and matrix proteins useful as	Purified respiratory syncytial virus (RSV) mixture comprises fusion protein (F), attachment protein		US1996679060A | WO1997CA497A	1996-07-12 | 1997-07-11	B04-G01 | B04-G21 | B04-N03 | B14-S11 | D05-H07 | D05-H09 | D05-H11A1 | D05-H17C | S03-E14H4	A61K0039155 (IPC 1-7) | A61K003939 (IPC 1-7) | C07K0014135 (IPC 1-7) | C07K001610 (IPC 1-	C07K0014005 | A61K003912 | A61K0039155 | A61P001104 | A61P003100 |	1998110527	WO1998002457A1 | AU199734311A | EP942928A1 | CN1230197A | US6020182A |	Dead	19980122CA2259594A1	BR199712970A | AT282633T | AU199734311A | AU716378B2 | CA2259594A1 |	Alive	SANOFI SA	Método/Processo
BR199807873A	2000-03-21	1998-03-02	ACAMBIS INC. (US) ST. LOUIS UNIVERSITY (US)	Vacinas de flavivírus quiméricos	New chimeric flavivirus vaccines comprising a yellow fever virus which does not express	A chimeric live, infectious, attenuated virus is claimed comprising:(a) a		US1997807445A | US19987664A | WO1998US3894A	1997-02-28 | 1998-01-15 | 1998-03-02	B04-E02 | B04-F11 | B14-S11A | D05-H07	A61K003912 (IPC 1-7) | A61K003912 | C12N000701 | C12N000704 | A61K003576 |	C07K0014005 | A61K003912 | A61P003112 | A61P003114 | C12N000700 |	1998520758	WO1998037911A1 | AU199864431A | NO199904185A | CZ199903064A3 | EP977587A1 |	Alive	19980903CA2282790A1	BR199807873A | AT297757T | AT468858T | AU199864431A | AU200118139A |	Alive	ACAMBIS INC. (US) ST. LOUIS UNIVERSITY (US)	vacina Geral
BR199809078A	2000-08-01	1998-04-06	BIO-RAD LABORATORIES INC.	Peptídeos sintéticos utilizáveis nos testes biológicos para a detecção das infecções devido aos	New synthetic peptide(s) useful for, e.g. detecting infection by human immune deficiency	Synthetic peptides (A), of 13-33 amino acids (aa) when monomeric or 26-66 when dimeric (either		FR19974356A | FR19982212A | WO1998FR691A	1997-04-09 | 1998-02-24 | 1998-04-06	B04-C01 | B04-N04A | B11-C08E | B12-K04A4 | D05-H06	C07K001416 (IPC 1-7) | C07K000100 | C07K0014005 | A61K003800 | A61K003816 |	C07K0014005 | A61P003112 | A61P003704 | C12N000700 | A61K003900 |	1998583190	WO1998045323A1 | FR2761993A1 | AU199873386A | FR2775287A1 | ZA1998029968 |	Alive	19981015CA2286344A1	BR199809078A | AT343590T | AU199873386A | AU740231B2 | BRPI9809078B1 |	Alive	BIO-RAD LABORATORIES INC.	Método/Processo
BR199911870A	2001-03-27	1999-06-28	QUEEN'S UNIVERSITY OF BELFAST | UNIVERSITY OF SASKATCHEWAN |	Vacina de parvovírus e circovírus de suíno	Use of a porcine circovirus antigen and a porcine parvovirus antigen for vaccination	(A) A novel antigenic preparation directed against porcine multisystemic wasting syndrome		FR19988777A | WO1999EP4698A	1998-07-06 | 1999-06-28	B04-B04C | B14-S11A | C04-B04C | C14-S11A | D05-H07	A61K0031295 (IPC 1-7) | A61K003912 (IPC 1-7) | A61K0039295 (IPC 1-7) | A61K0039395 (IPC 1-	C07K0014005 | A61K003912 | A61P003112 | A61P003120 | A61P003122 |	2000182091	WO2000001409A2 | FR2781159A1 | AU199949077A | US621788381 | BR199911870A |	Alive	19990409FR2769321A1	BR199911870A | AR53711A1 | AT245191T | AT299531T | AT364624T |	Alive	QUEEN'S UNIVERSITY OF BELFAST | UNIVERSITY OF SASKATCHEWAN |	Vacina Geral
BR200012500A	2002-04-02	2000-07-13	MERIAL	Vacina inativa contra a calicivírose felina	New vaccine for protecting cats against feline calcivirus, derived from viral isolates	Immunogenic composition or vaccine (A) against feline calcivirosis is based on a feline		FR19999420A | FR20001759A | WO2000FR2050A	1999-07-16 | 2000-02-11 | 2000-07-13	B04-B04C1 | B04-F01 | B04-F02 | B04-F05 | B04-F11 | B04-G08 | B04-G21 | B14-A02B3 | B14-S11A |	A61K003912 (IPC 1-7) | A61K0039125 (IPC 1-7) | A61P003114 (IPC 1-7) | C07K001610 (IPC	A61K0039125 | C12N000700 | A61K003912 | A61P003112 | A61P003114 |	2001147326	WO2001005835A1 | FR2796281A1 | FR2796282A1 | AU20006576 4A | BR200012500A |	Alive	20010119FR2796281A1	BR200012500A | AR24770A1 | AT280182T | AT526034T | AU200065764A |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
BR200209145A	2005-04-19	2002-04-23	EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. US	Vacina contra varíola	New clonal strain of attenuated vaccinia virus isolated from cultured cells where Dryvax has been	A new clonal strain of attenuated vaccinia virus (I) that is isolated from cultured cells in		US2001840751A | WO2002US12616A	2001-04-23 | 2002-04-23	B04-F11 | B14-A02 | B14-A02A4 | B14-S11A | C04-F11 | C14-A02 | C14-A02A4 | C14-S11A |	A61K0039285 (IPC 1-7) | C12N000704 (IPC 1-7) | C12N000700 (IPC 1-7) | A61K0039275 |	C12N000700 | A61P003112 | A61P003120 | A61K20395254 | C12N271024161	2003067614	WO2002085411A1 | EP1381389A1 | HU200303878A2 | US6723325B1 | AU2002258910A1 |	Alive	20021031CA2444747A1	BR200209145A | AU2002258910B2 | CA2444747A1 | CA2444747C | CN1527722A |	Alive	EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. US	vacina Geral
BR200306905A	2005-04-12	2003-01-15	SANOFI AVENTIS	Vacinas de flavivírus	Novel flavivirus comprising a hinge region mutation that reduces viscerotropism of	A flavivirus (I) comprising a hinge region mutation that reduces viscerotropism of		US2002348949P | US2002385281P | WO2003US1214A	2002-01-15 | 2002-05-31 | 2003-01-15	B04-F1100E | B04-N03 | B11-C08 | B12-K04E | B14-A02 | B14-G01 | B14-S11 | D05-H06 | D05-H07	A01K (IPC 1-7) | A61K (IPC 1-7) | A61K003912 (IPC 1-7) | A61K0039295 (IPC 1-7) | C07K (IPC	A61K003912 | C07K0014005 | A61P003112 | A61P003114 | C12N000700 |	2004053569	WO2003103571A2 | AU2003267937A1 | EP1471873A2 | US2005002968A1 | KR2004078666A |	Alive	20031218CA2473321A1	BR200306905A | AU2003267937A1 | AU2003267937B2 | AU2003267937C1 | AU2005216248A1 |	Alive	SANOFI SA	Vacina Geral
BR200316346A	2005-09-27	2003-11-13	SANOFI AVENTIS	Vacina para vírus do nilo ocidental	New nucleic acid molecule comprising sequences encoding the pre-membrane and envelope	A nucleic acid molecule comprises sequences encoding the pre-membrane and envelope	REIVINDICAÇÕES 1- Molécula de ácido nucléico compreendendo seqüências codi-	US2002426592P | WO2003US36623A	2002-11-15 | 2003-11-13	B04-B04C1 | B04-C01G | B04-E02H | B04-E03H | B04-F1100E | B04-N03A0E | B14-A02 |	A61K (IPC 1-7) | A61K0039295 (IPC 1-7) | C07H002104 (IPC 1-7) | A61K003900 (IPC 1-	A61K003912 | A61P003114 | C12N000700 | A61K20395254 |	2004420522	WO2004045529A2 | AU2003290985A1 | US2005005362 4A1 | EP1575979A2 | BR200316346A |	Alive	20040603CA2505942A1	BR200316346A | AT452900T | AU2003290985A1 | AU2003290985B2 | BRPI0316346B1 |	Alive	SANOFI SA	VACINA gERAL
BR200417509A	2007-05-08	2004-12-09	APOVIA INC | FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY	molécula de proteína quimérica de núcleo de vírus da hepatite b (hbc) recombinante,	Novel recombinant hepatitis B virus core (HBc) protein chimer molecule comprising sequence of HBc and	A recombinant hepatitis B virus core (HBc) protein chimer molecule (I) with a length of 150-375	REDIVINDICAÇÕES 1. Molécula de proteína quimérica de núcleo de vírus da hepatite B (HBO)	US2003732862A | US2004787734A | WO2004US41879A	2003-12-10 | 2004-02-26 | 2004-12-09	B04-B03E | B04-B04C1 | B04-C01G | B04-E02H | B04-E08 | B04-F10A3E | B04-F10A8E | B04-	A61K003900 (IPC 1-7) | A61K003900 (IPC 1-7) | A61K0039145 (IPC 1-7) | A61K003929 (IPC 1-7) | A61K0039295	A61K003915 | A61K0039145 | A61K003912 | A61K0039292 | A61P003116 |	2005458506	WO2005055957A2 | EP1708748A2 | NO200603157A | AU2004296886A1 | BR200417509A |	Alive	20020221CA2420037A1	BR200417509A | AP2003002752A0 | AT546156T | AU2001285452B2 | AU2001854 52A |	Alive	APOVIA INC | FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY	Vacina Recombinante
BR200508064A	2007-07-17	2005-02-28	SANOFI AVENTIS	flavivírus, composição de vacina e molécula de ácido nucléico	New flavivirus comprising a hinge region mutation that attenuates flavivirus, useful in vaccine	Flavivirus (I) (comprising a hinge region mutation that attenuates (I)) is new. INDEPENDENT	REIVINDICAÇÕES 1. Flavivírus compreendendo uma mutação de região de dobradiça	US2004789842A | WO2005US5949A	2004-02-27 | 2005-02-28	B04-F11B0E | B11-C08E | B12-K04E | B14-S11A | B14-S11D2 | D05-H07 | D05-H09 | D05-H12F	A61K000700 (IPC 1-7) | C07H002104 (IPC 1-7) | C12Q000170 (IPC 1-7) | A61K003900 |	C07K0014005 | A61K003912 | A61P003112 | A61P003114 | C12N000700 |	2006471949	WO2005082020A2 | AU2005216248A1 | EP1755539A2 | KR2006135844A | BR200508064A |	Dead	20031218CA2473321A1	BR200508064A | AU2003267937A1 | AU2003267937B2 | AU2003267937C1 | AU2005216248A1 |	Alive	SANOFI SA	Vacina Geral
BR200512421A	2008-03-04	2005-04-20	MERIAL	recombinantes de avipox expressando genes do vírus da doença febre aftosa	Novel recombinant avipox vector comprising nucleic acid molecule encoding foot-and-	A recombinant avipox vector (V1) comprising at least one nucleic acid molecule encoding	REIVINDICAÇÕES 1. Vetor deavipox recombinante compreendendo pelo menos uma	US2004563786P | WO2005US13523A	2004-06-25 | 2005-04-20	B04-E02F | B04-E08 | B04-F11A0E | B14-A02B3 | B14-S11A | C04-E02F | C04-E08 | C04-F11A0E | C14-	C12N001583 (IPC 1-7) | A61K003912 | A61K0039135 | C12N0015863 | C12N000700 |	A61K0039135 | A61K003912 | C12N000700 | A61K20395256 | A61K203953 |	2006056025	US2005028767 2A1 | WO2006073431A2 | EP1773387A2 | BR200512421A | US7527960B2 |	Alive	20051229US2005028767 2A1	BR200512421A | BRPI0512421B1 | CA2571560A1 | CA2571560C | DK1773387T3 |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina e Vetor
BRPI0607551A2	2009-09-15	2006-04-13	MERIAL	vacinas de combinação de helicobacter e circovírus porcino e métodos de uso	Immunogenic composition for eliciting immunological response against	An immunogenic composition for eliciting an immunological response against	REIVINDICAÇÕES 1. Composição imunogênica para provocar uma reação imunológica contra	US2005107219A | WO2006US13935A	2005-04-15 | 2006-04-13	B04-B04C1 | B04-E08 | B04-F1100E | B14-A01A | B14-A02A | B14-E08 | B14-E11 | B14-S11 | B14-S12 |	A61K003902 | A61K003912 | A61K0039285 | A61K0039295 | C07K001401 |	A61K003912 | A61K0039105 | C07K0014005 | C07K0016081 | C12N000700 |	2006814865	WO2006113372A2 | EP1871884A2 | CN101198699A | CA2604705A1 | TW200719912A |	Dead	19990409FR2769321A1	BRPI0607551A2 | AR53711A1 | AT245191T | AT299531T | AT364624T |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
BRPI0609949A2	2010-05-11	2006-04-24	SANOFI AVENTIS	FLAVIVÍRUS RECOMBINANTE, SEU USO NA PREPARAÇÃO DE VACINA,	New recombinant flavivirus comprises a mutation that provides a small decrease in	A recombinant flavivirus comprising a mutation that provides a small decrease in	1. Flavivírus recombinante que compreende uma mutação que fornece uma	US2005674415P | US2005674546P | WO2006US15241A	2005-04-24 | 2005-04-25 | 2006-04-24	B04-E02 | B04-F11B0E | B14-A02B9 | B14-S11A | B14-S11D2 | C04-E02 | C04-F11B0E | C14-	A61K003912 (IPC 1-7) | A61K003929 (IPC 1-7) | C07H002102 (IPC 1-7) | C12N000701 (IPC 1-	C12N000700 | A61P003114 | C07K0014005 | C12N271016234 | C12N277024122 |	2006815053	WO2006116182A1 | EP1874346A1 | AU2006239954A1 | US20080175862A1 | IN200705297P4 |	Alive	20060427AU2005295438A1	BRPI0609949A2 | AU2005295438A1 | AU2005295438B2 | AU2006239954A1 | CA2584228A1 |	Alive	SANOFI SA	Vacina Recombinante
BRPI0613287A2	2010-12-28	2006-06-07	SANOFI PASTEUR	CEPA DO VÍRUS DA DENGUE-2 VIVO ATENUADA, COMPOSIÇÃO IMUNOGÊNICA,	Novel live attenuated dengue-2 virus strain comprising live attenuated vaccine	A live attenuated dengue-2 virus strain comprising live attenuated vaccine 2 (LAV2) having a fully	1. CEPA DO VÍRUS DA DENGUE-2 VIVO ATENUADA, caracterizada pelo fato de que	US2005691274P | WO2006IB1513A	2005-06-17 | 2006-06-07	B04-E02 | B04-F11B | B04-N03E0E | B14-A02B9 | B14-S11A | B14-S11D2 | D05-H07 | D05-H12B2 |	C12N000708 (IPC 1-7) | A61K003912 | A61K0039193 | A61P003114 | C07H002102 |	C12N000700 | C12N000704 | C12N000708 | A61K003912 | A61P003114 |	2007150704	WO2006134443A1 | US20070026016A1 | EP1891210A1 | NO200706360A | AU2006257621A1 |	Alive	20061221AU2006257621A1	BRPI0613287A2 | AR53914A1 | AT475706T | AU2006257621A1 | AU2006257621B2 |	Alive	SANOFI SA	Vacina de vírus atenuado
BRPI0613328A2	2011-01-04	2006-05-18	SANOFI PASTEUR	CEPA DO VÍRUS DA DENGUE-1 VIVO ATENUADO, COMPOSIÇÃO IMUNOGÊNICA,	New live attenuated dengue-1 virus strain comprising a specific nucleotide sequence useful for	A live attenuated dengue-1 virus strain (DV1) comprising a specific sequence containing 10735	1. GEPA DO VÍRUS DA DENGUE-1 VIVO ATENUADO, caracterizada pelo fato de que	US2005691243P | WO2006IB1313A	2005-06-17 | 2006-05-18	B04-E02 | B04-F11B | B04-N03E0E | B14-A02B9 | B14-S11A | B14-S11D2 | D05-H07 | D05-H12B2 |	C07K001418 (IPC 1-7) | A61K003912 | A61K0039193 | A61K0039295 | A61P003114 |	C07K0014005 | A61K003912 | A61P003114 | C12N000700 | A61K20395254 |	2007150701	WO2006134433A1 | US20060292172A1 | EP1893637A1 | NO200706355A | AU2006257610A1 |	Alive	20061221AU2006257610A1	BRPI0613328A2 | AR53913A1 | AU2006257610A1 | AU2006257610B2 | CA2611934A1 |	Alive	SANOFI SA	Vacina de vírus atenuado

<table>
<tr><td>BRPI0618850A2</td><td>2011-09-13</td><td>2006-11-15</td><td>SANOFI PASTEUR</td><td>FORMULAÇÕES DE ESTABILIZAÇÃO PARA VÍRUS RECOMBINANTES</td><td>New formulation comprising sugar, preservative, dispersing agent, thermal stability</td><td>A new formulation comprising a sugar, a preservative, a dispersing agent, a thermal stability</td><td>REIVINDICAÇÕES 1. Formulação para manutenção de um vírus em uma forma estável, a</td><td>US2005597280P | WO2006CA1855A</td><td>2005-11-21 | 2006-11-15</td><td>B04-B04C8 | B04-C03A | B04-E02J | B04-E03J | B04-F1100E | B07-A02 | B10-A07B | B10-A17</td><td>C12N000700 (IPC 1-7) | A61K003900 | A61K0039002 | A61K0039008 | A61K0039012 |</td><td>A61K00390011 | A61K0039001104 | A61K0039001106 | A61K0039001134 | A61K0039001149 |</td><td>2007420152</td><td>WO2007056847A1 | EP1951865A1 | AU2006315026A1 | KR2008070866A | CN101360821A |</td><td>Dead</td><td>20070524AU2006315026A1</td><td>BRPI0618850A2 | AU2006315026A1 | AU2006315026B2 | CA2630349A1 | CN101360821A |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BRPI0714721A2</td><td>2013-04-24</td><td>2007-07-16</td><td>SANOFI PASTEUR</td><td>CONSTRUÇÃO DE VACINAS DE VÍRUS RECOMBINANTE POR INSERÇÃO DIRETA MEDIADA POR</td><td>Generating viral genome comprising a nucleic acid encoding a heterologous</td><td>Generating a viral genome comprising a nucleic acid molecule encoding a heterologous</td><td>1. Método para gerar um genoma viral compreendendo uma molécula de ácido nucléico que</td><td>US2006831013P | US2007880353P | WO2007US16078A</td><td>2006-07-14 | 2007-01-12 | 2007-07-16</td><td>B04-E02 | B04-E03 | B04-E08 | B04-F1100E | B04-N04 | B05-A01B | B11-C01A1 | B11-C10C |</td><td>A61K003912 (IPC 1-7) | A61K00317088 | A61K003576 | A61K003900 | A61K003912 |</td><td>C12N000700 | A61P003100 | A61P003112 | A61P003500 | A61P003704 |</td><td>2008D55922</td><td>WO2008036146A2 | WO2008036146A3 | EP2043681A2 | IN200900843P4 | AU2007297801A1 |</td><td>Alive</td><td>20080327AU2007297801A1</td><td>BRPI0714721A2 | AU2007297801A1 | CA2659592A1 | CA2659592C | CN101528254A |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BRPI0817247A2</td><td>2015-06-16</td><td>2008-09-26</td><td>SANOFI PASTEUR</td><td>PROCESSO DE PRODUÇÃO DO VIRUS DA GRIPE, APLICAÇÃO DO REFERIDO</td><td>Producing influenza virus, useful for producing vaccine against influenza, comprises</td><td>Production of influenza virus, comprises: (a) administering a vaccine against</td><td>Revendications 1. Un procédé de production du virus de la grippe selon lequel : a. On</td><td>FR200757884A | WO2008FR51730A</td><td>2007-09-26 | 2008-09-26</td><td>B04-E08 | B14-A02B2 | B14-G01 | B14-S11A | B14-S11D3 | C04-E08 | C14-A02B2 | C14-</td><td>A61K (IPC 1-7) | C12N000704 (IPC 1-7) | A61K0039145 (IPC 1-7) | A61P (IPC 1-7) | A61P003116</td><td>A61K0039145 | A61K003912 | A61P003116 | A61P003704 | C12N000700 |</td><td>2009G32141</td><td>FR2921387A1 | US20090081255A1 | WO2009050390A2 | WO2009050390A3 | TW200923093A |</td><td>Alive</td><td>20090326US20090081255A1</td><td>BRPI0817247A2 | AR68541A1 | AU2008313576A1 | AU2008313576B2 | CA2700288A1 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BRPI0908936A2</td><td>2017-03-28</td><td>2009-03-16</td><td>SANOFI PASTEUR</td><td>VACINAS DE FLAVIVÍRUS DE REPLICAÇÃO DEFEITUOSA E VETORES DE VACINA</td><td>New replication-deficient pseudoinfectious flavivirus comprising a flavivirus genome,</td><td>A replication-deficient pseudoinfectious flavivirus comprising a flavivirus genome</td><td>Claims I claim: 1. A replication-deficient pseudoinfectious</td><td>US200869451P | US200892814P | WO2009US1666A</td><td>2008-03-14 | 2008-08-29 | 2009-03-16</td><td>B04-E01 | B04-F11B0E | B14-G01 | B14-S11D2 | B14-S11D3 | C04-E01 | C04-F11B0E | C14-</td><td>A61K (IPC 1-7) | A61K0039205 (IPC 1-7) | A61K003576 | A61K003900 | A61K0039012 |</td><td>C12N001586 | A61K003912 | A61K0039155 | A61K0039205 | A61K0039295 |</td><td>2009N70283</td><td>WO2009114207A2 | WO2009114207A3 | AU2009223727A1 | EP2265284A2 | KR2011002845A |</td><td>Alive</td><td>20090917AU2009223727A1</td><td>BRPI0908936A2 | AU2009223727A1 | AU2009223727B2 | CA2717499A1 | CN102202687A |</td><td>Alive</td><td>SANOFI SA</td><td>Vacina Geral</td></tr>
<tr><td>BRPI0909820A2</td><td>2015-08-11</td><td>2009-03-02</td><td>SANOFI PASTEUR</td><td>PROCESSO PARA ESTABILIZAÇÃO DE COMPOSIÇÃO DE VACINA CONTRA GRIPE, PARA</td><td>Stabilizing influenza vaccine composition comprises diluting liquid bulk composition,</td><td>Stabilizing an influenza vaccine composition comprises: (a) diluting a liquid bulk</td><td>Claims 1. A process for stabilizing an influenza vaccine composition</td><td>EP2008290216A | WO2009EP52460A</td><td>2008-03-05 | 2009-03-02</td><td>A12-V01 | B04-A07E | B04-B01B | B04-B04C1 | B04-C02F | B04-C03 | B04-F10 | B04-F11 | B04-N03 |</td><td>A61K (IPC 1-7) | A61K0039145 (IPC 1-7) | A61K000914 (IPC 1-7) | A61K003900 | A61K003902 |</td><td>A61K00091694 | A61K003908 | A61K0039145 | A61K000914 | A61K000916 |</td><td>2009N52579</td><td>WO2009109550A1 | US20090232894A1 | AU2009221180A1 | MX2010008799A | EP2254594A1 |</td><td>Alive</td><td>20090911AU2009221180A1</td><td>BRPI0909820A2 | AR70800A1 | AU2009221180A1 | AU2009221180B2 | CA2716399A1 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>BRPI0915813A2</td><td>2019-04-09</td><td>2009-07-09</td><td>SANOFI PASTEUR</td><td>ESTABILIZANTE E COMPOSIÇÃO DE VACINA COMPREENDENDO UM OU MAIS</td><td>Stabilizing agent, for vaccine compositions comprising live attenuated flavivirus</td><td>Stabilizing agent (I) for vaccine compositions comprising one or more live attenuated</td><td>What is claimed is: 1. A stabilizer for vaccine compositions comprising one or</td><td>EP2008305390A | WO2009EP4980A</td><td>2008-07-09 | 2009-07-09</td><td>B04-D01 | B04-F11B | B06-D01 | B07-A02 | B07-D03 | B07-D09 | B10-A07B | B10-A17 | B10-B01B |</td><td>A61K (IPC 1-7) | A61K003912 (IPC 1-7) | A61K003912 | A61K0039125 | A61K0039295 |</td><td>A61K003912 | C12N000700 | A61K0031185 | A61K003900 | A61P003100 |</td><td>2010A60396</td><td>EP2143440A1 | US20100015180A1 | WO2010003670A1 | AU2009267401A1 | CA2729758A1 |</td><td>Alive</td><td>20100113EP2143440A1</td><td>BRPI0915813A2 | AR72796A1 | AU2009267401A1 | AU2009267401B2 | CA2729758A1 |</td><td>Alive</td><td>SANOFI SA</td><td>método/Processo</td></tr>
<tr><td>BRPI1014164A2</td><td>2020-12-01</td><td>2010-04-08</td><td>SANOFI PASTEUR</td><td>PROCESSOS PARRA PURIFICAR O VÍRUS DA RAIVA E PARA FABRICAR UMA VACINA CONTRA A</td><td>Purifying rabies virus comprises contacting supernatant of cell culture infected by</td><td>Purifying rabies virus (I), comprising a single step of ion exchange chromatography,</td><td>REVENDICATIONS 1. Un procédé de purification du virus rabique comprenant une seule étape de</td><td>FR200952310A | US2009231394P | WO2010FR50679A</td><td>2009-04-08 | 2009-08-05 | 2010-04-08</td><td>A04-A | A04-F06E | A12-L04A | B04-F11B | B14-G01 | B14-S11A | B14-S11D2 | C04-F11B | C14-G01</td><td>C12N (IPC 1-7) | C12N000702 (IPC 1-7) | A61K (IPC 1-7) | A61K0039205 (IPC 1-7) | A61K0039205 |</td><td>A61K0039205 | A61P003114 | C12N000700 | A61K003912 | C12N276020134 |</td><td>2010N08946</td><td>WO2010116096A1 | US20100260798A1 | AU2010233602A1 | CA2757895A1 | CN102282253A |</td><td>No associated DWPI family status</td><td>20101014CA2757895A1</td><td>BRPI1014164A2 | AR76242A1 | AU2010233602A1 | AU2010233602B2 | CA2757895A1 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>CN103031279B</td><td>2015-11-18</td><td>2006-04-24</td><td>SANOFI AVENTIS</td><td>重组黄病毒疫苗</td><td>Attenuated Flavivirus, useful for preparing a vaccine against Japanese Encephalitis Virus,</td><td>A recombinant Flavivirus comprising a membrane protein mutation, is new. INDEPENDENT</td><td>1.包含YF17D株黄热病病毒的嵌合黄病毒，其中该黄热病病毒中的膜蛋白和包膜蛋白用NY99株</td><td>US2005674415P | US2005674546P | CN200680022652A</td><td>2005-04-24 | 2005-04-25 | 2006-04-24</td><td>B04-E02 | B04-F11B0E | B14-A02B9 | B14-S11A | B14-S11D2 | D05-H07 | D05-H12B2 | D05-</td><td>A61K003912 (IPC 1-7) | C12Q000170 (IPC 1-7) | A61P004300 (IPC 1-7) | A61K003912 |</td><td>C07K0014005 | C12N000700 | A61P003114 | A61P003120 | A61P003704 |</td><td>2006332034</td><td>WO2006044857A2 | EP1809325A2 | NO200701924A | AU2005295438A1 | US20070269458A1 |</td><td>Alive</td><td>20060427AU2005295438A1</td><td>CN103031279B | AU2005295438A1 | AU2005295438B2 | AU2006239954A1 | BRPI0609949A2 |</td><td>Alive</td><td>SANOFI SA</td><td>Vacina de vírus atenuado</td></tr>
<tr><td>EP1572234A2</td><td>2005-09-14</td><td>2003-12-10</td><td>SANOFI PASTEUR</td><td>STABILISIERTE IMMUNOGENE CHIMÄRE HBC-PARTIKEL | PARTICULES</td><td>New recombinant chimer hepatitis B core (HBc) protein molecules useful in the fields of</td><td>A recombinant chimer hepatitis B core (HBc) protein molecule up to 600 or 380 amino acid</td><td>WHAT IS CLAIMED: 1. A recombinant chimer hepatitis B core (HBc) protein molecule up to</td><td>US2002432123P | WO2003US39164A</td><td>2002-12-10 | 2003-12-10</td><td>B04-B04C1 | B04-C01G | B04-N08 | B14-A02A5 | B14-N12 | B14-S11A | D05-H07</td><td>C12N (IPC 1-7) | A61K003900 | A61K003929 | A61K0039295 | A61K0039385 |</td><td>A61K0039292 | C07K0014005 | A61K003912 | A61K0039145 | A61P000116 |</td><td>2004468859</td><td>WO2004053091A2 | US20040146524A1 | AU2003300841A1 | EP1572234A2 | JP2006509026A |</td><td>Alive</td><td>20020221CA2420037A1</td><td>EP1572234A2 | AP2003002752A0 | AT546156T | AU2001285452B2 | AU200185452A |</td><td>Alive</td><td>SANOFI SA</td><td>Vacina Recombinante</td></tr>
<tr><td>EP2167651A1</td><td>2010-03-31</td><td>2008-06-26</td><td>SANOFI PASTEUR</td><td>VERFAHREN ZUR AUFREINIGUNG EINER VIRUSSUSPENSION | PROCEDE DE</td><td>Purifying a virus from a liquid suspension, e.g. for vaccine production, comprises subjecting</td><td>Purifying a virus from a liquid suspension comprises subjecting the suspension to continuous</td><td>REVENDICATIONS 1. Procédé d'obtention de virus à partir d'une suspension virale</td><td>FR20074607A | WO2008FR51170A</td><td>2007-06-27 | 2008-06-26</td><td>B04-F11 | B05-A03B | B07-A02 | B11-B03 | B14-S11 | D05-H06A | J01-K | J01-L01</td><td>A61K0039145 | A61P003116 | B01D002432 | B01D003300 | B03B000532 |</td><td>C12N000700 | A61P003116 | C12N276016051</td><td>2009B39990</td><td>FR2918074A1 | US20090023197A1 | WO2009007608A1 | AU2008274015A1 | EP2167651A1 |</td><td>Alive</td><td>20090102FR2918074A1</td><td>EP2167651A1 | AU2008274015A1 | AU2008274015B2 | CN101688188A | CN101688188B |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>EP2173865A2</td><td>2010-04-14</td><td>2008-07-10</td><td>SANOFI PASTEUR</td><td>VORRICHTUNG UND VERFAHREN ZUR GEWINNUNG BIOLOGISCHER WIRKSTOFFE AUS</td><td>Opening an egg; comprises positioning the egg in a reference opening so as to</td><td>Opening an egg; comprising: (a) positioning the egg in a reference opening so as to</td><td>What is claimed is: 1. A method for opening an egg; comprising: (a) positioning the egg</td><td>US2007948982P | WO2008US69660A</td><td>2007-07-10 | 2008-07-10</td><td>B04-F03 | B11-C06 | D05-H</td><td>C12N000700 | A23J000100 | A47J004314 | A61K003912 | C12M000100 |</td><td>A61K0039145 | A47J0043145 | A61K003912 | C12N000700 | C12N276016134 |</td><td>2009B45351</td><td>WO2009009670A2 | US20090053803A1 | WO2009009670A3 | WO2009009670A4 | EP2173865A2 |</td><td>Alive</td><td>20090115CA2692744A1</td><td>EP2173865A2 | CA2692744A1 | CA2692744C | EP2173865A4 | EP2173865B1 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>EP2414386A2</td><td>2012-02-08</td><td>2010-04-02</td><td>MERIAL</td><td>VOGELIMPFSTOFFE MIT NEWCASTLE-KRANKHEIT-VEKTOR | VACCINS AVIAIRES TRANSPORTÉS PAR</td><td>Composition useful for eliciting immune response against pathogen, preferably influenza virus in</td><td>Composition comprises an engineered Newcastle disease virus (NDV) vector</td><td>CLAIMS 1. A composition comprising (i) an engineered NDV vector and (ii) a</td><td>US2009166481P | WO2010US29825A</td><td>2009-04-03 | 2010-04-02</td><td>B04-C01 | B04-E01 | B04-E02J | B04-E03J | B04-E08 | B04-E99 | B04-F11B0E | B14-A02B2 | B14-G01 |</td><td>C07K001411 (IPC 1-7) | A61K0031713 | A61K003576 | A61K003900 | A61K003912 |</td><td>A61K0039145 | A61K003912 | A61K003917 | A61K0039275 | A61P003112 |</td><td>2010M77396</td><td>US20100255029A1 | WO2010115133A2 | WO2010115133A3 | CA2757030A1 | WO2010115133A8 |</td><td>Alive</td><td>20101007CA2757030A1</td><td>EP2414386A2 | CA2757030A1 | CA2757030C | CN102428099A | CN102428099B |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina Recombinante</td></tr>
<tr><td>EP2443232A2</td><td>2012-04-25</td><td>2010-06-15</td><td>CILIAN AG</td><td>SYSTEM FÜR DIE HETEROLOGE EXPRESSION EINES VIRENPROTEINS IN EINER</td><td>System for heterologous expression of viral protein in ciliate host cell, used to treat</td><td>A system for the heterologous expression of a viral protein and/or its fragment, comprises</td><td>What is claimed is: 1. A system for the heterologous expression of a viral protein or a</td><td>GB200910357A | WO2010EP58360A</td><td>2009-06-17 | 2010-06-15</td><td>B04-E01 | B04-E02F | B04-E03F | B04-E08 | B04-E99 | B04-F06 | B04-F0600E | B04-N03K0E | B14-</td><td>C12N000702 (IPC 1-7) | A61K003816 | A61K003900 | A61K003912 | A61K0039145 |</td><td>C12N000700 | C12N001579 | A61K0038162 | A61K003912 | A61K0039145 |</td><td>2010Q56714</td><td>GB2471093A | WO2010146043A2 | US20110008835A1 | WO2010146043A3 | CA2765799A1 |</td><td>Alive</td><td>20090729GB200910357D0</td><td>EP2443232A2 | CA2765799A1 | CA2765799C | CN102712909A | CN107083393A |</td><td>Alive</td><td>CILIAN AG</td><td>Vacina Recombinante</td></tr>
<tr><td>EP2475384A1</td><td>2012-07-18</td><td>2010-09-09</td><td>MERIAL</td><td>NEUE IMPFSTOFFFORMULIERUNGEN MIT SAPONINHALTIGEN HILFSSTOFFEN |</td><td>Vaccine composition of injectable oil-in-water emulsion, used to induce immune response</td><td>Vaccine composition comprising an injectable oil-in-water emulsion, comprises: an</td><td>What is claimed is: 1 . A vaccine composition comprising an injectable oil-in-</td><td>US2009241171P | WO2010US48256A</td><td>2009-09-10 | 2010-09-09</td><td>A12-V01 | B04-B01C3 | B04-C03 | B04-E08 | B05-A01B | B07-A02A | B10-C04E5 | B10-J02 |</td><td>A61K003902 (IPC 1-7) | A61K0039135 (IPC 1-7) | A61K003912 (IPC 1-7) | A61K0039295</td><td>A61K003900 | A61K003939 | A61K00090019 | A61K0009107 | A61K00390241 |</td><td>2011C67465</td><td>WO2011031850A1 | US20110129494A1 | AU2010292233A1 | CA2773486A1 | EP2475384A1 |</td><td>Alive</td><td>20110317CA2773486A1</td><td>EP2475384A1 | AR78169A1 | AU2010292233A1 | AU2010292233B2 | CA2773486A1 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Vacina Recombinante</td></tr>
<tr><td>EP2519635A1</td><td>2012-11-07</td><td>2010-12-28</td><td>SANOFI AVENTIS</td><td>HERSTELLUNG HETEROLOGER POLYPEPTIDE IN MIKROALGEN, EXTRAZELLULÄRE</td><td>Producing viral protein e.g. hemagglutinin protein and neuraminidase</td><td>Method (M1) for producing viral protein chosen from hemagglutinin (HA) protein,</td><td>WHAT IS CLAIMED IS: 1. A method for production of a viral protein selected</td><td>US2009290469P | US2009290441P | US2010413353P | WO2010US62276A</td><td>2009-12-28 | 2009-12-28 | 2010-11-12 | 2010-12-28</td><td>B04-C01G | B04-E99 | B04-F08A0E | B04-L05B0E | B04-N03K0E | B04-N0600E | B04-N08 |</td><td>C12N001544 (IPC 1-7) | A61K003912 | A61K0039145 | A61P003116 | C07K0014005 |</td><td>C12P002102 | A61K0039145 | A61P003112 | A61P003116 | A61P003704 |</td><td>2011J61760</td><td>WO2011090731A1 | CA2785971A1 | AU2010343095A1 | EP2519635A1 | CN102822343A |</td><td>Alive</td><td>20100916US20100233760A1</td><td>EP2519635A1 | AR75860A1 | AU2010225930A1 | AU2010225930B2 | AU2010339544A1 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>EP2519636A1</td><td>2012-11-07</td><td>2010-12-28</td><td>MERIAL | ROYAL DSM NV</td><td>HERSTELLUNG EINES HÄMAGGLUTININ-NEURAMINIDASE-PROTEINS IN MIKROALGEN |</td><td>Recombinant microalgal cell useful for production of hemagglutinin-neuraminidase</td><td>Recombinant microalgal cell comprises a nucleic acid molecule comprising a</td><td>WHAT IS CLAIMED IS: 1. A method for production of a hemagglutinin-</td><td>US2009290469P | WO2010US62274A</td><td>2009-12-28 | 2010-12-28</td><td>B04-E99 | B04-F08A0E | B04-L05B0E | B04-N0200E | B04-N08 | B14-S11A | B14-</td><td>C12N001545 (IPC 1-7) | A61K003917 (IPC 1-7) | A61K003917 | C07H002104 | C07K000100 |</td><td>C12Y030201018 | C12N000700 | C12N00092402 | C12N00158257 | C12N276018151 |</td><td>2011H78616</td><td>WO2011082189A1 | US20110195480A1 | CA2785867A1 | AU2010339544A1 | EP2519636A1 |</td><td>Alive</td><td>20100916US20100233760A1</td><td>EP2519636A1 | AR75860A1 | AU2010225930A1 | AU2010225930B2 | AU2010339544A1 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG | ROYAL DSM NV</td><td>Método/Processo</td></tr>
<tr><td>EP2687229A1</td><td>2014-01-22</td><td>2009-07-09</td><td>SANOFI PASTEUR</td><td>Stabilisator und Impfstoffzusammensetzung mit einem oder mehreren lebenden</td><td>Stabilizer, useful in vaccine composition for preparing vaccine, comprises live attenuated</td><td>Stabilizer comprises one or more live attenuated Flaviviruses, which comprises, in an</td><td>1. A stabilizer for vaccine compositions comprising one or more live attenuated</td><td>EP2008305390A | EP2009793888A</td><td>2008-07-09 | 2009-07-09</td><td>B04-D01 | B04-F11B | B04-F11B0E | B10-B02C | B14-A02B9 | B14-S11A | B14-S11D2 | B14-S11D3 |</td><td>A61K003912</td><td>A61K003912 | C12N000700 | A61K0031185 | A61K003900 | A61P003100 |</td><td>2014B91893</td><td>EP2687229A1</td><td>Dead</td><td>20100113EP2143440A1</td><td>EP2687229A1 | AR72796A1 | AU2009267401A1 | AU2009267401B2 | BRPI0915813A2 |</td><td>Alive</td><td>SANOFI SA</td><td>Método/Processo</td></tr>
<tr><td>EP2714722A1</td><td>2014-04-09</td><td>2012-05-23</td><td>BOEHRINGER INGELHEIM GMBH</td><td>GENETISCHER IMPFSTOFF GEGEN HENDRA- UND NIPAH-VIRUS | VACCINS</td><td>Composition used for e.g. inducing an immunogenic or protective response against Hendra virus</td><td>Composition comprises at least one expression vector, where the vector comprises a</td><td>CLAIMS 1. A composition comprising one or more expression vectors, wherein the</td><td>US2011491037P | WO2012US39026A</td><td>2011-05-27 | 2012-05-23</td><td>B04-B04C1 | B04-E08 | B04-E99 | B04-F11A0E | B14-G01 | B14-S03A | B14-S11A | C04-B04C1 |</td><td>A61K0039155 (IPC 1-7) | C07K0014115 (IPC 1-7) | A61K00317088 | A61K0039155 |</td><td>A61K0039155 | A61K003912 | C07K0014005 | C12N000700 | A61K2039505 |</td><td>2012Q65442</td><td>US20120301479A1 | WO2012166450A1 | AU2012262740A1 | CA2837582A1 | EP2714722A1 |</td><td>Alive</td><td>20121129US20120301479A1</td><td>EP2714722A1 | AU2012262740B2 | CA2837582A1 | CA2837582C | EP2714722B1 |</td><td>Alive</td><td>C.H. BOEHRINGER SOHN AG & CO KG</td><td>Método/Processo</td></tr>
<tr><td>EP2734230A1</td><td>2014-05-28</td><td>2012-02-02</td><td>CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC | UNIVERSITE PARIS-SUD 11 | MERIAL |</td><td>REKOMBINANTE KATZENLEUKÄMIEVIRUSVAKZINE DIE EIN OPTIMIERTES GEN DES HÜLLPROTEINS</td><td>New isolated polypeptide, comprising specific amino acid sequences, useful in</td><td>Isolated polypeptide, comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 (both</td><td>CLAIMS 1. A composition comprising: a) an expression vector comprising a</td><td>US2011509912P | WO2012US23658A</td><td>2011-07-20 | 2012-02-02</td><td>B04-C01G | B04-E02F | B04-E08 | B04-E99 | B04-F0100E | B04-F1100E | B04-N03K1 | B14-S11A |</td><td>A61K003912 (IPC 1-7) | C07K0014005 (IPC 1-7) | C12N001586 (IPC 1-7) | A61K003576 |</td><td>A61K003921 | C07K0014005 | A61K003104 | A61K0038162 | A61K003912 |</td><td>2012J24524</td><td>US20120183569A1 | AU2012284558A1 | CA2842055A1 | EP2734230A1 | HK1192454A |</td><td>Alive</td><td>20051013AU2005229411A1</td><td>EP2734230A1 | AT472334T | AU2005229411A1 | AU2005229411B2 | AU2012284558A1 |</td><td>Alive</td><td>CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC | UNIVERSITE PARIS-SUD 11 | C.H.</td><td>Vacina Recombinante</td></tr>
</table>

EP2741740A1	2014-06-18	2012-05-31	MERIAL	VAKUUMUNTERSTÜTZTE METHODE ZUR KONSERVIERUNG BIOLOGISCHER PRODUKTE,	Process for vitrifying biological material used for providing immune functions, involves formulating	Process for vitrifying biological material, involves formulating liquid biological preparation,	What is Claimed is: 1. A process for vitrifying biological material comprising the steps of	WO2011490987P | WO2012US40230A	2011-08-12 | 2012-05-31	B04-B03B | B04-B04C | B04-F01 | B04-F10 | B04-F11 | B04-N04 | B14-G01 | B14-S11D2 | C04-	A61K000919 (IPC 1-7) | F26B000506 (IPC 1-7) | A61K00317088 | A61K003800 | A61K003900 |	A61K000919 | C12N000700 | F26B000506 | A61K00090019 | A61K003513 |	2013C25125	US20130040370A1 | WO2013025274A1 | CA2844927A1 | EP2741740A1 | CN103841963A |	Alive	20130214US20130040370A1	EP2741740A1 | CA2844927A1 | CA2844927C | CN103841963A | CN103841963B |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Método/Processo
EP2802649A1	2014-11-19	2013-01-09	SANOFI PASTEUR	AUFREINIGUNG VON HERPESVIRUS | PURIFICATION DES HERPÈS VIRUS	Purifying herpes simplex virus particles from mammalian host cell culture, by treating	Purifying herpes simplex virus (HSV) particles from mammalian host cell culture, involves (a)	CLAIMS 1. A method for the purification of herpes simplex virus (HSV) particles from	US2012584461P | US2012649625P | WO2013US20780A	2012-01-09 | 2012-05-21 | 2013-01-09	A10-E24 | A12-M | A12-V01 | A12-W11L | B04-F11A | B04-L05A | B11-B03A | B14-G01 | B14-S11 |	A61K0039245 | A61K003912 | A61P003122 | A61P003704 | B01D001500 |	A61K0039245 | A61K003912 | B01D0015363 | C12N000700 | A61K20395254 |	2013L86837	WO2013106398A1 | CA2859916A1 | EP2802649A1 | US2015000495A1 | US9365832B2 |	Alive	20130718CA2859916A1	EP2802649A1 | AU2013208187A1 | AU2013208187B2 | CA2859916A1 | CA2859916C |	Alive	SANOFI SA	Método/Processo
EP3149479A2	2017-04-05	2015-05-29	SANOFI PASTEUR	EXPRESSION UND KONFORMATIONELLE ANALYSE VON MANIPULIERTEM INFLUENZA-	Analyzing expression and conformation of engineered hemagglutinin (HA) antigens, by	Method for analyzing expression and conformation of engineered hemagglutinin (HA)	We claim: 1. A method of analyzing expression and conformation of engineered	US62005728P | WO2015US33205A	2014-05-30 | 2015-05-29	B04-B04C2 | B04-E99 | B04-G01 | B04-G08 | B11-C07A5 | B11-C11 | B12-K04G | B14-A02B2 | B14-	A61K0039145 | C07K0014005 | C07K001411 | C07K001610 | G01N0033569 |	A61K0039145 | A61K003912 | A61K0039145 | C07K00161018 | C12N000700 |	2015778121	WO2015184272A2 | WO2015184272A3 | EP3149479A2 | US20170121373A1 | CA2986096A1 |	Indeterminate	20151203CA2986096A1	EP3149479A2 | CA2986096A1 | US20170121373A1 | WO2015184272A2 | WO2015184272A3	Indeterminate	SANOFI SA	Método/Processo
EP3182998A1	2017-06-28	2015-08-18	SANOFI PASTEUR	ALKYLIERTE INFLUENZAMPFSTOFFE | VACCINS CONTRE LA GRIPPE ALKYLÉS	Vaccine useful for preventing and treating influenza virus infection, comprises	Influenza vaccine comprises hemagglutinin comprising one or more alkylated	We claim: 1. An influenza vaccine comprising a hemagglutinin containing one or	US62038753P | WO2015US45689A	2014-08-18 | 2015-08-18	A12-W11L | B04-B04C1 | B04-N03K | B14-A02B2 | B14-S11A | D05-H07	A61K0039145 (IPC 1-7) | A61K003900 | A61K003912 | A61K0039145 | A61P003116 |	A61K0039145 | A61P003116 | A61P003704 | C12N000700 | A61K20395252 |	20161028D	US20160045590A1 | WO2016028776A1 | AU2015305690A1 | CA2957570A1 | KR2017042605A |	Alive	20160218US20160045590A1	EP3182998A1 | AU2015305690A1 | CA2957570A1 | CN106794241A | JP2017525766A |	Alive	SANOFI SA	Método/Processo
EP3294876A1	2018-03-21	2016-05-13	BOEHRINGER INGELHEIM GMBH	VERFAHREN ZUR HERSTELLUNG VON PORCINEM CIRCOVIRUS UND VON PCV2-	Producing porcine circovirus type 2 (PCV2) by preparing porcine kidney 15 cells (PK15) for	Method for producing porcine circovirus type 2 (PCV2), involves (a) preparing porcine	WHAT IS CLAIMED IS: 1. A method of producing porcine circovirus type 2	US62161457P | WO2016US32323A	2015-05-14 | 2016-05-13	B04-E99 | B04-F01 | B04-F11 | B14-S11A | B14-S11D1 | C04-E99 | C04-F01 | C04-F11 | C14-S11A |	A61K003912 | C12N000700 | C12N000702 | A61K003900 | C12N	A61K003912 | A61K20395252 | A61K23095552 | C12N275010034 |	201670475V	US2016033332A1 | WO2016183423A1 | EP3294876A1 | US9944904B2 | MX2017014414A |	Alive	20161117US20160333322A1	EP3294876A1 | HK1252427A1 | MX2017014414A | US10519427B2 | US20160333322A1 |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Método/Processo
EP3307761A1	2018-04-18	2016-06-09	SANOFI PASTEUR	VERFAHREN ZUR OPTIMIERUNG VON NUKLEOTIDSEQUENZEN, DIE MANIPULIERTE	Generating optimized nucleotide sequence for preparing influenza vaccine composition,	Generating an optimized nucleotide sequence involves providing an amino acid sequence of the	We claim: 1. A method of generating an optimized nucleotide sequence encoding	US62172949P | WO2016US36740A	2015-06-09 | 2016-06-09	B04-E01 | B04-E99 | B04-F11B0E | B04-N03K0E | B14-A02B2 | B14-G01 | B14-S11A | B14-S11D3 |	C07K001411 (IPC 1-7) | C07K001610 (IPC 1-7) | G01N0033569 (IPC 1-7) | C07K0014005 |	C07K001411 | C07K0014005 | C07K001610 | G01N0033569 | C12N276016122 |	2016770601	WO2016201127A1 | AU2016274770A1 | CA2986701A1 | SG11201709910A1 | EP3307761A1 |	Alive	20161215CA2986701A1	EP3307761A1 | AU2016274770A1 | AU2016274770B2 | CA2986701A1 | CN108290932A |	Alive	SANOFI SA	Método/Processo
EP3505632A1	2019-07-03	2010-12-28	SANOFI SA	HERSTELLUNG HETEROLOGER POLYPEPTIDE IN MIKROALGEN, EXTRAZELLULÄRE	Production of viral protein e.g. hemagglutinin protein, fusion protein or	Method (M1) of producing viral protein, involves culturing a recombinant	1. A method of producing a membrane protein, comprising: * providing a	US2009290441P | US2009290469P | US2010413353P | WO2010US2276A | EP2010844276A	2009-12-28 | 2009-12-28 | 2010-11-12 | 2010-12-28 | 2010-12-28	A61K003900 | A61K003912 | A61K0039145 | A61K003920S | A61P003112 |	C12P002102 | A61K0039145 | A61K003912 | A61P003112 | A61P003704 |	2011J88129	US20110189228A1 | JP2018121660A | EP3505632A1 | JP6666695B2 | JP2020096635A	Alive	20100916US20100233760A1	EP3505632A1 | AR75860A1 | AU2010225930A1 | AU2010225930B2 | AU2010339544A1 |	Alive	SANOFI SA	Método/Processo
EP3773709A1	2021-02-17	2019-03-27	FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY (VIB) | SANOFI PASTEUR	VERFAHREN ZUR HERSTELLUNG VON BREIT SCHÜTZENDEN IMPFSTOFFZUSAMM	Generating recombinant influenza neuraminidase polypeptide, by	Method for generating recombinant influenza neuraminidase (NA)	We claim: 1. A method for generating a recombinant influenza	US62649002P | US62718527P | WO2019US24327A	2018-03-28 | 2018-08-14 | 2019-03-27	B04-C01 | B04-E02H | B04-E08 | B04-E99 | B04-F0100E | B04-F0200E | B04-L05B0E | B04-N03K0E | B04-	A61K003900 | A61K003912 | A61K0039145 | C12N000700 | C12N000924 |	A61K0039145 | A61K003912 | C12N000700 | C12N00092402 | C12Y030201018 |	201983278S	WO2019191261A1 | CN112153981A | EP3773709A1 | US20210046176A1	No associated DWPI family status	20191003WO201919261A1	EP3773709A1 | CN112153981A | US20210046176A1 | WO2019191261A1	Alive	FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY (VIB) | SANOFI SA |	vacina recombinante
EP680331A1	1995-11-08	1994-01-21	INSTITUT MERIEUX	IMMUNOTHERAPIE PAR VIRUS RECOMBINE | IMMUNTHERAPIE DURCH	Attenuated recombinant virus used for cancer therapy comprises DNA encoding	A modified recombinant virus (A) has virus-encoded genetic functions	WHAT IS CLAIMED IS: 1. A modified recombinant virus, said modified	US19937115A | US1994184009A | WO1994U888A	1993-01-21 | 1994-01-19 | 1994-01-21	B04-F1100E | B14-A02 | B14-G01 | B14-H01B | B14-S11 | D05-H07 | D05-H12F | D05-H17A2 | D05-	C12N000700 (IPC 1-7) | A61K003576 (IPC 1-7) | A61K003800 (IPC 1-7) | A61K003816 (IPC 1-	C12N000700 | A61K00390011 | A61K0039001106 | A61K0039001138 | A61K0039001139 |	1994263767	WO1994016716A1 | AU199461652A | EP680331A1 | JP9503902A | AU684070B |	Dead	19821223IT1982249 48D0	EP680331A1 | AR241939A1 | AT198809007A | AT199009024A | AT199009025A |	Alive	INSTITUT MERIEUX	Vacina Recombinante
EP810876A1	1997-12-10	1995-07-20	SANOFI PASTEUR	KONJUGATE VON UNTEREINHEITEN DES INFLUENZAVIRUS | CONJUGUES DE	New protein conjugates partic. for use in vaccines obtd. by treating the protein to produce	A new method for forming a conjugate of a protein normally associated with cellular material	CLAIMS What we claim is: 1. A method of forming a conjugate of a protein normally	US1994280463A | WO1995US9235A	1994-07-26 | 1995-07-20	B04-N03 | B04-N04 | B07-D02 | B10-A18 | B14-S11 | D05-H07	A61K0039145 (IPC 1-7) | A61K003902 (IPC 1-7) | A61K0039385 (IPC 1-7) | C07K000110 (IPC 1-	C12N000700 | A61K003912 | A61K0039145 | A61K0039385 | A61P003116 |	1996116789	WO1996003145A1 | AU199532342A | ZA199505945B | NO199700080A | FI199700277A |	Dead	199511271IL114666D0	EP810876A1 | AT394120T | AU199532342A | AU707143B2 | CA2194183A1 |	Dead	SANOFI SA	Método/Processo
EP831899A1	1998-04-01	1996-06-03	SANOFI AVENTIS	REKOMBINANTE POXVIRUS-CALICIVIRUS ZUSAMMENSETZUNGEN UND	Modified recombinant virus contg. exogenous calicivirus DNA useful in vaccines	A novel modified recombinant virus (A) has virus-encoded genetic functions inactivated	-124 * WHAT IS CLAIMED IS; 1. A modified recombinant virus, said modified	US1995471025A | WO1996IB721A	1995-06-06 | 1996-06-03	B04-F1100E | B12-K04 | B14-S11A | C04-E05 | C04-F1100E | C04-G08 | C14-S11 | D05-H07 |	C12N001509 (IPC 1-7) | C12N001563 (IPC 1-7) | A61K003576 (IPC 1-7) | A61K003912 (IPC	C07K0014005 | A61P000704 | A61P003112 | A61P003702 | C07K001433 |	1997042857	WO1996039177A1 | AU199663152A | EP831899A1 | JP11511961A | US5989561A |	Dead	19821223IT1982249 48D0	EP831899A1 | AR241939A1 | AT198809007A | AT199009024A | AT199009025A |	Alive	SANOFI SA	Vacina Recombinante
EP868522A1	1998-10-07	1996-12-02	INSTITUT MERIEUX	VIRUS DE RECOMBINAISON COMBINE DE LA VARIOLE ET DE LA PERITONITE	A recombinant pox:virus containing feline infectious peritonitis virus sequences useful for	A recombinant poxvirus containing DNA from feline infectious peritonitis virus (FIPV) in a non-	WHAT IS CLAIMED IS: 1. A recombinant poxvirus containing therein DNA from	US1995566398A | WO1996US19274A	1995-12-01 | 1996-12-02	B04-E08 | B04-F1100E | B14-S11A | B14-S12 | C04-E08 | C04-F1100E | C14-S11A | C14-S12 |	C12N001509 (IPC 1-7) | C12N001563 (IPC 1-7) | A61K003576 (IPC 1-7) | A61K003912 (IPC	C07K0014005 | A61P002900 | A61P003100 | A61P003112 | A61P003120 |	1997310609	WO1997020054A1 | AU199712780A | EP868522A1 | US5858373A | JP2000501930A |	Dead	19970605CA2237807A1	EP868522A1 | AT237691T | AU199712780A | AU724172B2 | CA2237807A1 |	Dead	INSTITUT MERIEUX	Vacina Recombinante
EP910406A1	1999-04-28	1997-02-14	MERIAL	HERPESVIRUS CANINS RECOMBINES | REKOMBINANTE HUNDE-	Recombinant canine herpes virus and its genome useful as vaccine to protect canids against	Recombinant canine herpes virus (CHV) and its genome, are new. USEThe recombinant CHV or	What is claimed is : 1. A recombinant CHV. 2. A recombinant CHV genome.	US1996602010A | WO1997U4115A	1996-02-15 | 1997-02-14	B04-E01 | B04-F11 | B14-S11 | C04-E01 | C04-F1100E | C14-G02D | C14-H01 | C14-S11A | C14-S11B	C12N001509 (IPC 1-7) | A61K003170 (IPC 1-7) | A61K0039245 (IPC 1-7) | A61P003100 (IPC 1-	C12N001586 | A61P003100 | A61P003104 | A61P003110 | A61P003122 |	1997424758	WO1997029772A1 | AU199723278A | US5753235A | EP910406A1 | JP2000505297A |	Dead	19970821CA2243662A1	EP910406A1 | AT347375T | AU199723278A | AU728676B2 | CA2243662A1 |	Dead	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
JP0584837682	2016-01-27	2014-02-03	QUEEN'S UNIVERSITY OF BELFAST | UNIVERSITY OF SASKATCHEWAN |	The post-weaning multisystemic wasting syndrome virus from an pig|lid	New porcine circovirus from animals with porcine systemic wasting syndrome	A preparation of porcine circovirus (PCV) capable of being isolated from:a physiological or	1. Immunogenic pig circovirus II-type (PCVII) polypeptide including arrangement|seque	US199769233P | US199769750P	1997-12-11 | 1997-12-16	B04-C01 | B04-E01 | B04-E05 | B04-E08 | B04-F11 | B04-G21 | B04-G22 | B14-S11A | C04-C01 | C04-E01	A61K003170 (IPC 1-7) | A61K0031505 (IPC 1-7) | A61K004506 (IPC 1-7) | A61P003500 (IPC	C07K0014005 | A23C00190323 | A23C00190323 | A61K003912 | A61P003112 |	1999246947	FR2769321A1 | CN101445802A | PH11998002579B1 | CN101724606A | PH12008000394A1 |	Alive	19990409FR2769321A1	JP0584837682 | AR53711A1 | AT245191T | AT299531T | AT364624T |	Alive	QUEEN'S UNIVERSITY OF BELFAST | UNIVERSITY OF SASKATCHEWAN |	Vacina Recombinante
US20140341950A1	2014-11-20	2013-05-15	MERIAL	RECOMBINANT AVIAN PARAMYXOVIRUS VACCINE AND METHOD FOR	Composition useful for inducing immunological response in animal e.g. avian, equine,	Composition comprises recombinant avian paramyxoviruses (APMV) viral vector.	1-17. (canceled) 18. A composition or vaccine comprising a recombinant APMV viral vector.	US13894582A	2013-05-15	B04-E01 | B04-E02 | B04-E03 | B04-E08 | B04-E99 | B04-F11B | B04-F11B0E | B12-M19A | B14-A02B2 |	A61K0039155	C12N000700 | A61K003912 | A61K20395256 | A61K23954 | A61K2039541 |	2014U78658	US20140341950A1	Dead	20141120US20140341950A1	US20140341950A1	Dead	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
US20150110826A1	2015-04-23	2014-10-17	SANOFI AVENTIS	Production of Heterologous Polypeptides in Microalgae, Microalgal	Producing membrane protein, involves providing culture comprising recombinant	Method (M1) for producing a membrane protein, involves providing a culture comprising a	1-37. (canceled) 38. A method of producing a membrane protein, comprising:	US2009290441P | US2009290469P | US2010413353P | US2010980319A	2009-12-28 | 2009-12-28 | 2010-11-12 | 2010-12-28	B04-N03K | B04-N06 | B04-N08 | B14-S11 | D05-H07 | D05-H17A	A61K0039145 | C07K0014005 | C12N000700 | C12N000924 | C12P002102	C12P002102 | A61K0039145 | A61P003112 | A61P003116 | A61P003704 |	2015265543	US20150110826A1	Dead	20100916US20100233760A1	US20150110826A1 | AR75860A1 | AU2010225930A1 | AU2010225930B2 | AU2010339544A1 |	Alive	SANOFI SA	Método/Processo
US20150190503A1	2015-07-09	2015-01-06	UNIVERSITY OF CENTRAL FLORIDA | SANOFI PASTEUR	METHODS OF USING CEO2 AND TIO2 NANOPARTICLES IN MODULATION OF THE IMMUNE	Modulating an immune response comprises administering a pharmaceutical	Modulating an immune response in a subject comprises administering a pharmaceutical	1. A method of modulating an immune response in a subject comprising administering a	US2012668785P | WO2013US49578A	2012-07-06 | 2013-07-08	B04-B04C | B04-F04B1A | B04-F04B2A | B04-H02 | B04-H08 | B05-A03B | B14-A01A2 | B14-	A61K003324 | A61K0039245 | A61K003939 | A61K000914 | A61K000916 |	A61K003939 | A61K000919 | A61K000914 | A61K003324 | A61K003912 |	2014A80927	WO2014008503A1 | US20150190503A1	Dead	20140109WO2014008503A1	US20150190503A1 | WO2014008503A1	Dead	UNIVERSITY OF CENTRAL FLORIDA | SANOFI SA	método/Processo
US20200063174A1	2020-02-27	2019-09-03	SANOFI AVENTIS	Production of Heterologous Polypeptides in Microalgae, Microalgal	Making recombinant viral hemagglutinin (HA) protein, comprises providing recombinant	Making (M1) a recombinant viral hemagglutinin (HA) protein, comprises: providing a	1-37. (canceled) 38. A method of making a recombinant viral hemagglutinin (HA)	US2009290441P | US2009290469P | US2010413353P | US2010980319A | US14516634A	2009-12-28 | 2009-12-28 | 2010-11-12 | 2010-12-28 | 2014-10-17	B04-E99 | B04-N03K1 | B04-N06 | B12-M01B | B14-G01 | B14-S11A | B14-S11D3 | D05-C12 |	A61K0039145 | C07K0014005 | C12N000112 | C12N000700 | C12N000924 |	A61K0039145 | A61P003112 | A61P003116 | A61P003704 |	202017457Y	US20200063174A1	Alive	20100916US20100233760A1	US20200063174A1 | AR75860A1 | AU2010225930A1 | AU2010225930B2 | AU2010339544A1 |	Alive	SANOFI SA	Vacina Recombinante
US4327182A	1982-04-27	1981-01-22	AVENTIS SA	Purification of influenza sub-unit vaccine	Prepn. of purified influenza sub-unit vaccine by selective membrane filtration and surfactant	Prepn. of purified influenza sub-unit Vaccine contg. haemagglutin (HA) and neuraminidase	What I claim is: 1. A process for preparing a purified influenza sub-unit vaccine containing	US1981227240A	1981-01-22	B02-V | D05-H07	A61K003914 (IPC 1-7) | C12N000702 (IPC 1-7) | A61K0039145 | C12N000706	C12N000700 | A61K003912 | A61K00390145 | A61K20395252 | C12N276016134 |	198239261E	US4327182A | CA1177395A1	Dead	19820427US4327182A_	US4327182A | CA1177395A1	Dead	SANOFI SA	Método/Processo

US624554B1	2001-06-12	1991-11-25	AVENTIS SA	Production of virus and purification of viral envelope proteins for vaccine use	Envelope glyco-protein prepn. from enveloped virus e.g. para-myxoviral family, confers	Method of isolating an immunogenic glycoprotein (A) comprises: (a) growing an envelope	What we claim is: 1. A method of isolating immunogenic envelope	WO1990CA205A	1990-06-28	B02-V02 | B04-B04A6 | B12-M07 | D05-C12 | D05-H07	A61K0039155 (IPC 1-7) | C12P002100 (IPC 1-7) | C07K001514 (IPC 1-7) | C07K000320 (IPC 1-	C07K0014005 | C12N000700 | A61K003900 | C12N276018522 | C12N276018551 |	1991036585	WO1991000104A1 | EP480949A1 | JP4502410A | EP480949B1 | DE69023648D1 |	Dead	19890823GB1989149 68D0	US624554B1 | AT130198T | CA2056437A1 | CA2056437C | DE69023648D1 |	Dead	SANOFI SA	Método/Processo
US7361352B2	2008-04-22	2004-02-26	SANOFI AVENTIS | SANOFI PASTEUR	Influenza immunogen and vaccine	New recombinant hepatitis B virus core (HBc) protein chimer molecule that contains four	A recombinant hepatitis B virus core (HBc) protein chimer molecule with a length of 150-375	What is claimed is: 1. A recombinant hepatitis B virus core (HBc) protein chimer molecule with a	US2001930915A | US2002802299A | US2002820014A | US2002274616A | WO2003US5196A |	2001-08-15 | 2002-02-21 | 2002-02-21 | 2002-10-21 | 2003-02-21 | 2003-12-10	B04-E02F | B04-E08 | B04-F10A3E | B04-F10A8E | B04-N0300E | B04-N08 | B14-S11A | B14-	A61K003900 | A61K0039015 | A61K0039145 | A61K003929 | A61K0039295 |	2006413367	US20060115489A1 | US7361352B2	Dead	20020221CA2420037 A1	US7361352B2 | AP2003002752A0 | AT546156T | AU2001285452B2 | AU200185452A |	Alive	SANOFI SA	Vacina Recombinante
US7645456B2	2010-01-12	2004-04-16	EMERGENT PROD DEV GAITHERSBURG INC	Vaccinia virus strains	Novel clonal strain e.g. Dryvax, ACAM1000 or ACAM2000 of attenuated vaccinia	A clonal strain e.g. Dryvax (RTM: dried form of smallpox vaccine), ACAM1000 or ACAM2000 of	What is claimed is: 1. A pharmaceutical composition comprising an isolated clonal strain	US2001840751A | US2003445671A	2001-04-23 | 2003-05-27	B04-F1100E | B14-A02A4 | B14-S11A | B14-S11D2 | D05-H07 | D05-H12F	A61K0039576 | A61K0039275 | A61K0039285 | A61K0039295 | C12N000100 |	2006522364	WO2006076003A2 | US20090169512A1 | US20090324548A1 | US7645456B2 | WO2006076003A3	Alive	20021031CA2444747 A1	US7645456B2 | AU2002258910B2 | BR200209145A | CA2444747A1 | CA2444747C |	Alive	EMERGENT PROD DEV GAITHERSBURG INC	Método/Processo
US9101598B2	2015-08-11	2012-11-29	MERIAL	Recombinant Gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens	Composition or vaccine for inducing an immunogenic or protective response in an avian against	A composition or vaccine comprises one or more recombinant Gallid herpesvirus 3 (MDV-	What we claim is: 1. A vaccine composition comprising: 1) a recombinant	US2011564877P | US2012694957P	2011-11-30 | 2012-08-30	B04-E08 | B04-E99 | B14-S11D3 | B14-S12 | C14-S12 | D05-H12E	A61K 1-7) | A61K00317088 | A61K003576 | A61K003900 | A61K0039108 |	2013K31437	WO2013082317A2 | WO2013082317A3 | WO2013082317A8 | KR2014097515A | EP2785374A2 |	Alive	20130606CA2857025 A1	US9101598B2 | AR89039A1 | AR90401A1 | BR112014013276A2 | CA2857025A1 |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
US9446118B2	2016-09-20	2015-02-06	MERIAL	Newcastle disease virus vectored herpesvirus vaccines	Composition or vaccine for eliciting a protective response in an animal against Herpesvirus	A composition or vaccine comprises (i) one or more recombinant Newcastle Disease	What is claimed is: 1. A composition comprising: (i) a recombinant Newcastle Disease	US2010378575P | US13220196A	2010-08-31 | 2011-08-29	B04-B04C1 | B04-E08 | B04-E99 | B04-F1100E | B14-A02A3 | B14-G01 | B14-S11A | B14-S11D3 |	A61K003900 | A61K003912 | A61K003917 | A61K0039245 | C07K0014005 |	2015336616	US20150157704A1 | US9446118B2	Alive	20120301US2012005 2089A1	US9446118B2 | BR112013007486A2 | BR112013007486B1 | CA2809127A1 |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
US9555101B2	2017-01-31	2014-11-17	BOEHRINGER INGELHEIM GMBH	Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and	Composition or vaccine used for vaccinating and for eliciting a protective response against	A composition or vaccine comprises a recombinant Equine Herpesvirus-1 (EHV-1), where the EHV-1	What we claim is: 1. A composition comprising a recombinant Equine Herpesvirus-1 (EHV-	US2012613151P | US13840935A	2012-03-20 | 2013-03-15	B04-F11A0E | B14-S11D3 | C04-F11A0E | C14-S11D3 | D05-H07 | D05-H12F	A61K003900 | A61K003912 | A61K0039245 | C07K0014005 | C12N000700	201538708J	US20150190502A1 | US9555101B2	Alive	20130926CA2867893 A1	US9555101B2 | AR90450A1 | AU2013235423A1 | AU2013235423B2 | BR112014023414A2	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
US9616118B2	2017-04-11	2014-05-02	BOEHRINGER INGELHEIM GMBH	Newcastle disease virus vectored avian vaccines	Modifying genome of Newcastle disease virus (NDV) to produce engineered NDV vector to elicit	Modifying the genome of Newcastle disease virus (NDV) to produce engineered	What is claimed is: 1. A method for modifying the genome of Newcastle Disease	US2009166481P | US2010753597A	2009-04-03 | 2010-04-02	B04-E02F | B04-E03F | B04-E08 | B04-E99 | B04-F11B0E | B14-A02B2 | B14-G01 | B14-S11A | B14-	A61K003912 | A61K0039145 | A61K003917 | C07K0014005 | C12N001586 |	2014P72271	US20140234358A1 | US9616118B2	Alive	20101007CA2757030 A1	US9616118B2 | CA2757030A1 | CA2757030C | CN102428099A | CN102428099B |	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
US9682138B2	2017-06-20	2015-02-06	UNIVERSITE PARIS-SUD 11 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC |	Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus	New isolated polypeptide comprises mutated feline leukemia virus (FeLV) envelope	An isolated polypeptide comprising a mutated feline leukemia virus (FeLV)	We claim: 1. An isolated polypeptide comprising a mutated feline	US2007547399A | US2011509912P | US13365018A	2007-08-20 | 2011-07-20 | 2012-02-02	B04-C01G | B04-E02F | B04-E08 | B04-E99 | B04-F0100E | B04-F11A0E | B04-N03K1 | B14-G01 |	A61K003912 | A61K003921 | C07K0014005 | C12N000700 | A61K03900	2015604719	US20150283228A1 | US9682138B2	Alive	20051013AU200522 9411A1	US9682138B2 | AT472334T | AU2005229411A1 | AU2005229411B2 | AU2012284558A1 |	Alive	UNIVERSITE PARIS-SUD 11 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC |	Vacina Recombinante
US9713639B2	2017-07-25	2015-05-19	MERIAL	Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV)	Immunogenic composition useful for vaccinating host susceptible to porcine epidemic	Immunogenic composition (C1) comprises a recombinant polypeptide	The invention claimed is: 1. An immunogenic composition comprising a	US62000240P	2014-05-19	B04-C01G | B04-E02F | B04-E03F | B04-E99 | B04-N03K1E | B04-N04A | B14-A02B5 | B14-	A61K003912 | A61K0039215 | A61K0039225 | A61K0039295 | C12N000700 |	201571908Y	US20150328307A1 | WO2015179412A1 | US9713639B2	Alive	20151119US2015032 8307A1	US9713639B2 | US20150328307A1 | WO2015179412A1	Alive	C.H. BOEHRINGER SOHN AG & CO KG	Vacina Recombinante
US9856295B2	2018-01-02	2014-10-06	INSTITUT GUSTAVE ROUSSY | MERIAL | UNIVERSITE PARIS-SUD 11 | CENTRE NATIONAL DE LA	Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus	Composition useful to vaccinate animal against feline leukemia virus (FeLV) and to treat FeLV	Composition comprises an expression vector comprising at least one polynucleotide	What we claim is: 1. A composition comprising an expression vector comprising a first	US2011509912P | US13364993A	2011-07-20 | 2012-02-02	B04-E08 | B04-E99 | B14-A02B1 | B14-G01 | B14-S03A | B14-S11A | B14-S12 | D05-H12E	A61K003104 | A61K003816 | A61K003912 | A61K003921 | A61K003975 |	201509642N	US20150030623A1 | US9856295B2	Alive	20051013AU200522 9411A1	US9856295B2 | AT472334T | AU2005229411A1 | AU2005229411B2 | AU2012284558A1 |	Alive	INSTITUT GUSTAVE ROUSSY | C.H. BOEHRINGER SOHN AG & CO KG | UNIVERSITE PARIS-SUD 11 | CENTRE NATIONAL DE LA	Método/Processo
EP310316A2	1989-04-05	1988-09-26	SMITHKLINEBEECHAM PLC	Virus TGEV du porc comme vaccin pour le chien | TGEV-Virus vom Schwein als Impfstoff für Hunde	Use of transmissible gastroenteritis virus of swine for mfr. vaccine for preventing canine	The use of transmissible gastroenteritis (TGE) virus of swine for the mfr. of a vaccine for	1. The use of transmissible gastroenteritis virus of swine for the manufacture of a	US1987101822A	1987-09-28	B02-V02 | B03-F | B04-B02B4 | B05-A03A | B12-L09 | C02-V02 | C03-F | C04-B02B4 | C05-	A61K003900 (IPC 1-7) | A61K003912 (IPC 1-7) | A61K0039225 (IPC 1-7) | C12N000704 (IPC 1-	A61K003912 | A61K0039225 | A61K0039155 | A61K0039265 | A61P003112 |	1989101609	EP310316A1 | AU198822814A | AU198822843A | DK198805341A | DK198805342A |	Dead	19880926DK1988053 41D0	EP310316A2 | AT117899T | AT98680T | AU198822814A | AU198822843A |	Dead	GLAXOSMITHKLINE PLC	Adjuvant sars
EP640098A1	1995-03-01	1993-05-07	PFIZER INC	GENE S DU CORONAVIRUS CANIN ET SES APPLICATIONS | HUNDECORONAVIRU	Isolated protein sequence comprises a sequence from the protein of a canine coronavirus (CV) opt.	A vaccine comprises (i) one or more recombinant Newcastle Disease	What is claimed is: 1. An isolated protein sequence comprising a selected sequence	US1992880194A | WO1993US4692A	1992-05-08 | 1993-05-07	B02-V02 | B04-B04A1 | B04-B04A5 | B04-B04C6 | B12-K04A | C02-V02 | C04-B04A1 | C04-	C07K0014005 (IPC 1-7) | A61K0039215 (IPC 1-7) | C12N001550 (IPC 1-7) | C12Q000168	1993386474	WO1993023423A1 | AU199342515A | EP640098A1 | JP7508421A | AU670092B |	Dead	19920517CA2096010 A1	EP640098A1 | AT225805T | AU199191286A | AU199342515A | AU666298B |	Dead	PFIZER INC	Vacina coronavirus
EP310317A2	1989-04-05	1988-09-26	SMITHKLINEBEECHAM PLC	Inactivation de virus et de bactéries | Inaktivierung von Viren und Bakterien	New inactivated virus or bacterium compsns. are inactivated by ascorbate treatment	New pharmaceutical compsns. are free of live viruses or bacteria and contain an inactivated virus	1. A pharmaceutical composition which is substantially free from live viruses or bacteria and Vaccine, enthaltend inaktiviertes infektiöse-Vogelbronchitis-	US1987101822A	1987-09-28	B02-V02 | B04-B02B1 | B04-B02B4 | B12-J04 | B12-L09 | C02-V02 | C04-B02B1 | C04-B02B4 |	C12N000704 (IPC 1-7) | A61K003902 (IPC 1-7) | A61K003912 (IPC 1-7) | A61K003915 (IPC 1-	A61K003912 | A61K003917 | A61K0039215	1989101610	EP310317A1 | EP310317B1 | DE3886332D1 | ES2061673T3	Dead	19880926DK1988053 41D0	EP310317A2 | AT117899T | AT98680T | AU198822814A | AU198822843A |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP186368A2	1986-07-02	1985-12-10	SCHERING-PLOUGH CORP	Préparations biologiques | Biologische Zubereitungen	Immunising poultry against infections bronchitis using inactivated avian infectious bronchitis	Novel vaccines contain inactivated avian infectious bronchitis virus VLO 10110/AVI/9 and/or		GB198431253A	1984-12-11	B02-V02 | B04-B02B4 | B12-K06 | B12-L09 | C02-V02 | C04-B02B4 | C12-K06 | C12-L09 | D05-H07	A61K003912 | A61K003917 | A61K0039215		EP186368A1 | DK198505699A | ZA198509428B | EP186368B1 | DE3582422D1 |	Dead	19850123GB1984312 53D0	EP186368A2 | AT62134T | DE3582422D1 | DK170923B1 | DK198505699A |	Dead	MERCK & CO. INC.	Adjuvante
EP106831A2	1984-04-25	1983-10-11	SMITHKLINE BECKMAN - ANIMAL HEALTH PRODUCTS	Souches modifiées du virus de la diarrhée virale bovine, leur préparation et	Thermosensitive Bovine viral diarrhoea vaccine by mutagenesis of BDV strains with nitrous	Living vaccine against bovine viral diarrhoea virus, which induces immunity in cattle	Claims for the Contracting States: Al"	US1982434155A	1982-10-13	B02-V | B12-L09 | C02-V | C12-L09 | D05-H	A61K003912 (IPC 1-7) | C12N000700 (IPC 1-7) | C12N000706 (IPC 1-7) | A61K003915 (IPC	C12N000700 | A61K003912 | A61P003112 | A61K20395254 | A61K2039552 |	1984109347	EP106831A1 | AU198318529A | NO198303717A | JP59089631A | DK198304720A |	Dead	19831012FI1983037 17A0	EP106831A2 | AT48948T | AU198318529A | AU572050B | CA1216234A1 |	Dead	SMITHKLINE BECKMAN - ANIMAL HEALTH PRODUCTS	Adjuvante
EP11865A1	1980-06-11	1979-11-29	GLAXOSMITHKLINE PLC	Vaccin contre la péritonite infectieuse des félins et procédé pour sa préparation |	Inactivated feline infectious peritonitis vaccine prodn. by serial passage of virulent virus isolate	Prepn. of an inactivated feline infectious peritonitis (FIP) vaccine comprises serial	Patentansprüche 1. Impfstoff zur	GB197846666A	1978-11-30	B02-V | B04-B02B | C02-V | C04-B02B | D05-H07	A61K0039215	A61K0039215 | A61K003912 | A61K20395252 | A61K20395254 | A61K2039552 |	198041898C	EP11865A1 | DK197905069A | JP55076820A | ZA197906477B | EP11865B1 |	Indeterminate	19800531DK1979050 69A_	EP11865A1 | AT1044T | AU197953291A | DE2962921D1 | DK197905069A |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP11864A1	1980-06-11	1979-11-29	GLAXOSMITHKLINE PLC	Souche atténuée du virus de la péritonite infectieuse des félins, procédé pour sa préparation et	Attenuated feline infectious peritonitis virus and vaccine obtd. by serial passage of virulent	An attenuated strain of feline infectious peritonitis (FIP) virus, which stimulates antibody prodn.	Patentansprüche 60 1. Abgeschwächter	GB197846603A	1978-11-30	B02-V | B04-B02B | C02-V | C04-B02B | D05-H07	A61K0039215	A61K0039215 | A61K003912 | A61K20395254 | A61K2039552 | A61K203970 |	198041897C	EP11864A1 | DK197905070A | JP55076819A | ZA197906476B | EP11864B1 |	Indeterminate	19800531DK1979050 70A_	EP11864A1 | AT1070T | AU197953292A | DE2962920D1 | DK197905070A |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP2365826A1	2011-09-21	2009-12-01	INSTITUT PASTEUR | SMITHKLINEBEECHAM PLC	IMPFSTOFF | VACCIN	Immunogenic composition, useful to treat e.g. severe acute respiratory syndrome,	Immunogenic composition comprises: an immunogenic severe acute respiratory	CLAIMS 1. An immunogenic composition comprising: (a) an immunogenic	GB200822001A | WO2009EP66089A	2008-12-02 | 2009-12-01	A10-E07B | A10-E08A | A12-V01 | A12-W11L | B03-H | B04-C01 | B04-C03C | B04-N0300E | B04-	A61K003576 | A61K003912 | A61K0039215 | A61K003939 | A61K004722 |	2010G48422	WO2010063685A1 | CA2744663A1 | EP2365826A1 | CN102316896A | US20120045469A1 |	Dead	20090107GB2008220 01D0	EP2365826A1 | CA2744663A1 | CN102316896A | GB200822001D0 | JP2012510449A |	Dead	INSTITUT PASTEUR | GLAXOSMITHKLINE PLC	Adjuvante
EP2162148A2	2010-03-17	2008-06-20	INSTITUT PASTEUR | SMITHKLINEBEECHAM PLC | VICKLES B	IMMUNOGENE ZUSAMMENSETZUNGEN IN ZUSAMMENHANG MIT DEM SARS	New vaccine composition comprises immunogenic severe acute respiratory	A vaccine composition comprising: (a) an immunogenic severe acute respiratory	GB200711858A | WO2008TT1A	2007-06-19 | 2008-06-20	B04-C01G | B04-C02V | B04-N03E | B04-N08 | B08-B | B12-M11F | B14-A02B5 | B14-K01D |	A61K003900 | A61K003912 | A61K0039215 | A61K0009127 | A61P003100 |	C07K001610 | A61K003912 | A61K0039215 | A61K003939 | A61P003112 |	2009L37598	WO2009085025A2 | WO2009085025A3 | EP2162148A2 | CA2704283A1 | US20100233250A1 |	Dead	20070725GB2007118 58D0	EP2162148A2 | CA2704283A1 | GB200711858D0 | JP2011506267A | US20100233250A1 |	Dead	INSTITUT PASTEUR | GLAXOSMITHKLINE PLC | VICKLES B	Adjuvante

EP1778283A2	2007-05-02	2005-06-30	GLAXOSMITHKLINE PLC	VACCINZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON CORONAVIRUSINFEKTION |	Composition useful for treating and preventing coronavirus infection comprises	A composition (C1) comprises a multivalent fusion coronavirus immunogen	CLAIMS 1. A method for treating or preventing a coronavirus	US2004584704P | WO2005US23598A	2004-06-30 | 2005-06-30	B04-B01B | B04-B04C | B04-C02V | B04-L05C | B04-N03A | B04-N08 | B12-M12Q | B14-	A61K0039215 (IPC 1-7) | A61K003816 | A61K0039215 | A61K003939 | A61K0009127 |	A61K0039215 | A61K003912 | A61P001100 | A61P003112 | A61P003114 |	2006464341	WO2006068663A2 | US2006028124A1 | AU2005319716A1 | EP1778283A2 | IN200700326P2 |	Dead	20060629AU2005319716A1	EP1778283A2 | AU2005319716A1 | CA2572389A1 | CN101022827A | JP2008505114A |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP640097A1	1995-03-01	1993-05-07	SMITHKLINEBEECHAM PLC	COMPOSITIONS ET PROCEDES DE VACCINATION CONTRE LES CORONAVIRUS |	Chimeric coronavirus S protein used in diagnostic, vaccinal and therapeutic compsns.	A chimaeric coronavirus S protein (I) comprises a first coronavirus S protein fragment and at	WHAT IS CLAIMED IS: 1. A chimeric coronavirus S protein comprising a first	US1992882171A | WO1993US4384A	1992-05-08 | 1993-05-07	B02-V02 | B04-B04A1 | B04-B04A5 | B04-B04C3 | B11-C08 | B12-K04A | D05-C12 | D05-H07 | D05-	C07K001300 (IPC 1-7) | C07K000300 (IPC 1-7) | C12N001509 (IPC 1-7) | A61K003912 (IPC 1-	C07K0014005 | A61P003112 | A61K003800 | A61K003900 | C07K231940 |	1993386473	WO1993023422A1 | AU199342410A | EP640097A1 | JP8501931A | EP640097A4 |	Dead	19931125CA2134898A1	EP640097A1 | AU199342404A | AU199342410A | AU678970B2 | AU678971B2 |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP640096A1	1995-03-01	1993-05-07	SMITHKLINEBEECHAM PLC	VACCIN UNIVERSEL CONTRE LE CORONAVIRUS | UNIVERSELLES CORONAVIRUS	Universal corona-virus vaccine comprising a polypeptide contg. a conserved domain of	(A) A polypeptide is claimed comprising a universal conserved domain of a coronavirus or an	Claims 1. A polypeptide comprising a universal conserved domain of a	US1992882171A | WO1993US4365A	1992-05-08 | 1993-05-07	B02-V02 | B04-B04A1 | B04-C01G | B12-L09 | C02-V02 | C04-B04A1 | C04-C01G | C12-L09 |	C07K001300 (IPC 1-7) | C07K000300 (IPC 1-7) | C12N001509 (IPC 1-7) | A61K003800 (IPC 1-	C07D047118 | C07K0014005 | A61P002900 | A61P003112 | A61P003114 |	1993386472	WO1993023421A1 | AU199342404A | EP640096A1 | JP7508176A | EP640096A4 |	Dead	19931125CA2134898A1	EP640096A1 | AU199342404A | AU199342410A | AU678970B2 | AU678971B2 |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP557455A1	1993-09-01	1991-11-14	PFIZER INC	PROTEINES S DE RECOMBINAISON DE CORONAVIRUS FELIN | REKOMBINANTE FELINE	Recombinant feline corona-virus S proteins useful for vaccines, therapeutic and diagnostic	A peptide or protein (A) useful in the diagnosis, treatment or prophylaxis of a disease caused by a	What is claimed is: 1. A peptide or protein useful in the diagnosis, treatment or prophylaxis of a	US1990613066A | US1991698927A	1990-11-14 | 1991-05-13	B02-V02 | B04-B04A1 | B04-B04A5 | B04-B04C3 | B11-C07A | B12-A06 | B12-K04A4 | C02-	C12N001562 (IPC 1-7) | A61K0039215 (IPC 1-7) | A61K003942 (IPC 1-7) | C07H002104	C07K0014005 | A61P003112 | C07K00161063 | C12Q0001701 | A61K003800 |	1992199951	WO1992008487A1 | AU199191286A | ZA199108988B | EP557455A1 | CA2096010A1 |	Dead	19920517CA2096010A1	EP557455A1 | AT225805T | AU199191286A | AU199342515A | AU666298B |	Dead	PFIZER INC	Adjuvante
EP310317A3	1990-02-14	1988-09-26	SMITHKLINEBEECHAM PLC					US1987101822A	1987-09-28						No associated DWPI family	19880926DK198805341D0	EP310317A3 | AT117899T | AT98680T | AU198822814A | AU198822843A |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP310316A3	1990-02-14	1988-09-26	SMITHKLINEBEECHAM PLC					US1987101822A	1987-09-28						No associated DWPI family	19880926DK198805341D0	EP310316A3 | AT117899T | AT98680T | AU198822814A | AU198822843A |	Dead	GLAXOSMITHKLINE PLC	Adjuvante
EP186368A3	1987-02-04	1985-12-10	SCHERING-PLOUGH CORP					GB198431253A	1984-12-11						No associated DWPI family	19850123GB198431253D0	EP186368A3 | AT62134T | DE3582422D1 | DK170923B1 | DK198505699A |	Dead	MERCK & CO. INC.	Adjuvante
EP106831A3	1986-01-22	1983-10-11	SMITHKLINE BECKMAN - ANIMAL HEALTH PRODUCTS					US1982434155A	1982-10-13						No associated DWPI family	19831012FI198303717A0	EP106831A3 | AT48948T | AU198318529A | AU572050B | CA1216234A1 |	Dead	SMITHKLINE BECKMAN - ANIMAL HEALTH PRODUCTS	Adjuvante
WO2008155316A1	2008-12-24	2008-06-17	SMITHKLINEBEECHAM PLC | INSTITUT PASTEUR	COMPOSITIONS IMMUNOGÈNES ASSOCIÉES À LA PROTÉINE S DU CORONAVIRUS	New vaccine composition comprises an immunogenic severe acute respiratory	New vaccine composition comprising: (a) an immunogenic severe acute respiratory	CLAIMS 1. A vaccine composition comprising: (a) an immunogenic SARS	GB200711858A	2007-06-19	B01-D02 | B04-A07E | B04-B01B | B04-C01 | B04-C02V | B04-N03 | B14-A02B5 | B14-K01D |	A61K0039215 | A61P003100 | C07K0014005 | A61P003114 | C07K0014165	C07K001610 | A61K003912 | A61K0039215 | A61K003939 | A61P003112 |	2009B09436	WO2008155316A1	Dead	20070725GB2007118858D0	WO2008155316A1 | CA2704283A1 | EP2162148A2 | GB200711858D0 | JP2011506267A |	Dead	GLAXOSMITHKLINE PLC | INSTITUT PASTEUR	Vacina Coronavírus

Derwent Innovation | Search results for: | Collections searched:

Publication Number	Publication Date	Application Date	Optimized Assignee	Title (Original)	Title - DWPI	Abstract - DWPI	Claims	Priority Number	Priority Date	DWPI Manual Codes	IPC - Current - DWPI	CPC - Current - DWPI	DWPI Accession	DWPI Family	Dead/Alive DWPI	INPADOC Family ID	INPADOC Family Members	Dead/Alive INPADOC Family Status	Ultimate Parent	Categoria
BR200206312A	2004-02-17	2002-01-03	UNIVERSITY OF SASKATCHEWAN | UNIVERSITY OF BRITISH COLUMBIA	Composição de vacina, uso sobrenadante de cultura celular de escherichia coli	Vaccine composition useful for eliciting immunological response in ruminant and for	A vaccine composition (I) comprises an enterohemorragic Escherichia coli		US2001259818P | WO2002CA19A	2001-01-04 | 2002-01-03	B04-B04C | B04-F10A3 | B10-A22 | B14-A01A3 | B14-G01 | B14-S11B | B14-S12 | C04-B04C	A61K0039108 (IPC 1-7) | A61K003939 (IPC 1-7) | A61P003104 (IPC 1-7) | C07K000102	A61K00390258 | A61P003100 | A61P003104 | A61P003106 | A61P003704 |	2002557723	WO2002053181A1 | US20020160020A1 | EP1349570A1 | BR200206312A | AU2002218927A1 |	Alive	20020711CA2433792A1	BR200206312A | AR69722A1 | AU2002218927B2 | CA2433792A1 | CA2433792C | EP1349570A1 | EP1349570B1 | EP2295075A1 | ES2446984T3 | JP05322718B2 | JP2004516333A | JP2009132742A | JP2013151499A | MX2003006042A | NZ527322A | US20020160020A1 | US20080145384A1 | US20090068230A1 | US20140065188A1 | US7300659B2 | US8586057B2 | WO2002053181A1 |	Alive	UNIVERSITY OF SASKATCHEWAN | UNIVERSITY OF BRITISH COLUMBIA	Vacina
BR200309901A	2008-08-12	2003-05-08	CENT NACIONAL BIOPREPARADOS | INST FINLAY CENT INVESTIGACION-PRODN VAC	composição de vacina para alergia, método de produção e uso da mesma no tratamento de	Therapeutic or prophylactic vaccine against allergy, comprises allergen linked to bacterial	Vaccine (A) against allergy contains:proteolipos ome (PL) derived from a Gram-	Reivindicações 1. T 1/3 .Ξ.:..=-..".."..= Ξ:: ΣΞ".5 1. "Composição de vacina para doenças	CU200291A | WO2003CU7A	2002-05-08 | 2003-05-08	B04-B04C | B04-F10A | B04-N04 | B12-M11F | B14-G01 | B14-G02A | B14-K01A | B14-S11	A61K003935 (IPC 1-7) | A61K003939 (IPC 1-7) | A61K003816 (IPC 1-7) | A61K0039395	A61K003935 | A61P003700 | A61K203955505 | A61K203955583 | A61K203955594 |	2004012014	WO2003094964A1 | AU2003229258A1 | EP1520587A1 | KR2005025175A | AU2003229258A8 |	Alive	20031111AU2003229258A1	BR200309901A | AR39982A1 | AT514431T | AU2003229258A1 | AU2003229258A8 | CN100540052C | CN1658900A | CU22983A1 | DK1520587T3 | EP1520587A1 | EP1520587B1 | ES2368731T3 | KR1058350B1 | KR2005025175A | MX2004011070A | MY146106A | PT1520587E | US20060110435A1 | US7648709B2 | WO2003094964A1	Alive	CENT NACIONAL BIOPREPARADOS | INST FINLAY CENT INVESTIGACION-PRODN VAC	Vacina
BR200311777A	2005-03-29	10/06/2003	SMITHKLINEBEECHAM PLC | INST FINLAY CENT INVESTIGACION-PRODN VAC	Composição de vesícula meningocócica multivalente, vacina para o tratamento	Multivalent meningococcal bleb composition useful for treating Neisserial disease,	Multivalent meningococcal bleb composition comprises bleb with homologous	REIVINDICAÇÕES 1. Composição de vesícula meningocócica multivalente,	GB200213622A | WO2003EP6094A	2002-06-13 | 2003-06-10	B04-C02F | B04-F10B | B14-A01 | B14-G01 | B14-S11B | D05-H07	A61K0039095 (IPC 1-7) | A61K0039095 | A61K0039116 | A61K0009127 | A61P003104 |	A61K0039095 | A61P003100 | A61P003104 | C07K001422 | A61K203952	2004082081	WO2003105890A2 | AU2003236734A1 | BR200311777A | EP1565211A2 | NO200500132A |	Dead	20020724GB200213622D0	BR200311777A | AR40204A1 | AU2003236734A1 | CA2488782A1 | CL2003001192A1 | CN100387298C | CN1668329A | CU23552A1 | EP1565211A2 | GB200213622D0 | IL165693D0 | JP2005531614A | KR2005049431A | MX2004012568A | NO200500132A | NO200500132D0 | NZ560766A | PE20040562A1 | RU2005100509A | US20060110412A1 | UY27843A1 |	Alive	GLAXOSMITHKLINE PLC | INST FINLAY CENT INVESTIGACION-PRODN VAC	Vacina
BR200316271A	2005-10-11	2003-11-14	INST FINLAY CENT INVESTIGACION-PRODN VAC	Método para a obtenção de preparados vacinais conjugados multivalentes,	Preparation of multivalent conjugated vaccines, useful for preventing bacterial infections,	Method for producing multivalent conjugated vaccines (A) comprising	REIVINDICAÇÕES 1. Método para a obtenção de preparados vacinais conjugados	CU2002257A | WO2003CU13A	2002-11-14 | 2003-11-14	B04-B04C1 | B04-C02 | B05-A01A | B05-A01B | B05-C08 | B11-C01 | B14-G01 | B14-S11B |	A61K003902 (IPC 1-7) | A61K004748 (IPC 1-7) | A61K003902 | A61K0039095 |	A61K0039095 | A61K0039102 | A61K0047646 | A61K20396037 | A61K20396068 |	2004411651	WO2004043489A1 | AU2003281909A1 | EP1582217A1 | BR200316271A | CN1738642A	Dead	20040527CA2506090A1	BR200316271A | AU2003281909A1 | CA2506090A1 | CN1738642A | EP1582217A1 | WO2004043489A1	Dead	INST FINLAY CENT INVESTIGACION-PRODN VAC	Métodos
BR200316687A	2005-10-18	2003-11-27	INST FINLAY CENT INVESTIGACION-PRODN VAC	Composição e adjuvante vacinal e método para a obtenção de estruturas cocleares	Vaccine useful for treating or preventing bacterial, viral or protozoal infections, allergy	A vaccine composition (A) comprises proteolipid cochlear structures (B)	1. Composição vacinal caracterizada pelo fato de que compreende estruturas cocleares	CU2002292A | WO2003CU16A	2002-11-27 | 2003-11-27	B04-B01B | B04-B04C | B04-C02 | B04-C02V | B04-E01 | B04-F01 | B04-N03 | B04-N04 |	A61K003902 (IPC 1-7) | A61K0009127 (IPC 1-7) | A61K003900 | A61K0039002 |	A61K00090043 | A61K00090019 | A61K0009006 | A61K0039008 | A61K00390275 |	2004441088	WO2004047805A1 | AU2003281911A1 | BR200316687A | EP1602360A1 | US20060134134A1	Alive	20040610CA2518906A1	BR200316687A | AR42237A1 | AR89022A2 | AT530166T | AU2003281911A1 | CA2518906A1 | CN1744883A | CN1744883B | CU23313A1 | DK1602360T3 | EP1602360A1 | EP1602360B1 | EP2347764A2 | EP2347764A3 | ES2376227T3 | HK1088827A1 | US20060134134A1 | WO2004047805A1 | ZA200504729B	Alive	INST FINLAY CENT INVESTIGACION-PRODN VAC	Vacina
BR200408409A	2006-03-21	2004-03-19	INST FINLAY CENT INVESTIGACION-PRODN VAC	composição de vacina contra o cólera	Oral vaccine against cholera comprises tablet containing inactivated cells of Vibrio cholerae,	Vaccine (A) against cholera comprises inactivated cells of Vibrio cholerae; agglutinants (I);	REIVINDICAÇÕES 1. Composição de vacina contra o cólera, @Law pelo fato de ser composta	CU200361A | WO2004CU5A	2003-03-20 | 2004-03-19	A12-V01 | B04-C02A | B04-C02B | B04-C03A | B04-F10A9 | B04-N02 | B05-A01B | B05-A03B |	A61K (IPC 1-7) | A61K0039106 (IPC 1-7) | A61K000928 (IPC 1-7) | A61K0039106 |	A61K0039107 | A61P003104 | A61K000920 | A61K2039521 | A61K2039522 |	2004709811	WO2004082711A1 | EP1614427A1 | BR200408409A | JP2006520332A | KR2005109978A |	Dead	20040930CA2519225A1	BR200408409A | AR43621A1 | CA2519225A1 | CN1791426A | CU23334A1 | EC2005SP5997A | EP1614427A1 | JP2006520332A | KR2005109978A | PE20041064A1 | US20060246094A1 | WO2004082711A1 | ZA200507576B	Alive	INST FINLAY CENT INVESTIGACION-PRODN VAC	Vacina
BR200416218A	2007-01-02	2004-11-10	INST FINLAY CENT INVESTIGACION-PRODN VAC | CENT INVESTIGACION ESTUDIOS	composições de vacina para controle da amebíase com base na proteína de superfície de 112	Vaccine for controlling infection caused by Entamoeba histolytica,	The active agent comprises a 112 kDa Entamoeba histolytica surface protein which has	Reivindicações 1. Composições de vacina para o controle da amebíase	CU2003259A | WO2004CU13A	2003-11-11 | 2004-11-10	B04-C01 | B04-E03F | B04-N03 | B04-N0300E | B14-A03A | B14-S11B2 | D05-C11 | D05-H07 |	A61K0039002 (IPC 1-7) | A61K0039002 | A61P003304 | C07K001444 | C12N001530	A61K0039002 | A61P003304 | A61K203953 | Y02A005030	2005366753	WO2005044300A1 | EP1695715A1 | BR200416218A | IN200602070P4	Dead	20050519WO2005044300A1	BR200416218A | EP1695715A1 | WO2005044300A1	Dead	INST FINLAY CENT INVESTIGACION-PRODN VAC | CENT INVESTIGACION ESTUDIOS	Vacina
BR200418332A	2008-02-06	2004-12-28	CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD | INST FINLAY CENT	adjuvantes vacinais, formulação vacinal, uso da formulação vacinal e esquema de imunização	Vaccine adjuvant useful for preparing vaccines against microbial infections or cancer, comprises	A vaccine adjuvant (A) comprises a proteoliposome (PL), or its derivatives, that can induce a	REIVINDICAS ;ÕES 1. Adjuvantes vacinais caracterizados pelo fato de que são um	CU2003312A | WO2004CU17A	2003-12-30 | 2004-12-28	B04-B04C1 | B04-B04C8 | B04-N04 | B12-M11F | B14-A01 | B14-A02 | B14-A03 | B14-A04	A61K0039095 | A61K003939 | A61K000900 | A61K0009127	A61K00090019 | A61K00090043 | A61K00091272 | A61K0039095 | A61K003939 |	2005497832	WO2005063287A1 | EP1716866A1 | AU2004308553A1 | KR2007036020A | BR200418332A |	Dead	20050714AU2004308553A1	BR200418332A | AR51059A1 | AU2004308553A1 | CA2552271A1 | CU23420A1 | EP1716866A1 | ES2301418A1 | ES2301418B1 | KR2007036020A | UY28706A1 | WO2005063287A1	Alive	CAMBRIDGE UNIVERSITY | INST FINLAY CENT INVESTIGACION-PRODN VAC	Adjuvante
BR200508160A	2007-08-07	2005-03-18	CENT QUIMICA FARM | INST FINLAY CENT INVESTIGACION-PRODN VAC	composições de vacina obtidas a partir de streptomyces	Vaccine for preventing or treating e.g. tuberculosis, comprises wild	The vaccine contains a wild strain of Streptomyces or a mutant strain or recombinant derived	Reivindicações 1. "Composição de vacina", obtida de Streptomyces, caracterizada pelo	CU200451A | WO2005CU2A	2004-03-18 | 2005-03-18	B04-F10B5 | B14-A01B1A | B14-G02A | B14-G02D | B14-H01 | B14-P01 | B14-S11B1 | B14-	A61K003900 (IPC 1-7) | A61K003904 (IPC 1-7) | A61K003900 | A61P001500 |	A61K003900 | A61K003904 | A61P001500 | A61P001518 | A61P003104 |	2005658889	WO2005087259A1 | EP1743651A1 | AU2005221262A1 | BR200508160A | KR2007026454A |	Alive	20050922AU2005221262A1	BR200508160A | AT419868T | AU2005221262A1 | CA2559633A1 | CA2559633C | CN1960751A | CU23460A1 | DE602005012252D1 | EP1743651A1 | EP1743651B1 | ES2323080T3 | JP04875606B2 | JP2007529432A | KR2007026454A | MX2006010616A | RU2006136806A | US20070292452A1 | WO2005087259A1	Alive	CENT QUIMICA FARM | INST FINLAY CENT INVESTIGACION-PRODN VAC	Vacina
BR200517139A	2008-09-30	2005-12-06	UNIVERSITY OF GLASGOW | INST FINLAY CENT INVESTIGACION-PRODN VAC	peptídeos que imitam as regiões antigênicas do vírus da hepatite a	New hepatitis A virus mimotypic peptides, useful in diagnostic assays for detecting antibodies against	Four new peptides (I), recognized by antibodies against hepatitis A virus (HAV) but having	Reivindicações 1. Peptídeo que é reconhecido por anticorpos contra o vírus da hepatite A	CU2004270A | WO2005CU11A	2004-12-06 | 2005-12-06	B04-C01C | B04-G08 | B11-C07A | B12-K04A4A | B14-A02B3 | B14-S11A | B14-S11D3 | D05-	C07K001410 (IPC 1-7) | A61K003929 (IPC 1-7) | A61P003114 (IPC 1-7) | G01N0033576	G01N00335768 | A61P003114 | C07K000706 | C07K000708 | C07K0014005 |	2006558608	WO2006060969A1 | EP1832602A1 | BR200517139A | ZA200705034B | CA2623753A1 |	Alive	20060615CA2623753A1	BR200517139A | CA2623753A1 | CU23553A1 | EP1832602A1 | WO2006060969A1 | ZA200705034B	Alive	UNIVERSITY OF GLASGOW | INST FINLAY CENT INVESTIGACION-PRODN VAC	Método/Processo
BRPI0921578A2	2019-09-24	2009-11-19	INST FINLAY CENT INVESTIGACION-PRODN VAC	VACINAS UNITEMPORAIS	Vaccine formulations for preventing and treating infections or tumor diseases comprises	Vaccine formulations comprises proteoliposomes or their derivatives applied	VACUNAS UNITEMPORALES 1. Formulaciones vacunales caracterizadas	CU2008215A | WO2009CU8A	2008-11-19 | 2009-11-19	B04-B01B | B04-B04C | B04-N04 | B14-A01 | B14-A02 | B14-A04 | B14-H01 | B14-S11 |	A61K (IPC 1-7) | A61K0039095 (IPC 1-7) | A61K0009127 (IPC 1-7) | A61P (IPC 1-7) | A61P003704	A61K0039095 | A61K00390017 | A61K003905 | A61K003908 | A61K0039099 |	2010F97465	WO2010057447A1 | CA2744048A1 | EP2359850A1 | IN201100970P3 | US20110256214A1	Indeterminate	20100527AU2009317725A1	BRPI0921578A2 | AU2009317725A1 | CA2744048A1 | CN102497879A | CU20080215A7 | EP2359850A1 | EP2359850A4 | US20110256214A1 | WO2010057447A1 | ZA201103645B	Alive	INST FINLAY CENT INVESTIGACION-PRODN VAC	Vacina
EP1470249A2	2004-10-27	2002-12-02	UNIVERSITY OF BRITISH COLUMBIA	EFFEKTOREN ANGEBORENER IMMUNITÄT | EFFECTEURS D'IMMUNITE INNEE	Identifying a polynucleotide regulated by one or more sepsis or inflammatory	Identifying a polynucleotide or pattern of polynucleotides regulated by one or	WHAT IS CLAIMED IS: 1. A method of identifying a polynucleotide or	US2001336632P | WO2002CA1830A	2001-12-03 | 2002-12-02	B04-E03A | B04-F01 | B04-N04A | B11-C08E | B11-C08F2 | B11-C10 | B12-K04E | B14-A01 | B14-	A61K00317088 (IPC 1-7) | A61K00317088 | A61K003800 | A61K003804 |	A61K003810 | A61K00381709 | C12Q00016883 | G01N0033564 | A61K0038193 |	2003513768	WO2003048383A2 | US20040001803A1 | AU2002365675A1 | US20040180038A1	Alive	20030612CA2468907A1	EP1470249A2 | AU2002365675A1 | AU2002365675B2 | AU2004271668A1 | CA2468907A1 | CA2538069A1 | CN100357324C | CN101215601A | CN1615368A | CN1901933A | EP1667707A1 | HK1075677A1 | IL162300D0 | IL174099D0 | JP2005536985A | JP2007505048A | KR2004077669A | KR2007033314A | MX2006002828A | NZ533721A | NZ563261A | SG159382A1 | TW200526690A |	Alive	UNIVERSITY OF BRITISH COLUMBIA	Método/Processo
EP2548572A2	2013-01-23	2011-05-05	INST FINLAY CENT INVESTIGACION-PRODN VAC	UNTERSTÜTZE TOLEROGENE ALS MALARIA-IMPFSTOFF | TOLÉROGÈNES	Vaccine formulation used for immunization of mammals against tolerogens and for	Vaccine formulation uses potent additives that evoke cellular immune response related to	1. Vaccine formulations for immunising mammals against tolerogens with	CU201083A | WO2011CU2A	2010-05-05 | 2011-05-05	B04-B04C1 | B04-B04C9 | B04-C02 | B04-N04 | B05-B01P | B14-A03B | B14-G01 | B14-	A61K0039015 | A61P003306 | A61K	A61K0039015 | A61P003306 | A61K203955 | A61K203955555 | A61K203955594 |	2011N90889	WO2011137876A2 | WO2011137876A3 | EP2548572A2 | RU2012151576A | EP2548572A4	Dead	20111110WO2011137876A2	EP2548572A2 | AR81008A1 | CU20100083A7 | EP2548572A4 | RU2012151576A | WO2011137876A2 | WO2011137876A3	Indeterminate	INST FINLAY CENT INVESTIGACION-PRODN VAC	Vacina
EP2689775A1	2014-01-29	2012-07-25	CBQ CENT BIOACTIVOS QUIMICOS | INST FINLAY CENT INVESTIGACION-	Cochlea mit nur einem mikrobenassoziierten Molekularmuster (MAMP) | Cochleate	Vaccine adjuvant to treat infections disease comprises self-assembled, coiled cochlear	A vaccine adjuvant comprises cochlear structures that are self-assembled, coiled, having	1. Vaccine adjuvant characterized by cochlear structures that are self-assembled, coiled,	EP2012177817A	2012-07-25	B04-B04C | B14-A01 | B14-A02 | B14-A04 | B14-S09 | B14-S25 | D05-H07	A61K0039095 | A61K003939 | A61K000900	A61K003939 | A61K00090019 | A61K00090043 | A61K0009006 | A61K2039543 |	2014C31910	EP2689775A1	Dead	20140129EP2689775A1	EP2689775A1	Dead	CBQ CENT BIOACTIVOS QUIMICOS | INST FINLAY CENT INVESTIGACION-	Vacia e Adjuvante
EP2777712A1	2014-09-17	2012-11-02	INST FINLAY CENT INVESTIGACION-PRODN VAC	HILFSSTOFFE FÜR POLYSACCHARIDIMPFSTOFFE UND DARAUS ERHALTENE FORMULIERUNGEN	Adjuvanted immunogenic composition for mucosal and parenteral	Adjuvanted immunogenic composition for mucosal and parenteral	1. Immunogenic adjuvated composition containing non conjugated	CU2011202A | WO2012CU6A	2011-11-02 | 2012-11-02	B04-B04C1 | B04-B04C2 | B04-C02 | B14-G01 | B14-S11 | D05-H07	A61K003900 | A61K0039095 | A61K0039112 | A61P003704	A61K0039095 | A61K00390275 | A61P003704 | A61K203954 | A61K203955505 |	2013H16518	WO2013064129A1 | AU2012331548A1 | EP2777712A1 | CA2888754A1 | EP2777712A4	Dead	20130510CA2888754A1	EP2777712A1 | AU2012331548A1 | CA2888754A1 | CU20110202A7 | EP2777712A4 | WO2013064129A1	Indeterminate	INST FINLAY CENT INVESTIGACION-PRODN VAC	Adjuvante
EP301992A2	1989-02-01	1988-07-30	CENT NACIONAL BIOPREPARADOS	Vaccin contre Neissèria meningitidis groupe B, gammaglobuline et facteur de	Vaccine against gp. B Neisseria meningitidis contg. high mol. wt. protein antigenic complex,	A vaccine with wide long-lasting protective range against different pathogenic	1 .-Method for obtaining a vaccine against the different pa-thogenic serotypes of group B	CU1987125A	1987-07-30	B02-V02 | B04-B04C6 | B04-B04J | C02-V02 | C04-B04C6 | C04-B04J | D05-H07	A61K003909 (IPC 1-7) | A61K0039095 (IPC 1-7) | C07K001612 (IPC 1-7) | C12N000120	A61K0039095 | C07K001422 | C07K001452 | C07K00161217 | A61K003900	1989033857	EP301992A1 | JP1125328A | AU198820312A | NO198803647A | AU199181349A |	Dead	19890201EP301992A2	EP301992A2 | AT122893T | AU198820312A | AU199181349A | AU199453197A | AU199674226A | AU615461B | AU706213B2 | CA1341199C | CU21888A1 | DE3853854D1 | DE3853854T2 | EP301992A3 | EP301992B1 | ES2074445T3 | GR3017218T3 | IN167607B | JP1125328A | RU2023448C1 | US5597572A | US5747653A	Dead	CENT NACIONAL BIOPREPARADOS	Vacina
US20050019270A1	2005-01-27	2003-07-23	UNIVERSITY OF ALBERTA	Formulation of powder containing nanoparticles for aerosol delivery to the lungs	Aerosol delivery formulation of powder containing nanoparticles, useful for lung specific	Formulation (I) of a powder containing nanoparticles for aerosol delivery to the lung comprises	What is claimed is: 1. A method of formulating a powder containing nanoparticles for	CA2435632A	2003-07-21	B12-M01A | B12-M11G | B14-H01N | B14-K01	A61K000912 (IPC 1-7) | A61L000904 (IPC 1-7) | A61K000914 (IPC 1-7) | A61K000951	A61K00090075 | A61K00091635	2005111852	US20050019270A1 | CA2435632A1	Dead	20050121CA2435632A1	US20050019270A1 | CA2435632A1	Dead	UNIVERSITY OF ALBERTA	Método/Processo
WO2008025171A1	2008-03-06	2007-08-31	UNIVERSITY OF BRITISH COLUMBIA | UNIVERSITY OF SASKATCHEWAN	VACCINS ET PROCÉDÉS POUR LE TRAITEMENT OU LA PRÉVENTION D'INFECTIONS	New vaccine composition comprising an isolated Salmonella species cell culture	A new vaccine composition comprising an isolated Salmonella species cell culture	What is Claimed: 1. A vaccine composition comprising an effective immunizing	US2006841213P	2006-08-31	B04-B01C3 | B04-B04C1 | B04-F10A8 | B04-N03 | B04-N0300E | B10-A22 | B12-M03 | B14-	A61K0039112 | A61K003939 | A61P003104 | A61P003704 | C12N000120	C12N000120 | A61K00390275 | A61P003104 | A61P003704 | Y02A005030	2008E71350	WO2008025171A1 | CA2662174A1 | JP2010501599A	Dead	20080306CA2662174A1	WO2008025171A1 | CA2662174A1 | JP2010501599A	Dead	UNIVERSITY OF BRITISH COLUMBIA | UNIVERSITY OF SASKATCHEWAN	Método/Processo
WO2012025831A2	2012-03-01	2011-08-24	UNIVERSITY OF BRITISH COLUMBIA	PROTÉINES VACCINALES CONTRE SALMONELLA	Composition for preventing or treating a Gram negative bacterial infection, comprises	A composition comprises an immunizing amount of an isolated polypeptide and a	What is Claimed: 1. A composition comprising an effective immunizing amount of an	US2010376619P	2010-08-24	B04-B04C2 | B04-C01B | B04-E99 | B04-N04A | B14-A01A8 | B14-S11B1 | B14-S12 | D05-	A61K003902 | A61K0039112 | A61P003104 | A61P003704 | C07K	A61K00390275 | A61P003104 | A61P003704 | A61K2039542 | A61K2039543 |	2012C75138	WO2012025831A2 | WO2012025831A3	Dead	20120301WO2012025831A2	WO2012025831A2 | WO2012025831A3	Dead	UNIVERSITY OF BRITISH COLUMBIA	VACINA PROTEÍNA
WO2020135898A1	2020-07-02	2019-04-08	CHENGDU AOLISHENG BIOTECHNOLOGY CO LTD | FINLAY VACCINES INST	DÉRIVÉS D'OLIGOSACCHARIDES SYNTHÉTIQUES COMME VACCIN CONTRE	New synthetic oligosaccharide derivative used in pharmaceutical composition used as	Synthetic oligosaccharide derivative (I) is new. Synthetic oligosaccharide	REIVINDICACIONES 1. DERIVADOS DE OLIGOSACÁRIDOS SINTÉTICOS COMO VACUNA CONTRA	CU2018159A	2018-12-28	B04-C02X | B04-N04 | B14-A01A1 | B14-S11B1 | B14-S11D3	A61K003910 | A61K0039385 | A61P003104 | C07H001504 | C07H001518	A61K0039099 | A61K0039385 | A61P003104 | C07H001504 | C07H001518 |	202059412T	WO2020135898A1 | CN111819184A	No associated DWPI family status	20200702WO2020135898A1	WO2020135898A1 | CN111819184A | CU20180159A7	Alive	CHENGDU AOLISHENG BIOTECHNOLOGY CO LTD | FINLAY VACCINES INST	Método/Processo

Derwent Innovation		Search results for:	Collections searched:																	
Publication Number	Publication Date	Application Date	Optimized Assignee	Title (Original)	Title - DWPI	Abstract - DWPI	Claims	Priority Number	Priority Date	DWPI Manual Codes	IPC - Current - DWPI	CPC - Current - DWPI	DWPI Accession	DWPI Family	Dead/Alive DWPI	INPADOC Family ID	INPADOC Family	Dead/Alive	Ultimate Parent	Categoria
RU2738081C1	2020-12-07	2020-10-14	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Пептидные иммуногены и вакцинная композиция против коронавирусной	PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST	Presented are immunogenic peptides used as a component of a vaccine composition	1. Пептидный иммуноген, используемый в качестве компонента	RU2020133915A	2020-10-14	B04-B04C | B04-E99 | B04-N04 | B14-A02B5 | B14-G01 | B14-S11A | B14-S12 | D05-H07 | D05-	A61K0039215 | A61P003114 | C07K001400 | C07K001610 | C12Q00016806	C07K001400 | A61K0039215 | A61P003114 | C07K001610	2020C7767S	RU2738081C1	No associated DWPI family status	20201207RU2738081 C1	RU2738081C1	Alive	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Vacina Sars Cov 2
RU2743595C1	2021-02-20	2020-12-09	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Вакцинная композиция против коронавирусной инфекции COVID-19	VACCINE COMPOSITION AGAINST COVID-19	Invention relates to biotechnology. Disclosed is a vaccine against COVID-19. The vaccine	1. Вакцинная композиция против коронавирусной инфекции COVID-19, характеризующаяся	RU2020140741A	2020-12-09	B04-B04C | B04-E99 | B04-N03K0E | B14-A02B5 | B14-S11A | D05-H07 | D05-H99	A61K0039215 | A61P003114 | C07K001400 | C07K001610	C07K001400 | A61K0039215 | A61P003114 | C07K001610	202125363B	RU2743595C1	No associated DWPI family status	20210220RU2743595 C1	RU2743595C1	Alive	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Vacina Sars Cov 3
RU2743594C1	2021-02-20	2020-12-09	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Пептидные иммуногены, используемые в качестве компонентов	PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION	Invention relates to biotechnology. Disclosed are the following peptide immunogens: the	1. Пептидный иммуноген, используемый в качестве компонента	RU2020140742A	2020-12-09	B04-B04C | B04-E99 | B04-N04 | B14-A02B5 | B14-S11A | D05-H07 | D05-H99	A61K0039215 | A61P003114 | C07K001400 | C07K001610	C07K001400 | A61K0039215 | A61P003114 | C07K001610	202124907K	RU2743594C1	No associated DWPI family status	20210220RU2743594 C1	RU2743594C1	Alive	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	vacina
RU2743593C1	2021-02-20	2020-12-09	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Пептидные иммуногены и вакцинная композиция против коронавирусной	PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19	Invention relates to biotechnology. Disclosed are the following peptide immunogens: the	1. Пептидный иммуноген, используемый в качестве компонента	RU2020140743A	2020-12-09	B04-E99 | B04-N03K1E | B04-N04A | B04-N08 | B14-A02B5 | B14-G01 | B14-S11A | D05-H07	A61K0039215 | A61P003114 | C07K001400 | C07K001610	C07K001400 | A61K0039215 | A61P003114 | C07K001610	2021253630	RU2743593C1	No associated DWPI family status	20210220RU2743593 C1	RU2743593C1	Alive	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	VACINA
RU2740366C1	2021-01-13	2020-06-26	KAZAN EPIDEMIOLOGY MICROBIOLOGY RES INST	СПОСОБ ПОЛУЧЕНИЯ АНТИГЕНОВ СТАФИЛОКОККА ЗОЛОТИСТОГО С	METHOD FOR PRODUCING STAPHYLOCOCCUS AUREUS ANTIGENS USING LYSOZYME	Invention relates to the field of biotechnology. Disclosed is a method of producing	Способ получения антигенов из клеточных стенок бактерий, отличающийся тем,	RU2020121925A	2020-06-26	A10-E09 | A12-V01 | A12-W11L | B04-B04C1 | B04-C02E3 | B04-L05B | B11-A02C2 | B14-C03 |	A61K0039085 | A61P003100 | C12R0001445	A61K0039085 | A61P003100 | C12R0001445	202112574H	RU2740366C1	No associated DWPI family status	20210113RU2740366 C1	RU2740366C1	Alive	KAZAN EPIDEMIOLOGY MICROBIOLOGY RES INST	Método rprodução de antígenos
RU2733834C1	2020-10-07	2020-07-28	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S	ARTIFICIAL ECTOS_SC2 GENE ENCODING AN ECTODOMAIN OF THE SARS-COV-2	Invention relates to biotechnology, molecular biology, genetic engineering and medicine. What	1. Искусственный ген, используемый для создания вакцины против коронавируса SARS-	RU2020125810A	2020-07-28	B04-E02F | B04-E03F | B04-E08 | B04-E99 | B04-F11B0E | B14-A02B5 | B14-G01 | B14-S03A | B14-	A61K0039215 | C12N001586 | C12N000700	C12N000700 | A61K0039215 | C12N001586	2020A5933H	RU2733834C1	No associated DWPI family status	20201007RU2733834 C1	RU2733834C1	Alive	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Vacina
RU2733832C1	2020-10-07	2020-07-28	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру,	ARTIFICIAL GENE STBL_RBD_TRM_SC2 , CODING A BICISTRONIC STRUCTURE	Described is an artificial gene Stbl_RBD_TrM_SC2 used to create a vaccine against SARS-	1. Искусственный ген Stbl_RBD_TrM_SC2, используемый для создания вакцины	RU2020125809A	2020-07-28	B04-E02F | B04-E03F | B04-E08 | B04-E99 | B04-F11B0E | B14-A02B5 | B14-G01 | B14-S03A | B14-	A61K0039215 | C12N001586 | C12N000700	C12N000700 | A61K0039215 | C12N001586	2020A5932B	RU2733832C1	No associated DWPI family status	20201007RU2733832 C1	RU2733832C1	Alive	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Vacina
RU2723410C2	2020-06-11	2018-12-07	OMSK NATURAL FOCAL INFECTIONS RES INST	СРЕДСТВО ДЛЯ ПОЛУЧЕНИЯ ПРЕПАРАТОВ ДЛЯ ДИАГНОСТИКИ РИККЕТСИОЗА,	AGENT FOR PREPARING PREPARATIONS FOR DIAGNOSING RICKETTSIAL DISEASE	Invention refers to biotechnology and concerns application of Rickettsia sibirica subsp. sibirica Baevo-	Применение штамма Rickettsia sibirica subsp. sibirica "Баево-107/87" для	RU2018143566A	2018-12-07	B11-C08E1 | B12-K04G1C | D05-H04	A61K003902 | C12N000120 | C12Q000104	A61K003902 | C12N000120 | C12Q000104 | Y02A005030	20057828P	RU2723410C2 | RU2018143566A	No associated DWPI family status	20200608RU2018143 566A3	RU2723410C2 | RU2018143566A3 | RU2018143566A	Alive	OMSK NATURAL FOCAL INFECTIONS RES INST	Método rprodução de antígenos
RU2713723C1	2020-02-06	2018-11-15	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Искусственные гены, кодирующие белки-иммуногены EV.CTL и EV.Th, рекомбинантные	ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS, RECOMBINANT	Invention refers to biotechnology and molecular biology. Disclosed are artificial genes used	1. Искусственный ген, используемый для создания вакцины против вируса Эбола,	RU2018140382A	2018-11-15	B04-B04C1 | B04-E02 | B04-E03 | B04-E08 | B04-E99 | B14-A02B | B14-S11A | D05-H07 | D05-	A61K003912	A61K003912	2020183640	RU2713723C1	Alive	20200206RU2713723 C1	RU2713723C1	Alive	VECTOR VIROLOGY &BIOTECHNOLOGY STATE RE	Vacina
RU2703280C1	2019-10-16	2018-11-07	ROST MICROBIOLOGY PARASITOLOGY RES INST	Способ подготовки проб материала для идентификации вида нематод методом MALDI	METHOD OF PREPARING SAMPLES OF MATERIAL FOR IDENTIFICATION OF	Invention refers to medicine and veterinary science and can be used for identification of	Способ подготовки проб материала для идентификации вида нематод методом MALDI	RU2018139361A	2018-11-07	B04-B04D5 | B04-F07 | B11-C08A | B11-C08C2 | B11-C08D3 | B11-C11 | B12-K04G | C04-	A61K003900 | G01N0033483	G01N0033483 | A61K003900 | G01N00336848	201994517S	RU2703280C1	Alive	20191016RU2703280 C1	RU2703280C1	Alive	ROST MICROBIOLOGY PARASITOLOGY RES INST	Método rprodução de antígenos
RU2701145C1	2019-09-25	2019-07-10	YEKATERINBURG VIRAL INFECTIONS RES INST	Способ генотипирования энтеровирусов методом секвенирования 1A-	METHOD FOR ENTEROVIRUS GENOTYPING BY GENOME REGION 1A-1B SEQUENCING	Invention relates to molecular biology, laboratory diagnostics, virology and epidemiology	Способ генотипирования энтеровирусов методом секвенирования 1A-	RU2019121521A	2019-07-10	B04-E01A | B04-E05 | B04-E99 | B04-F11B | B11-C08E3 | B11-C08F7A | B11-C08F8 | B11-C11 |	A61K0039125	A61K0039125 | C12Q00016806 | C12Q00016876 | G01N003350	201987598H	RU2701145C1	Alive	20190925RU2701145 C1	RU2701145C1	Alive	YEKATERINBURG VIRAL INFECTIONS RES INST	Método rprodução de antígenos
RU2689161C1	2019-05-24	2018-10-04	KAZAN EPIDEMIOLOGY MICROBIOLOGY RES INST	СПОСОБ ПОЛУЧЕНИЯ БАКТЕРИАЛЬНЫХ АНТИГЕНОВ	METHOD OF PRODUCING BACTERIAL ANTIGENS	Invention refers to medicine and biotechnology and can be used for obtaining antigens	Способ получения антигенов из клеточных стенок бактерий, отличающийся тем,	RU2018135145A	2018-10-04	A10-E09 | A12-V01 | B04-B04C1 | B04-C02E3 | B04-L05C1 | B11-A02C3 | B11-B03A | B12-M11P |	A61K0039085 | A61P002900	A61K0039085 | A61P002900	201951058K	RU2689161C1	Alive	20190524RU2689161 C1	RU2689161C1	Alive	KAZAN EPIDEMIOLOGY MICROBIOLOGY RES INST	Método rprodução de antígenos
RU2682677C2	2019-03-20	2017-09-07	YEKATERINBURG VIRAL INFECTIONS RES INST	СПОСОБ ПОСТЭКСПОЗИЦИОННОЙ ПРОФИЛАКТИКИ КЛЕЩЕВОГО	Preventing tick-borne encephalitis comprises administering drug after removing tick in	Preventing tick-borne encephalitis comprises administering a drug to a tick bite, after	Способ профилактики клещевого энцефалита путем введения в место	RU2017131476A	2017-09-07	B04-G08 | B11-C04 | B12-M12C | B12-M12K | B14-A02B9 | B14-C03 | B14-N16 | D05-H11	A61K0039395 | A61P003112	A61K0039395 | A61P003112 | Y02A005030	201926314G	RU2017131476A | RU2682677C2	Alive	20190307RU2017131 476A3	RU2682677C2 | RU2017131476A3 | RU2017131476A	Alive	YEKATERINBURG VIRAL INFECTIONS RES INST	Método rprodução de antígenos
RU2681546C1	2019-03-11	2018-10-09	YEKATERINBURG VIRAL INFECTIONS RES INST	Способ экстренной профилактики клещевого вирусного энцефалита	METHOD OF EMERGENCY PREVENTION OF TICK - BORNE ENCEPHALITIS	Invention relates to the pharmaceutical industry, namely to a prevention method of tick-borne	Способ профилактики клещевого энцефалита путем введения в	RU2018135501A	2018-10-09	B04-G08 | B11-C04 | B12-M02D | B12-M02F | B12-M12B | B14-A02B9 | B14-C03 | B14-N16 | D05-	A61F001302 | A61K0039395 | A61P003112	A61F001302 | A61K0039395 | A61P003112 | Y02A005030	201930423N	RU2681546C1	Alive	20190311RU2681546 C1	RU2681546C1	Alive	YEKATERINBURG VIRAL INFECTIONS RES INST	Método rprodução de antígenos
RU2681229C1	2019-03-05	2017-11-03	APPL MICROBIOLOGY BIOTECHNOLOGY RES CENT	Нуклеотидная последовательность, кодирующая полипептид DBPAG, перспективный для	New nucleotide sequence encoding DPBAG polypeptide used for the diagnosis of Lyme	Invention relates to the field of biotechnology, specifically to the production of an	1. Нуклеиновая кислота, кодирующая слитный полипептид DBPAG,	RU2017138441A	2017-11-03	B04-E02F | B04-E03F | B04-F10A3E | B04-N03J0E | B04-N0400E | B04-N08 | B11-C08E | B12-K04F	C07K001420 | C07K001900 | C12N001531 | C12N001563 | G01N0033569	A61K00390225 | C07K001420 | C12P002102 | G01N0033569 | Y02A005030	201929108M	RU2681229C1	Alive	20190305RU2681229 C1	RU2681229C1	Alive	APPL MICROBIOLOGY BIOTECHNOLOGY RES CENT	Método rprodução de antígenos
RU2661085C1	2018-07-11	2017-06-01	VECTOR VIROLOGY & BIOTECHNOLOGY STATE	Рекомбинантные белки, содержащие антигенные эпитопы белков Core, Small	Recombinant proteins containing antigenic epitopes of proteins core, small envelope, ns2a and	Invention relates to recombinant proteins containing antigenic epitopes of proteins Core, Small	1. Рекомбинантный белок (Z1), содержащий антигенные эпитопы белка Core	RU2017119301A	2017-06-01	B04-B04C1 | B04-E99 | B04-G08 | B04-G27G | B04-G27M | B04-N03K1E | B11-C07A4 | B12-K04G1B	A61K003912 | C07K001418	A61K003912 | C07K001418 | G01N0033569 | Y02A005030	201862196W	RU2661085C1	Alive	20180711RU2661085 C1	RU2661085C1	Alive	VECTOR VIROLOGY & BIOTECHNOLOGY STATE	Método rprodução de antígenos
RU2642258C1	2018-01-24	2016-12-27	VEKTOR VIROLOGY & BIOTECHNOLOGY RES	Рекомбинантный химерный полипептид-иммуноген nTBI, обладающий	Recombinant chimerical ntbi polypeptide-immunogen with ability to induce	Recombinant chimerical polypeptide-immunogen is proposed, including	Рекомбинантный химерный полипептид-иммуноген, включающий	RU2016151969A	2016-12-27	B04-B04C1 | B04-N03K0E | B04-N0600E | B04-N08 | B14-A02B1 | B14-G01 | B14-S11A |	A61K003912 | A61P003704 | C12N0015117 | C12N001549 | C12N001570	A61K00090019 | A61K003912 | C12N0015117 | C12N001570 | C12N274015011	2018132892	RU2642258C1	Alive	20180124RU2642258 C1	RU2642258C1	Alive	VEKTOR VIROLOGY & BIOTECHNOLOGY RES	Vacina recombinante
RU2635998C1	2017-11-17	2017-01-09	VEKTOR VIROLOGY & BIOTECHNOLOGY STATE	Пептиды-иммуногены и вакцина "ЭпиВакЭбола" против лихорадки	Immunogen peptides and "epivakebol" vaccine against ebola fever with application of	Immunogen peptide used as a component of the vaccine against Ebola fever, characterized	1. Пептид-иммуноген, используемый в качестве компонента	RU2017100415A	2017-01-09	B04-E99 | B04-G08 | B04-N04A | B14-A02B | B14-G01 | D05-H07 | D05-H10 | D05-H99	A61K003800 | A61K003939 | A61P003112	A61K003800	201780140U	RU2635998C1	Alive	20171117RU2635998 C1	RU2635998C1	Alive	VEKTOR VIROLOGY & BIOTECHNOLOGY STATE	Vacina

RU2627631C1	2017-08-09	2016-10-11	VEKTOR VIROLOGY & BIOTECHNOLOGY STATE	Способ получения гипериммунной сыворотки, содержащей гетерологичные	Method for production of hyperimmune serum containing heterologic	Method for hyperimmune serum production contains heterologous immunoglobulins	1. Способ получения гипериммунной сыворотки, содержащей	RU2016140008A	2016-10-11	B04-B04D4 | B04-B04D5 | B04-E01 | B04-E02F | B04-E03F | B04-F11A | B04-G08 | B04-G26 | B11-	A61K003942 | C07K001608	A61K003942	201773639X	RU2627631C1	Alive	20170809RU2627631C1	RU2627631C1	Alive	VEKTOR VIROLOGY & BIOTECHNOLOGY STATE	Método rprodução de antígenos
RU2621868C1	2017-06-07	2016-06-24	VEKTOR VIROLOGY & BIOTECH STATE SCI CENT	Рекомбинантный штамм VACΔ6 вируса осповакцины с нарушенными	Recombinant stain of vacDELTA6 vaccinia virus with broken genes of viralence c3l, n1l, j2r, a35r,	Recombinant strain of VACΔ6 vaccinia virus with broken genes C3L, N1L, J2R, A35R, A56R, B8R on	Рекомбинантный штамм VACΔ6 вируса осповакцины с нарушенными	RU2016125515A	2016-06-24	B04-F11A0E | B14-A02A4 | B14-S11A | B14-S11D2 | B14-S11D3 | D05-H12F	A61K0039285 | C12N001500 | C12N000700	C12N000700 | A61K0039285 | C12N001500	2017686635	RU2621868C1	Alive	20170607RU2621868C1	RU2621868C1	Alive	VEKTOR VIROLOGY & BIOTECH STATE SCI CENT	Vacina recombinante
RU2617051C1	2017-04-19	2016-05-04	EXPERIMENTAL MEDICINE INST | VEKTOR VIROLOGY BIOTECHNOLOGY SCI CENT	Способ получения микрокапсулированной формы живой культуральной вакцины против	Method of obtaining microencapsulated forms of live culture vaccine against seasonal and	Method includes obtaining a substance of influenza virus, a simultaneous	1. Способ получения микрокапсулированной формы живой гриппозной	RU2016117526A	2016-05-04	B04-F11B | B12-M11E | B14-S11A | C04-F11B | C12-M11E | C14-S11A | D03-H01T2B | D05-	A61K0039165 | A61K000900 | C12N000700	A61K0039165	201764439L	RU2617051C1	Alive	20170419RU2617051C1	RU2617051C1	Alive	EXPERIMENTAL MEDICINE INST | VEKTOR VIROLOGY BIOTECHNOLOGY SCI CENT	vacina
RU2616266C1	2017-04-13	2015-12-18	MOSC EPIDEMIOLOGY MICROBIOLOGY RES INST	Способ получения иммуноглобулинового препарата для наружного применения	Method for obtaining immunoglobulin preparation for external application	Invention relates to medicine and biotechnology and deals with method for obtaining	Способ получения иммуноглобулинового препарата для наружного применения,	RU2015154398A	2015-12-18	B04-G01 | B11-B03A | B12-M12B | D05-H13	A61K0039395 | A61P003100	A61K0039395	201763754P	RU2616266C1	Alive	20170413RU2616266C1	RU2616266C1	Alive	MOSC EPIDEMIOLOGY MICROBIOLOGY RES INST	Método rprodução de antígenos
RU2607006C1	2017-01-10	2016-03-03	ST PETERSBURG PASTEUR EPIDEMIOLOGY MICRO	Тест-штамм Leptospira interrogans серогруппы Icterohaemorrhagiae	Test strain leptospira of interrogans serogroup icterohaemorrhagiae serovar copenhageni	Invention relates to medical biotechnology and can be used for detection of	Тест-штамм Leptospira interrogans серогруппы Icterohaemorrhagiae	RU2016107907A	2016-03-03	B04-F10A | B04-G07 | B11-C07A | B12-K04G1C | B14-G01 | D05-H04	A61K003902 | C12N000120 | C12R000101 | G06F000500 | G06F000906 |	C12N000120 | G06F000500 | G06F000906 | G09G000514 | A61K003902 |	2017517415	RU2607006C1 | WO2017151012A1	Dead	20170110RU2607006C1	RU2607006C1 | WO2017151012A1	Dead	ST PETERSBURG PASTEUR EPIDEMIOLOGY MICRO	Método rprodução de antígenos
RU2588388C1	2016-06-27	2015-04-20	VEKTOR VIROLOGY & BIOTECH RES CENT	РЕКОМБИНАНТНЫЙ ШТАММ Л-ИВП 1421ABJCN ВИРУСА ОСПОВАКЦИНЫ С НАРУШЕННЫМИ	Recombinant strain l-ivp 1421abjcn pox virus virulence genes with broken a56r, b8r, j2r, c3l, n1l	Described is a recombinant attenuated strain of vaccinia virus with broken virulence	Рекомбинантный штамм Л-ИВП 1421ABJCN вируса осповакцины с нарушенными	RU2015114861A	2015-04-20	B04-F11A0E | B14-A02A4 | B14-S11D2 | D05-H12F	A61K0039285 | C12N000700		201640972D	RU2588388C1	Alive			No associated INPADOC family	VEKTOR VIROLOGY & BIOTECH RES CENT	Vacina recombinante

Derwent Innovation

Publication Number	Publication Date	Application Date	Optimized Assignee	Title (Original)	Title - DWPI	Abstract - DWPI	Claims	Priority Number	Priority Date	DWPI Manual Codes	IPC - Current - DWPI	CPC - Current - DWPI	DWPI Accession	DWPI Family	Dead/Alive DWPI	INPADOC Family ID	INPADOC Family	Dead/Alive	Ultimate Parent	Categoria
BR112012007180A2	2016-03-29	2010-09-28	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	FORMULAÇÃO DOS ANTÍGENOS DA SUPERFÍCIE E DO NUCLEOCAPSÍDIO DO VÍRUS DA	Formulation of surface antigens (HBsAg) and nucleocapsid (HBcAg) of hepatitis	Formulation of surface antigens (HBsAg) and nucleocapsid (HBcAg) of hepatitis	REIVINDICACIONES 1. FORMULACION DE ANTIGENOS DEL VIRUS DE LA HEPATITIS B PARA LA	CU2009164A | WO2010CU3A	2009-09-29 | 2010-09-28	B04-B04C1 | B04-E01 | B04-N03K | B14-A02A5 | B14-G01 | B14-S11A | B14-S11D3 | B14-S21 |	A61K (IPC 1-7) | A61P (IPC 1-7) | A61K003929 | A61K000910 | A61K000914 |	A61K0009145 | A61K000910 | A61K003912 | A61K003912 | A61K003912 | A61K003912 | A61P003112 |	2011D72385	WO2011038701A1 | CA2775794A1 | KR20120805984 | EP2484343A1 | AU2010302740A1 |	Dead	20110407CA2775794 A1	BR112012007180A2 | AU2010302740A1 | CA2775794A1 | CN102665687A | CU23740A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina
BR112014004620A2	2017-03-21	2012-08-24	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	USO DO `PEPTÍDEO ATIVADOR DA ADENILATO CICLASE DE PITUITÁRIA', COMPOSIÇÃO DE	Use of pituitary adenylate cyclase-activating polypeptide (PACAP) for use as molecular	Use of pituitary adenylate cyclase-activating polypeptide (PACAP) is claimed for use as	REIVINDICACIONES 1. DEL PACAP COMO ADYUVANTE MOLECULAR PARA VACUNAS	CU2011167A | WO2012CU4A	2011-08-26 | 2012-08-24	B04-B04C2 | B04-E01 | B04-N02 | B04-N0200E | B14-A01 | B14-A02 | B14-B02 | B14-B10 | B14-G01 |	K61K (IPC 1-7) | A61K003900 (IPC 1-7) | A61K0039002 (IPC 1-7) |	A61K003939 | A61K003900 | A61K00390003 | A61K0039002 | A61K00390208 | A61K003912 |	2013D29977	WO2013029570A1 | AU2012303887A1 | CA2844898A1 | PH12014500397A1 | KR2014064847A |	Alive	20130307CA2844898 A1	BR112014004620A2 | AU2012303887A1 | AU2012303887B2 | BR112014004620B1 | CA2844898A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR112014007491A2	2017-04-04	2012-10-01	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SEQUÊNCIAS DE AMINOÁCIDOS PARA O CONTROLE DE PATÓGENOS	New antimicrobial peptide from tilapia (Oreochromis niloticus) gill extract, useful for controlling	A peptide comprising an amino acid sequence selected from SEQ ID No. 1-3, or an amino acid	REIVINDICACIONES 1. SECUENCIAS DE AMINOÁCIDOS PARA EL CONTROL DE PATÓGENOS	CU2011181A | WO2012CU5A	2011-09-30 | 2012-10-01	B04-B04C1 | B04-E02F | B04-E03F | B04-E99 | B04-N02A | B04-N02A0E | B04-N04A | B04-N04A0E	K61K (IPC 1-7) | C07K (IPC 1-7) | A23K000116 | A61K003800 | A61K003804 |	A61K003939 | A61K00381706 | A61P003100 | A61P003104 |	2013F06271	WO2013044890A1 | CA2849040A1 | AU2012315083A1 | KR2014070597A | EP2767290A1 |	Alive	20130404CA2849040 A1	BR112014007491A2 | AR88176A1 | AU2012315083A1 | AU2012315083B2 | CA2849040A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR112018069738A2	2019-02-05	2017-03-14	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSIÇÃO FARMACÊUTICA, USO DE UM ANTÍGENO DO NÚCLEO DO VÍRUS	Pharmaceutical composition for manufacturing medicament for immunoprophylaxis	Pharmaceutical composition comprises surface antigen of hepatitis B (HBcAg) comprising	REIVINDICACIONES 1 . Composición farmacéutica que se caracteriza porque comprende el	CU201638A | WO2017CU50001A	2016-03-31 | 2017-03-14	B04-B04C1 | B14-H01E5 | B14-S11C | D05-H07	K61K (IPC 1-7) | A61K003912 (IPC 1-7) | C07K (IPC 1-7) | C07K0014005 (IPC 1-7) | A61K0031664 |	A61K003912 | A61K003912 | A61K0039292 | A61K003939 | A61P000116 | A61P003120 |	2017683422	WO2017167317A1 | TW201735945A | AR108009A1 | CA3017778A1 | AU2017243136A1 |	Alive	20171005CA3017778 A1	BR112018069738A2 | AR108009A1 | AU2017243136A1 | CA3017778A1 | CN109219449A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR112019008624A2	2019-07-09	2017-10-30	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	USO DE UM PEPTÍDEO SECRETAGOGO DO HORMÔNIO DO CRESCIMENTO,	Use of growth hormone secretagog peptide as a molecular adjuvant for manufacturing	Use of growth hormone secretagog peptide of SEQ ID NO. 1 or 2 is claimed as a molecular	REIVINDICACIONES 1. USO DE PEPTIDO SECRETAGOGO DE LA HORMONA DE CRECIMIENTO COMO	CU2016161A | WO2017CU50006A	2016-11-01 | 2017-10-30	B04-B04C | B04-C01B | B04-E99 | B04-F10 | B04-F11 | B04-J05 | B04-N04 | B14-A01 | B14-A02 |	A61K003900 | A61K003808 | A61K003825 | A61K003838 | A61K003900 |	A61K003912 | A61K003825 | A61K00390003 | A61K003902 | A61K039165 |	201836383G	WO2018082719A1 | CA3041944A1 | AU2017353072A1 | BR112019008624A2 | KR2019079648A |	Alive	20180511CA3041944 A1	BR112019008624A2 | AU2017353072A1 | CA3041944A1 | CL2019001191A1 | CU20160161A7 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR112019013542A2	2020-02-04	2017-12-20	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSIÇÃO DE VACINA, USO DE UM POLIPEPTÍDEO, E, MÉTODO PARA O TRATAMENTO DE	Vaccine composition used for treating diseases related to the overexpression of interleukin 15 (IL-	A vaccine composition comprises a polypeptide containing a mutant Hepatitis B vaccine	REIVINDICACIONES 1) Una composición vacunal caracterizada porque comprende un	CU2016194A | WO2017CU50008A	2016-12-30 | 2017-12-20	B04-H02Q0E | B04-N0200E | B04-N08 | B14-C03 | B14-C09B | B14-E08 | B14-E10C1 | B14-G02D |	A61K003900 (IPC 1-7) | C07K001624 (IPC 1-7) | A61K003900 | A61K003939 | A61P002900 |	C07K0016244 | A61K003900 | A61K00390114 | A61K003939 | A61P002900 |	201852545T	WO2018121802A1 | CN110300762A | EP3564264A1 | BR112019013542A2 | MX2019007906A |	Alive	20180705WO201812 1802A1	BR112019013542A2 | CN110300762A | CU20160194A7 | EP3564264A1 | MX2019007906A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR112020022784A2	2021-02-02	2019-06-04	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | TOKO YAKUHIN	ADMINISTRAÇÃO TRANSNASAL DE VACINA CONTRA HEPATITE B	Hepatitis B vaccine nasal administration system comprises hepatitis B surface antigen and/or	nasal administration system comprises (i) hepatitis B surface antigen (HBs	JP2018107797A | WO2019JP22136A	2018-06-05 | 2019-06-04	B04-B04C1 | B04-F11A | B12-M01 | B12-M12Q | B14-A02A5 | B14-C03 | B14-S11A	A61K003929 (IPC 1-7) | A61K000906 (IPC 1-7) | A61K000912 (IPC 1-7) | A61K003900 |	A61K003939 | A61K00390043 | A61K000906 | A61K000912 | A61K003929 |	2019A48407	WO2019235464A1 | AU2019283122A1 | CA3099430A1 | TW202002950A | IN202047055545A |	No associated DWPI family status	20191212CA3099430 A1	BR112020022784A2 | AU2019283122A1 | CA3099430A1 | CN112368018A | EP3804752A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | TOKO YAKUHIN	Vacina
BR200307121A	2006-04-11	2003-01-22	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	antigeno de superficie do virus da hepatite b como um imunoestimulador da mucosa e as	Multivalent vaccine for nasal administration, comprises hepatitis B surface antigen as	A multivalent vaccine (A) for nasal administration comprising the hepatitis B surface	REIVINDICAÇÕES 1. Formulação de vacina multivalente para administração nasal contendo	CU200219A | WO2003CU1A	2002-01-24 | 2003-01-22	B04-B04C2 | B14-A01 | B14-A02 | B14-G01 | B14-S11A | B14-S11B | B14-S12 | D05-H07	A61K003929 (IPC 1-7) | A61K003939 (IPC 1-7) | A61K003929 | A61K003939	A61K003929 | A61K003912 | A61K203954 | A61K203954 3 | A61K2039545 |	2003608169	WO2003061692A2 | AU2003210123A1 | EP1493447A2 | KR2004081469A | US20050025780A1 |	Alive	20030731CA2471727 A1	BR200307121A | AR38311A1 | CA2471727A1 | CN1703241A | CU23031A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR200318026A	2005-12-06	2003-12-19	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Antigenos recombinantes do virus da hepatite a, e, uso dos antigenos	New recombinant antigens from hepatitis A virus, useful in vaccines and as diagnostic	Recombinant antigens (rAg) of the hepatitis A virus (HAV) are produced in plant cells from	1. Antígenos recombinantes do virus da Hepatite A, caracterizados pelo fato de que são	CU200331A | WO2003CU17A	2003-01-31 | 2003-12-19	B04-A0800E | B04-B04C1 | B04-E08 | B04-F0800E | B12-K04A4 | B14-A02B3 | B14-S11A | D05-C11	C12N001582 (IPC 1-7) | C07K001410 (IPC 1-7) | A01H000100 | A61K003929 | A61P003114 |	C07K0014005 | A61P003114 | C12N00158257 | A61K003900 | C07K231900 |	2004581005	WO2004067747A1 | AU2003291913A1 | EP1589111A1 | MX2005008221A | BR200318026A |	Dead	20040812CA2510482 A1	BR200318026A | AR42960A1 | AU2003291913A1 | CA2510482A1 | CN1745174A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
BR200415654A	2006-12-19	2004-10-20	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	composições farmacêuticas para uso terapêutico, uso do antigeno de superficie do virus da	Pharmaceutical composition for treating hepatitis B infection, contains hepatitis B virus	Pharmaceutical composition contains a hepatitis B virus surface antigen obtained by	REIVINDICAÇÕES 1. Composições farmacêuticas para uso terapêutico, caracterizadas pelo	CU2003240A | WO2004CU11A	2003-10-20 | 2004-10-20	B04-B04C1 | B04-F09D0E | B11-A01 | B11-C07A6 | B11-C08D2 | B14-A02A5 | B14-A02A7 | B14-	A61K003939 (IPC 1-7) | A61K003900 | A61K003912 | A61K003921 | A61K003929 |	C07K0014005 | A61K003912 | A61K003921 | A61K003929 | A61K0039292 |	2005333221	WO2005037311A1 | EP1676587A1 | MX2006004387A | AU2004281098A1 | BR200415654A |	Alive	20050428AU200428 1098A1	BR200415654A | AR46063A1 | AU2004281098A1 | AU2004281098B2 | CA2542680A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR200416178A	2007-01-09	2004-11-03	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	método de incorporação de antigeno em vesiculas de membrana externa	Inserting antigens into outer membrane vesicles of bacteria, useful for boosting	A complex is formed between the antigens and a preparation of proteins from outer	REIVINDICAÇÕES 1. Método para a incorporação de antigenos em vesículas de	CU2003254A | WO2004CU12A	2003-11-04 | 2004-11-03	B04-B04C1 | B04-C02F | B04-E01 | B04-N03 | B14-A01 | B14-S11B1 | B14-S11D3 | D05-H07 | D05-H12	C07K001422 (IPC 1-7) | A61K003900 (IPC 1-7) | A61K003900 | A61K0039095 | C07K001422 |	C07K001422 | A61K003900	2005346854	WO2005042571A1 | EP1688428A1 | AU2004284969A1 | BR200416178A | US20070166333A1 |	Alive	20050512AU200428 4969A1	BR200416178A | AR46921A1 | AU2004284969A1 | CA2543206A1 | CU23377A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
BR200417309A	2007-09-11	2004-12-02	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	proteina nmb1125 e seu uso em formulações farmacêuticas	Protein useful for vaccines against e.g. meningococcal disease, comprises N meningitidis protein	A Neisseria meningitidis protein NMB1125 which is an antigen capable of generating a	REIVINDICAÇÕES 1. Proteína de N. meningitidis denominada NMB1125,	CU2003285A | WO2004CU15A	2003-12-03 | 2004-12-02	B04-B04C1 | B04-C02F | B04-E03F | B04-N03A | B11-C088 | B12-K04A4B | B14-S11B1 | B14-	A61K0039095 (IPC 1-7) | C07K001422 (IPC 1-7) | A61K004800 (IPC 1-7) | C12N000121 (IPC 1-7) |	C07K001422 | A61P003104 | A61P003704 | A61K003900 | A61K239523 |	2005425386	WO2005054281A2 | EP1693378A2 | NO20060302A | AU2004294376A1 | MX2006006266A |	Alive	20050616AU200429 4376A1	BR200417309A | AR47263A1 | AT444305T | AU2004294376A1 | CA2547317A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	vacina geral
BR200417334A	2007-03-27	2004-12-02	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	proteina nmb0928 e uso da mesma em formulações farmacêuticas	Protein useful for vaccines against e.g. meningococcal disease, comprises N meningitidis protein	An N. meningitidis protein NMB0928 is claimed which is an antigen capable of generating a	REIVINDICAÇÕES 1. Proteína de N. meningitidis denominada NMB0Q28, a qual	CU2003286A | WO2004CU16A	2003-12-03 | 2004-12-02	B04-A0800E | B04-B04C1 | B04-C02F | B04-E03F | B04-H06 | B04-A01 | B04-N0300E | B04-	A61K0039095 (IPC 1-7) | A61K003939 (IPC 1-7) | A61K004800 (IPC 1-7) | C07K001422 (IPC 1-7) |	C07K001422 | A61P003104 | A61P003704 | A61K003900 | C07K0016300 7 |	2005425387	WO2005054282A1 | EP1693379A1 | NO20060317A | AU2004294377A1 | MX2006006267A |	Alive	20050616AU200429 4377A1	BR200417334A | AR46937A1 | AT456573T | AU2004294377A1 | CA2547537A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	
BR200514884A	2008-06-24	2005-08-29	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	composição vacinal para gerar resposta imune celular e humoral protetora contra a infecção	Vaccine for hepatitis C, comprises suitable proportions of capsid protein and structural proteins	A vaccine comprising suitable proportions of capsid protein and structural proteins E1 and E2 for the	REIVINDICAÇÕES 1'. Composição vacinal para gerar resposta imune celular e humoral	CU2004189A | WO2005CU5A	2004-09-03 | 2005-08-29	B04-B04C1 | B04-C02 | B04-E08 | B14-A02A7 | B14-G01 | B14-S11A | B14-S11B1 | D05-H07 |	A61K003929 (IPC 1-7) | A61K003900 | A61K0039095 | A61K003929 | A61K0039295 |	A61K0039095 | A61K003912 | A61K003929 | A61K0039292 | A61P000116 |	2006204128	WO2006024240A2 | EP1785143A2 | AU2005279590A1 | KR2007057861A | CN101043902A |	Alive	20060309AU200527 9590A1	BR200514884A | AR52639A1 | AU2005279590A1 | AU2005279590B2 | CA2577918A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BR200515403A	2008-07-22	2005-09-16	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	peptídeo, corrente de ácido nucleico, formulação farmacêutica, formulação de	New peptide, useful for treating e.g. rheumatoid arthritis or Crohn's disease, inhibits activity of	Peptide (I) that antagonizes the activity of interleukin-15 (IL-15) and includes the amino	1. w l. Peptídeo antagonista da atividade da interleucina-IS caracterizado pelo	CU2004198A | WO2005CU7A	2004-09-17 | 2005-09-16	B04-C01B | B04-E03F | B04-G01 | B04-G21 | B04-N04A | B14-C09B | B14-E10C1 | B14-L06 | B14-N17C	C07K001454 (IPC 1-7) | A61K003800 | A61K003820 | A61K003900 | C07K0014435 |	C07K00145443 | A61P001706 | A61P001902 | A61P002900 | A61P003702 |	2006241010	WO2006029578A1 | EP1801119A1 | AU2005284529A1 | KR2007072876A | JP2008512994A |	Alive	20060323AU200528 4529A1	BR200515403A | AR51924A1 | AT434623T | AU2005284529A1 | AU2005284529B2 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina de subunidade
BR200515893A	2008-08-12	2005-09-22	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	proteina humana de estresse térmico, composição farmacêutica e	Peptides for treating arthritis, comprise 60 KDa human heat shock protein and form epitopes for T-	The peptides comprise the 60 kDa human heat shock protein and form epitopes for T-cells.	1. Peptídeos da proteína humana de estresse térmico de 60 kDa que	CU2004207A | WO2005CU8A	2004-09-24 | 2005-09-22	B04-C01D | B04-C01E | B04-C01F | B14-C09	A61P001902 (IPC 1-7) | C07K001447 (IPC 1-7) | A61K003800 | A61K003816 | A61K003817 |	C07K001447 | A61P001902 | A61P001904 | A61P002900 | A61P003706 |	2006283689	WO2006032216A2 | EP1803732A2 | AU2005287757A1 | KR2007073787A | CN101065398A |	Alive	20060330AU200528 7757A1	BR200515893A | AR51928A1 | AR74924A2 | AT546462T | AU2005287757A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
BRPI0115859B1	2020-10-13	2001-11-29	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	MÉTODO DE OBTENÇÃO DE ESTRUTURAS ANTIGÊNICAS AGREGADAS DE	Preparing aggregated antigenic structures, useful for diagnosis or vaccination,	Producing aggregated antigenic structures (A) with immunogenicity, where selected	1. Método de obtenção de estruturas antigênicas agregadas de alta	CU2000279A | WO2001CU9A	2000-12-01 | 2001-11-29	B04-B04C | B11-C08D2 | B11-C08D3 | B12-K04A4 | B14-A02A5 | B14-A02A7 | B14-A02B1 | B14-	A61K003900 (IPC 1-7) | A61K003912 (IPC 1-7) | A61K003929 (IPC 1-7) | A61K003900 |	A61K0039292 | A61K003912 | A61P003100 | A61P003112 | A61P003114 |	2002471804	WO2002043756A2 | AU200221518A | EP1346727A2 | KR2003068161A | BR200115859A |	No associated DWPI family status	20020606WO200204 3756A2	BRPI0115859B1 | AR31437A1 | AT465752T | AU200221518A | AU2002221518B2 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BRPI0616224A2	2013-02-19	2006-09-18	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSTO FARMACÊUTICO	Vaccine for treatment or prevention of dengue fever, contains the capsid	Vaccine (A) that (i) can induce a protective immune response against dengue virus (DV)	1. Composto farmacêutico, caracterizado pelo fato de que é uma vacina capaz de	CU2005168A | WO2006CU8A	2005-09-16 | 2006-09-18	B04-B04C1 | B04-E02 | B04-E03 | B04-E08 | B04-F0100E | B04-N03E0E | B04-N08 | B11-B03 | B14-	A61K003912 (IPC 1-7) | A61K0039295 (IPC 1-7) | C07K001418 (IPC 1-7) | A61K003912 |	A61K003912 | A61P003112 | A61P003114 | A61K203955505 |	2007272216	WO2007031034A1 | EP1944038A1 | AU2006291863A1 | KR2008048068A | CN101304760A |	Alive	20070322AU200629 1863A1	BRPI0616224A2 | AR58049A1 | AU2006291863A1 | AU2006291863B2 | BRPI0616224B1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante

BRPI0618865A2	2011-09-13	2006-11-21	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	ÁREA TOPOGRÁFICA E ALTAMENTE CONSERVADA, MOLÉCULAS, ÁCIDO NUCLEICO,	New highly conserved region exposed on mature flaviviruses, useful as broad-spectrum	A highly conserved topographical region (A) that (a) is exposed on the mature virus and (b)	REIVINDICAÇÕES 1. I. Área topográfica e altamente conservada, caracterizada pelo	CU2005229A | WO2006CU15A	2005-11-22 | 2006-11-21	B04-C01 | B04-E02F | B04-E03 | B04-E08 | B04-F0100E | B04-G08 | B04-G23 | B04-N03 | B04-N04 | B04-C01C | B04-E03F | B04-E99 | B04-N04A | B12-K04A4 | B14-A01A5 | B14-S11B1 |	C07K001418 (IPC 1-7) | A61K003912 | C07K0014005 | C07K001608 | C07K001900 |	C07K0014005 | A61K003912 | A61P003114 | A61K003900 | A61K203955566 |	2007526259	WO2007059715A2 | WO2007059715A3 | WO2007059715A8 | EP1958959A2 | AU2006317350A1 |	Dead	20070531AU2006317350A1	BRPI0618865A2 | AR58215A1 | AU2006317350A1 | CA2630629A1 | CN101360758A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina
BRPI0620937A2	2011-11-29	2006-12-28	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PEPTÍDEOS DE CARBOHIDRATO MIMÉTICO E USO DOS MESMOS EM FORMULAÇÃO	New peptide antigens that generate an immune response against carbohydrates	Peptides (I), designated NMGBPS1-25 are new. They are antigens that	1. Peptídeos denominados NMGBPS 1-25, caracterizados por serem antígenos	CU2005283A | WO2006CU20A	2005-12-29 | 2006-12-28	B04-B04C2 | B04-C01C | B04-E03F | B04-E99 | B04-N04A | B12-K04A4 | B14-A01A5 | B14-S11B1 |	C07K001422 (IPC 1-7) | A61K003816 | C07K001422 | G01N003368	C07K001422 | A61P003104 | A61K003900	2007639174	WO2007073706A2 | AU2006331226A1 | EP1982994A2 | NO2008301A | KR2008090477A |	Dead	20070705AU2006331226A1	BRPI0620937A2 | AR58736A1 | AU2006331226A1 | CA2634067A1 | CN101389643A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina
BRPI0708354A2	2011-05-24	2007-02-28	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	ANTÍGENO VACINAL QUIMÉRICO CONTRA O VIRÚS DA PESTE SUÍNA CLÁSSICA E COMPOSIÇÃO DE	New chimeric vaccinating antigen, used for protection against classical swine fever virus,	Chimeric vaccinating antigen (A) against classical swine fever virus (CSFV) contains (a) the extracellular	1. Antigeno vacinal quimerico contra o virus da peste suina clássica (VPPC) caracterizado pelo	CU200652A | WO2007CU8A	2006-02-28 | 2007-02-28	B04-C01G | B04-H05A | B04-N03E | B04-N06 | B14-S11A | B14-S11D3 | B14-S12 | C04-C01G |	A61K003912 (IPC 1-7) | C07K001418 (IPC 1-7) | C07K0014705 (IPC 1-7) |	C07K0014005 | A61K003912 | A61P003112 | A61P003114 | C07K001470575 |	2007739746	WO2007098717A2 | WO2007098717A3 | EP1994943A2 | KR2008111023A | CN101426525A |	Alive	20070907CA2638830A1	BRPI0708354A2 | AR59648A1 | AT490782T | BRPI0708354B1 | CA2638830A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BRPI0708383A2	2011-05-24	2007-02-28	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	ANTÍGENO VACINAL QUIMÉRICO CONTRA O VÍRUS DA INFLUENZA AVIÁRIO E COMPOSIÇÃO DE	Antigen for vaccine against avian influenza virus, contains extracellular	The antigen contains the extracellular segments of haemagglutinin (HA) from the AIV capsid	1. Antígeno vacinai quimérico contra o virus da influenza aviária (IA), caracterizado pelo	CU200651A | WO2007CU9A	2006-02-28 | 2007-02-28	B04-B04C1 | B04-N03 | B14-A02B2 | B14-G01 | B14-S11A | B14-S11D3 | B14-S12 | D05-H07	C07K001900 (IPC 1-7) | A61K0039145 (IPC 1-7) | A61K0039215 |	C07K0014005 | A61K003912 | A61K0039385 | A61P003112 | A61P003116 |	2008J36961	WO2007098718A1 | WO2007098718A8 | EP1997831A1 | KR2008113217A | AU2007219571A1 |	Dead	20070907AU2007219571A1	BRPI0708383A2 | AR59647A1 | AU2007219571A1 | CA2638832A1 | CL2007000526A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina
BRPI0814452A2	2015-01-06	2008-07-31	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSIÇÃO QUE CONTÉM UM PEPTÍDEO PENETRADOR EM CÉLULAS, USO DE	New composition comprises cell-penetrating peptide, e.g. Limulus anti-lipopolysaccharide	A composition comprising cell-penetrating peptide, where the peptide is selected from	REIVINDICACIONES 1. Composición que contiene un péptido penetrador a células, donde dicho péptido	CU2007180A | WO2008CU6A	2007-07-31 | 2008-07-31	B04-B04C1 | B04-B04C8 | B04-N02 | B04-N0200E | B04-N04 | B04-N08 | B14-A02A6 | B14-G01 |	A61K (IPC 1-7) | C12N001562 (IPC 1-7) | C07K (IPC 1-7) | C12N (IPC 1-7) | A61K003912 |	A61K003912 | A61P003500 | A61P003704 | C07K0014025 | C12N001562 |	2009F14205	WO2009021468A1 | CA2694735A1 | KR2010045498A | MX2010001288A | EP2186526A1 |	Alive	20090219CA2694735A1	BRPI0814452A2 | AR68329A1 | CA2694735A1 | CA2694735C | CN101808658A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BRPI0817898A2	2015-05-05	2008-10-17	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SEQÜÊNCIA POLINUCLEOTÍDICA, COMPOSIÇÃO FARMACÊUTICA, VACINA, VETOR DE	New polynucleotide sequence that encodes for a protein which comprises	A polynucleotide sequence that encodes for a protein which comprises	REIVINDICACIONES VARIANTES INGENIERIZADAS DE PERTACTINA PARA USO VACUNAL.	CU2007240A | WO2008CU9A	2007-10-30 | 2008-10-17	B04-B04C1 | B04-E02F | B04-E02J | B04-E03F | B04-E03J | B04-E08 | B04-F10A1 | B04-G07 |	A61K (IPC 1-7) | C12N (IPC 1-7) | A61P (IPC 1-7) | C07K (IPC 1-7) | A61K00317088 |	G01N003356911 | A61K0039099 | A61P003104 | A61P003704 | C07K0014235 |	2009H96221	WO2009056076A1 | CA2702697A1 | EP2216045A1 | KR20100093548A | MX2010004706A |	Alive	20090507CA2702697A1	BRPI0817898A2 | AR69086A1 | CA2702697A1 | CN101878038A | CN101878038B |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
BRPI9704641B1	2010-03-09	1997-01-17	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PROTEÍNA DE FUSÃO, VETOR DE EXPRESSÃO DE PROTEÍNAS DE FUSÃO EM E. COLI,	Fusion protein for use as immunogen in vaccines contains stabilising peptide derived from N-	A new fusion protein consists of a stabilising peptide (I) derived from the first 47 N-terminal	1. Proteína de fusão a qual contém um peptídio estabilizador fundido a uma proteína	CU199610A | WO1997CU1A	1996-01-17 | 1997-01-17	B04-E08 | B04-F10A3 | B04-F10A3E | B04-G21 | B04-N04 | B14-S11 | C04-E08 | C04-F10A3 | C04-F10A3E	A61K0039095 (IPC 1-7) | C12N001562 (IPC 1-7) | C07K000122 (IPC 1-7) | C07K001416 (IPC	C07K0014005 | A61P003104 | A61P003112 | C07K001422 | C07K0016121 7 |	1997402193	WO1997026359A1 | AU199715396A | EP816506A1 | BR1997046414 | HU199800730A2 |	Dead	19970724CA2214840A1	BRPI9704641B1 | AR5651A1 | AT198491T | AU199715396A | AU722317B2 |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
BRPI991594 6B1	2010-12-14	1999-12-01	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	FORMULAÇÃO DE VACINA PARA A ADMINISTRAÇÃO NASAL COMPREENDENDO	Vaccine for nasal administration, useful e.g. against hepatitis B, comprises viral	Pharmaceutical composition (A) for nasal use comprises:viral surface antigen (I);	1. Formulação de vacina para a administração nasal, caracterizada pelo fato de que	CU1998183A | WO1999CU6A	1998-12-02 | 1999-12-01	B04-B04C1 | B04-F11 | B12-M01A | B12-M07 | B12-M11 | B14-A02A5 | B14-S11A | D05-H07	A61K003929 (IPC 1-7) | A61K0039295 (IPC 1-7) | A61K003900 | A61K003912 |	A61K003929 | A61K003912 | A61P003112 | A61P003704 | A61K20395258 |	2000412161	WO2000032229A1 | BR199915946A | EP1136077A1 | CN1332637A | CN1191853C |	Dead	20000608CA2352777A1	BRPI9915946B1 | AR21414A1 | AT331528T | BR199915946A | CA2352777A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CA2214840A1	1997-07-24	1997-01-17	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SYSTEME D'EXPRESSION D'ANTIGENES HETEROLOGUES EN TANT QUE			CLAIMS: 1. Fusion protein which contains a stabilizer peptide derived from the	CU199610A	1996-01-17								No associated DWPI family	19970724CA2214840A1	CA2214840A1 | AR5651A1 | AT198491T | AU199715396A | AU722317B2 |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CA2275440A1	1998-06-25	1997-12-17	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	VACCIN POUR L'IMMUNO-CASTRATION REVERSIBLE DES MAMMIFERES			CLAIMS A vaccine preparation for the immunocastration of mammals, consisting of peptide p Glu His	CU1996120A | WO1997CU8A	1996-12-17 | 1997-12-17								No associated DWPI family	19980625CA2275440A1	CA2275440A1 | AR9840A1 | AU199853975A | AU736538B2 | BR199713735A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina Geral
CA2277816A1	1998-07-23	1998-01-13	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | IPK INST MEDICINA	EPITOPES DE LA PROTEINE PRE-M/M DU VIRUS DE LA DENGUE, PEPTIDES SYNTHETIQUES			CLAIMS 1. Synthetic peptides or mimetic compounds belonging to Dengue	CU199713A | WO1998CU1A	1997-01-15 | 1998-01-13								No associated DWPI family	19980723CA2277816A1	CA2277816A1 | AT284444T | AU199856499A | AU743414B2 | BR199807486A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | IPK INST MEDICINA	Vacina e Adjuvante
CA2283344A1	1998-09-11	1998-03-05	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	FORMULATIONS IMMUNOSTIMULANTES A USAGE VACCINAL			CLAIMS: 1. A vaccine formulation for nasopharyngeal use characterized	CU199727A | WO1998CU3A	1997-03-06 | 1998-03-05								No associated DWPI family	19980907ZA9818978 | _	CA2283344A1 | AR9866A1 | AT295182T | AU199866077A | BR199808832A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina Geral
CA2427539A1	2003-05-01	2001-11-01	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PROCEDE PERMETTANT D'OBTENIR DES STRUCTURES ANTIGENIQUES QUI			CLAIMS 1. Method for obtaining antigenic structures able to enhance the specific	CU2000242A | WO2001CU7A	2000-11-03 | 2001-11-01								No associated DWPI family	20020510WO2002036160A2	CA2427539A1 | AR31182A1 | AU200214938A | AU2002214938B2 | BR200107424A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CA2429543A1	2003-05-20	2001-11-29	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	METHODE D'OBTENTION D'AGREGATS D'ANTIGENES ET LEUR UTILISATION			CLAIMS 1. Method for obtaining highly immunogenic aggregated antigenic	CU2000279A | WO2001CU9A	2000-12-01 | 2001-11-29								No associated DWPI family	20020606WO2002043756A2	CA2429543A1 | AR31437A1 | AT465752T | AU200221518A | AU2002221518B2 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CA2453260A1	2003-01-30	2002-07-12	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	FORMULATION VACCINALE AMELIOREE PAR LA COMBINAISON D'UN ADN ET D'UN			CLAIMS 1. A vaccine formulation having as components, a DNA that expresses	CU2001171A | WO2002CU5A	2001-07-16 | 2002-07-12								No associated DWPI family	20030130CA2453260A1	CA2453260A1 | AR34771A1 | AU2002325783B2 | BR200211181A | CA2453260C |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CA2453300A1	2003-01-30	2002-07-12	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | PEDROKOURI	CHAINES CHIMERES CODANTES POUR PROTEINES INDUISANT DES EFFETS DIRIGES			CLAIMS 1. Chimeric nucleotide chains characterized by being the specific	CU2001172A | WO2002CU6A	2001-07-16 | 2002-07-12								No associated DWPI family	20030130CA2453300A1	CA2453300A1 | AT349466T | BR200211178A | CA2453300C | CN100378123C |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | PEDROKOURI	Método /Processo
CA2510482A1	2004-08-12	2003-12-19	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	ANTIGENES RECOMBINES DU VIRUS DE L'HEPATITE A OBTENUS A PARTIR DE CELLULES			CLAIMS 1. Hepatitis A virus recombinant antigens wherein they are obtained in	CU200331A | WO2003CU17A	2003-01-31 | 2003-12-19								No associated DWPI family	20040812CA2510482A1	CA2510482A1 | AR42960A1 | AU2003291913A1 | BR200318026A | CN1745174A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
CA2542680A1	2005-04-28	2004-10-20	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSITIONS PHARMACEUTIQUES A USAGE THERAPEUTIQUE			CLAIMS 1. Pharmaceutical composition for the treatment of the coinfection of the	CU2003240A | WO2004CU11A	2003-10-20 | 2004-10-20								No associated DWPI family	20050428AU2004281098A1	CA2542680A1 | AR46063A1 | AU2004281098A1 | AU2004281098B2 | BR200415654A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CA2543206A1	2005-05-12	2004-11-03	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	METHODE D'INTRODUCTION D'ANTIGENES DANS DES VESICULES DE LA MEMBRANE			CLAIMS 1. Method for antigen incorporation into bacterial outer	CU2003254A | WO2004CU12A	2003-11-04 | 2004-11-03								No associated DWPI family	20050512AU2004284969A1	CA2543206A1 | AR46921A1 | AU2004284969A1 | BR200416178A | CU23377A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo

CA2547317A1	2005-06-16	2004-12-02	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PROTEINE NMB1125 ET SON UTILISATION DANS LES FORMULATIONS PHARMACEUTIQUES	CLAIMS: 1. Antigen capable to generate in the recipient organism a protective response	CU2003285A | WO2004CU15A	2003-12-03 | 2004-12-02	No associated DWPI family	20050616AU200429 4376A1	CA2547317A1 | AR47263A1 | AT444305T | AU2004294376A1 | BR200417309A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
CA2547537A1	2005-06-16	2004-12-02	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PROTEINE NMB0928 ET UTILISATION DANS DES FORMULATIONS PHARMACEUTIQUES	CLAIMS 1. Protein of N. meningitidis named NMB0928 characterized by	CU2003286A | WO2004CU16A	2003-12-03 | 2004-12-02	No associated DWPI family	20050616AU200429 4377A1	CA2547537A1 | AR46937A1 | AT456573T | AU2004294377A1 | BR200417334A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
CA2577918A1	2006-03-09	2005-08-29	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSITION VACCINALE CONTRE LE VIRUS DE L'HEPATITE C	CLAIMS 1. Vaccine composition to generate protective cellular and humoral	CU2004189A | WO2005CU5A	2004-09-03 | 2005-08-29	No associated DWPI family	20060309AU200527 9590A1	CA2577918A1 | AR52639A1 | AU2005279590A1 | AU2005279590B2 | BR200514884A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CA2579798A1	2006-03-23	2005-09-16	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PEPTIDE ANTAGONISTE DE L'INTERLEUKINE-15	CLAIMS 1. An IL-15 activity antagonist peptide characterized by comprising an	CU2004198A | WO2005CU7A	2004-09-17 | 2005-09-16	No associated DWPI family	20060323AU200528 4529A1	CA2579798A1 | AR51924A1 | AT434623T | AU2005284529A1 | AU2005284529B2 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
CA2581110A1	2006-03-30	2005-09-22	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PEPTIDES ET LEUR DERIVE DU TYPE APL DE LA HSP60 ET COMPOSITIONS PHARMACEUTIQUES	CLAIMS 1. Peptides of the human heat shock protein of 60 kDa that constitute	CU2004207A | WO2005CU8A	2004-09-24 | 2005-09-22	No associated DWPI family	20060330AU200528 7757A1	CA2581110A1 | AR51928A1 | AR74924A2 | AT546462T | AU2005287757A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
CA2688587A1	2008-12-04	2008-05-30	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SEQUENCES D'ACIDE NUCLEIQUE MY32 ET D'ACIDES AMINES ET VACCIN DESTINE A LA LUTTE CONTRE	CLAIMS: 1. An isolated nucleid acid sequence comprising the sequence	CU2007124A | WO2008CU3A	2007-05-31 | 2008-05-30	No associated DWPI family	20081204CA2688587 A1	CA2688587A1 | CA2688587C | CL2008001596A1 | CU23634A1 | DK2168978T3 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
CU20110167A7	2013-06-28	2011-08-26	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSICIÓN VACUNAL QUE COMPRENDE EL PÉPTIDO ACTIVADOR DE LA ADENILATO	1. REIVINDICACIONES COMPOSICION VACUNAL QUE COMPRENDE EL	CU2011167A	2011-08-26	No associated DWPI family	20130307CA2844898 A1	CU20110167A7 | AU2012303887A1 | AU2012303887B2 | BR112014004620A2 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina Geral
CU20110181A7	2013-05-31	2011-09-30	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSICIÓN PARA EL CONTROL DE PATÓGENOS	1. REIVINDICACIONES SECUENCIAS DE AMINOÁCIDOS PARA EL CONTROL DE	CU2011181A	2011-09-30	No associated DWPI family	20130404CA2849040 A1	CU20110181A7 | AR88176A1 | AU2012315083A1 | AU2012315083B2 | BR112014007491A2	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CU20120153A7	2014-06-27	2012-11-05	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	ANTÍGENOS VACUNALES QUIMÉRICOS CONTRA EL VIRUS DE LA HEPATITIS C	1. REIVINDICACIONES ANTÍGENOS VACUNALES QUIMÉRICOS	CU2012153A	2012-11-05	No associated DWPI family	20140508CA2901346 A1	CU20120153A7 | AR93341A1 | AU2013339846A1 | AU2013339846B2 | CA2901346A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CU20120179A7	2014-08-28	2012-12-27	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSICIÓN VACUNAL CONTRA EL VIRUS DENGUE	1 Composición vacunal que se caracteriza porque comprende a) al menos un	CU2012179A	2012-12-27	No associated DWPI family	20140703CA2894134 A1	CU20120179A7 | AR94238A1 | AU2013369626B2 | CA2894134A1 | CA2894134C |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina Geral
CU20160038A7	2017-11-07	2016-03-31	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LOS ANTÍGENOS DE LA SUPERFICIE Y DE LA	1 Composición farmacéutica que se caracteriza porque comprende ei antígeno de; core del	CU201638A | WO2017CU50001A	2016-03-31 | 2017-03-14	No associated DWPI family	20171005CA3017778 A1	CU20160038A7 | AR108009A1 | AU2017243136A1 | BR112018069738A2 | CA3017778A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	Vacina e Adjuvante
CU20160161A7	2018-06-05	2016-11-01	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	COMPOSICION VACUNAL QUE COMPRENDE UN PÉPTIDO SECRETAGOGO DE	1. REIVINDICACIONES COMPOSICION VACUNAL QUE COMPRENDE UN	CU2016161A	2016-11-01	No associated DWPI family	20180511CA3041944 A1	CU20160161A7 | AU2017353072A1 | BR112019008624A2 | CA3041944A1 | CL2019001191A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	Vacina Geral
CU20160194A7	2018-08-06	2016-12-30	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	COMPOSICIÓN VACUNAL QUE COMPRENDE UN MUTANTE DE LA INTERLEUCINA-15	1. REIVINDICACIONES COMPOSICIÓN VACUNAL QUE COMPRENDE UN	CU2016194A	2016-12-30	No associated DWPI family	20180705WO201812 1802A1	CU20160194A7 | BR112019013542A2 | CN110300762A | EP3564264A1 | MX2019007906A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	Vacina e Adjuvante
CU23377A1	2009-05-28	2003-11-04	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	METODO PARA LA INCORPORACION DE ANTIGENOS EN VESICULAS DE MEMBRANA	1. REIVINDICACIONES MÉTODO PARA LA INCORPORACIÓN DE ANTÍGENOS EN	CU2003254A	2003-11-04	No associated DWPI family	20050512AU200428 4969A1	CU23377A1 | AR46921A1 | AU2004284969A1 | BR200416178A | CA2543206A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
CU24075B1	2015-01-29	2011-08-26	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSICIÓN VACUNAL QUE COMPRENDE EL PÉPTIDO ACTIVADOR DE LA ADENILATO	1. COMPOSICION VACUNAL QUE COMPRENDE EL PÉPTIDO ACTIVADOR DE LA ADENILATO	CU2011167A	2011-08-26	No associated DWPI family	20130307CA2844898 A1	CU24075B1 | AU2012303887A1 | AU2012303887B2 | BR112014004620A2 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CU24076B1	2015-01-29	2011-09-30	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSICIÓN PARA EL CONTROL DE PATÓGENOS	1. REIVINDICACIONES COMPOSICION PARA EL CONTROL DE PATÓGENOS	CU2011181A	2011-09-30	No associated DWPI family	20130404CA2849040 A1	CU24076B1 | AR88176A1 | AU2012315083A1 | AU2012315083B2 | BR112014007491A2	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CU24112B1	2015-08-27	2012-11-05	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	ANTÍGENOS VACUNALES QUIMÉRICOS CONTRA EL VIRUS DE LA HEPATITIS C	1. REIVINDICACIONES ANTÍGENOS VACUNALES QUIMÉRICOS	CU2012153A	2012-11-05	No associated DWPI family	20140508CA2901346 A1	CU24112B1 | AR93341A1 | AU2013339846A1 | AU2013339846B2 | CA2901346A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
CU24188B1	2016-07-29	2012-12-27	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	COMPOSICIÓN VACUNAL CONTRA EL VIRUS DENGUE	1 Composición vacunal caracterizada porque contiene a) un antígeno quimérico	CU2012179A	2012-12-27	No associated DWPI family	20140703CA2894134 A1	CU24188B1 | AR94238A1 | AU2013369626B2 | CA2894134A1 | CA2894134C |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina Geral
CU24454B1	2019-11-04	2016-03-31	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LOS ANTÍGENOS DE LA SUPERFICIE Y DE LA	1. REIVINDICACIONES COMPOSICION FARMACEUTICA QUE COMPRENDE LOS	CU201638A | WO2017CU50001A	2016-03-31 | 2017-03-14	No associated DWPI family	20171005CA3017778 A1	CU24454B1 | AR108009A1 | AU2017243136A1 | BR112018069738A2 | CA3017778A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	Vacina e Adjuvante

CU24473B1	2020-02-04	2016-11-01	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	COMPOSICIÓN VACUNAL QUE COMPRENDE UN PÉPTIDO SECRETAGOGO DE			1. REIVINDICACIONES COMPOSICION VACUNAL QUE COMPRENDE UN	CU2016161A	2016-11-01						No associated DWPI family	20180511CA3041944 A1	CU24473B1 | AU2017353072A1 | BR112019008624A2 | CA3041944A1 | CL2019001191A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA	Vacina e Adjuvante
DE69130724T2	1999-06-17	1991-10-07	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Verfahren zur Gewinnung von rekombinantem Hepatitis B Virus (HEP B)				CU1990155A	1990-10-08						No associated DWPI family	19920415EP480525A 2	DE69130724T2 | AT175445T | AT324451T | AU199185574A | AU649482B |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
DE69703813T2	2001-08-09	1997-01-17	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE			• REIVINDICACIONES 1.- Proteína de fusión caracterizada porque contiene un	CU199610A | WO1997CU1A	1996-01-17 | 1997-01-17						No associated DWPI family	19970724CA2214840 A1	DE69703813T2 | AR5651A1 | AT198491T | AU199715396A | AU722317B2 |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
EP1029549A1	2000-08-23	1999-09-03	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	FORMULATION D'ACIDES NUCLEIQUES ET ACEMANNANE | ZUSAMMENSETZUN	Vaccine containing nucleic acid and acemannan, useful for treating or preventing cancer	A vaccine (A) comprisingnucleic acid (I), free, adsorbed or encapsulated in	REIVINDICACIONES 1. Una formulación vacunal de ácidos nucleicos y acemanano	CU1998126A | WO1999CU4A	1998-09-07 | 1999-09-03	B04-B04C2 | B04-C02 | B04-E02 | B14-B02 | B14-H01 | B14-S11B | B14-S11C | C04-B04C2 | C04-C02	A61K003170 (IPC 1-7) | A61K003900 (IPC 1-7) | A61K0031715 (IPC 1-7) | A61K003939 (IPC 1-	A61K003921 | A61K00390011 | A61K003912 | A61K003939 | A61P003704 |	2000270975	WO2000013704A1 | EP1029549A1 | BR199906761A | CN1287493A | US6358933B1 |	Dead	20000316CA2308444 A1	EP1029549A1 | AR20403A1 | AT289518T | BR199906761A | CA2308444A1 |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
EP1334727A2	2003-08-13	2001-11-01	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	METHODE, ANTIGENE STRUKTUREN ZU ERHALTEN, WELCHE SPEZIFISCHE	Preparation of antigenic structures having enhanced cross-reactivity and immunogenicity,	Preparation of antigenic structures (I) which potentiate specific cross-reactivity.	1. Method for obtaining antigenic structures able to enhance the specific cross reactivity	CU2000242A | WO2001CU7A	2000-11-03 | 2001-11-01	B04-C03E | B04-N04 | B12-K04 | B14-A01 | B14-G02 | B14-H01 | B14-S09 | C04-C03E | C04-N04 |	A61K003912 (IPC 1-7) | A61K003174 | A61K0031785 | A61K003900 | A61K003912 |	A61K003912 | A61K003921 | A61K003929 | A61K0039292 | A61K0039385 |	2002444347	WO2002036160A2 | AU200214938A | BR2001074224A | KR2002080360A | EP1334727A2 |	Alive	20020510WO200203 6160A2	EP1334727A2 | AR31182A1 | AU200214938A | AU2002214938B2 | BR200107424A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
EP1417973A2	2004-05-12	2002-07-12	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	DURCH KOMBINATION VON DNA UND ANTIGEN VERSTÄRKTE VAKZINEFORMULIER	Vaccine containing both DNA and protein antigen, useful for prevention or treatment of	Vaccine (A) comprises DNA (I) that expresses a protein (II), and a protein antigen (III),	1. A vaccine formulation having as components, a DNA that expresses a protein and a	CU2001171A | WO2002CU5A	2001-07-16 | 2002-07-12	B04-B04C1 | B04-C01G | B04-E03 | B04-E03F | B04-N04A | B14-A02A5 | B14-A02A7 | B14-	A61K003912 (IPC 1-7) | A61K003112 | A61K003929 | A61P003100 | A61K0031713 |	A61K003929 | A61K003912 | A61K0039292 | A61P003112 | A61P003114 |	2003229541	WO2003007986A2 | EP1417973A2 | KR2004028924A | AU2002325783A1 | BR2002111181A |	Alive	20030130CA2453260 A1	EP1417973A2 | AR34771A1 | AU2002325783B2 | BR2002111181A | CA2453260A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
EP1418180A2	2004-05-12	2002-07-12	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | INST MEDICINA	CHAINES CHIMERES CODANTES POUR PROTEINES INDUISANT DES EFFETS DIRIGES	New chimeric nucleic acids, useful in vaccines against dengue fever, encode fusion	Chimeric nucleotide sequences (I) which are specific combinations of sequences (S1)	1. Chimeric nucleotide chains characterized by being the specific combination of	CU2001172A | WO2002CU6A	2001-07-16 | 2002-07-12	B04-E02H | B04-N0400E | B04-N08 | B14-A02B2 | B14-S03 | B14-S11A | D05-H12C | D05-H14 |	C07K001418 (IPC 1-7) | C12N001500 (IPC 1-7) | A61K003816 | A61K003900 |	C07K0014005 | A61P003112 | A61P003114 | A61P003702 | A61P003704 |	2003229576	WO2003008571A2 | EP1418180A2 | AU2002325784A1 | KR2004030056A | BR2002111178A |	Alive	20030130CA2453300 A1	EP1418180A2 | AT349466T | BR2002111178A | CA2453300A1 | CA2453300C |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | INST MEDICINA	Vacina e Adjuvante
EP2022506A2	2009-02-11	2007-04-26	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	VERFAHREN ZUR BEHANDLUNG VON FLAVIVIRUS-INFEKTION, MOLEKÜLE UND	Flavivirus infection blocking method, involves interfering in interaction of virus envelope protein	The method involves interfering in the interaction of the virus envelope protein with a cell	1. A method for blocking the infection by flaviviruses, comprising the	CU200691A | WO2007CU14A	2006-04-28 | 2007-04-26	B04-N04 | B11-C08 | B12-K04A | B14-A02B9	A61K (IPC 1-7) | A61K003900 (IPC 1-7) | C07K001610 (IPC 1-7) | A61K003804 | A61K003816 |	C07K0014005 | C07K001470596 | C07K00148107 | A61K003800 | A61K003900 |	2007882794	WO2007124698A2 | WO2007124698A3 | EP2022506A2 | AU2007246076A1 | CN101472606A |	Alive	20071108AU200724 6076A1	EP2022506A2 | AR60827A1 | AU2007246076A1 | AU2007246076B2 | CA2650591A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
EP2915544A1	2015-09-09	2013-10-28	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	CHIMÄRE IMPFSTOFFE ANTIGENE GEGEN HEPATITIS C VIRUS | ANTIGÈNES	New chimeric vaccine antigen against hepatitis C virus (HCV) comprises e.g. first	Chimeric vaccine antigen against hepatitis C virus (HCV) comprising: (a) a first segment	1. A chimeric vaccine antigen against hepatitis C virus (HCV) comprising a) a first segment	CU2012153A | WO2013CU6A	2012-11-05 | 2013-10-28	B04-B04C | B04-E99 | B14-A02A7 | B14-G01 | B14-S11A | B14-S11D3 | D05-H07	A61K (IPC 1-7) | A61K003912 (IPC 1-7) | A61K003912 | A61K003929 | A61K003939 |	A61K003912 | A61K003929 | A61P003114 | C07K000708 |	2014H91650	WO2014067498A1 | AU2013339846A1 | KR2015079694A | CA2901346A1 | AR93341A1 |	Alive	20140508CA2901346 A1	EP2915544A1 | AR93341A1 | AU2013339846A1 | AU2013339846B2 | CA2901346A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
EP2939691A1	2015-11-04	2013-12-16	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	VAKZINE ZUSAMMENSETZUN G GEGEN DENGUEVIRUS | COMPOSITION	Vaccine composition used for inducing immune responses against Dengue virus (DV) comprises	A vaccine composition comprises (I) at least one antigen comprising at least	1. Vaccine composition characterized in that it comprises a) at least one antigen	CU2012179A | WO2013CU8A	2012-12-27 | 2013-12-16	B04-B04C1 | B04-E99 | B04-N03K | B04-N03K0E | B04-N08 | B14-A02B9 | B14-S11A | B14-S11D3 |	A61K003912 (IPC 1-7) | A61P003114 (IPC 1-7) | C07K0014005 (IPC 1-7) | A61K0031702 |	A61K003912 | A61P003112 | A61P003114 | A61P003704 | A61P004300 |	2014M81294	WO2014101903A1 | CA2894134A1 | AU2013369626A1 | KR2015100660A | AR94238A1 |	Alive	20140703CA2894134 A1	EP2939691A1 | AR94238A1 | AU2013369626B2 | CA2894134A1 | CA2894134C |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina Geral
EP3263594A1	2018-01-03	2008-05-30	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	AMINOSÄURE- UND NUKLEINSÄURESEQ UENZEN UND IMPFSTOFF ZUR STEUERUNG VON	New isolated nucleic acid sequence, useful for manufacturing a vaccine to induce	An isolated nucleic acid sequence that comprises SEQ ID NO: 1, sequences not defined here	1. An isolated nucleid acid sequence comprising the sequence identified as SEQ ID	CU2007124A | EP2008757900A	2007-05-31 | 2008-05-30	B04-B04C | B04-E02 | B04-E03 | B04-E99 | B04-N04 | B04-N0400E | B04-N08 | B14-A01 | B14-A02 |	A61K003817 | A61K003900 | A61K003938 | A61K003939 | A61P003300 |	A61K00390003 | A61P003300 | A61P003314 | A61P003704 | C07K001443509 |	2008O20582	WO2008145074A2 | WO2008145074A3 | EP2168978A2 | US2010022127 1A1 | US20130280290A1 |	Alive	20081204CA2688587 A1	EP3263594A1 | CA2688587A1 | CA2688587C | CL2008001596A1 | CU23634A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
EP474313A2	1992-03-11	1991-09-06	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Séquence nucléotidique codant pour une protéine de la membrane externe de Neisseria	Nucleotide sequence coding for P64K protein of N.MENINGITIDIS for preparation of	A recombinant polynucleotide comprises a nucleotide sequence coding for a protein	1. A recombinant polynucleotide, comprising a nucleotide sequence coding for a protein	CU1990145A	1990-09-07	B02-V02 | B04-B02B1 | B04-B02C | B04-B04A1 | B04-B04A5 | B04-B04C5 | D05-C12 | D05-H07 |	C07K001422 (IPC 1-7) | A61K0039095 (IPC 1-7) | A61K003940 (IPC 1-7) | C07K001610 (IPC	C12Y010801004 | A61P003104 | C07K001422 | C07K00161217 | C07K001640 |	1992081855	EP474313A1 | AU199183683A | CA2050749A1 | FI199104129A | NO199200500A |	Dead	19910903FI1991041 29A0	EP474313A2 | AR245778A1 | AT152175T | AU199183683A | AU657487B |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
EP480525A2	1992-04-15	1991-10-07	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Méthode pour l'obtention d'un antigène de surface du virus de l'hépatite B (HEP B)	Hepatitis B virus vaccine contg. HBU surface antigen obtd. using new method giving higher	Hepatitis B surface antigen (HBsAq) is recovered from Pichia pastous cells contg. the HBsAq	1. A process for recovering hepatitis B surface antigen from Pichiapastoris cells containing a	CU1990155A	1990-10-08	B02-V02 | B04-B02B | B04-B04A3 | B04-B04C1 | B12-K04A4 | D05-H03B | D05-H07 | D05-H11	C12P002102 (IPC 1-7) | A61K003929 (IPC 1-7) | C12N000512 (IPC 1-7) | C12P002108 (IPC 1-	C07K0014005 | A61P000116 | A61P003112 | C07K0016082 | C12N0015815 |	1992125181	EP480525A1 | AU199185574A | JP5076370A | EP480525A3 | AU649482B |	Dead	19920415EP480525A 2	EP480525A2 | AT175445T | AT324451T | AU199185574A | AU649482B |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
EP588750A2	1994-03-23	1993-08-05	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Procédé pour la production de polypeptides recombinants contenant des	Recombinant polypeptide(s) bearing epitope(s) from different HIV isolates used for	Prodn. involves the design and construction of synthetic genes coding for chimeric	1. A method for the production of recombinant polypeptides containing epitopes	CU199289A	1992-08-05	B04-C01G | B04-E02F | B04-E08 | B04-F0100E | B04-F0500E | B04-G08 | B04-G21 | B04-N03A0E | B12-	C12N001549 (IPC 1-7) | A61K003921 (IPC 1-7) | A61K0039395 (IPC 1-7) | C12N000520 (IPC 1-	C07K0014005 | C07K00161063 | A61K003900 | C12N274016122	1994094299	EP588750A2 | EP588750A3	Dead	19940323EP588750A 2	EP588750A2 | EP588750A3	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
EP864649A2	1998-09-16	1991-10-07	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Verfahren zur Herstellung von recombinantem Hepatitis B Oberflaechenantigen	Production of recombinant hepatitis B virus surface antigen comprises cultivating	Production of a recombinant hepatitis B virus surface antigen (HBsAg) comprises:	1. Recombinant hepatitis B surface antigen, obtainable by a process comprising	CU1990155A | EP1991202615A	1990-10-08 | 1991-10-07	B04-B04C2 | B04-F05 | B04-F10 | B04-G21 | B14-A02A5 | B14-S11A | D05-H07 | D05-H11A1 | D05-H11A2 | D05-	C12N001551 (IPC 1-7) | A61K003929 (IPC 1-7) | C07K001402 (IPC 1-7) | C07K001608 (IPC 1-	C07K0014005 | A61P000116 | A61P003112 | C07K0016082 | C12N0015815 |	1998469233	EP864649A2 | EP864649B1 | DE69133525D1 | DE69133525T2 | ES2264183T3 |	Dead	19920415EP480525A 2	EP864649A2 | AT175445T | AT324451T | AU199185574A | AU649482B |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
EP959079A1	1999-11-24	1997-12-17	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	VACCIN POUR L'IMMUNO-CASTRATION REVERSIBLE DES MAMMIFERES |	New analogue of gonadotropin releasing hormone has proline residue at position 6 and is	A new peptide (GnRHm1) inhibits release of gonadotropin and has sequence: Glu-	1. A peptide that inhibits the release of gonadotropins, having the sequence: * Glu-His-Trp-Ser-	CU1996120A | WO1997CU8A	1996-12-17 | 1997-12-17	B04-C01B | B04-N02 | B14-G02D | B14-S11 | C04-C01B | C04-N02 | C14-G02D | C14-S11 | D05-H07	C07K000723 (IPC 1-7) | C07K000723 | A61K003900	C07K000723 | A61K003900	1998362717	WO1998027111A1 | AU199853975A | EP959079A1 | BR199713735A | MX199905693A |	Dead	19980625CA2275440 A1	EP959079A1 | AR9840A1 | AU199853975A | AU736538B2 | BR199713735A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	vacina geral
EP966535A1	1999-12-29	1998-01-13	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | IPK INST MEDICINA	EPITOPES DE LA PROTEINE PRE-M/M DU VIRUS DE LA DENGUE, PEPTIDES SYNTHETIQUES |	New peptide(s) and fusion proteins useful for diagnosis and treatment of flavivirus infection	New synthetic peptides (I) or mimetics comprise amino acids 3-31, 57-92, 69-93 or 103-124	REIVINDICACIONES 1-. Péptidos sintéticos o compuestos miméticos de la	CU199713A | WO1998CU1A	1997-01-15 | 1998-01-13	B04-C01 | B04-G01 | B04-G08 | B04-N03 | B04-N03A | B04-N03B0E | B04-N04 | B12-K04 | B12-	C12N001540 (IPC 1-7) | A61K003800 | A61K003912 | A61K0039395 | A61P003112 |	C07K0014005 | A61P003112 | A61K003800 | A61K003900 | C12N277024122 |	1998414111	WO1998031814A1 | AU199856499A | NO199903468A | EP966535A1 | BR199807486A |	Dead	19980723CA2277816 A1	EP966535A1 | AT284444T | AU199856499A | AU743414B2 | BR199807486A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | IPK INST MEDICINA	Método /Processo
EP971737A1	2000-01-19	1998-03-05	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	FORMULATIONS IMMUNOSTIMULAN TES A USAGE VACCINAL | ZUSAMMENSETZUN	Naso-pharyngeal vaccine formulation used as immunomodulatory agent includes	Vaccine formulation for nasopharyngeal use contains the surface antigen of hepatitis B virus	REIVINDICACIONES: 1. Una formulación vacunal para uso nasofaríngeo caracterizada porque	CU199727A | WO1998CU3A	1997-03-06 | 1998-03-05	B04-B04C1 | B14-A02A5 | B14-S11 | C04-B04C1 | C14-A02A5 | C14-S11	A61K003939 (IPC 1-7) | A61K003929 (IPC 1-7) | A61K0039295 (IPC 1-7) | A61K0039095 |	A61K003939 | A61K003912 | A61K003929 | A61K203954 | A61K2039543 |	1998531508	WO1998039032A1 | ZA199801897B | AU199866077A | EP971737A1 | CN1252002A |	Dead	19980907ZA981897B |	EP971737A1 | AR9866A1 | AT295182T | AU199866077A | BR199808832A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
EP985729A2	2000-03-15	1999-08-13	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Streptokinasemutant en | Mutants de streptokinase	Recombinant production of streptokinase mutants, useful as thrombolytic agents	Production of streptokinase mutants (I) by transforming a host cells with an	1. A method for producing streptokinase mutants by expression of a gene	CU1998119A	1998-08-14	B04-C01C | B04-E02E | B04-E03E | B04-E08 | B04-F0100E | B04-F04 | B04-L02 | B14-F01B | B14-K01	C12N001531 (IPC 1-7) | A61K003909 (IPC 1-7) | C07K0014315 (IPC 1-7) | C12N000121 (IPC 1-	C07K00143153 | A61K003800 | A61K003900 | C07K231900	2000226041	ES9857229A2 | AU199943424A | CA2277554A1 | US6309873B1 | US6413759B1 |	Dead	20000214CA2277554 A1	EP985729A2 | AT294239T | AU199943424A | AU769916B2 | CA2277554A1 |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo

KR500782B1	2005-11-25	1997-09-13	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	용합단백질로서의 이종성 항원유전자 발현 시스템			1. Encephalomeningitis bacteria B: 4: the sequence number it is induced from the	CU199610A | WO1997CU1A	1996-01-17 | 1997-01-17						No associated DWPI family	19970724CA2214840 A1	KR500782B1 | AR5651A1 | AT198491T | AU199715396A | AU722317B2 |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
MX2014003892A	2014-07-09	2014-03-28	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SECUENCIAS DE AMINOACIDOS PARA EL CONTROL DE PATOGENOS.			1, - Secuencia de aminoácidos que se caracteriza porque comprende una secuencia de	CU2011181A | WO2012CU5A	2011-09-30 | 2012-10-01						No associated DWPI family	20130404CA2849040 A1	MX2014003892A | AR88176A1 | AU2012315083A1 | AU2012315083B2 | BR112014007491A2	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
MY132817A	2007-10-31	1998-03-05	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	FORMULATIONS FOR IMMUNOLOGICAL POTENTIATION OF VACCINES			1. A nasopharyngeal vaccine formulation comprising a particulated antigen in soluble state and	CU199727A	1997-03-06						No associated DWPI family	19980907ZA981897B	MY132817A | AR9866A1 | AT295182T | AU199866077A | BR199808832A |	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
MY134885A	2007-12-31	2002-07-10	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	VACCINE FORMULATION POTENTIATED BY THE COMBINATION OF DNA AND AN				CU2001171A	2001-07-16						No associated DWPI family	20030130CA2453260 A1	MY134885A | AR34771A1 | AU2002325783B2 | BR200211181A | CA2453260A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	vacina geral
PT2749291T	2017-11-24	2012-08-24	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	UTILIZAÇÃO DE PACAP COMO UM ADJUVANTE MOLECULAR PARA VACINAS				CU2011167A	2011-08-26						No associated DWPI family	20130307CA2844898 A1	PT2749291T | AU2012303887A1 | AU2012303887B2 | BR112014004620A2 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
SG11202011004A1	2020-12-30	2019-06-04	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | TOKO YAKUHIN	HEPATITIS B VACCINE TRANSNASAL ADMINISTRATION SYSTEM			1. (i)B型肝炎表面抗原(HBs抗原)とB型肝炎ヌクレオキャプシド抗原(HBc抗原)の	JP2018107797A | WO2019JP22136A	2018-06-05 | 2019-06-04						No associated DWPI family	20191212CA3099430 A1	SG11202011004A1 | AU2019283122A1 | BR112020022784A2 | CA3099430A1 | CN112368018A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | TOKO YAKUHIN	vacina
WO1998023754A1	1998-06-04	1997-11-25	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | IPK INST MEDICINA	PROCEDE POUR L'EXPRESSION DES GENES DES VIRUS DE LA DENGUE | PROCEDIMIENTO	New genes coding for dengue virus type 2 and 4 envelope proteins and Pichia pastoris expression	New recombinant polynucleotides (I) comprise a sequence encoding at least part of a Flavivirus E	REIVINDICACIONES 1. Polinucleótidos recombinantes caracterizados porque comprenden	CU1996107A	1996-11-25	B04-E02F | B04-E08 | B04-F0900E | B04-N0300E | B12-K04 | B14-S11A | D05-H07 | D05-H09 | D05-	C12N001540 (IPC 1-7) | C07K001418 | C12N000121 | C12N001540 | C12N000704 |	C07K0014005 | C12N000700 | A61K003900 | C12N271024162 | C12N277024122 |	1998322731	WO1998023754A1 | AU199853973A | CN1258317A | BR199713540A | MX199904908A	Dead	19980604WO199802 3754A1	WO1998023754A1 | AU199853973A | BR199713540A | CN1258317A | CU22666A1	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | IPK INST MEDICINA	Método /Processo
WO1998025960A1	1998-06-18	1997-12-12	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SEQUENCES DERIVEES DU GENOME DU VIRUS DE L'HEPATITE C ET LEUR UTILISATION |	New cDNA sequences from hepatitis C virus useful for recombinant	New cDNA sequences (I) derived from hepatitis C virus (HCV) are obtained	REIVINDICACIONES 1. Secuencias nucleotídicas de ADNc derivadas del genoma del virus de	CU1996119A	1996-12-12	B04-E01 | B04-E08 | B04-F09 | B04-F11 | B04-N03 | B12-K04 | B14-A02 | B14-S03 | B14-S11A | D05-H07	C12N001418 (IPC 1-7) | C12Q000170 (IPC 1-7) | C07K0014005 | C07K001418 |	C07K0014005 | A61K003800 | A61K003900 | C12N277024222	1998348454	WO1998025960A1 | AU199853974A	Dead	19980618WO199802 5960A1	WO1998025960A1 | AU199853974A | CU22642A1	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	
WO2005032585A1	2005-04-14	2004-10-04	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | FERNÁNDEZ MOLINA	COMPOSITIONS PHARMACEUTIQUES CONTENANT DES ANTIGENES DU VIRUS DE	Vaccine composition for boosting cellular immune response against human papilloma virus	A composition comprising human papilloma virus (HPV) antigens or portions linked via	REIVINDICACIONES COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN ANTÍGENOS DEL	CU2003224A	2003-10-09	B04-B04C1 | B04-C01 | B04-H04C | B04-N04 | B04-N0400E | B14-H01 | B14-S11A | D05-A01A4 | D05-	A61K003912 (IPC 1-7) | C07K0014025 (IPC 1-7) | C07K0014005 |	G01N003357411 | A61K003912 | A61P003500 | A61P003504 | C07K0014005 |	2005296057	WO2005032585A1	Dead	20050414WO200503 2585A1	WO2005032585A1 | AR45815A1	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA | FERNÁNDEZ MOLINA	Vacina e Adjuvante
WO2005049076A1	2005-06-02	2004-11-18	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	UTILISATION DE POLYSACCHARIDES CAPSULAIRES DE <I>NEISSERIA MENINGITIDIS</I>	Mucosal immunopotentiator for vaccines, useful for treatment or prevention of viral	Mucosal immunopotentiator (A) for pharmaceutical formulations	REIVINDICACIONESP OLISACÁRIDOS CAPSULARES DE Neisseria meningitidis COMO	CU2003270A	2003-11-19	B04-B04C1 | B04-B04C2 | B04-F10A1 | B04-F11 | B04-N03 | B04-N04 | B14-A01 | B14-A02 | B14-S11A	A61K0039095 (IPC 1-7) | A61P003104 (IPC 1-7) | A61K0039095 | A61K003910 | A61K0039102 |	A61K003939 | A61K0039095 | A61K0039102 | A61P003104 | A61K2039543 |	2005386482	WO2005049076A1	Dead	20050602WO200504 9076A1	WO2005049076A1 | AR46840A1 | CU23404A1	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
WO2008104133A1	2008-09-04	2008-02-27	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	THÉRAPIE COMBINÉE POUR LE TRAITEMENT DE L'HÉPATITE B CHRONIQUE |	Use of a proteoliposomal immune preparation comprises protein "S" hepatitis B virus	Use of a proteoliposomal immune preparation comprises protein "S" hepatitis B virus	REIVINDICACIONES TERAPIA COMBINADA PARA EL TRATAMIENTO DE LA HEPATITIS B	CU200750A	2007-02-28	B04-B03D | B04-B04C1 | B04-F11A | B04-G08 | B04-N03 | B04-N03E0E | B05-B01E | B11-C07A |	A61K003929	A61K003939 | A61K0039292 | A61K0038162 | A61K003912 | A61K003939 | A61K004506 |	2008L86078	WO2008104133A1	Dead	20080904WO200810 4133A1	WO2008104133A1 | AR65504A1	Dead	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante
AR60827A1	2008-07-16	2007-04-27	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	METODO PARA BLOQUEAR LA INFECCION POR FLAVIVIRUS, MOLECULAS Y USOS				CU200691A	2006-04-28						No associated DWPI family	20071108AU200724 6076A1	AR60827A1 | AU2007246076A1 | AU2007246076B2 | CA2650591A1 | CA2650591C |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
AR68329A1	2009-11-11	2008-07-30	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	PEPTIDOS PENETRADORES A CELULAS Y SU USO FUSIONADOS A BIOMOLECULAS CON				CU2007180A	2007-07-31						No associated DWPI family	20090219CA2694735 A1	AR68329A1 | BRPI0814452A2 | CA2694735A1 | CA2694735C | CN101808658A |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Método /Processo
AR88176A1	2014-05-14	2012-09-27	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	SECUENCIAS DE AMINOACIDOS PARA EL CONTROL DE PATOGENOS			1. Secuencia de aminoácidos que se caracteriza porque comprende una secuencia de	CU2011181A	2011-09-30						No associated DWPI family	20130404CA2849040 A1	AR88176A1 | AU2012315083A1 | AU2012315083B2 | BR112014007491A2 | CA2849040A1 |	Alive	CENTRO DE INGENIERIA GENETICA Y BIOTECHOLGIA	Vacina e Adjuvante

Type of candidate vaccine	Desenvolvedor(es)	Estratégia de Busca por Empresas - Base DWPI	Número de Pedidos de Patente	Número de Famílias	DATA	Filtro *quando necessário	Resultado final após Leitura
NVX-Cov 2373	NOVAVAX	CK=(("NOVAVAX")) OR CK=((NOVV) AND AIC=((A61K 39*))	798	79	09/04/2021		57
RBD-Dimer	Anhui Zhifei Farmácia Biológica Longcom	CK=((ANHU-N)) AND AIC=(a61k0039);	97	76	10/04/2021		41
SCB-2019	Clover Biopharmaceuticals	CK=(clover OR (CLOV-N)) AND AIC=(a61k0039);	3	3	12/04/2021		3
	Dynavax Technologies Corporation	CK=((DYAN-C) OR (DYNA-N)) AND AIC=(a61k0039);	576	61	13/04/2021	C12N7	16
VAT00002	Sanofi	CK=((SNFI-C) OR (SANO-N)) AND AIC=(a61k 39);	11.854	829	12/04/2021	AIC=((C12N7*))	89
	GSK	CMP=(("GLAXO" OR "CELLZOME" OR "CORIXA" OR "GENELABTECH" OR "HUMGEN" OR	39	18	13/04/2021		18
UB-612	United Biomedical	CK=((UNBI-N)) AND AIC=((A61K0039*));	641	49	11/04/2021		41
Soberana 2	Instituto Finlay de Vacinas	PA=((INSTITUTO ADJ FINLAY ADJ DE ADJ VACUNAS) and (CT ADJ DE ADJ QUIMICA ADJ FARMACEUTICA));	3.679	619	09/04/2021		20
EpiVacCorona	Vektor State Research Center of Virology and Biotechnology	PA=(Federalnoe ADJ byudzhetnoe ADJ uchrezhdenie ADJ nauki OR (FEDE-N) OR (FEDE-N)) AND AIC=(a61k0039);	346	346	10/04/2021	AIC=(a61k0039)	24
Abdala	O Centro de Ingeniería Genética y Biotecnología	PA=(Ingeniería ADJ Genética ADJ y ADJ Biotecnología) AND AIC=(A61K0039);	897	176	11/04/2021	A61K39/00;A61K39/39; A61K39/29; A61K39/12	118